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Summary 
Although there have been recent advances in HIV treatment, women still do not have a 
means to protect themselves from sexual transmission of HIV discreetly. Microbicides are 
products that would be applied vaginally to prevent HIV acquisition. Several microbicide 
products are being tested for their effectiveness in preventing HIV, and further studies of 
cervical barriers, such as the diaphragm, are planned. If found effective introduction and 
distribution systems need to be developed quickly to ensure women can access products and 
introduce them into their relationships. This study looks at determinants of women's 
demand for different barrier methods for HIV prevention to learn lessons for the 
introduction of new technologies such as microbicides and the diaphragm. 
A discrete choice experiment (DCE) was undertaken to identify critical factors to women's 
uptake of products. An iterative approach to the development of the DCE tool was taken. 
Qualitative group and individual interviews with women generated a wide range of 
potential factors influential to demand. An attribute identification workshop was introduced 
as a systematic method to reduce these attributes to the most important factors and identify 
the best way to represent them in the survey; this included the presentation of product 
effectiveness by the risk of HIV acquisition and becoming pregnant. During this workshop, 
women were given individual worksheets on which to rank the importance of the different 
attributes and levels in their decision to introduce, use and collect products. This provided 
individual responses in a group interview setting, which generated quantitative ranks on 
importance of attributes and their levels. Subsequently, a representative community survey 
was conducted among 1017 women in three Johannesburg townships. Women were asked 
questions about their socio-demographic backgrounds, their reproductive health histories 
and their preferences for different barrier methods and their distribution and promotion 
were elicited by a DCE. 
This study showed the usefulness of the attribute identification workshop in providing a 
structured framework for using women's attribute and level rankings to identify the 
importance of attributes generated in qualitative interviews and reduce these into a feasible 
and comprehensible DCE instrument. The analysis of women's preferences showed that 
there was a strong interest in the new barrier methods, microbicides in particular. The level 
of HIV effectiveness was very important in women's choices and will have an important 
impact on product uptake. Additionally, women who were successful in using condoms 
were predicted to have lower uptake of new products. Preferences for different distribution 
channels and ways of collecting product or advertising messages did not vary between 
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products. However there was diversity in women's preferences for advertising messages, in 
particular in their valuation of promoting products for enhanced sexual pleasure, where 
employed women rated it positively. 
This study shows that women are very capable of using hierarchical messages about HIV 
effectiveness to make informed choices about how to best protect themselves from HIV in 
their situations. The different barrier methods can be distributed through similar distribution 
systems, but having a range of advertising strategies is likely to increase uptake of products 
by widening their appeal across different groups of women. 
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CHAPTER 1. INTRODUCTION 
SECTION I: BACKGROUND 
Chapter 1. Introduction 
1.1. Background 
HIV/AIDS continues to take its toll on economies, communities, families, and individuals 
around the world Eil. Approximately 33 million people are infected with HIV globally; 67% 
live in Sub-Saharan African [2j. In this region, women are disproportionately affected, 
accounting for nearly 60% of all people living with HIV [21. Among the youth (15-24 years), 
this difference is even more extreme, with a prevalence that is four times greater among the 
young women in South Africa than among the young men [Z1. 
Not only are girls and women biologically more susceptible to acquire HIV in a sex act, but 
there are a range of socio-political factors contributing to their vulnerability [31. The ABC 
(Abstinence, Be faithful, use a Condom) method has largely failed women, for whom none 
of these components may be a feasible alternative because [41: `A'. Women's economic 
survival may rely on sexual partnerships; they may want to become pregnant; and/ or sex 
may not be consensual [5]. `B'. Being faithful will not protect a women if her partner is 
unfaithful [4,5); `C'. Firstly, male and female condoms can be difficult to access, in general, 
and secondly, condom use can be especially difficult to negotiate within steady partnerships 
[6,7), which now constitute a substantial source of infection for women 181. The female 
condom has provided some women with a tool they can initiate, but uptake has been limited 
as yet, and still relies on the consent of the male partner. There is a huge need for methods 
19 that women can initiate and use more discretely "121. 
However, it is not all doom and gloom for women. The roll-out of anti-retroviral therapy 
(ART) has exceeded expectations; with around 3 million people on treatment at the end of 
2007, and about two-thirds of this number live in Sub-Saharan Africa [21. In most countries 
more women are accessing treatment than men thanks to screening during pregnancy within 
programmes to prevent mother to child transmission in addition to the HIV treatment 
programmes available to both men and women 121. However, the number of newly-infected 
people is rising more quickly than the number who are receiving treatment; and though very 
important, treatment will not solve the epidemic [131. During the 2008 International AIDS 
Conference the importance of dual efforts that support both treatment and prevention was 
emphasised, as was the need for new prevention tools . 
X13] 
13 
CHAPTER 1. INTRODUCTION 
Some of the new prevention options that are being tested, in particular the diaphragm and 
microbicides, may provide women with more options to protect themselves, if they are 
found to be effective (Box 1-1). Additionally, a second generation female condom has just 
received regulatory approval in the United States by the Federal Drug Administration [14]. It 
is these products (microbicides, the diaphragm, and the female condom) with the male 
condom that will be referred to as barrier methods for HIV prevention. 
The diaphragm and other cervical barriers are being explored for effectiveness against HIV 
[15"171 
. It is thought that the mechanism of action of the diaphragm is by generating a 
physical barrier over the cervix, which is considered a key point of entry for HIV [18]. 
Although the only large scale effectiveness trial undertaken on the diaphragm showed no 
impact over and above the male condom [19,201, further analysis of the trial data is being 
undertaken and new trials with improved product designs are being explored. 
Microbicides are substances that, when applied vaginally, may reduce the risk of HIV 
infection. A number of different applications are being explored (Box 1-1), including gels, 
tablets, foams, films and possibly slow release rings [4). First generation products act to 
block viral entry and would be coitally-dependent products, i. e. to be inserted prior to the 
sex act isl. In addition, a new generation of antiretroviral-based products is being developed 
to target HIV replication more specifically [211. The aim is for these formulations to be long- 
[211 acting so they can be used at regular intervals, unassociated with a specific sex act 
In the long term, it is thought that the greatest protection against HIV and STI may lie in a 
combination of products; either combinations of chemical compounds or a combination of 
gels with physical barriers such as the diaphragm. 
14 
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Box 1-1 HIV Prevention Trial Pipeline 
Microbicide - HSV-2 treatment - Microbicide - Oral TDF - IDU Oral TDF, 
cellular sulphate susceptibility PR02000 & Thailand Truveda, 
BufferGel 
Male circumcision- Microbicide - HSV-2 treatment - Oral Truveda - Tenofovir Gel - 
infectiousness carraguard infectiousness MSM (iPrEx) VOICE 
Oral TDF - West Female Barrier- Oral TDF - MSM Microbicide - Oral Truveda - 
Africa (Ph II) diaphragm US (Phil) Tenofovir Gel Fern PrEP 
CAPRISA 
Microbicide - HSV-2 treatment Vaccine - Oral Truveda - Index Partner 
SAVVY Prime/Boost Heterosexual Treatment 
Thailand Botswana 
Male Vaccine - Microbicide - Oral Truveda - Microbicide - 
Circumcision - adenovirus PR02000 Partners PrEP Dapivirine IPM 
Susceptibility Step/Phambili 
2006 2007 2008 2009 2010-2011 2012+ 
r__.., n k..... innrem 
-.. I. 1-- 1- u %---, 
Once an effective new product is found, there are still a number of critical steps and 
potential bottlenecks between getting a product from the factory to the bed. An overview of 
these can be found in Source: Rosenburg (2008) 1231 
Figure 1-1. 
R&D! 
Manufacturing 
Clinical & 
Regulatory 
Behavioural Trial Support & Acceptability Intr 
Research Research 
Delivery 111ýIýIý11111ý ýi + !! Operations Resear Research 
Policy &I Impact Modellinq 
Advocacy Mobilisation of 
Marketing Market Research 
Source: Rosenburg (2008) j23) 
Figure 1-1 Critical path to microbicide access 
To introduce products, country level regulatory approval must be obtained. For 
antiretroviral-based microbicides, it is likely that regulatory approval will only be granted as 
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a prescription-only product, thereby restricting product distribution to the formal medical 
sector. Early generation products, which do not contain antiretroviral agents, may become 
available over the counter. This would allow for more flexible distribution systems 
including social marketing. The mobilisation of policymakers is necessary to adopt products 
into national and local health policy. Distribution systems must be designed to ensure 
availability, accessibility and affordability of products [231; this includes gaining support 
from providers for the product. Finally, products and their distribution need to be acceptable 
to consumers (women and their partners) so that they will be used consistently. It is the last 
of these steps that this thesis aims to address. 
1.2. Study aims 
This study aims to explore the determinants of urban South African women's uptake of 
barrier methods for HIV prevention to inform the distribution of new barrier methods2. In 
particular it aims to answer the following policy questions: 
" How is the uptake of new barrier methods likely to vary by product characteristics, such 
as effectiveness, and by women's characteristics, such as use of current barrier methods 
(substitution)? 
" How can new barrier methods best be distributed and promoted to facilitate women to 
access and introduce them into their partnerships? 
" Can distribution systems and promotion be used to target different groups of women, 
such as those not able to use condoms? 
The main approach will be the application of a discrete choice experiment (DCE). In 
doing so, a number of methodological questions around the development of DCE study 
tools will be addressed, specifically: 
" How to systematically reduce the broad range of attributes and levels elicited during the 
qualitative research to a useable number that can be used in the DCE instrument? 
" Can relative product effectiveness' / risk reductions be portrayed satisfactorily to allow 
women in a relatively low literacy setting to make valid choices? 
2 The terms `methods' and `technologies' are used interchangeably. `Method' is the standard 
terminology, but `technology' emphasises the fact that the focus is on the use of products, not HIV risk 
reduction strategies related to behaviour change such as abstinence or partner reduction. New barrier 
methods are considered microbicides and the diaphragm, male and female condoms are the existing 
barrier methods. 
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1.3. Thesis outline 
This thesis can be divided into 4 sections: Section 1 provides the background, including the 
review of the literature; Section 2 provides the methods; Section 3 presents the empirical 
results; and Section 4 draws out the main conclusions. 
In the background section, Chapters 2 to Chapter 4 present a review of the existing relevant 
literature, which establishes a background to the results presented in later chapters. The 
literature review starts with an examination of the empirical literature on the determinants 
of demand for health and health care, specifically focussing on for reproductive health 
goods and services, particularly in South Africa in Chapter 2. The neoclassical economics 
framework for studying demand is presented in Chapter 3. This describes how demand is a 
function of the product's own price, the prices of substitutes, income, and preferences [24]. 
However, neoclassical economics does not provide a framework for studying the uptake of 
new goods or services. The theoretical framework for studying demand in this thesis is 
. based on two main theories: diffusion theory and Lancaster's theory of demand 
[25.27] 
Diffusion theory specifies general characteristics that influence the speed and level of 
uptake [271. Lancaster's theory of demand describes the full value of the good or service as 
the sum of the value of its attributes. In Chapter 4 the review of empirical research methods 
describes the operationalisation of Lancaster's theory of demand in discrete DCEs. The 
value of the attributes is empirically obtained from DCEs wherein people are asked to make 
choices that force trade-offs [28,291. This then allows for the identification of critical factors 
that influence uptake. 
The second section presents the aims and the iterative methods for developing and 
implementing the community survey instrument in Chapters 5 to 8. Drawing on the review, 
the thesis aims and objectives are presented in Chapter 5 along with a framework for 
studying the determinants of demand for barrier methods. Three main realms of 
determinants are identified: firstly, determinants at the user level, such as partner types, 
education level, and desire for additional children. Secondly, determinants at the technology 
level, related to the physical characteristics of the products, such as the ability to use it in 
secret and its effectiveness. Finally determinants at the distribution strategy level are 
considered, such as where and how products can be collected, and the ways in which they 
are promoted. 
Chapter 6 presents the iterative process of the qualitative research (FGDs) in generating a 
wide range of attributes and levels deemed important by the target group and of the IDI's to 
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pilot the study instrument. Chapter 7 focuses on the attribute identification workshop. This 
is a new methodology for identifying key attributes to include in the DCE, based on 
women's own prioritisation of attributes. It concludes that the final choice of attributes and 
levels should be a balance between those critical attributes that women choose and 
attributes that can be changed, as well as information relevant to developing introduction 
and distribution strategies. Chapter 8 provides the details of the community survey 
implementation of the DCE study, among a random sample of 1017 adult sexually active 
women who were interviewed in Greater Johannesburg. 
Section 3 of the thesis describes results from the community survey. Chapter 9 provides a 
description of the sample and compares the survey population with socio-demographic 
characteristics of nationally representative surveys to explore the generalisability of the 
results on women's preferences [30] [31] 
Chapter 10 analyses women's socio-demographic and behavioural characteristics to explore 
the existence of market segments using principal components analysis, cluster analysis and 
ANOVA. Subsequently, an analysis of women's directly elicited preferences (willingness to 
pay responses) for the products reduces the wide range of factors down to a reasonable 
number of socio-demographic characteristics to carry forward in the analysis of preferences 
elicited in the DCE. 
In the last two results chapters the DCEs are analysed. The first one on preferences for 
physical attributes (Chapter 11) and second one on preferences for distribution attributes 
(Chapter 12). Both analyses use the multinomial logit model as the base model. In Chapter 
11 the physical attributes analysis also uses the nested logit model. This estimator models 
the choice to switch from the use (or non-use) of a condom during the last sex act separately 
from the choice between new barrier methods. 
The analysis of distribution attributes in Chapter 12 looks at women's preferences for 
different distribution channels, how they would like to collect products at these outlets, and 
the types of promotional messaging that are used. This analysis also evaluates the use of the 
random parameters logit model, which allows for heterogeneity in preferences between 
women. The interaction between distribution strategies and products is tested in order to 
verify whether the various products will need different distribution systems. 
The concluding chapter summarises the methodological and empirical results of the thesis. 
These are compared with the existing literature, their validity and generalisability is 
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considered, as well as caveats and areas for future research. This chapter aims to reflect on 
the research methods, process and results as a whole and the contribution that the thesis 
makes to the field of DCE and HIV prevention research. The lessons that can be learned for 
future introduction of new barrier methods are discussed. 
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Chapter 2. Determinants of demand for health care 
services and products in LMIC 
2.1. Introduction 
This chapter seeks to review the relevant literature and summarise the evidence on key 
factors leading to women's uptake of new products and services. The review first looks 
broadly at determinants of the demand for health care; then reviews the literature on 
demand for more related services and products, i. e. reproductive health services and 
products, and barrier methods. The final section looks at these issues in the South African 
context. 
2.2. Determinants of demand for health care services 
Studies of the demand for health and health care have a long history, and date back to the 
1970s [321, with Grossman's human capital model [33,341. This model conceptualises health 
as a capital stock variable that is the output of a production function, and health care as one 
of the inputs that can increase that stock over time. Empirical studies of the demand for 
health care have shown consumption of services to be sensitive to price and individuals' 
income [35,361 Ensor defines demand as determined by factors at the individual level, 
community factors and prices [37]. He also provides a framework for analysing access to 
health care in terms of supply and demand side barriers. Demand side barriers are: 
information on health care choices/providers; education; indirect consumer costs (distance 
costs and opportunity costs i. e. waiting and treatment time); household preferences; 
community and cultural preferences, attitudes and norms; price and availability of substitute 
products and services. On the supply side he identifies: input prices and input availability 
(wages and quality of staff, and price and quality of drugs and other consumables); 
technology; management/staff efficiency. Barriers that are interactions between the supply 
and demand side are: direct price of service of a given quality (including informal 
payments) and quantity rationing. 
Muela and Aye identify additional factors related to the utilisation of services: Firstly, 
social networks and solidarity can affect the price faced by the individual patient [38,39] 
Secondly, the type of payment mechanism (such as cash, credit, payment in kind, etc. ) will 
affect the choice between providers. Typically the formal government health sector will 
only accept cash payments at the time of service, whereas the private and traditional health 
sector may be more flexible in the payment mechanisms they accept, thus increasing access 
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to the latter types of health services in times of need. The perceived aetiology of the disease 
will also influence health-seeking behaviours 1403. Though quality of staff is included above, 
technical skills and their interpersonal qualities should be explicitly differentiated as the 
latter was shown to be particularly important in service utilisation [413. This could be 
expected to be even more important for stigmatised services such as treatment of and 
protection from STIs. 
During the 1990s user fees were implemented throughout Africa as part of many macro- 
economic recovery plans calling for decentralisation and as a way to improve sustainability 
and quality of services. Many studies of the determinants of demand followed. To study 
the impact of these fees on demand, empirical studies of changes in utilisation of health 
services following introduction or removal of user fees in Africa confirm the barriers 
presented by Ensor above ß42,38,43 -46, ao, 47-52,39,53 -621 [411 
In general, the impact of user fees on service utilisation differed widely from country to 
country. Most studies showed a decrease in utilisation of services by the very poor, despite 
official policies to protect the poor, because the implementation of means testing and fee 
waivers proved difficult 1631. Only if the implementation of user fees was accompanied by 
large improvements in quality did utilisation not drop E641. In the next section we discuss a 
framework for introducing contraceptive methods in terms of factors relating to the 
services, to the product and to the user. This framework is subsequently used to organise 
the literature review of the demand for reproductive health services and products and barrier 
methods for HIV prevention. 
2.3. A framework for introducing new contraceptive methods 
The previous section briefly reviewed the determinants of the demand for health services. 
This section presents an existing framework for facilitating the introduction of 
contraceptives and then raises specific issues around the uptake of reproductive health 
goods and services. 
During the 1990's, after three decades of experience introducing new contraceptive 
technologies in developing countries, the World Health Organisation (WHO) reviewed 
introduction strategies for contraceptives to revised its strategy. This 30-year history has 
highlighted the shortcomings of a technology-driven single method approach distributed 
through as many channels as possible, and has taught the importance of taking the broader 
social and institutional contexts into account in the development of strategies for 
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contraceptive introduction [65-6']. The WHO Strategic Approach provides a framework to 
move away from a product-driven approach and emphasises the interactions between the 
users, the service and the technology (Figure 2.1) ([68] p83). 
" Users' perspectives 
" Medical Profile 
" Reproductive health needs & rights 
" Socio-cultural and gender influences 
User 
Technology 
Service " Method-mix characteristics 
" Policies, program structure " Efficacy 
" Personnel, facilities, management " Side effects 
" Availability and accessibility " Administration 
" Quality of care " Reversibility 
" Duration 
E+aalanry 
Figure 2-1 Systems framework guiding the strategic approach to contraceptive 
introduction 
In response to research showing that contraceptive prevalence increases with the range of 
methods provided, this framework focuses on method-mix. The process of introduction has 
three stages: Strategic assessment of need; Research; and Use of research for policy and 
planning. These stages are flexible, interactive and have participatory potential with local 
actors. Though it generally has provided a useful framework, there are challenges in its 
implementation [69]. Using the framework above, the literature covering determinants of 
demand for family planning goods and services is reviewed. 
Studies of the determinants of women's acceptance/use of different contraceptive methods 
were undertaken as early as 1940 [701. More than half a century later this is still a productive 
area of research. Detailed insights into user preferences for product attributes tend to be 
obtained through focus group discussions. Repeated rounds of national demographic 
surveys such as the Demographic Health Survey (DHS) have facilitated rigorous 
quantitative analysis of demand determinants at individual, community and service levels 
(e. g. Chen; Steele; Frankenburg; Burgard; Steele; Magadi; Chayovan) [71'7'1. Preferences 
[12] for contraceptive technology attributes have also been investigated . 
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2.4. Determinants of at the service level 
At the distribution system level, studies in family planning have shown that increasing 
contraceptive choice and improvement of other supply side factors has led to increased 
contraception use [75,76,74,78,79,69,80,73,81-83] Chayovan defines accessibility of 
contraceptives as the amount of effort required to obtain them [72]. He presents this effort in 
nine dimensions: absolute and relative distance to contraceptive outlets, absolute and 
relative travel time to outlets, range of services provided, maturity of services and outlets in 
that community, convenience of transport to outlet, quality of service (waiting time, the 
technical and interpersonal skills of the staff), and the cost of the service. However, the 
study is methodological, and does not show results in terms of the relative importance of the 
different dimensions. More concretely, the key distribution strategy attributes that have 
been shown to facilitate contraceptive and barrier method uptake are: staff attitude, waiting 
time, opening hours, privacy of service, reliability of stock, price, distance to services, and 
media attitudes [84 6s, 85-89] [90,91] 
The other quantitative studies show that contraceptive prevalence increased with improved 
contraceptive supply, training of providers and IEC in Tanzania [73]. In Rwanda, personal 
communications about contraception at health centres reduced unmet need 1921. It also 
increased with the availability of a wider range of contraceptive technologies (although this 
did not lead to much substitution between the methods) and closer distribution sources in 
Morocco [761. Steele also showed a selection effect of users choosing public versus private 
service providers [77)" As the quality of government services improved, their use increased 
relative to the community health posts; as increased field worker visits drew clients to the 
community health posts and away from government clinics, the inverse relationship was 
[74] found with community health post prices . 
2.5. Determinants at the user level 
At the user level, partner types and pregnancy preferences are frequently mentioned as 
important factors influencing use. Individuals tend to underestimate their risk of HIV and 
STI (93-971. Women who desire pregnancy are less likely to use existing barrier methods to 
protect themselves against infections [98'101] 
In South Africa DHS data were used to compare contraceptive use in pre- and post- 
apartheid periods across racial groups and found little change in use patterns . 
(71j 
Kleinschmidt found that condom use in South Africa was determined less by lack of 
knowledge or difficulties accessing condoms, than by personal and partner characteristics 
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and attitudes 1991. This was reconfirmed in a recent study in Rwanda [92]. Specific 
preferences and concerns related to barrier methods are also shown to vary by life-stage, 
culture and other contextual factors [102"10 in [105] 
2.6. Determinants at the product level 
Studies of user preferences for women's barrier methods for HIV prevention are many, and 
have tended to focus on preferences for product attributes. There are more than 100 studies 
of acceptability/user preferences for the female condom cited in number of reviews [106,66, 
107-109] as well as over 75 published pieces on microbicides (or placebo products) with many 
more presented as conference abstracts [110,108,111-127]. A smaller but growing number of 
studies on diaphragm acceptability have been published [128,129,17] [130-132,116,133-144] [136,145, 
1461. Focusing on technology attributes, these studies have shown that women are interested 
and willing to use new methods for HIV prevention [lad, 129 ,148-151 ,108 ,142 ,95 ,110 ,152 ,153,143,1541 
In Mexico women identified contraceptive method effectiveness, lack of amenorrhea and 
other side effects as the most important attributes [121. Reactions to female barrier methods 
were the least positive with women expressing concerns about their inconvenience in terms 
of insertion, disposal (female condoms and sponge) and cleaning. They predicted that 
female condoms would be as unacceptable to their partners as male condoms. However, 
covert use was not a priority, though it was considered useful for `some women'. 
Internationally, the lack of methods that women can use without their partner's consent has 
been a critical motivation for developing microbicides. Yet, participants in the MDP trial of 
microbicides efficacy have overwhelmingly informed their partners of their participation, 
and expressed the need for discreet products rather than secret products [155j. Just over half 
(54%) of women in a diaphragm safety and efficacy trial had disclosed at their six month 
follow-up visit [135]. Naturally self-selection of trial participants means they are unlikely to 
be representative of the population as a whole. 
Product introduction lessons from the female condom 
Female condom introduction can provide important insights to guide introduction strategies 
for other new methods. Warren et al. summarised key factors to successful female condom 
programming in Box 2-1 [651 
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Box 2-1 Key elements of a quality female condom distribution programme 
" An identified target audience to whom the messages and product are well delivered to ensure that 
users have a consistent supply; 
" Training for providers to ensure that possible provider biases do not negatively influence potential 
users; 
" Face-to-face communication to equip potential users with information and skills; 
"A broad reproductive health focus that integrates family planning and HIV/AIDS prevention; 
"A mix of public and private sector distribution; and 
In a study of lessons learned from the female condom, Kaler interviewed key stakeholders 
and found that: champions at all stakeholder levels are critical; there is a need to move 
quickly to large scale distribution rather than numerous pilots and acceptability studies; the 
female condom needs to be positioned by status attributes (glamour) rather than protective 
attributes; talking about sex and HIV prevention, an important part of female condom 
programmes, have public health benefits in themselves, yet are hard to measure; no quick 
fixes should be expected as it takes time for products to be adopted; and evaluation after 
one to three years is not sufficient for the product to take off 11071. In a very short (2-month) 
evaluation the impact of an intervention on female condom uptake in Zimbabwe, Napierala 
et al showed that liking of the female condom increase with use over the 2 month period, 
but that the female condom remained a niche product adding important protection for some 
women, while adding an additional tool to those mixing barrier methods [1561. Madan 
reviews the female condom programme in Zimbabwe and reminds us that it is the 
programme, not just the product, that determined the success of the female condom and that 
it is not a magic bullet solving all problems, including gender imbalances [67]. Brown 
expanded this to include lessons from the female condom, IUD and contraceptive implants, 
providing 12 lessons: set realistic targets for uptake and impact; cost-effectiveness is 
important for policy makers' decisions; make a choice of methods available to 
accommodate different and changing user needs; ensure strong and sustained project 
support at all levels; plan in the long term as it takes time to establish supply and demand 
for new products; respond quickly to real or perceived user problems; avoid stock-outs; 
consider the local context in product positioning; an integrated approach is likely to be more 
sustainable than vertical programmes; plan for scaling up; second generation products may 
['s'3 give new opportunities; expect the unexpected 
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2.6.1. Willingness to pay 
Four studies have elicited women's WTP for microbicides [158-161]3 Of these, three produced 
estimates for South Africa. Hill estimated that at five times the price of a condom, 52% of 
respondents would still be interested in using microbicides, increasing to 63%, and 79% as 
microbicides decrease to two times and one time the price of a condom, respectively. 
Becker, on the other hand, asked providers for how much they thought microbicides could 
be sold 11581. Providers stated that 30 Rand would be appropriate, which is approximately 
equal to the price of STI treatment. However, community members mentioned that 
condoms are free, and therefore a maximum price of 5 Rand would be the correct price. 
Cohen used conjoint rating to gain insights into the valuation of single use versus reusable 
microbicides [159,119 Respondents in her study from the Dominican Republic and South 
Africa stated that they preferred the more expensive one (5 Rand) to the less expensive one 
(2 Rand), holding other attributes constant. This suggests microbicides may be a Veblen 
good (see page 36). 
2.6.2. Substitution away from male condoms 
Although the efficacy of new barrier methods will only be known when trial results become 
available, it is likely that in their first generation they will not provide the per sex act 
protection that male and female condoms provide. Policy makers have been concerned 
about substitution; this could be a switch from using nothing to using one of the new 
methods (socially desirable), or it could be a change from using condoms to a new method 
(socially undesirable). Foss et al. showed that an individual's level of protection from HIV 
is not only determined by the method of protection used, but also the consistency of its use 
(use-effectiveness) [1621. This can be addressed by promoting new methods within a mix of 
methods and using hierarchical messages [87,163]; and within programmes providing risk 
reduction interventions 1164. Studies exploring substitution between male and female 
condoms have generally shown: some substitution, though there are higher numbers of 
overall protected sex acts; a mixed impact on STI incidence; and in some locations 
increased male condom use due to women's improved bargaining power [165"1711. Studies of 
substitution from condoms to spermicides show mixed results [162,172,173 No study has 
estimated the influence of prices on these substitution rates, with the exception of estimates 
of sex-worker price differentials between condom-protected and unprotected commercial 
[174, acts in India and South Africa "a, 1751 
3 Yong Holt (2002) used conjoint rating to estimate trade-oils between microbicide attributes, but did not 
include a cost attribute 11231. 
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Z. 7. Determinants of demand in the context of South Africa 
South Africa has experienced a decade of transformation in all areas of society and 
government infrastructure since the end of Apartheid. Reproductive health services have 
undergone dramatic changes: from parallel systems for whites and non-whites and many 
vertical programmes, to an integrated system focused on primary health care E713. During 
Apartheid family planning was aggressively promoted as a means to reduce the size of the 
black population E"1. This, together with many other Apartheid policies, has contributed to 
a strong mistrust of the motives of many government services. 
Contraceptive prevalence is far higher than the rest of Sub-Saharan Africa, with around 
64%-84% of women using some modern method. Hormonal contraceptives were especially 
promoted among the black population, as a long term method that was not reliant on regular 
supplies, and which could be delivered through mobile clinics to remote areas. In 1998, 
62% of black women were using modern methods such as injectables, compared to only 4% 
of white women. Method choice was not often provided to black women [176] in ["]. More 
recently, injectables have been mentioned as a contraceptive method that can be used 
covertly, and have been promoted with the idea that they reduce poor compliance [177 
The South African government has shown commitment to providing barrier methods 
through the public sector, distributing over one million female condoms a year [178]. The 
strategic approach mentioned above was followed to introduce the female condom and 
emergency contraception in the past decade. The female condom introduction has been 
scaled up from an initial 15 pilot sites in family planning clinics to 350 sites in the public 
sector clinics, workplaces and other hotspots ['J. The female condom has also been 
distributed through social marketing in private sector outlets [651. A participatory providers' 
training was developed to prepare the providers with the skills to introduce female condoms 
1191. This is critical to successful introduction as provider attitudes have been shown to 
limit contraceptive choice and they are key gatekeepers in introducing new methods [179,177] 
Reuse of the female condom has been reported in many developing countries 11801. In South 
Africa, a study of the acceptability of reuse among mostly sex-workers found high 
acceptability and ability to follow reuse safety guidelines [180) 
Dual protection is also part of the South African reproductive health policy. Dual 
protection is the use of methods to prevent both pregnancy and disease by using either one 
method for each aim (e. g. a condom plus hormonal contraception), or a method that 
27 
CHAPTER 2. EMPIRICAL EVIDENCE ON DETERMINANTS OF DEMAND 
achieves both (such as the male or female condom alone). Three published studies look at 
the determinants of use of dual protection in South Africa [99°181°1821. 
Reported dual protection was used in 10%- 12% of the most recent sex acts. Individual 
determinants for not using condoms were: less education, older age, rural residence, married 
or cohabitating (in contrast to casual/occasional partner), only one partner (compared to 
more than one), not fearing pregnancy (compared to being pregnant, intending to become 
pregnancy or infertile), knowledge of only one purpose for the condom (pregnancy or STI 
prevention rather than both). "Dual method use, rather than being a consensual choice, 
generally occurs only when a man's aim of protecting himself from STIs coincides with his 
female partner's goal of preventing unwanted pregnancy" [183]. Public or private 
distribution channels used for contraceptives did not significantly affect condom use. 
However, problems with access to condoms did significantly affect certain population 
groups, including youth, rural women, those with non-regular partners, and poorer 
households 1991. 
Information failure is widespread, especially among the youth. A review covering the 
1990s showed that young people lacked correct information on methods to prevent 
HIV/AIDS, and side effects of condoms E961. They also underestimated their risk, including 
those who were already HIV positive (IM]. Men showed higher rates of denial of risk than 
women 
11851 
Men's attitudes towards microbicides are generally positive, though they express concerns 
about interference in sexual pleasure, including concern about the additional lubrication 
they provide [1861. Reinforcing the finding by Myer [1831, men expressed a preference for a 
microbicide that would only protect against STIs over one that would only protect against 
pregnancy. Fifty-four to seventy-five percent of men stated a willingness to pay for a 
microbicide; STI clinic patients showed the least WTP and university students showed the 
most. 
A qualitative study among policy makers, community members (potential users) and health 
care providers showed that HIV-prevention efficacy was important, but it was understood 
that even a microbicide with a 40-70% effectiveness against HIV would be of great value, 
given the low levels of condom use at present E158]. Preferences for contraceptive 
microbicides vary widely, emphasising the importance of having two formulations to meet 
different people's preferences. Though broad-based distribution was deemed appropriate, it 
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was thought that, initially, distribution channels should be restricted to channels where 
personal counselling of hierarchical messages is feasible. 
Reproductive health in South Africa cannot be discussed without raising the issue of gender 
relations and violence. There are strong double standards, where extramarital affairs by 
men are often accepted and condom use within marriages remains low [1871. Married men 
are more likely to be HIV+ than women, suggesting that they are more likely than the 
women to bring the infection into the relationship [187]. Covert use of barrier methods are 
attractive to women, however they also reported fear of violence if discovered 1144 ° 1871. Sex 
is frequently associated with coercion in South Africa 1188,1891 in 11901. Not only is rape 
common, women are also disadvantaged economically 11911. In urban South Africa, 
1192 transactional sex and partner violence are prevalent ' 193] 
2.8. Lessons from review of determinants of demand 
Despite many studies on user preferences, there are still gaps in the literature around how 
factors, beyond the specific method attributes, influence use. These include individual 
characteristics such as partner type, age, and desire for pregnancy; as well as supply side 
factors such as how distribution channels and advertising affect the demand for barrier 
methods for HIV prevention [194,103,195,106,108]and the trade-offs between them. This 
information is important to enable interventions to be developed in low and middle-income 
countries that meet women's needs for HIV prevention by facilitating access and 
stimulating demand. Moreover, none of the studies have quantified the trade-offs or 
interactions between the different characteristics of technologies and distribution systems, 
which is needed to inform introduction and distribution strategies. 
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Chapter 3. Economic theory of demand 
3.1. Introduction 
This chapter will begin with a review of the neoclassical theory of demand. Since the goods 
considered here are not entirely private goods, the theory of externalities and public goods 
will be discussed, followed by theories of the demand for new products and strategies to 
increase demand. 
3.2. Neoclassical demand theory 
3.2.1. Consumer theory 
Neoclassical economics theory of demand considers the perspective of individual 
consumers who make choices to maximise their wellbeing (utility). By maximising their 
utility, consumers are expressing their preferences. Consumers are assumed to be rational 
agents, and their preferences are assumed to conform to a number of axioms: they are 
complete, reflexive, and transitive. Completeness means that all bundles of goods can be 
compared and ranked to assess which bundles are preferred and which are considered equal. 
Reflexivity means that a bundle is preferred equally to the same bundle (itself). It should be 
noted here that a good has both a time and a space dimension and if one of these changes, it 
is no longer conceptualised as the same good. These changes in valuation of goods will be 
quantified in our analysis of valuation of distribution channels. Transitivity means that if A 
is preferred to B and B is preferred to C, then A must also be preferred to C. 
A number of assumptions are made about `well-behaved' preferences. They are monotonic, 
that is: more is better. Although satiation can occur, we assure that demand is evaluated at 
quantities less than the satiation point. We also assume that combinations of goods are 
better than only one or only the other. Preferences are graphically represented in 
indifference curves, representing different amounts of bundles of goods that provide the 
same amount of utility (make the consumers equally well off). They are mathematically 
represented in the utility function U=f (xi, x2), where utility (U) is a function of the 
consumption of different goods: good 1 (x1) and good 2 (x2). 
These assumptions about preferences guide the shape of the indifference curves. 
Monotonicity implies that the slope of the indifference curves is negative. Curves further 
away from the axis are better. The preference for combinations of goods rather than 
extremes dictates that the curve is convex. The slope of the curve represents the marginal 
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rate of substitution between the bundles. The marginal rate of substitution shows how much 
of one good or bundle of goods one is willing to give up to obtain a given amount of the 
other good. This can also be seen as the marginal `willingness to pay' to buy the other 
good. Convexity of the indifference curve implies a diminishing marginal rate of 
substitution. In other words, the consumer would be willing to trade less of x1 for a given 
amount of x2, the less they have of x, (moving to the left on the indifference curves in 
Figure 3-1). The closer the marginal rate of substitution is to -1, the easier it is to substitute 
between the two goods; the closer to 0 indicates that the goods are more complementary 
(the consumer needs some of both goods to make them happy, rather than either one or the 
other as in the case of substitutes). 
X2 
ý, ý_ 
XI 
Figure 3-1 Indifference curves 
Although a consumer is equally well off at each point on a given curve, relative prices and 
the consumer's budget determine the utility maximising consumption point, that is where 
the ratio of prices is equal to the marginal rate of substitution . The quantity of a good 
demanded (Qi) is then a function of the consumer's income (m), the good's own price (pl) 
and the price of its substitutes (p2): 
Q1 =f (Pr, P2 m)" Eq. 3-1 
Underlying this function are the consumer's preferences (represented by his/her utility 
function). 
The demand curve represents the relationship between the price of a good and its demand 
and shows the utility (benefit) gained by consuming consecutive quantities of a good. It is 
downward sloping, showing how the first unit of a good tends to provide more utility and is 
valued higher than further units. At a given price (p*), a consumer will purchase the 
amount of the good at which their marginal benefit from the unit of good is equal to the 
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marginal cost of purchasing that unit good (the price). At this point the consumer has 
obtained more benefit for each previously purchased unit than they have paid. This surplus 
benefit is called consumer surplus and is represented in Figure 3-2 as the shaded area above 
p* and below the demand curve. The demand curve also represents the consumers 
`marginal willingness to pay' for each unit of good because each point on the curve 
measures what the consumer is willing to pay for the last unit. 
P 
P* 
Figure 3-2 Demand curve 
The responsiveness of demand to changes is captured by a unit free measure called 
"elasticity". This was developed as a measurement of responsiveness, and allows for 
responsiveness to change at different quantities. Common demand elasticities are price, 
cross-price and income, but demand elasticities can also be measured for the responsiveness 
of demand to other stimuli such as advertising. 
Formally, elasticities are measured by: % change in the quantity demanded 
% change in the stimulus 
Demand is said to be elastic when it changes by a greater percentage than the percentage 
change of the stimulus, and inelastic when it changes by a lesser percentage. Elasticities 
can help to understand the impact on demand of actions like taxes and subsidies that change 
prices faced by consumers. For example, Townsend showed the impact of increasing 
cigarette prices on smoking in different socio-economic groups and shows the sin tax is 
highly regressive; and Kondo showed how the vaccine subsidies have little effect on 
vaccine uptake in urban areas, but are quite effective in rural areas in Japan 196,1971 h 
Basic utility theory has been extended by von Neumann and Morgenstern to include 
uncertainty 11981. Expected utility theory states that people make decisions and choices to 
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maximise their expected utility, incorporating the probabilities of the different outcomes. In 
the case of perfect substitutes, for example, expected utility (E(U)) can be represented by 
the following function: E(U)=f (it1x1+it2x2) where n, and n2 are the probabilities of getting x, 
and x2, respectively. This is easiest to think of in terms of entering a lottery, but can also be 
thought about in terms of HIV risk. If we ignore the impact of risk preferences and 
diminishing marginal utility of money, then an individual would enter a lottery if their 
E(U)ente, > E(U)not enter. If it is a fair lottery and five people enter and pay £2 to enter, then 
there is a 20% chance of winning £10 and an 80% chance of losing £2. The expected gain is 
0, on average they are equally well off by entering or not. Expected utilities for condom use 
consider the sure utility loss due to condom use, compared to the expected utility gain 
related to the risk of HIV protection. To use a condom for HIV prevention, the expected 
utility must be greater than the expected utility of not using a condom: 
E(U)condom> E(U)no 
condo. 
Where: 
E1 
"condom- 
Ucondom +E(U)avoid H/V 
The probabilities in this function relate to the probability that the condom will prevent an 
HIV infection (E(U)avojd mv), and thus to the probability that: she is not HIV infected herself 
and her partner is HIV infected; and the per sex act transmission probability. 
However, observed choices are often seen to not adhere to the axioms of expected utility 
theory. Kahneman and Tversky explained this in their seminal paper on Prospect Theory, 
which explains how attitudes towards risk affect choice, with different valuations for 
expected gains and losses 11993. The implication of this for the example above is that 
expected utility of using a condom will be perceived/ evaluated differently if presented as a 
95% chance of remaining HIV negative or as a 5% chance of becoming HIV infected. 
3.2.2. Aggregate demand4 
At the market level, individuals' demand and consumer surpluses can be aggregated to 
obtain the market demand for a good and the aggregate consumer surplus5. However, 
aggregate demand is not simply the relationship between prices and aggregate (or average) 
income, because demand is a function of the specific income levels of individuals. 
Therefore aggregate demand is a function of prices, aggregate incomes, and income 
distribution [201] 
4 Based on Mas-Colell, et. [1995), Chapter 4 `Aggregate demand'12001. 
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3.2.3. Market equilibrium 
In a perfectly competitive market, consumers will continue to trade goods with each other to 
the point where their marginal rates of substitution for all goods are equal. This is a 
competitive market equilibrium [2001. At this point no consumer can be made better off 
without making someone else worse off. This is called a Pareto efficient allocation of 
goods, and is known as the First Welfare Theorem. The Second Welfare Theorem says: 
when consumers have convex preferences as described above, each Pareto optimal 
allocation will correspond to a set of relative prices that represent a relative scarcity of 
goods, and has a market equilibrium. Each distribution of income will have a new market 
equilibrium and new Pareto optimal allocation of resources. When markets are not 
competitive, people are not only concerned with their own consumption, but with that of 
other consumers (externalities). Or if consumers are not price takers, the market may not 
lead to Pareto optimal resource allocations: government intervention may lead to improved 
efficiency. This is discussed in more detail in Section 3.2.4 
3.2.4. Externalities 
Externalities and public goods 
Externalities are direct benefits or harm to one person resulting from another person's 
consumption or production(241. That means that the marginal private cost or benefit is not 
equal to the marginal social cost or benefit, and that the market, left to its own devices, will 
not come to the optimal consumption/production of the good. Often these market failures 
can be rectified by correct assignment of property rights. In the case of public goods this is 
not possible. Public goods are goods that are non-rival and non-excludable. Non-rival 
means that consumption of the good or service by one person does not reduce its 
consumption by another. Non-excludability means that either people cannot avoid 
consuming it, or be prevented from consuming it, or the cost of excluding consumption is 
unacceptably high. Thus all people consume the same quantity of the public good. Left to 
the market, a good with a positive externality would not be provided as the costs of 
provision could not be recovered. The only efficient form of provision of a pure public 
good is public provision, where the cost of providing it can be centrally and involuntarily 
collected through taxes, thereby alleviating the free rider problem. The problem is then 
how much of the good to provide. The efficient level of provision of the public good is 
where the marginal social benefit is equal to the marginal social cost. The total marginal 
s The assumption of additivity only holds for goods with no externalities. 
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social benefit is the sum of the individual marginal benefits, which is the sum of all 
individuals' marginal willingness to pay. 
Although there are a few examples of pure public goods (such as global environment and 
defence at a national level), most goods with public good characteristics also have private 
good characteristics (the air was traditionally cleaner on the west side of UK cities due to 
the direction of the wind blowing industrial pollution eastwards, it is not a coincidence that 
housing was more expensive to the west). Lancaster calls these mixed goods or impure 
public goods [251. He shows that both public and private provision of mixed goods leads to 
inefficient levels of provision, below the optimal level. The socially optimal level of 
provision is accomplished through an appropriately subsidised price, leading to both private 
and public expenditures on the good. However, in the absence of the appropriate subsidy, 
public provision is closer to the social optimum than private provision. 
With infectious disease prevention, this means that a person using something to prevent 
contracting a disease (a barrier method for HIV prevention) will only value the private 
characteristics (benefit) of prevention to themselves and not the public characteristics 
(social benefit) of preventing secondary infections. Therefore the marginal private benefit 
will always be less than the marginal social benefit. This is graphically represented in 
Figure 3-3. 
is 
Quantity 
MPB: marginal private benefit; MSB: marginal social benefit; MSC: marginal social cost 
Figure 3-3 Externalities 
The lower prevalence faced by society as a result of fewer secondary infections is largely 
non-rival and non-excludable (unless abstinence is feasible). The implications of this are 
that the demand for HIV-prevention will be lower than socially desired, and the market 
equilibrium will not lead to a Pareto efficient allocation. This calls for interventions to 
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stimulate demand. Supply side strategies that could play a role in stimulating demand will 
be discussed in Section 3.5. 
Other relevant externalities6 
The externalities discussed above focus on the functional attributes of barrier methods for 
HIV prevention in terms of their disease prevention capacity. Many goods also have non- 
functional attributes which contribute to the utility derived from them. Non-functional 
attributes with externalities are discussed here, i. e. those effects on demand that are 
dynamic and interpersonal in nature. Although often assumed away in economics because 
of their complexities, non-functional attributes have been recognised as an issue since the 
development of the neoclassical theory around the turn of the 20`h century. There are three 
types of non-functional external effects on utility: 
1. The bandwagon effect: where the demand for a commodity is increased due to others 
consuming it (being part of a group, keeping up with the Joneses); 
2. The snob effect: where the demand for a commodity is decreased due to others 
consuming it (showing difference from a group); and 
3. Veblen effect: where demand increases for the commodity because it bears a higher 
price (conspicuous consumption). 
The bandwagon effect is where people want something because specific other people also 
have it, such as `Madonna glasses', where in the 1980's all the teenagers were wearing a 
specific style of sunglasses initially worn by Madonna; another such commodity is the 
washable nappies among `environmentalists'. In health behaviour one can think of trendy 
sports, such as jazz dance in the 1970's, calenetics in the 1980's and Pilates in the 1990's, 
and smoking habits, which are very fashion sensitive. Although using barrier methods for 
HIV-prevention may appear to be a private activity, there is evidence of the snob effect in 
particular related to barrier method use. When the female condom was introduced, it was 
initially targeted at sex-workers. This targeting led to the stigmatisation of female condoms 
as a product used only in commercial sex acts. Thus the targeting (which was not 
necessarily related to use) of female condoms to type of sex act led to a drop in its demand 
for other types of sex acts. Anecdotal evidence of the Veblen effect has also been reported 
in South Africa, where purchasing an expensive condom confers a higher value to the 
sexual encounter. The implications of the snob effect are that consumers need to perceive 
that others in their consumer group are consuming the product (the bandwagon effect), but 
6 This section draws heavily on: Liebenstein (1950) X2021 
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that it is not being consumed by other groups (the snob effect). Another implication is that 
a range of commodity prices may improve welfare solely due to their relative price 
differences. In practice it may be difficult to distinguish the snob and the Veblen effects. 
Marketing has been successful in applying these theories to the practice of product 
differentiation in order to reach different consumer groups, and supplying commodities at 
different prices (i. e. price discrimination, more in Section 3.5. ). We will now move from 
the traditional neoclassical economics framework to Lancaster's theory of demand, which is 
particularly helpful when studying new goods or services. 
3.3. Lancaster's theory of demand 7 
Lancaster's theory of demand was developed in reaction to the concept of goods held by 
traditional neoclassical economics. Traditionally, goods had a circular definition: `goods 
are what are thought of as goods' (Lancaster (1966), p132[251). There was no way to 
account for the fact that some goods were more similar than others. There was also no way 
of predicting preferences and demand for new goods or quality variations. In Lancaster's 
seminal paper `A new approach to consumer theory', he introduced a new notion of goods, 
as being part of a production function of utility, rather than direct sources of utility. More 
specifically, a good is an input providing characteristics, of which the valuation is the 
output, i. e. utility. 
Box 3-1: The essence of the new approach 
1. The good, per se, does not give utility to the consumer; it possesses characteristics, and these 
characteristics generate utility. 
2. In general, a good possesses more than one characteristic, and many characteristics are shared 
by more than one good. 
3. Goods in combination may possess characteristics that are different from those pertaining to the 
goods separately. 
From: Lancaster, 1966, p. 134 . 
This section draws heavily on Lancaster's 1966 paper `A new approach to consumer theory'. 129. 
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The characteristics of goods are objective across consumers, i. e. they provide the same 
characteristics to all consumers, but the valuation of these characteristics can vary among 
consumers. 
The model can be described as follows: 
  Goods (x) or combinations of goods are consumed in activities (y); 
  Activities provide characteristics (z); 
" Utility is a function of these characteristics. 
x=Ay, where A is the vector of goods required for the vector of activities. 
z=By, where B is the vector of characteristics provided by the activities. 
Assumptions are that x has a linear and objective relationship (via vector A) with y, and y 
has a linear and objective relationship (via vector B) with z. Objectivity means that these 
vectors hold for all consumers. 
Utility is then determined by the valuation of the characteristics by individuals U(z). Utility 
has the standard properties of the utility function described earlier, but is indirectly 
determined by consumption of goods rather than directly. The consumer faces the 
following choice, subject to the budget constraint (k): 
Maximise U(z) 
Subject to px <_ k 
with z= By 
x=Ay 
X, y, Z ý 0 
Activities are analogous to services, which are made up of sets of goods and are the source 
of characteristics. This can be simplified by the assumption that goods and activities have a 
one-to-one relationship, such that z=Bx. From here onwards, this assumption will be 
maintained. Utility can be described in terms of goods, and the budget constraint can be 
linked to utility, but only through the transformation of characteristics to goods and vice 
versa, respectively. Central in this approach is the role of this transformation (z=Bx), and 
the properties of B, the transformation matrix also called the consumption technology of the 
economy and consumer behaviour. B is a matrix of constants and z=Bx is linear. These 
properties make it possible to obtain a unique solution to the maximisation problems faced 
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by consumers. The structure of the matrix also formalises relationships between goods, in 
terms of substitutability and complementarity. Intrinsic commodity groups are groups of 
goods and characteristics that have specific characteristics which can only be acquired from 
that set of goods, and that set of goods provides only those characteristics. In this case 
demand for the group can be carried out independently of the market for other commodity 
groups. Within intrinsically related groups, goods can be intrinsically perfect substitutes, 
when the two goods provide exactly the same characteristics in the same proportions 
(although total quantities provided may differ), or close substitutes or complements. 
There are different cases of this model. 1. The number of characteristics is greater than the 
number of goods. Lancaster associates this with simple economies. 2. The `complex 
economy' case is where there are more goods than characteristics. This is the most efficient 
case, as the consumer can choose between the different bundles of goods that satisfy their 
characteristic preferences based on price, and subject to their budget constraint. 3. The 
special case, when there is a one-to-one relationship between goods (activities) and 
characteristics, is the same as the traditional model where utility is a direct function of 
goods. 
As with traditional theory, utility maximisation occurs where the slopes of the `what can be 
purchased' line is equal to the slope of the indifference curve. In this case, what can be 
purchased is not represented by the price ratios, rather the characteristics frontier represents 
the different levels of characteristics that can be purchased, given the prices of the goods 
that provide those characteristics. Figure 3-4 represents the consumers' choice in case 
number 2, when there are more goods than characteristics. e1e2e3 represents the 
characteristics frontier, el represents the maximum quantity of x, the consumer can 
purchase, given the price of x1 and their budget constraint. Combinations of goods on this 
frontier are technically efficient. A combination of x1 and x3 is not efficient, since more 
characteristics can be obtained for the same amount of money from combinations of xl and 
x2 or x2 and x3. Conceptually, the characteristics frontier is equivalent to the production 
possibility frontier in production theory. Consumers can consume anywhere along this 
frontier depending on preferences for characteristics. This consumer would consume a 
combination of x2 and x3 to maximise utility. 
If the price of x2 increases slightly, and the consumer's preferences are convex in 
characteristics, the traditional substitution effect can occur where the slope of e2e3 becomes 
flatter and the consumer consumes x3 in larger proportions than before the price change. If 
the price of x2 rises such that e2 lies below the line ele3i the consumer would switch to a 
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combination of x, and x3. This is referred to as an efficiency substitution effect. In contrast 
to traditional theory, this effect is independent of the individual preferences, and can occur 
even in the absence of convex preferences of characteristics. The consumer can continue to 
consume characteristics in fixed proportions (an L-shaped utility curve) while substituting 
between goods. 
ZI 
0 
V. 
Z2 
Figure 3-4 Optimal choices 
This provides a framework for predicting the impact of introducing a new commodity (or a 
newly differentiated version of a good) at different prices on its own demand and on the 
demand for other goods within an intrinsic commodity group. Assuming the new 
commodity provides slightly different proportions of z, and z2, it can be represented by a 
new ray, x,,. If the price is too high (between the origin and the characteristics frontier), it 
will be dominated by the other goods and not be purchased on the grounds of technical 
efficiency. If the price is outside the original characteristics frontier it will provide a new 
point, expanding the frontier, and the demand for x will depend on consumer preferences. 
If the price was even lower (eL) it could expand the frontier to the point where it replaces x3. 
This model also provides a more flexible analysis of choice under risk. Where expected 
utility theory states that people maximise their utility based on expected returns, Lancaster's 
approach can define characteristics by the different outcomes, such as maximum loss, 
maximum gain, and expected returns, so that people can have different utility weights for 
the different outcomes. 
This framework can incorporate physical product characteristics, but also characteristics 
that are more similar to services, such as characteristics of distribution channels. Data for 
11 Adapted from Lancaster Figs. 1-6 
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estimating the B-matrix (representing consumption technology) and constructing a 
characteristics frontier can either be obtained from revealed market data, or from survey 
data. Chapter 4 reviews methods for estimating consumption technology using preference 
elicitation methods, but first a review of the sociology and marketing literature on the 
uptake of new products is presented. 
3.4. Demand for new products: diffusion and adoption of innovations9 
Lancaster's theory of demand provides a framework for estimating the valuation of 
characteristics of goods and services, and estimating their demand. Early diffusion theory 
puts the demand for new goods into a wider social context. Diffusion is commonly defined 
as: "the acceptance and spread of a new technology in a market or user community" [210] 
The process of diffusion focuses on four areas (in italics). "Diffusion is defined as the 
process by which an innovation is communicated through certain channels over time among 
the members of a social system" [27] An innovation is any idea, product, or practice that is 
new to the person or decision unit adopting it. This is a broad concept as the theory was 
developed by a wide range of behavioural disciplines, including rural sociology, 
communication studies, agricultural economics, marketing, etc. Communication channels 
are usually divided into interpersonal `word-of-mouth' communication systems and mass 
media /advertising. Social systems refer to network interconnectedness, norms, etc. 
The classic model of diffusion was introduced by two sociologists in 1943, who studied the 
adoption of hybrid corn by Iowa farmers [2111. During the 1960s numerous models of 
diffusion were developed, most popularly the adoption curve. The adoption curve shows 
the rate of adoption as an S-shaped curve when plotted as the cumulative number or % of 
adopters over time (Figure 3-5). Key in this model is time and the binary nature of adopting 
an innovation. Either one adopts or one does not. Initially, a small group of innovators take 
on the innovation. As the innovation gains popularity the curve becomes steep, after which 
few additional people (late adopters) adopt the innovation. Adopters are classified by their 
time of adoption, starting with the fastest adopters: innovators, early adopters, early 
[212,271 majority, late majority and laggards 
Three different innovations are shown in Figure 3-510. The first innovation diffuses very 
quickly, and is adopted by many users. The second innovation is less quick to be adopted 
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but also reaches high levels of use. Innovation 3 takes the longest to adopt and levels out at 
a much lower level; it may be considered an unsuccessful innovation [2133. The three 
diffusion phases that can be distinguished by this standard model on the market side are: 
introduction, growth, and maturity [2141. From the perspective of consumer decisions these 
[215, are: awareness, interest, evaluation, purchase, confirmation 5,27J 
adopters 
late adopters 
Innovation 1 
Innovation 2 
................... 
Innovation 3 
early adopters 
.......... 
time 
Figure 3-5 The classic diffusion model 
The rate of adoption is considered linked to the other areas of diffusion mentioned above 
(the innovation itself, the channels of communication, and the social system) with a few 
additions. Rogers and Shoemaker added to these determinants the characteristics of the 
adopters themselves, measured by `innovativeness'[2161. They define this as "the degree to 
which an individual is relatively earlier in adopting an innovation than other members of his 
system.. . By relatively earlier 
is meant earlier in terms of actual time of adoption rather than 
whether the individual perceives he adopted the innovation relatively earlier than others in 
his system. " Rogers also added type of innovation decision and promotion effort of agents 
of change ([27], Chapter 6). The latter is grouped within channels of communication and 
includes supply side efforts to increase adoption, such as advertising. Types of innovation 
decisions relate to the speed with which decisions can be made. The decision to adopt can 
be made at three levels: 1. optionally by individuals; 2. collectively by a group; 3. 
authoritatively by a leader/legislator. Depending on the system, authoritative decisions tend 
to lead to the fastest adoption, followed by optional decisions. Collective decisions to adopt 
tend to be the slowest. Rogers claims that 49%-87% of variation in the adoption of 
9 This section builds on the book: Diffusion of Innovations by E. Rogers (1995), and is supplemented by 
original articles. The original Rogers book dates back to 1962, this newer version is an update and 
remains largely the bible of innovation diffusion. New research about product diffusion builds on this 
seminal work within adapted frameworks for public health, see for example [203-209,68,661 
10 This figure is adopted from Rogers 1995 p11121, and Markus 1987 p495 [211 
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innovations can be accounted for by five general perceived attributes of an innovation ([271, 
Chapter 6): 
1. Relative advantage: The perceived improvement of the innovation relative to existing 
'substitute goods'. " Econo mists would call this the incremental benefit, although a 
lower cost can also fall into this attribute. This is expected to be positively related to 
the rate of adoption. 
2. Compatibility: The extent to which the innovation is perceived as familiar (similar to 
existing goods), to conform to social values and to fulfil the needs of potential adopters. 
The image of the intervention is part of this attribute, including name and product 
positioning. This is expected to be positively related to the rate of adoption. 
3. Complexity: "... the degree to which the innovation is perceived as relatively 
complicated and hard to use. " (t271p242). This is expected to be negatively related to the 
rate of adoption. 
4. Trialability: Whether or not the innovation can be tried. This is high for frequently 
purchased consumer goods and relatively low for expensive durable goods. Testing a 
product reduces the risk and uncertainty about the benefits of a good. This is expected 
to be positively related to the rate of adoption. 
5. Observability: The extent to which the benefits of adopting the innovation can be 
observed. This is an important attribute contributing to the slow uptake of preventive 
innovations. The more observable the benefits, the quicker the rate of adoption. 
Interestingly, Rogers identifies general attributes, while Lancaster leaves them to be fully 
elicited from the potential consumers. However, due to their generality they still need 
operationalising by potential consumers, and are therefore consistent with Lancaster's 
theory of demand. 
Diffusion theory has commonly been applied to model the uptake of technological 
innovations by firms and sellers of new products/services to consumers over time and space 
([211 in [2181). We can distinguish between process innovations aimed at technological 
11 Diffusion theory deals with innovations beyond new products or production processes, incorporating 
education about public health innovations and beyond. To capture this broadness, the literature refers to 
'ideas'. This concept is adapted to the present context of new goods. 
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innovations for firms and their production processes and product innovations targeted at 
[2191 consumers 
The classic model fits conceptually well with much of the early diffusion research done in 
economics and marketing in the 1960s. This focussed on the rate of adoption of process 
innovations, particularly in developing countries. In marketing, much of the consumer 
diffusion research that focussed on product innovations has examined durable goods (e. g. 
Bass, 1969; Krishnan, 1999; van den Bulte, 2000; Tsur, 1990; Ireland & Stoneman, 1986) 
[212,219-2221. This research conceptually followed the framework of process innovations and 
other search goods, where adopters (firms) have an initial investment to switch technologies 
and reap the benefits in following time periods. Adoption is then a binary choice. These 
models include a component of risk related to an investment type purchase. The risk of 
purchasing consumer durables is considered to decrease with information. The inclusion of 
risk involved with the purchase is of lesser importance when analysing frequently 
purchased consumer goods, due to their high triability. However, when the nature of the 
benefits of the products examined combines high triability with uncertainty of effects (HIV 
prevention is not guaranteed); one does not know the full individual benefit of consuming 
the good (low observability). 
One of the most widely applied consumer diffusion models is the Bass model. This model 
looks at consumer acceptance and first purchases of durable goods. On the adoption curve 
the Bass model places sales quantity on the vertical axis rather than the number of adopters. 
This "sales curve" gives more flexibility in terms of applying the model to consumer 
diffusion processes and is more applicable to recurrent purchases, such as barrier methods 
for HIV prevention. This allows the incorporation of different phases of adoption and 
forms of the sales curve. Dodson and Muller show a variation of shapes of the sales curve 
for frequently purchased goods ([2231 p1572-1573, Figs 4-7). They assume the shape 
depends on the trial and repurchase rates and a contact coefficient (Figure 3-6). The contact 
coefficient represents the impact of communication channels, both advertising and word-of- 
mouth. 
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Sales 
Curve A shows the sales curve where the repeat purchase rate is greater than the trial rate, 
with a relatively small contact coefficient, while curve B shows the same pattern with a 
large contact coefficient (this is identified by the slower initial uptake as contact takes time 
to introduce). Curve C shows sales when the trial rate is greater than the repeat purchase 
rate, with a large contact coefficient. D shows this with a small contact coefficient. The 
introduction of the female condom followed sales curves in the forms of C or D, with high 
initial sales that stabilised at a lower rate. The initial peak is novelty or trial sales. 
Consumer diffusion literature also covers the area of supply side strategies for introducing 
new goods. This will be covered in the following section. 
3.5. Supply side strategies to stimulate demand 
Given the positive externalities associated with HIV-prevention and the subsequent use of 
barrier methods, the aim of this section is to look at ways in which intervention can increase 
the uptake of these goods. As shown above, individuals' demand for a product is 
determined by its cost, the (perceived) benefits, and of course their income. Some of these 
benefits are functional, related to the inherent commodity attributes, and others are non- 
functional, related to everything else, including who uses the products. On the cost side, 
direct costs (product prices) can be influenced. Some indirect costs, such as travel costs, 
can be affected by the distribution channels through which products are obtained. 
Increasing the (perceived) benefits of the products has many more dimensions. While 
pricing and distribution channels affect affordability and accessibility on the cost side, they 
also tend to affect perceived quality on the benefits side. In this section, industrial 
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economics and marketing theories are examined for guidance on maximising adoption and 
continued use of barrier methods for HIV-prevention, specifically in terms of increasing 
consumers' perceived benefits. 
3.5.1. Targeting and market segmentation12 
Market segmentation is the practice of dividing a large heterogeneous market of consumers 
into more homogenous consumer groups [225. By doing this, products and marketing 
methods can be tailored to specific groups, in terms of distribution channels, product 
differentiation, promotion, pricing, etc. For firms, the major advantage of this is appealing 
to more consumers, and potentially capturing more of the consumer surplus through price 
discrimination. Segmentation can be based on geographic locations, age, gender, social 
class, psychographic characteristics, and behavioural factors, or a combination of different 
factors. Market segments are identified through qualitative and quantitative studies, 
including conjoint analysis. [2261 From a private sector perspective the effectiveness of using 
market segmentation to target consumers depends on: ease of identification, accessibility as 
discrete segments, size and profitability, and the extent to which differentiated products or 
services can be developed ("actionability"). Although these effectiveness factors mostly 
apply to privately provided goods, the profitability requirement can be interpreted as 
effectiveness in terms of increasing barrier method use and the impact of the increased 
barrier method use on HIV incidence and the wider epidemic. 
Once market segments have been identified, a targeting strategy must be developed. There 
are three main strategies to targeting: 
" Undifferentiated marketing uses a single strategy to reach the widest group, ignoring the 
existence of market segments. This can achieve economies of scale as the level of 
output is greatest and all units are the same. 
9 Differentiated marketing uses differentiated products and services to target different 
market segments. This means developing products/services for different groups, which 
entails additional production costs such as packaging. The advantage is that the total 
sales are likely to be higher, and prices can also be differentiated by target group, 
capturing more of the consumer surplus. 
9 Concentrated marketing focuses on targeting specific market segments, as opposed to 
all segments. 
12 Based on Kotler, [1999], Chapter 911. 
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Each of these strategies has its advantages. New products tend to be introduced in a single 
variety, then as the market matures and demand increases the product can be differentiated 
to meet the different demands of the market segments. Production capacity to produce 
variety must also be developed. 
3.5.2. Pricing13 
In perfectly competitive markets such as those discussed in Section 2.1, all goods are 
homogeneous, and consumers and producers are price-takers at an equilibrium price that is 
equal to the marginal costs for the firms. When a product is introduced, prices need to be 
set and can be a choice variable. In neoclassical economics it has been shown that profits 
are greatest when prices are set where the price elasticity of demand is equal to (-)1 [2271. 
Marketing uses two techniques to set prices [2241. The first method starts at the cost of 
producing the good then uses a mark-up. This is cost-based pricing. Value-based pricing 
starts with the consumers' perceived valuation of the product (willingness to pay) and then 
develops/designs the product such that its cost matches (or is less than) the consumers' 
willingness to pay. Pricing can also take into account the product's price relative to 
competitor's prices for similar goods (competition-based pricing). 
The other issue related to pricing of a new product is product positioning relative to 
substitute goods, which can be done in terms of quality or price. Pricing strategies may also 
change over the life of a product. Market-skimming pricing sets prices relatively high at 
first, selling only to those consumers with a high WTP. Then as time goes by the price is 
lowered step by step, capturing more of the consumer's surplus than through a single market 
clearing price. The opposite strategy is market-penetration pricing, where prices are set 
relatively low, quickly capturing a large market share, thereby enabling further economies 
of scale. This type of pricing strategy will maximise profits only when price elasticities are 
high and there are economies of scale to be achieved. 
Product mix pricing strategies are used by companies that sell multiple products. Such 
companies use this strategy for pricing their different products, either for a segmented 
market, complementary products, optional additions, etc. With product line pricing, a 
company attempts to segment the market by producing a line of goods and matching 
differences in perceived quality with differences in prices. The other types of product mix 
pricing strategies are not as relevant to the current study. 
13 Based on Kotler, 1999, Chapter 16 Iml. 
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Price-adjustment strategies adjust prices for a product to the different circumstances of their 
customers. Using marketing terminology, these include: discount pricing, psychological 
pricing, promotional pricing, value pricing, geographical pricing, and international pricing. 
Psychological pricing was discussed above as Veblen goods, where the price itself has a 
value and is used to signal quality, where quality is hard to assess. This requires that the 
segmented prices match the differences in consumers' willingness to pay and demand. 
Price changes may need to be made in reaction to changes in demand, input prices, or the 
prices of substitutes. This is somewhat outside the scope of this study. 
3.5.3. Promotion (marketing communication) 12241 
There are four main forms of promotion that can be used to communicate the benefit of a 
good to prospective consumers (promotional tools): personal selling/communication, 
advertising, sales promotion, and public relations. Barrier methods for HIV-prevention 
involve intensive personal communication, through health care professionals and sales 
people providing advice, and between women and peer educators. The way in which the 
products are introduced and promoted to these intermediaries is therefore extremely 
important. The other three tools fall into non-personal communication. 
The aim of these communication forms have parallels with the stages of consumer decision- 
making, discussed in the diffusion theory section. In marketing they are defined as: 
awareness of product, knowledge of product characteristics, liking a product, preference 
over substitutes, conviction of preference, purchase of product. The ordering of these 
stages may differ depending on the type of product. Search goods (where most product 
information is obtained prior to purchase) are more likely to follow this sequence, whereas 
experience goods (where the quality of the goods can be learned through use) are more 
likely to be purchased before forming an opinion about the product for repurchase [228]. The 
choice to use a barrier method and which type to use is likely to follow the latter sequence. 
The use of sales promotions can assist in stimulating consumers to try a new product and 
build relationships with retailers. Advertising takes on a number of forms and objectives, 
varying according to product life stage. New product introduction requires informative 
advertising. During growth and when there is competition from substitutes, persuasive and 
comparison advertising is used. For mature products reminder advertising is used to 
maintain interest in the product. 
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Micro-economic theory and advertising 
As presented earlier, consumer theory states that demand for a product is a function of its 
own price, the price of competing products, and consumer incomes. Advertising is 
suggested to influence demand either through a shift in or a change in the shape of the 
demand curve [229], specifically: 
1. Shift in the demand curve: Advertising can entice new consumers into the market 
(increase the total demand) or can lead to substitution away from competitors' products. 
2. Change the shape of the demand curve: advertising can change tastes and preferences. 
This will affect price elasticities. Branded advertising can lead to lower price elasticities 
(a smaller demand response to price changes), while generic advertising can lead to 
higher price elasticities (a larger demand response). High price elasticities increase 
competition within a market and thus welfare, while low price elasticities reduce 
competition and welfare. 
The net welfare effect of advertising are widely debated (23o, 2311 in [232]), [233-237,232,238] 
Marshall ([230) in (2390 identified advertising effects as either having a 'combative role', with 
the aim of decreasing competition by increased product differentiation, or a 'constructive 
role' which increases competition through increased information (increasing welfare). These 
effects are not mutually exclusive, and could cancel each other out leading to a neutral 
welfare effect ([240] in [241]) 
Another view on the manner in which advertising affects demand, by Becker and Murphy, 
argues that advertising does not shift the demand curve, rather it is part of the overall 
preferences of consumers, albeit not necessarily providing positive utility [2331. In this 
framework, advertising is a complement of the advertised good, and is sold to consumers at 
potentially negative prices. An example is television advertising, where the programmes are 
paid for through advertising. Consumers are compensated for watching adverts by being 
provided with free programmes, in sum generating positive utility. They could also watch 
pay television, where there are fees but no adverts. The total welfare effect on a consumers 
is the utility from receiving the advertising (potentially negative) plus and utility from 
increased consumption of the good (positive or it would not be consumed). 
Advertising has been widely used for HIV prevention in South Africa through billboards, 
TV and radio shows, newspaper and magazine advertisements, concerts, and even mass cell 
phone text messaging [242,243. Government has linked up with private sector advertising 
companies to design effective mass media campaigns (2431. These all include messages 
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promoting safer sex, partner reduction and the use of condoms for HIV-prevention in 
particular. 
3.5.4. Distribution channels 
"The channel of distribution is "... all those organisations through which a product must 
pass between its point of production and consumption. " ([224 p 895). The standard 
marketing textbook discussion of distribution channels focuses on private sector distribution 
channels and the linkages between the manufacturer and the consumer, such as the 
warehouse, the wholesaler, and the retailer. Functions of the distribution channel are: 
information gathering and distribution, promotion of the product, contact with prospective 
buyers, matching the product to the buyers needs, negotiation, physical distribution, 
financing, and risk taking. All of these are aimed at facilitating transactions. Traditionally, 
distribution channels were a system of independent firms maximising their own profits. 
Under the control of a mother company, vertical marketing systems (such as franchises) 
work together to maximise the system's profits rather than the profit of independent firms. 
Horizontal marketing systems occur when companies at the same level decide to 
collaborate. Hybrid marketing systems are a mix, and use different systems to reach 
different market segments (consumer groups). This is common in large markets. Some of 
the problems are that the different systems then face competition from each other, and they 
can be difficult to manage. 
Options for distributing HIV barrier methods are broader than the private sector retail 
outlets 14. When dealing with public health goods, the health sector is the most likely initial 
distribution channel. While the final contact in the private retail sector is the sales person, 
in the health sector it is the health care worker. Where barrier methods are left to be 
collected in privacy (either for free or purchased in coin-operated machines), no customer 
service and usage information is available. 
Clinic-based distribution can take place through the public or private sectors. Public 
distribution, clinical or otherwise, tends to provide contraceptives for free or at a nominal 
charge [244j. Public distribution does not need to be limited to clinics; it can make barrier 
methods available at a wide range of locations, such as pharmacies, workplaces, libraries, 
etc. Private clinic distribution tends to have higher prices, yet can provide higher perceived 
quality, 'friendlier' service and more flexible opening hours. Other private distribution 
14 The initial fitting of the diaphragm is the exception as this must be done in a medical setting. 
Thereafter the variable input (spermicide or eventually microbicides) can be distributed through private 
sector channels. 
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channels include supermarkets, pharmacies, and other retailers, and sell commodities at a 
profit. 
Community-based distribution was developed to reach populations that live far from clinics, 
mostly rural populations. Community-based distribution uses community outreach workers, 
and/or peers to provide outreach, as well as information, education and communication 
(IEC), and distribute contraceptives, usually free or subsidised [245,246] Social marketing is 
often considered as a distribution mechanism, but is broader and as such is covered in more 
detail in the next section. 
3.5.5. Social marketing 
Social marketing is the application of private sector tools to stimulate positive behaviour 
change [247» las, 89] The notion of social marketing was first put into words by 1951 by 
Wiebe who asked "Why can't you sell brotherhood like you sell soap? "12491. The idea that 
social change could be initiated using private sector marketing methods has since grown 
into a discipline of its own. One early definition of social marketing is that "social 
marketing is the design, implementation, and control of programs calculated to influence 
the acceptability of social ideas and involving considerations of product planning, pricing, 
communication, distribution, and marketing research" [250] in [251]. Underlying this definition 
is the idea of voluntary change, making adopting the desired behaviour more advantageous 
than not adopting it. Kotler and Zaltman (1971) later formalised the link between social 
marketing and private sector marketing tools (the marketing mix), more commonly known 
as the four Ps: product, promotion, place and price, and defined their meanings in the 
[247 context of social marketing, as follows , 251, Zaaý 
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Box 3-2 The meanings of the four P's as applied to social marketing 
Product: These are the benefits that will be acquired by adopting the desired behaviour change. 
Behaviour change can also include uptake of the desired product and/or services. 'Products' are 
designed or packaged to fit the target consumers' tastes and desires to make adoption something 
that provides tangible benefits to individual consumers. 
Price: These are all costs to consumer, be it direct, indirect, tangible and/or intangible to adopt the desired 
behaviour. 
Place: The distribution and response channels through which motivation can be translated into action. For 
products or services these are the distribution systems and outlets through which they can be 
accessed. 
Promotion: The communication/persuasion strategy to inform consumers of each of the above P's, that is: 
what the benefits are to that specific group of consumers, how it can be adopted and at what 
sacrifice/cost. Though mass media/advertising is most commonly associated with social marketing, 
promotion also includes personal one-on-one selling/promotion, unpaid publicity, and sales 
promotions. 
Underlying each of these activities is consumer/market research and continuous monitoring 
and evaluation to inform and re-inform the design of the social marketing programme (in 
each of the dimensions of the four P's). Consumer research aims to understand the market 
segments. It goes beyond demographic groupings common in public health, to group 
consumers by their current behavioural characteristics, attitudes and aspirations 1247). Based 
on this, the programme can be planned to best increase uptake/adoption among the target 
audience. 
3.5.6. Social marketing of public health products 
Public health products are "commodities that are used for treatment of diseases of public 
health importance or for the promotion of health, which can be distributed through the retail 
level without a `service' attached to them. "42521. All barrier methods for HIV prevention can 
be considered public health products, with their public health importance lying in their 
prevention of HIV, not only for the user but for society as a whole. The positive 
externalities related to their use mean that although there is still a role for markets, the 
market equilibrium will be lower than socially desirables. Market intervention is thus 
expected to improve outcomes ýý [2 . 
However, public health products also have a number of characteristics that support the use 
of the market for their distribution [2521. Most benefits accrue directly to the users 
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themselves (private goods) [252. Within product categories, they tend to be relatively 
homogeneous goods, and generally have low barriers to entry and exit for suppliers [252 
Thus one could argue there might be space for both private and public sector provision. As 
mentioned above, private sector provision may reach just small segments of consumers in 
some developing countries, because private sector condoms are often too expensive for the 
majority. For example, in many countries with very low income levels, there just is no 
private sector market for condoms; the willingness and ability to pay for condoms is too low 
to support private sector provision. The public sector can distribute condoms affordably for 
consumers (free), but can have problems with inconsistent supplies. Quality may also be 
low or perceived as low [2531. Social marketing tackles the space in between private and 
public distribution systems. 
Social marketing organisations use subsidised, usually donor sponsored, products to be able 
to offer public health products at `affordable' prices, but not free. The most popular 
application of social marketing in public health interventions in developing countries are 
family planning and reproductive health, maternal and child health (including malaria 
interventions) and HIV/AIDS[254] , which tend to include distribution of public 
health 
products. 
Although HIV barrier methods themselves would be considered as experience goods (goods 
of which quality can be learned through repeat purchases, which tend to have relatively low 
advertising elasticities because information is primarily obtained through use), demand for 
barrier methods will be more derived demand: people will tend to purchase them as a means 
of purchasing pregnancy and/or disease prevention. In that sense, barrier methods then 
become a credence good (a good of which the quality is rarely learned) [255,256] in [228] 
Other examples of credence goods are car seats, anti-wrinkle creams and vitamin 
supplements. As the quality of credence goods is very difficult for a consumer to assess, 
they rely on other signals, such as price and advertising, to provide information on whether 
to use the product and which brand of the product to use. This is how social marketing 
programmes, by distributing products at a positive price, send out a message that suggests 
higher quality products. 
Advertising by social marketing organisations is usually both generic and brand specific. 
Generic mass media and IEC campaigns aim to promote the use of condoms in general and 
thus to increase the size of the whole market, potentially leading to a crowding-in effect for 
15 See Section 3.2.4 for more discussion of externalities. 
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different brands. Brand specific advertising is used to differentiate products, often on the 
basis of packaging and pricing, and aims to increase a brand's market share (potentially 
leading to a crowding-out effect for other brands). When introducing multiple social 
marketing brands targeted at different consumer groups, branded advertising can also 
increase the size of the market within these target groups, rather than causing substitution 
between existing users of other brands. 
3.6. Applications of theory to current study 
This chapter has reviewed the basic consumer theory in economics, then moves on the 
Lancaster's new theory of demand, the theory of diffusion of innovations from sociology, 
and finally considers the marketing perspective of stimulating uptake of goods. 
The concept of marginal rate of substitution plays an important role in this research. The 
marginal rate of substitution between different barrier method attributes and between 
different distribution channel attributes will be estimated. The foregoing reminds us that, in 
the case of `regular' concave preferences, the marginal rate of substitution will depend on 
the baseline quantities (levels) of each good (attribute), and will change as these baseline 
quantities change. 
Expected utility theory is important when analysing the choice of whether or not to use any 
barrier method. Barrier methods for HIV prevention are used to prevent an uncertain event 
with uncertain consequences. First, it is often not known if the partner is HIV-infected. 
Second, even if he is, it is not certain that transmission will occur in that sex act. With the 
introduction of antiretroviral therapy, even the consequences of becoming HIV-infected are 
uncertain. On the other hand, the immediate negative utility of using a barrier method has 
much less uncertainty surrounding it. Lancaster's theory of demand, where products are 
conceptualised as providing a package of characteristics leading to utility, can also 
incorporate the concept of uncertainty. Lancaster leaves specific characteristics of the 
products open. The diffusion literature suggests five general dimensions of product 
attributes that affect the speed of their adoption. The review of the marketing literature 
shows that it is not only the product attributes that are critical to uptake, but also the 
perception of the product and the systems through which it is distributed. 
This study will contribute to the theory by testing women's consistency with the 
fundamental axioms of economics and with the applicability of diffusion theory and its five 
key product dimensions to the introduction of new barrier methods for HIV prevention. 
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The application of this theory to practically collecting data to estimate utility and demand 
and its analysis is discussed in the following chapter. 
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Chapter 4. Discrete choice experiment methods 
4.1. Introduction 
In Chapter 2, the theory of demand and uptake of new product uptake was reviewed. Here 
different approaches and methodological issues related to designing, implementing and 
analysing discrete choice experiments (DCEs) are reviewed. This chapter is based on the 
following texts: Louviere et al. (2003)[2573, Bateman (2002)[2581, Ryan (2001)[291, and 
Mitchell (1989) [259]. It is supplemented by stated preferences (mainly DCE) literature listed 
in Pubmed either in health economics, policy or services journals or focussing on specific 
topical areas of interest (women, sexual and reproductive health, risk presentation, low and 
middle income countries, qualitative methods in DCE). Given the exponential growth in the 
use of stated preference methods in health in recent years 12601, I concentrate on the more 
recent studies published from 2005 onwards. Ninety-three relevant papers were identified, 
of which 74 applied DCE or conjoint analysis methods, and the remaining 19 were 
theoretical or literature reviews containing no new empirical data. 
This chapter starts by providing a rationale for focussing on DCEs in my thesis followed by 
a discussion of the specific steps and methodological issues involved in conducting them. 
4.2. Methods for studying product uptake prior to introduction 
Methods for studying the demand for goods that are not yet commercially available, such as 
microbicides and diaphragms for HIV prevention, can be drawn from methods designed to 
value non-market goods. The development of these methods started in environmental 
economics, specifically for valuing public goods, such as environmental commodities (such 
as nature reserves and clean streets). Mitchell and Carson provide a clear overview of the 
direct and indirect methods that are used to value non-marketed goods (Table 4-1)[2593. The 
most commonly applied methods are in bold an d are discussed in more detail in the 
subsequent sections. 
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Table 4-1 Behavioural-based methods of valuing public goods 
Direct Indirect 
Observed market Referenda Household production 
behaviour Simulated markets Hedonic pricing 
(revealed preferences) Parallel private markets Actions of bureaucrats or politicians 
Responses to Contingent valuation Contingent ranking 
hypothetical markets Allocation game with tax refund* Willingness to (do something) 
(stated preferences) Spend more-same-less survey Allocation games 
question* Priority evaluation techniques 
Conjoint analysis 
Indifference curve mapping 
From Mitchell and Carson Table 3-2 p. 75 12591; * specific to public goods where tax payer funds are allocated. 
Observed market behaviour valuation methods are also referred to as revealed preference 
methods. They are designed to value existing goods that are not sold, but for which 
opportunity costs can be observed for its consumption. Hedonic pricing estimates the value 
of specific (non-market) characteristics of a good or services by variations of how much 
people are willing to pay for the good or service with its specific characteristics. For 
example, Levy and Quigley used this method to estimate people's willingness to pay for 
quality and quantity of health care services using data from the Ghana Living Standards 
Survey [2611. Another typical example of hedonic pricing is estimating the value of 
neighbourhood characteristics such as cleaner streets by the difference between house prices 
in cleaner and less clean areas [2621. Although in principle this is a method with strong 
validity, in practice the data requirements are very intensive, as sufficient observations are 
needed to control for all other factors affecting demand for a good or service. Importantly 
for our application, the good or service needs to exist. When obtaining observational data 
on preferences is not possible, stated preference methods can be employed. Stated 
preferences are responses to hypothetical markets (rather than observations based on actual 
purchasing behaviour) and can be used on a more experimental basis to estimate values for 
hypothetical products. These methods are discussed in detail below. 
4.3. Stated preference techniques 
As microbicides and cervical barriers for HIV prevention do not yet exist, and the female 
condom is not widely known in South Africa, only hypothetical (also known as stated 
preference) methods can be used. Two methods are commonly used to estimate people's 
preferences for hypothetical goods: contingent valuation and choice experiments (2631. In 
contingent valuation the respondent is asked explicitly about their willingness to pay for a 
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certain good. 16 Advantages of contingent valuation are its relative simplicity, its consistency 
with welfare economic theory. And it generates data that allow for the direct estimation of 
inverse demand curves. The main disadvantage is that it does not give us any information 
about preferences for the specific attributes of the good or service and how uptake may vary 
with different levels of the attributes. As predicting uptake and determinants thereof is our 
17 main interest contingent valuation methods are not discussed further in this thesis. 
The indirect methods need a step in between to link the responses to their marginal utilities 
and willingness to pay. There are a number of different indirect methods for eliciting 
preferences for hypothetical goods. Those involving manipulations of attributes and levels 
have their roots in Lancaster's theory of demand, and in mathematical psychology through 
Luce and Tukey (1964) who first designed "conjoint" measurement [2661. Respondents are 
presented repeatedly with scenarios made up of changing levels of attributes that describe a 
good or service and are asked to indirectly value them, using a range of possible methods 
such as rankings, ratings, and paired comparison and DCE. DCEs let people choose 
between alternatives (sometimes versus the status quo). The advantage of DCE is that 
respondents are faced with trade-offs between product attribute levels, representing more 
closely the choices made in everyday life, rendering them more realistic [2671, and it is 
consistent with random utility theory. 
Frequently in the literature, `conjoint analysis' is referred to as an umbrella term capturing 
different types of conjoint analyses including DCEs and ranking, rating, paired comparison 
[2681. It must be noted, however, that the most prominent researchers in this area do not 
consider DCE part of conjoint analysis Louviere 2000 [269] in Ryan 2008 [2681 and Amaya- 
Amaya (2008) [28j, thanks to its theoretical underpinnings in random utility theory [270]. This 
is also the method that allows estimation of the marginal rate of substitution between barrier 
methods and the valuation of the attributes of different distribution channels. 
16 Alternatively respondents can be asked to accept it being taken away in the case of willingness to 
accept (WTA). As microbicides do not exist, it would be impossible for people to estimate how much 
they would have to be paid to give it up, therefore WTA will not be discussed any further. 
" Uptake predictions have been made using CV and conjoint rating for HIV vaccines, microbicides, and 
STI vaccines 12`4, '23,2631. However, CV does not allow for understanding the specific attributes of the 
product or service that influence rates of uptake. 
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4.4. Introduction to discrete choice experiments'8 
DCE19 is rooted in both Lancaster's theory of demand (described in Chapter 3 and Random 
Utility Theory, and provides values that can be interpreted as marginal benefits. 
Respondents are presented with two or more choice sets (scenarios) and are asked to select 
their preferred scenario. Each scenario represents different levels of a number of 
product/service attributes. The aim of DCEs is to estimate the probability of an individual 
choosing to consume a specific service or set of attributes, x, given their observable 
individual characteristics (socio-economic status) s and the choice alternatives (choice set) 
available to them A, of which x is one of the alternatives: P(x I s, A) Vx EA 20. In doing 
so individuals are assumed to be maximising their utility. Stated the other way around, 
DCE aims to estimate the importance of the observable determinants of utility (the 
attributes of a good or service and individuals' characteristics) in making consumption 
choices. This is derived from their ranking of the alternatives in the choice experiments. 
They are assumed to base their choices on full information, using all the information in 
making their decisions, and to be compensatory in their choices, that is be willing to trade 
off between the alternatives, depending on their attributes and levels. 
Utility, U, in the random utility theory framework can be considered to have a systematic 
component, V, and a random component, c, representing unobserved differences in tastes. 
The systematic utility V derived from the consumption of attributes is based on the 
individual's observable characteristics (socio-demographic characteristics) s and the 
consumption choice alternatives A available to them: U; q = 
Vjq + siq . 
V is the sum of individual q's objective utilities fi of the service/benefit set of attributes of 
alternative i with attributes k and the subjective utilities s of consuming ik: 
K 
Vi9- ELI /3 s. 
Discrete choice models, originally developed by Daniel McFadden, can be used to estimate 
utility values for the different attributes and their levels [2711. These are a family of 
16 This section is based on Louviere (2000) and Bateman (2002). 
19 This type of preference elicitation has been captured by numerous names: conjoint analysis, choice 
modelling, discrete choice modelling, stated preference discrete choice modelling, etc. 
20 The choice set represents all alternative choices that could be made at that given time. These 
alternatives are provided with stated preferences. DCM are also used with revealed preference data, in 
which case the consumers choice set used in the decision making process is not observed and must be 
modelled (Swait 2001, Ben-Akiva 1995). 
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econometric models developed to analyse choice data and can accommodate both revealed 
and stated preference data. Discrete choice models assume that: choices are mutually 
exclusive and the choice that is made maximises utility, given the alternatives available at 
that time. The ratio of two attribute coefficients (ßs) is the marginal rate of substitution 
between the two attributes. When one of these is expressed in monetary terms, it provides 
the marginal willingness to pay for a change in the other attribute. Other outputs that can be 
estimated from discrete choice experiments are: elasticities and cross-elasticities, 
willingness to pay for a specific product (given the levels of its attributes), identification of 
market segments and their group-specific willingness to pay, projection of market shares 
between substitute products, and estimates of aggregate welfare changes. 
Box 4-1 shows the key stages in conducting a DCE study as defined by the major authors in 
conjoint analysis and DCE (based on Green, 1978, Ryan 2001, Bateman 2002, Louviere 
2003, Henscher 2005 [258,272,257,29,273]) Each of these basic texts includes small variations to 
these steps, which are incorporated below. 
Box 4-1 Steps in conducting a DCE 
1. Define study objectives 
2. Conduct supporting qualitative study 
3. Identify/select attributes 
Assign levels to the attributes 
4. Develop and pilot data collection instrument 
Select stimulus presentation: verbal description, pictorial, etc. 
Reduce number of scenarios to manageable level 
Choose experimental design: full versus fractional factorial design and construct choice sets 
5. Define sample characteristics 
6. Choose survey procedure and perform data collection 
Elicit preferences 
7. Test for reliability, validity consistency and other potential biases 
8. Conduct model estimation 
Select a model of preferences P74 
Analyse data using regression technique 
8. Conduct analysis to answer policy questions 
There seems to be one important step omitted: testing for violations of the fundamental 
axioms of economics and other biases. Below I use these stages to provide a framework for 
presenting the methodological issues in discrete choice experiments. The sections are based 
on the texts by the main authors mentioned above 
[259,272,257,29,2731 
, only references 
from 
alternative sources are mentioned. 
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4.5. Define study objectives 
DCEs can be used to address a wide range of questions. Health care and environmental 
applications have obtained aggregate values for proposed interventions to guide resource 
allocation between different services and to estimate the uptake of new services [274]. 
Marketing applications have aimed: to assess how consumers value different potential 
attributes of new products/services to feed into the design process, to forecast demand for 
new products or different promotional/advertising messages and their impact on product 
uptake, to identify market segments and potential for product differentiation (optimal multi- 
product production strategies), and to estimate market shares of substitute products [272j. 
Similar questions have been addressed in the transportation, agricultural and environmental 
economics literature [258]. In health economics, most of the applications aim to value the 
impact of interventions on social welfare. In more recent years there has been a move to use 
stated preference methods to inform intervention development and identify factors that 
would increase uptake [275"287,264,288]. However, the use of DCE to predict uptake of 
services/ products is still rare, since 2005 only five DCE studies were found in the health 
economics literature, [281,283,285,289,290 with actual predictions of the percentages of the 
target group likely to take the product up. 
The objectives of the study will determine the subsequent steps (presented below). 
4.6. Conduct supporting qualitative research to predict uptake 
Consumers may make their consumption decisions based on very different attributes than 
researchers can foresee. The consumer decision process was described by McFadden to 
illustrate that we can only observe/capture some of the variables that influence 
consumption choices. Actual values, perceptions, preferences, and market behaviour 
cannot be directly measured [271]. Several authors stress that the consumer decision-making 
process should be explored in depth through qualitative research to inform the design of the 
stated preference methods (i. e. the attributes and levels and their representation) [291,292] 
Qualitative research can further provide insights into "personal characteristics that affect 
choice, sources of utility differences, choice set characteristics including size and whether 
different decision rules are used and if so why and when. Other issues that may be of 
interest are attitudes that affect demand, substitute and complementary products, etc. " ([257) 
p258). 
Although the literature on stated preferences refers to qualitative research generally, in 
practice it tends to mean interview-based qualitative methods, allowing the respondent to 
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give his/her own interpretation of the issues [293]. This can be either on an individual basis 
or in a group discussion. These two approaches are discussed below, followed by a section 
on qualitative analysis methods. These sections are largely based on Green and Browne 
(2006) and Pope and Mays (2006) [294,295] 
4.6.1. Individual interviews 
Semi-structured and in-depth interviews are widely used in health research both as an end 
themselves and as a means to developing survey instruments [2%, 2971. Semi-structured 
interviews employ a topic guide to discuss a predetermined range of topics but allow for 
divergence when interesting issues are raised by the interviewee. In-depth interviews aim 
to cover fewer topi cs m ore int ensively, with follow-on questions developing from the 
interview itself rather than determined before hand [2961. They further have many 
methodological aspects in common (which are not per se exclusive to individual 
interviews). It is often helpful to start with fairly general and easy to answer questions. This 
helps to establish the type of language to use and to establish a rapport with the interviewee. 
Questions are open-ended to encourage the interviewee to expand on the questions; non 
judgemental and neutral to encourage the interviewee to provide truthful responses and to 
ensure the interviewer is not imposing their own opinions on the interview. Finally 
questions need to be clear and concrete to help the interviewee provide the desired 
information. 
In addition to being a method for eliciting a broad or detailed understanding of the topic 
area, individual interviews can be used to pre-pilot survey tools. For the latter, the research 
question is: is the interviewee interpreting the questions in the way they were intended and 
able to answer in a meaningful way and how best to improve the questions in the survey 
instrument. To such an end the analysis is often far simpler than traditionally undertaken 
analysis of qualitative interviews. 
4.6.2. Focus group discussions 
The focus group discussion moves from a single interviewer-interviewee relationship, to a 
setting where group dynamics are of key interest. Though a moderator is present to guide 
the discussion, but the participants take a very active role in the research [297j. The 
interactions, discussions and debates between participants provide an additional layer of 
information that could otherwise not be obtained (297,2981. It is particularly appropriate for 
identifying cultural/ group norms and attitudes (2981. A group setting can allow for debate 
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and disagreement thus collecting a wider range of opinions than otherwise achievable 
through individual interviews. 
Focus group discussions usually have between 8 and 12 participants [2971 and last between 1 
and 2 hours [298]. It is important to consider how participants are selected and grouped 
together, as this can either facilitate or stifle free lively discussions. Similar to the semi- 
structured interview, a topic guide is used. In focus groups an initial ice breaker is needed to 
start everyone off talking, and similar to semi-structured interviews it is recommended to 
start with general questions and move on the more specific questions, with not more than 
five main questions [2971. These can be supplemented by objects or other relevant materials 
to focus the discussion [298]. The discussion can be brought to a close with a summary of the 
main points. 
Both focus groups and individual interview are best documented using recordings that are 
subsequently transcribed (and translated if necessary) in full [297,298 . 
4.6.3. Analysis of qualitative interview data 
In contrast to quantitative data analysis that starts once all the data is collected, the 
processing of qualitative data starts during collection and tends to be an iterative process, 
where the earlier interviews feed into subsequent interviews [299j. 
Two rigorous approaches to analysing qualitative data in health research are commonly 
used: Grounded theory and Framework analysis [300,301] Grounded theory approaches the 
data with the aim of discovering theory and developing hypotheses, then tests the 
hypotheses in an iterative manner until a saturation of ideas is achieved. This process can 
be very time-consuming. Framework analysis is a structured approach that aims to meet 
specific policy research goals. This entails five steps: familiarisation with the data; 
identification of themes that are both obtained from the data and also predetermined; 
coding of the text/data; organising and summarising the data in a table; and interpretation. 
Slightly less intensive methods of analysis are thematic analysis and content analysis. 
Thematic analysis is a commonly-used method, aimed at identifying themes in the data [3021. 
It entails grouping the data by themes and reviewing the range of concepts across transcripts 
by theme. Content analysis proceeds to count the frequencies of the appearance of the 
themes. 
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When using the qualitative interviews for the sole purpose of designing a survey, even 
simpler techniques can be applied, such as compiling a list containing the range of topics 
raised, however this does miss the richness of such data. 
4.7. Identify attributes and levels 
The method for identifying attributes depends on the study objectives and availability of 
information. Information can be obtained from such varied sources as: literature reviews, 
focus group discussions, individual interviews, direct questioning, or it is determined from 
[258, policy questions or randomised controlled trial outcomes , 303] 
Of the 74 conjoint analysis and DCE applications in health economics since 2005 [304,275,305- 
307,276,308-310,292,311,277,312,278,313-322,279,323-326,123,327,328,280,329][281,330,331,282,332,283,333-335,285, 
286,336-340,289,341-358,290,359-362,265] 
9 16% (12) did not mention how the attributes were 
identified [312-317,325,282,358,290,360,361] Of the 63 studies that did, the most popular method 
was literature review, included in 34 studies [304,307,276,308,310,277,278,318,363,321-323,327,280,329, 
332,283,333,334,285,286,336-338,340,341,344,345,347,353,355,357,362,265] FGDs, IDIs and expert opinion 
were used by 17,18 and 17 studies, respectively (Table 4-2). 
Table 4-2 Frequencies of methods used for identifying attributes 
Literature FGD IDI Expert Policy References 
review opinion relevance 
Literature review 12 3 4 4 4 
[304,307777"Mr=, 277,278,3115,363,321-323, 
327,280,329,332,283,333,334,285,286,336-338, 
340,341,344,345,347,353,355,357,362,265] 
FGD 3 9 1 0 0 [75,307,321-324,326,123.328,330,331.333.337,289, 
352,3541 
IDI 4 1 7 2 0 1292,309,320,335,343,356,359,318,279,334,338,339, 
354,265,277,347,357,322] 
Expert opinion 4 0 2 4 0 PX 306,308,277 319,322,279,281,333,337,339,348- 
348,353,355,357) 
Policy relevance 4 0 0 0 5 1305,275,300, na, 340,342, U9-351,304 
Used >2 methods 7 3 4 7 1 (309,277,333,337,347,357,324 
Total applications 34 16 18 17 10 
The diagonal bolded numbers indicate studies that only use a single method; not-bolded are the numbers of studies 
that used a combination of two methods or more. 
A major challenge is to move from the qualitative interviews, where a wide range of 
attributes tend to be suggested, to a concise and usable set of attributes and levels. Only 17 
studies provided detail on how they subsequently moved from the data collected in the 
preliminary stages to the attributes included in the DCE (318,277,347,275,324,123,289,354,306.349,292, 
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320,335,279,352,3561, although 20 studies did mention that they pre-tested the questionnaire as 
part of the DCE development process 1323,337,332,283,285,278,319,338,265,326,328,325,281,346,339,318,279,352, 
292,3561. Most (15) of the studies that did describe their analytical procedures included the 
collection of qualitative data from either focus group discussions or in-depth interviews. 
These are presented in Table 4-3. 
Table 4-3 Approaches for moving from FGD and IDI data to attributes and levels 
FGD IDI Both # studies References 
Theoretical frameworks 
Thematic analysis 11 2 P18,1231 
Content analysis 22 4 1309,324,335, ges) 
Framework 1 1 P201 
Constant comparative (grounded theory) 2 2 1,2921 
Ad hoc methods 
Ranking exercise 112 [mn, 3541 
List all attributes mentioned 23 [279,3 
Study team consensus 213 [275,354 
realistic ranges for levels 112 [347,3521 
FGD: Focus group discussions; IDI: In-depth interviews 
Note: 5 studies used multiple approaches; therefore the number of approaches is greater than the number of studies. 
A number of different theoretically-based approaches have been applied to analysing the 
qualitative data: content, thematic analysis, constant comparative analysis, framework 
analysis. Equally common were the less theoretically rooted approaches, including attribute 
rankings, collating a list of attributes mentioned to be further distilled down in a next 
iteration, study team consensus and realistic ranges (for levels only). These were often 
done iteratively and in combination X292,352,32o, sýaý 
However, despite acknowledgement of the importance of the qualitative work in designing 
the questionnaire and identifying appropriate attributes and levels for DCEs and the 
mention of analysis methods, few studies have documented the qualitative process in 
sufficient detail to allow the rigour of the methods to be assessed or provide lessons for 
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researchers seeking guidance on how best to move from the qualitative data to a limited 
number of concrete attributes 21. 
Coast et at. (2007) provides the most detailed account of how attributes and levels can be 
identified using qualitative methods based on a case study about access to dermatology 
services [2921. Three iterations of semi-structured interviews were undertaken with 
dermatology patients. The first round was exploratory to find out the aspects of 
dermatology services that were important to people. Based on four interviews constant 
comparative analysis was applied to identify key themes, comparing newly emerging 
themes with themes from previous interviews until no new themes arise (saturation). This 
also provided the basis to develop a coding schedule for further interviews. In the second 
iteration, 11 more interviews continued to explore general preferences but begun to confirm 
issues that were raised in the first iteration. Some attributes (waiting times and provider 
expertise) appearing most important in the first iteration were confirmed in the second 
iteration interviews which allowed for a preliminary search for appropriate levels from 
other sources. Associated trial results and current NHS practice were examined for realistic 
values for waiting times; medical training was considered as a way of presenting expertise. 
These first 15 interviews were coded and analysed using a thematic approach and content 
analysis. This generated the conceptual attributes to be included and a range of possible 
descriptors. In the last four interviews, participants were asked their understandings of the 
different descriptors and the one they felt best described the concept. The most prominent 
definitions were accepted and subsequently used in the DCE. 
This study also raised an important methodological issue of the tension between the usual 
aim of using qualitative research methods to gain a deep understanding versus the 
`reductive' aim of trying to summarise key dimensions of services into a concise list of 
attributes and levels. 
A more practical approach was taken by de Bekker-Grob et al. 1277] in a study of 
osteoporosis treatment. In their two-step approach, the literature was reviewed for all 
potentially relevant attributes and levels of osteoporosis drug treatment, they then used 
individual interviews with medical experts and the target population to obtain rankings of 
the importance of attributes of osteoporosis treatment. 
21 In the contingent valuation literature this is equally rare: Smith (2003) reviewed the CV literature to 
assess the methods used to construct the CV scenario and found a similar lack of transparency and 
methodological rigour 1301. Borghi (2007) has set a precedent in the CV literature explicitly detailing the . [process of developing the CV market using focus groups ý'ý 
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This section has reviewed the recent literature on using qualitative methods to develop 
attributes and levels for DCEs, the next section looks at broader issue of DCE design. 
4.8. Develop and pilot data collection instrument 
Once the different key dimensions of preference are identified from the qualitative research, 
the next step is to pull this together into an instrument that is feasible and comprehensible to 
respondents, and will generate data which can be used to estimate preferences. The steps to 
developing such an instrument are described below. 
4.8.1. Select stimulus presentation 
Attention also needs to be paid to how best to present the scenarios to improve realism and 
avoid responded fatigue and/or overload. There are two issues related to the presentation of 
scenarios. The first relates to the size of each scenario/choice (number of alternatives, 
attributes and levels) and the second relates to the size of the experiment (number of 
scenarios presented). 
Stimuli presentation 
In the previous chapter, the issue of people valuing negative risks differently from positive 
risk (prospect theory) was discussed. The implication of this theory is that the presentation 
of a risk attribute will affect the value that is place on it, i. e. whether the probability is 
presented as a loss or a gain. Concerns about such framing effects related to the presentation 
of the risk attribute in DCEs have been raised by a number of authors [327,366-368] In terms of 
communicating risk in recent studies, a range of presentation styles have been used ranging 
from numerical representations in terms of percentage risk reductions [321,353] or in numbers 
of cases detected or missed (e. g. 55 out of 100) (327] to pictorial representations using 
[317, `humanoids' to represent changes in risks such as shown in Figure 4-1 », 369] 
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Figure 4-1 Pictorial presentation of the uncertainty of benefits and risks of hepatitis B 
vaccines 
Edwards reviewed the literature on how best to communicate health risks and concludes 
that the framing effect should be countered by presenting risk impacts both in terms of gains 
and losses and that a visual presentation can improve risk communication. Recent work on 
this has confirmed the significance of the framing effect on the valuation of risks. Howard 
tested for framing effects in DCE related to presenting the same health outcome in terms of 
a gain or a loss and confirmed that it affected decision making, and thus the estimated utility 
values. Though there does appear to be evidence on the presence of framing effects in 
presenting risk, the range of representations used suggests there is no conclusive evidence 
on the best way to communicate risk in DCEs. 
The debate around the usefulness of pictorial representations and/ or actual physical aids is 
not limited to the presentation of risk. Dahan noted that the use of visual aids may, more 
generally, improve external predictive validity by increasing the realism of the stimuli [3701. 
Jaeger compared presenting apple packages on photo cards with prototype (real) 
presentation and was not able to find that stimuli presentation affected choice results L371ý 
Five studies applied DCE in low and middle income countries [276,324,283,335,2891 of which 
four studies represented their scenarios pictorially. Though not stated explicitly, this high 
rate suggests this may be related to the lower literacy rates in these settings. 
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Scenario presentation 
In addition to the alternatives with attributes and levels, a no-purchase option can be helpful 
in making the choice realistic, however there are two specific caveats to this option. The 
first is that it is an easy option when the other choices are difficult to make [367]. The second 
is that respondents may have different perceptions of the opt-out options' attribute levels. 
This can be overcome by specifying the status quo or opt-out scenario, or by eliciting this 
from the respondent. 
It is recommended that the number of attributes be kept relatively small, i. e. between four 
and six attributes per choice, to avoid information overload which can lead to less valid 
responses [372]. If WTP values are to be elicited then price needs to be one of the attributes. 
It is important that the levels are realistic and practically achievable (2581 p 259). For 
hypothetical goods the relevant price levels can be obtained through pilot contingent 
valuation studies, the literature, or focus group discussions. 
Pearmain remains the most cited reference on the appropriate number of choice sets to 
present and suggests that fatigue sets in between 9 and 16 choice sets [373]. In recent DCE 
applications in health, the average number of scenarios was 11, ranging from 4 to 28. [319, 
321-326,328,280,329,281,331,332,334,335,285,286,336,338-340,289,341,344,346,347,374,375,290] Two studies 
actually test for fatigue effects. Hensher tested for fatigue effects and found no evidence of 
this when presenting up to 32 choice sets [376]. Coast compared estimates in a8 or 16 choice 
sets questionnaire and found not significant differences [3101. Henscher actually found when 
the choice sets were too few (4 or less) intra-respondent variability was insufficient to 
[3761 model individual choices . 
4.8.2. Choose experimental design, construct choice sets, reduce number of 
scenarios to manageable level 
Not only does the tool need to be comprehensible for participants, but there are also a 
number of properties that are desirable for estimation, and will influence the sophistication 
of the models that can be estimated with the data. The experimental design aims to get the 
most information from participants using the least amount of questions. 
The greatest amount of information is obtained from a full factorial design. Such a design 
presents people with all possible permutations. This quickly gets unmanageable. For 
example, if there are four attributes with three levels each, the experiment would contain 
34=81 profiles. However, it is unusual to value every interaction. Studies have shown that 
two-way interactions tend to account for around 95% of variance ([2571, p 94). For this 
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reason, fractional factorial designs select a combination of profiles that allow for all main 
effects and selected interactions to be estimated, and thus greatly reduce the number of 
profiles (and respondents) needed. This helps to reduce the number of profiles (and thus 
choice sets) needed, but the most efficient choice sets still need to be constructed from the 
attributes and levels. However, even with a fractional factorial design, if many attributes 
and levels are chosen, the design can still lead to designs that are too large to be manageable 
for a single person. The solution to this is to break the design into individual size blocks 
(groups of choice sets from the main design). 
Huber and Zwerina identified four key aspects of efficient design: orthogonality, level 
balance, utility balance, and minimum overlap [37]. An orthogonal design is a design 
without any correlation between the attributes, which allows for estimation of preferences 
for each attribute. Level balance means that each level appears an equal number of times. 
If this is lacking, the frequently occurring level will be overemphasised, leading to an 
upward bias on its level of significance ([378.379] in [2731, p143). Utility balance aims to 
generate choice sets that are difficult to choose between, thereby forcing the participant to 
make close choices. This allows for more precise parameter estimates [3801. Minimal 
overlap means having as few as possible attributes with the same level across the 
alternatives. The more overlap there is in a choice set, the less information is obtained. If 
all alternatives have the same level, no information on that attribute can be derived from 
that choice set. 
There are a number of computer programmes that can be used to generate orthogonal 
designs, such as SPSS and SPEED, or they can be based on published optimal designs such 
as those from Burgess and Street 13811. From these design profiles choice sets need to be 
created. When using SAS, the full choice set is generated 13821. 
In practice, the final design of the choice experiment is a trade off between the realism of 
scenarios and technical optimality of experimental design. 
4.9. Define survey sample characteristics22 
The approach to sampling DCE study participants is important to enable generalisation 
from the research. Simple random samples and exogenously stratified random samples are 
commonly used. Random sampling should normally be done through a household survey, 
with repeat visits if needed. More convenient than a household sample is to recruit a 
' This section is based on sections 6.7 and 6.8 in 1271 
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random sample from a central location, or a household survey where households that are 
absent are replaced by a predetermined formula, such as the third household on the left. 
Sample size calculations are made based upon the probability of the different responses and 
the minimum required level of certainty (10% usually). However, this assumes knowledge 
of preferences and choice probablilities prior to the study in which we are trying to estimate 
just these. This is a problem with sample size calculations of any scientific study, and in 
particular when the product category does not exist. 
Because of this, often choice studies have ignored the theory of sample size calculations and 
have chosen sizes on more practical grounds, such as budgets and use an estimate of sample 
size needed to estimate choice models. Henscher states this should be at least 50 per 
alternative [273] if not attempting to estimate any covariates. A method for achieving this 
when it is not possible to make a priori guesses about frequencies of choice is to start with 
an initial quota, which checks the chosen alternative as the data collection proceeds and 
continues increasing the sample size until the minimum sample per alternative is achieved. 
In these consideration about sample size, we are looking for the required number of choice 
responses, rather than the number of people. In general, DCEs use one respondent to 
evaluate more than one choice set. Although this does not conform to the assumption that 
each of the choice responses are independent, it is important to emphasise to the respondent 
that each choice must be answered without taking previous answers into account. However, 
the lack of independence associated with using a single respondent to make multiple 
choices creates wider confidence intervals and lower statistical efficiency. This needs to be 
corrected by using econometric models for panel data, such as random and fixed effects 
models. This is discussed in more detail in Section 4.11. below. 
In the recent literature, sample sizes have ranged from 30 to 2684 respondents with an 
average of 486 respondents, who have been presented with between 5 and 20 choices each 
with an average of 12 choice sets. The average sample size was 5776 observations per 
study. In the 
4.10. Choose survey procedure and perform data collection 
DCE surveys can be conducted using mail, the web, telephone, and face-to-face interviews 
[25'x. Interviews can be pencil and paper or computer-based; each has their respective 
advantages and disadvantages. Mail-based can be cheap on labour, but can have large 
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losses due to non-response. Web-based can be private, potentially allowing respondents to 
be more honest in response to personal questions. Sethuraman found that valuations of 
attributes depicted with visual aids were higher when administered through a web-based 
questionnaire than a paper-based mail questionnaire [383] Telephone surveys can be less 
expensive than face-to-face interviews, and more personal than web-based or mail 
questionnaires. Face-to-face interviews are the most personal but can be highly labour- 
intensive and thus expensive. The advantages of computer-generated questionnaires are 
that they can be adaptive and reduce errors related to skipping questions and errors in data 
entry. However, even very small handheld computers can be quite expensive, and add an 
element of danger for interviewers, especially in areas with less than ideal security, such as 
South African townships. Paper and pencil is simple and safe, but is data-entry intensive 
and subject to human error when completing the questionnaire and entering the data. 
4.11. Assess reliability, validity, consistency and other potential 
problems. 
Questionnaire design is riddled with issues about how to verify whether `true' information 
is being collected. There is much literature on the ideal psychometric properties of 
questionnaires. Usually problems in using questionnaire-based data relate to validity and 
reliability. Reliability relates to how robust a reply is over time and whether the same 
response will be collected if re-asked. Validity refers to whether or not the instrument 
measures what it attempts to measure and is true and accurate (unbiased) 13841. The different 
dimensions of validity are presented in Box 4-2. However, it must be noted that different 
authors refer to these concepts differently, and do not always include all the dimensions in 
their descriptions of validity. 
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Box 4-2 Overlapping dimensions of validity 
Face validity: Is the presentation of the good/ scenario understandable and plausible? 
Content validity. Does it measure all aspects of what we want it to measure? Is the presentation of the 
good/ scenario understandable and plausible? 
Criterion validity: The correlation of a scale with some other measure of the trait under study; ideally, a 
'gold standard'" . 
Construct validity or concurrent validity or convergent validity. Is the measure related to other indicators of 
the same thing? 3871 For example, do the willingness to pay values correspond with real 
prices? (Mitchell and Carson, 1989) 12591) Does the measure converge or is it consistent with other 
measures measuring the same thing (construct)? 11. This is a more practical version of criterion 
validity and relaxes the assumption that there is a gold standard 'true' measurement available 1384). 
Predictive validity (external validity): How well the responses on 'intent to buy predict actual purchasing 
behaviour outside of the studied population. External validity can be tested in a number of ways. 
Natter used three tests: 1. The correlation between model forecasts and actual observation 
(market shares) focusing on price and brand variations, which validates quality of price effect 
estimates, 2. The absolute deviation between average forecasted and observed market shares 
per market segment, which validates quality of level estimates per segment. 3. The mean square 
error between the predicted and observed market shares validating external forecasting 
performance P8M. 
Internal validity: How well does the model predict responses within the study population? MI A common 
test used is the 'hit rate'. The hit rate is the percentage of accurately predicted purchase and 
accurately predicted not-purchase choices for responses not included in the estimation 
procedure. This is often done on choices specifically included in the experiment for this purpose, 
called 'hold-out questions. 
Theoretical validity: Is the measure consistent with the a priori theoretical expectations before conducting 
the survey? Ryan calls this internal validly 12101. This can be tested comparing the expected sign 
of the variable with the sign of the estimated coefficient. 
Some of the more general issues are related to internal and external validity [3891. First, there 
are general concepts based on intuition: face, content, and construct validity. 
A second dimension of validity is associated with measurable outcomes, and examines the 
correlation between a measure and a related concept. This dimension includes criterion 
validity, concurrent and convergent validity. Predictive validity describes how the outcome 
can predict the responses to questions that were not included in the estimation. This can be 
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both internal and external. Internal validity relates to how well the responses hold within 
the surveyed sample (i. e. predict responses within the sampled population), and external 
validity relates to how generalisable the results are to outside the sample [3891 
4.11.1. Biases and other effects 
As well as potential biases caused by the format of the question, there are a few additional 
problems related to stated preference surveys that are not directly linked to the question 
format. Hypothetical bias (also known as scenario miss-specification 13903) arises when the 
scenario presented is unrealistic or is not fully understood by the respondents, leading to 
intent (responses to questions) diverging from actual behaviour. If the sequence in which 
questions are posed influence the response, then we have a question-order bias. Both Scott 
and Day found that the order in which the attributes are presented in the choices influenced 
their coefficient estimates [391,392]. In contrast, Ryan did not find an ordering effect in her 
[270] conjoint rating experiment 
Several biases are thought to be lower in indirect elicitation methods than in direct 
elicitation methods such as contingent valuation, but may still occur. These are: 
Strategic bias, when respondents purposely over- or under-estimates their values in order to 
influence the outcome of the study and thus the price and/or the provision of the good. 
Compliance bias is when people misrepresent their true values to please the interviewer or 
the sponsor of the study. Implied value cues, including starting point bias and range bias, 
[393 implicitly suggest a `correct' answer to the respondent 
Status quo bias or endowment effect arises when the values placed on goods already owned 
or experienced are higher than those not in one's possession or those that have not been 
experienced [394-3961. Moreover, attributes that are unfamiliar or which the respondents have 
not experienced may not be taken into account in the choice process [270]. If this is the case, 
there are implications for the sampling of participants in such experiments, especially in 
health care where this may lead to different valuations of service between patients and non- 
patients. 
Structural reliability - whether or not the number of attribute levels on responses has an 
[3971 effect - was explored by Ratcliffe . She tested this by comparing the responses of 
questionnaires differing only in attribute levels. Responses were compared for attribute 
dominance and differences in model parameters. A third test was undertaken by modelling 
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utility with slope dummies to detect differences in the slopes of the two questionnaire 
responses. Evidence on this was mixed: the attributes with differences in levels received 
higher importance with more levels, however the other attributes were not affected, nor was 
the portion of responses with dominant attributes. 
Another set of problems can arise if the preferences estimated from the responses are not 
consistent with economic theory in terms of adhering to monotonicity, transitivity, stability, 
and completeness (for definitions of these concepts please see Section 3.2. ). 
Violations of monotonicity (i. e. more is better) is observed through lexicographic 
preferences, where there is no substitution between any attribute, i. e. respondents are not 
willing to trade at all, and dominant preferences, where respondents choose a specific 
attribute level every time it is offered 13983. Dominant and lexicographic preferences are 
frequently explored in conjoint analyses with a health services focus, but rarely mentioned 
in studies in other disciplines such as marketing, transport economics and agricultural 
economics. Within the health valuation literature lexicographic preferences have been 
reported in a few studies [399-401] in [402] Studies reported wide variations in the share of 
respondents displaying dominant preferences, ranging from 0% to 48% [394,403' 404,303,3993 
This lack of trading can be due to respondents using 'fast and frugal' heuristics; that is 
simplifying the task to a manageable level by evaluating the choice-based scenarios purely 
on a single attribute rather than on the full scenario presented [4051 Thus one of the basic 
key assumptions is violated. Dominance can also be caused by a hierarchical choice 
process, which is discussed in more detail in the section on model estimation above. 
Another explanation could be that the range of attribute levels included in the scenarios is 
not wide enough to reach the levels at which the respondent is willing to trade (framing 
effects) 14051 . This was shown to 
be a major contributor to non-trading responses 1 1. One 
study shows the contrary can also be the case: Scott suggests that when variation in levels is 
too great, increases in other attributes are not large enough to compensate for the larger 
drop in one attribute level, leading it to seem like a dominant attribute23E21. This shows the 
importance of getting attributes and levels right, and exploring willingness to trade between 
these attributes and levels in face-to-face interviews during questionnaire development and 
the pilot. 
Dominance can be tested by including a profile in which one of the choices is 
unambiguously better than the other. This can range from a choice set where the levels are 
23 Although this may also be seen as the ranges of the other attribute levels being too small. 
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the same for at least one attribute, and the other attribute levels are equal or better for one of 
the options (across-pair monotonicity), to a choice set where all attribute levels are better 
than those in the other option (the dominant pair test). When there is no substitution 
between attributes and levels, marginal rates of substitution cannot be estimated. Most 
empirical applications in health care have included a dominant pair test in their survey. 
Studies report violations of monotonicity between 1% and 27% [407,394,398,408,404,303,409,410] 
Transitivity can be assessed by looking at the utility rankings of the attributes: if a>b>c then 
a>c. If this is shown in the estimates of the preferences, then transitivity holds. Explicit 
exploration of transitivity is rare [411-414] Two studies (van der Pol 2001 and McIntosh 2006) 
have tested transitivity and found it was violated between 6% and 11% [412,414] 
Stability and completeness: If people develop their valuations while undertaking DCE 
surveys their preferences display instability and violate the axiom of completeness [415417], 
one of the fundamental building blocks of neoclassical economics. Stated preference 
surveys force completeness of preferences if they do not include a `don't know' option, and 
thus cannot test for consistency in preferences in terms of completeness [418]. Stability of 
preferences can be tested by repeating one or more choice sets at the beginning and end of 
the survey 14181. Ryan and San Miguel set out to test violations of this axiom and could not 
find evidence that preferences were being formed during the process of completing the 
questionnaire (incompleteness of preferences) [415]. Jaeger argues that training exercises 
may help respondents develop their preferences for more complex and less familiar 
[371] products 
Finally McFadden adds two key issues relating to the validity of choice model estimates: 1. 
Omitted variables in the choice experiment and the estimated model; 2. Selection of a choice 
model 12711. These will be further discussed in the following modelling section. 
4.12. Conduct model estimation 
Traditionally, discrete choice experiments have been analysed using the multinomial logit 
(MNL) model. This model is fairly simple to estimate and interpret and has been the most 
widely applied. However, its validity is based on the relatively restrictive assumption of 
independence of irrelevant attributes (IIA). 
IIA means that choices are not affected by the possible alternatives: the choice between a 
car and a bus should not depend on the availability of a train; if the choice does depend on 
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the availability of a train, then IIA is violated. The implication of this is that the random 
terms in the utility function must be independent between alternatives and have identical 
distributions. 
The nested logit model (NL) and the random parameters logit (RPL) model relax the 
assumption of IIA. Here follows a description of the MNL model, its estimation and outputs 
and justifies the application of the NL and RPL models. 
4.12.1. The multinomial logit (MP4L) model 
Section 4.4. presents the basic MNL model. It presents an individual's utility24 for a choice 
alternative i as made up of a systematic component V and a random component e 
U, =Vi+e Eq. 4-1 
If there is a probability of each alternative being chosen and IIA (see Chapter 3) holds, then 
we can estimate: 
exp V. P. _ Eq. 4-2 ±expVj 
j-1 
and 
k 
Vj9 =I Pik X jq Eq. 4-3 k=1 
where P; is the probability of choosing the ith alternative, and where X are the attributes as 
perceived by individual q, and j is the alternative with k attributes, Vjq is utility of an 
alternative j to individual q with specific attributes (the socio demographic characteristics s, 
above) and levels X. Sometimes these socio-demographic characteristics are presented more 
explicitly, to show V as a function of the product characteristics, X, and the individual's s. 
The impact of s on the choice probability is modelled in generic experiments, like this one, 
by interacting s with X. 
This model, estimated by the maximum likelihood estimator, can then provide estimates of 
the utility parameters, ßs, for the choice alternatives j using the equation above. The ßs of 
those attributes can be added as in the equation above to obtain the utility. 
24 It is important to remember that these utilities are relative measures, and therefore relative to the 
utilities of the other alternatives in the choice set. When using effects coding, the mean utility is set to 0, 
and the parameter estimates of categorical variables are presented as deviations from their means (0). 
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The output also provides a t-ratio for each utility parameter. When significant this can be 
interpreted to influence an individual's choice, i. e. that the attribute is important to the 
decision maker. Goodness of fit for such models is evaluated using the likelihood-ratio 
index (also called the p2 statistic) and an analysis of how well the model predicts the actual 
choices made. However, Train (2003, p) has pointed out that the ratio of predicted to actual 
choices is not helpful as it ignores the whole concept of probabilities and imposes p=1 on 
the alternative with the highest predicted utility. Although the IIA assumption is often 
violated, in the aggregate the MNL model appears quite robust and is the most commonly 
applied model for analysing choices. 
Theoretical expectations and the likelihood ratio test are used to guide the choice of socio 
demographic variables. The likelihood ratio test (LR) tests the hypothesis that the 
restrictions imposed on model parameters are valid [4191. In this case, the unrestricted models 
are those where socio-demographic characteristics are included as interaction terms, and the 
restricted models which constrain the interactions to 0. The MNL model uses maximum 
likelihood to obtain estimates; one of the outputs is the log-likelihood function, which is a 
measure of goodness of fit. The test statistic is: 
LR = -2[1nLr-InLr] 
with a distribution with J degrees of freedom. J is the number of parameters added (e. g. 
the number of restrictions imposed in the restricted model). 
As mentioned above, the main shortcoming of the MNL model [420] is the IIA condition, 
implying a proportional substitution pattern between choices. A second issue with the MNL 
model is that it can only take heterogeneity of consumer tastes into account when they 
correlate systematically with observable variables, the unobservable variations between 
people is not incorporated. This latter can be accounted for with a random parameters logit 
(RPL) model. However, despite these shortcomings, it has been shown that the MNL is 
very robust to these misspecifications and can estimate average preferences satisfactorily 
[273,420] 
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4.12.2. Nested Logit 
The NL model is quite popular as it relaxes the IIA assumption while maintaining ease of 
computation of the MNL mode125. It depicts choices in hierarchical levels with partitioned 
choice sets. Within the partitions (branches), IIA must hold, but between the branches the 
model relaxes the IIA assumption. The nested model can explicitly model `non- 
participation' (the no-change choice) 14211 (Figure 4-2). 
Participate Not participate (C) Branches j 
AB 
Elemental alternatives k 
Figure 4-2 NL tree structure 
Starting from the utility function defined above in Equation 3-1: U; = Vi + e, , the NL 
model allows the variance of E; to differ between the nests, but not within. This means that 
E; is the sum of the unobservable utility at the branch level ej and at the elemental 
alternatives level Ekli . The utilities are then modelled separately at the 
different levels can 
be partitioned into two choices: 1. Participate, Not participate, with an associated utility 
Uj; and 2. If participate, which new barrier method alternative, and its associated utility 
Uklf 
. 
E(J, k) = Ei + Ekpi , 
U(j, k) = Uj + Uk1J and V (j, l) = V! + Vkll 
Basically, the unconditional probability of choosing a specific alternative UJ k is the sum of 
the marginal probability at the branch level PP and the conditional probability at the 
elemental alternative level, p 26 k1J . 
' Some recent applications are 
[421,307,329,362] 
26 Calculation of probabilities from utility parameters is not as straightforward in the NL model. As they 
entail extensive equations it has been chosen not to present them or calculate them. Instead probabilities 
are obtained using the Prob command in LIMDEP. 
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P(j, k) = Pj + PkIi Equation 4-4 NL probabilities 
The scale parameter is the part of the variance of the unobserved utility that is allowed to 
vary between nests (for more detail, see [273] or [4211), and provides the link between these 
levels. The inclusive value is the ratio of the scale parameters of the upper 2j to the lower 
level eck . 
2. 
IV = 
Pk 
For identification purposes, one of the scale parameters must be normalised to 1, this is 
usually done at the upper (branch) level. The IV provides the basis for testing the 
appropriateness of the NL model. The closer to I it is, the closer the levels are to having the 
same variance in their error terms: if it is 1, the model collapses to a MNL model. The 
closer it is to 0 the greater the perceived similarities are between the alternatives within the 
nest. To test if the parameter is significantly different from 1, the Wald test is applied: 
Wald - test ='Vpaeter 
-1 
std error 
with a t-distribution. 
NLOGIT includes a command for generating NL unconditional utilities and probabilities, 
and further specification allows for the retrieval of marginal and conditional utilities and 
probabilities. 
4.12.3. Random Parameters Logit 
The above models estimate average preferences across the sample population. However, we 
know that people's preferences differ, i. e. there is preference heterogeneity. Some of this is 
observed and accounted for by the MNL and NL models above through interaction terms, 
however it is likely that these observable variables do not capture the entire scope of 
heterogeneity. This unobserved heterogeneity is commonly accounted for using the RPL 
model, a more generalised form of the MNL model [305,312,278,323,326,327,281,331,339,346,359]. 
The RPL model relaxes the IIA assumption and can account for multiple observations from 
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respondents, [4221 but it cannot incorporate nested decision making processes27. The RPL 
model accounts for both heterogeneity across respondents' observations and in tastes. The 
model produces a range of coefficient values (preference/taste variations, i. e. marginal 
utilities) in the population using a distribution and standard deviation. 
The coefficient distributions represent different ("essentially arbitrary"t4231) assumptions 
about the form of preference heterogeneity. Popular distributions are normal, log-normal, 
triangular, or uniform. The normal distribution is generally the default and models the 
variation as a function of the standard deviation and is symmetric [423. The lognormal 
distribution is often applied for values that should be restricted to positive values, such as 
WTP values. Triangular distribution is symmetric but models the distribution linearly over 
the range of the values. Uniform distributions are often used to represent distribution of 
dummy variables. Fixed parameters essentially model the parameters with a distribution of 
0. An insignificant parameter distribution coefficient indicates the parameter can be 
estimated without the distribution. 
Estimation is achieved by simulation. However, the calculation of WTP is more intricate 
since it is not just two coefficients being divided, as in the RPL and NL models, but two 
coefficients with distributions around them to obtain a WTP value with a distribution. 
Simulation procedure: In running simulations Halton sequences are more efficient than 
random sequences because they obtain draws that are more evenly distributed over the 
domain of the distribution. This makes the simulation run more efficiently and allows 
convergence to occur with fewer model iterations ([424] in [273], [4251) Generally models with 
more iterations specified are less likely to achieve convergence in more complex models, 
including RPL models with correlations. Train (1999) has shown that 50 draws using 
Halton sequences give less simulation error than 500 draws using a random sequence. 
Henscher, Rose, and Greene, 2005 [2731 suggest 25 draws using a Halton sequence is 
sufficient (p615), though 100 is better. The other advantage is that the same estimates are 
obtained with each model run; with random draws the output will change each time, making 
it very hard to compare different model specifications. 
27 It is for this reason that we will only apply this model to the distribution DCE. Moreover, it will not 
really be possible to change product profiles so the RPL with correlations model would not provide 
additional policy relevant information. 
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4.12.4. IIA testing 
Testing for IIA can be done within the MNL model, or in the advanced models. To test for 
violations of the IIA assumption in the MNL model a test was developed by Hausman and 
McFadden [4261 It involves removing one alternative from the choice set and testing if the 
choice probabilities remain constant. There are two problems with conducting this test. 
First, it assumes a labelled experiment; where removing an alternative means removing 
something meaningful, e. g. removing bus from the transport modes car, bus, train. In this 
case, where the experiments are generic, it does not have any behavioural meaning. Second, 
more than two alternatives need to be in the choice set to be able to remove one and still 
have a choice. Alternatively, one can assume IIA is violated, precede to the more advanced 
estimation models, and test for their appropriateness. To check if the NL model is 
appropriate it is necessary to test whether the branches are necessary. If the inclusive value 
is between 0 and I and statistically significant, the NL model is appropriate. The 
significance levels of the standard deviations of the random parameters are reviewed to test 
for violations of the IM and RPL model. 
4.12.5. Attribute functional forms 
Green raises the issue of how preferences are modelled 1272,4271" The importance of 
these preference models is to guide the choice of functional form for the attributes in 
the equation to estimate utilities. From: Green 1978 and 2001[272,4271 
Figure 4-3 shows three models of preferences graphically and their function forms: 
Preference Preference Preference 
Level of attribute 
1. Vector model 
I 
Sj=Ew, y, 
P'1 
Level of attribute 
2. Ideal point model 
Z d, =w, ( 
, P-xP) 
P. 1 
From: Green 1978 and 2001 [272,427 
Figure 4-3 Models of Preference 
Level of attribute 
3. Part-worth function model 
I 
Si = 
W, 
Yip) 
p=1 
where Sj are preferences for the f` stimulus; Wp are the individual's weights given to the t 
attributes, and Y is the level of the pt' attribute of theh stimulus; d is the distance from the 
ideal point Xp; f is the function of the part-worths. 
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1. In the vector model, preferences are assumed to have a linear relationship with 
attribute levels. 
2. The ideal point model represents preferences where attributes have an optimal level; 
preferences for room temperature might display such a form, tea temperature would 
display the opposite form where hot tea and ice tea are preferred to luke warm tea. 
3. The part-worth model, the most commonly applied model and the most flexible 
because it does not impose a specific relationship, can be converted into the other 
models, and can accommodate categorical attributes. It allows for each attribute 
level to have its own utility. However, this flexibility is obtained at the cost of 
predictive validity and reliability, as many more parameters need to be estimated. 
4.12.6. Data coding 
Effects coding has been used for categorical variables. This means that the coefficients must 
be interpreted as divergence from the mean. To retrieve the coefficient of the omitted 
category, we take [-1* sum (coefficients other levels in attribute)]. Not including a constant 
in the estimation imposes a mean utility of 028 14281. This makes it easier to interpret relative 
values of the marginal utilities. 
4.13. Conduct analysis to answer policy questions 
Most DCE study objectives are linked to specific policy questions, linked to estimating 
social welfare or predicting how products or services would be adopted with different 
characteristics. For these specific analyses are needed. 
4.13.1. Responsiveness of choices to attribute changes: estimation of 
elasticities 
Elasticities can be calculated for percentage changes in the probability of choosing a given 
alternative in response to a percentage change in attribute level. The formula for individual 
level elasticities from the outputs of a MNL model is (2571, p59): 
Epq =ß X& q (5 - P,, 
) where J. =1 
if i=j (direct point elasticity) 
X, kq 0 if ij (cross point elasticity) 
2$ A constant is used for labelled experiments to capture the mean value of the label, however for generic 
experiments this is meaningless since A and B have no useful meaning, and might only capture a 
preference for the left hand side option over the right hand side option. 
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It should be noted that the III) assumption of the MNL model restricts cross elasticities to 
being equal over all alternatives. Models that relax this assumption need different formulae 
for calculating elasticities. An additional issue with elasticities is that they do not make 
sense for categorical variables, because percentage changes have no meaning. In such 
instances the response of a change to a scenario can be found in the marginal effect. The 
marginal effect estimates the change in the choice probabilities resulting from a change in 
the attribute. For example, the impact of choice of transport options if the choice has all the 
same attributes excepting that it was a car rather than a bus, can then be attributed to the 
marginal value of car over bus. 
4.13.2. Market segments 
Market segmentation aims to identify groups of consumers with similar preferences, that 
then can inform the marketing strategy, including advertising campaigns, where to 
distribute and package products and at which price [429]. Market segments can be identified 
either a priori, and tested for relevance within the DCE estimation process by using cross- 
products of demographic or other individual data with the DCE attributes [430], or ex post 
using either a two-step clustering approach where an cluster analysis of determinants of 
estimated utilities is undertaken to identify targetable demographic characteristics or a 
simultaneous approach using ANOVA [4311. Most common is the first approach, where 
suspected co-factors are included into the estimation procedure [4301 The two-step process is 
common in marketing, where consumers are first grouped based on purchase intents and 
product attributes, followed by linking market segments to consumer variables. 
Alternatively, a mixed model ANOVA can be estimated including both conjoint and 
consumer variables and their interactions. For more detail on the estimation procedures see 
Naes [4311. These data can be used to adapt targeted strategies/services for market segments. 
4.13.3. Market shares 
Utilities of the different alternatives feed into the probabilities of choosing a given 
alternative. This predicts the choices of the sample population and the market shares in that 
population. Changes in market shares following the introduction of a new product could 
also be predicted in this way, although this is contested by Louviere who argues that this is 
not possible since values are based on hypothetical markets. [2571 
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4.13.4. Aggregation of preferences for welfare estimation and 
aggregate prediction 
To estimate social welfare and/or uptake at the community or society level, preferences 
must be aggregated. Methods for aggregating preferences to predict choices are: [432] 
" Representative agent: assumes population preferences are the same as sample 
preferences with average population characteristics. 
0 Classification: segments are marketed into relatively homogenous groups, then use a 
representative agent within segments; aggregation is based on weighted averages. 
0 Statistical differentials: builds on the representative agent method by using the observed 
variance in preference to model preference heterogeneity. 
" Sample enumeration: elicits preferences from a 'representative' sample, then aggregates 
based on the sum of the individual predictions. 
However, all of these methods implicitly assume that the consumers face the same choice 
set, when in fact not all the alternatives may be available to them. Genc suggests an 
adjustment to the first three methods to incorporate heterogeneity in choice sets at a 
population level, and shows this greatly improves aggregate demand estimations. [432] 
Lancsar shows that the current methods for estimating WTP and marginal willingness to 
pay to obtain values of aggregate welfare are not consistent with welfare theory and random 
utility theory. More specifically, they are only correct if choices were made with certainty, 
and we know this is not the case [4331 She proposes using a compensated variation approach 
based on a method developed by Small and Rosen 14341 This method estimates the welfare 
impact (WTP estimate) by incorporating probabilities of uptake of the different options; that 
is "the expected value takes account of the change in utility, weighted by the probability of 
choosing that option. " [435] This is shown to lead to much lower estimates of WTP if the 
probability of uptake is <1. Ryan shows that for estimating individual level WTP, assuming 
uptake, the current methods are consistent with theory [4351 However, when estimating 
aggregate welfare implications of policy changes where there are multiple alternatives that 
can be chosen by a population, it is important to consider how uptake may vary across the 
different options. 
4.14. Methodological lessons and research gaps 
The review of the methodological literature shows that discrete choice methods are very 
suitable for estimating the impact of different product and distribution system attributes on 
the demand for new barrier methods for HIV prevention. This method is consistent with 
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economic theory and provides more detailed information on preferences for specific 
characteristics than directly elicited methods such as contingent valuation. However, the 
review highlights the many methodological challenges. The development of the study 
instrument should not be underestimated. Qualitative research among the sample population 
is critical to inform the design of attributes, levels and their presentation. 
The review of methods clarified that the choice of model depends on the empirical data. 
These models will be explored for their suitability to the data and their consistency with 
theoretical expectations. Though the MNL model is likely to generate baseline estimates of 
women's preferences, these are likely to be refined using more sophisticated models such as 
NL and RPL models, which can take hierarchical choices and preference heterogeneity into 
account. 
This chapter has highlighted two key gaps in the literature. Firstly, the paucity of rigorous 
determination of the attribute levels to be used in DCE and lack of guidance applying 
rigorous and systematic methods for reducing the attributes to a manageable number. 
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SECTION II: DESIGN AND IMPLEMENTATION OF THE SURVEY 
Chapter 5. Thesis aims and objectives 
5.1. Introduction 
In order for new female-initiated methods to be most effective, it is critical to facilitate 
women's access to barrier methods for HIV-prevention that suit their situation and needs. 
As soon as effective new methods are found, it is crucial to ensure access to and use of them 
as quickly and widely as possible. This study adapts existing economic methods described 
in the literature review to explore the determinants of women's demand for barrier methods 
for HIV prevention. 
5.2. Aim 
This study aims to understand the determinants of urban South African women's demand 
for existing and new barrier methods for HIV prevention, in order to inform the 
development of strategies for the introduction and distribution of new methods in urban 
South Africa. 
5.2.1. Specific Objectives 
1. Develop methods that can be used to obtain quantitative rankings from women on the 
attributes and levels to be included in the DCE, linking the qualitative focus group 
discussions to the DCE design. 
2. Explore the existence of market segments, and the variables that define them. 
3. Analyse the determinants of women's demand for barrier methods and assess potential 
substitution from the male condom to new methods. 
4. Analyse the determinants of women's demand for distribution and promotion strategies; 
and the interaction of these preferences with women's characteristics and type of barrier 
method. 
5. Use the findings from the empirical analysis to identify key factors to be considered 
when introducing new methods for HIV prevention, and propose introduction and 
distribution strategies for new barrier methods in urban South Africa and elsewhere. 
6. Assess if the relative product. effectiveness' / risk reductions can be portrayed 
satisfactorily to allow women in a relatively low literacy setting to make choices that 
reflect their preferences? 
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Determinants of Women's Demand 
User attributes ie life courselpartner types, etc. 
Technology attributes 
Valuation of physical attributes of 
barrier method 
Distribution 
strategy attributes 
Valuation of distribution channel and 
promotion strategy attributes 
1. Are market 2. What is the impact of 3. How do preferences for 4. What is the impact of 
segments technology attributes on distribution strategy and tech- distribution strategy 
identifiable? substitution and demand? nology attributes interact? attributes on demand? 
Study aim: 
To inform development of introduction strategies and distribution systems 
for new barrier methods for HIV prevention 
11 
Figure 5-1 Framework for studying the determinants of demand for barrier methods 
Figure 5-1 provides an overview of the study and how the components interact. User 
attributes (used interchangeably with individual attributes) include socio-economic status 
and income, fertility desires, sexual partnership types, risk perception, etc...; Technology 
(used interchangeably with barrier method) attributes include: efficacy, price, discreteness, 
insertion time, disposal options, side effects, etc..; Distribution strategy attributes include: 
promotional activities, channel type, provider quality and attitudes, privacy, price and 
opportunity cost, supply reliability, etc. Country level attributes include: income, 
population, HIV prevalence, etc. Cell 1 (Are markets segments identifiable? ) will guide 
policy on the potential identification of user groups with similar preferences to tailor 
introduction and distribution by user groups. Cell 2 will look all predict the uptake of 
barrier methods by new users, as well as substitution between barrier methods by existing 
users. Cell 3 will inform whether distribution strategies need to be tailored to the different 
new technologies. Cell 4 will show where different groups of women prefer to access their 
barrier methods. Together these components will feed into the ultimate policy aim - to 
stimulate women's demand for and access to all HIV prevention barrier methods, through 
the development of improved distribution systems and an introduction strategy for new HIV 
prevention barrier methods. 
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These questions are approached through a number of analyses. Table 5-1 details the steps of 
applying a DCE and how these were operationalised to address our study questions. The 
theoretical underpinnings of DCEs and a review of different methods were presented in the 
literature review Chapters 3 and 4. The development of the survey and the DCE survey 
methods for this study are described in this section (Chapter 6 to Chapter 8). 
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Table 5-1 An overview of the study steps 
Steps Description and where presented 
1. Define study objectives " To estimate women's preferences for: 
o product attributes 
o distribution strategy attributes (Chapter 5) 
2. Conduct supporting "8 focus group discussions, 6 IDIs and 2 attribute identification 
qualitative study workshops (Chapter 6) 
3. Identify/select attributes " Obj 1: Develop method to reduce attributes and levels to feasible 
size. 
oA attribute identification workshop to identify the critical 
dimensions to be included in the DCE (Chapter 7) 
4. Develop and pilot data " Design DCE choice sets (Chapter 8) 
collection instrument 
" Pilot among 100 women (Chapter 8) 
5. Define sample " Sexually active women aged 18-45 in three urban township 
characteristics locations representing different socio-economic strata (Chapter 8) 
6. Choose survey procedure " 1017 face-to-face interviews conducted by female interviewers 
and perform data collection using a paper-based questionnaire with DCE choice sets in a 
flipchart (Chapter 8) 
7. Test for reliability, validity " Assess the generalisability of the achieved sample, and consider 
consistency and other for potential biases in the DCE data (Chapter 9) 
potential biases 
8. Conduct model estimation " ObJ 2: Identify market segments 
o Key socio-demographic variables to include in the discrete 
and choice models 
(Chapter 10) 
9. Conduct analysis to answer " Obj 3: Analyse determinants of demand for barrier methods and 
policy questions their attributes, and substitution away from male condoms 
o The exploration of three discrete choice models (multinomial 
logit, nested logit and random parameters logit) (Chapter 11) 
" Obj 4: Analyse determinants of demand for distribution channels 
and promotional messaging 
o The exploration of two discrete choice models (multinomial 
logit and random parameters logit) (Chapter 12) 
" Obj 5: Inform new bamer method introduction strategy. 
o Discuss the implications of the estimated preferences for 
uptake and distribution of new barrier methods (Chapter 13) 
ObJ. 6: consider the interpretation of the risks presented in the 
DCE (Chapter 13) 
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5.3. Justification of study site 
This study took place in Ekurhuleni, an area of greater Johannesburg, South Africa. This 
site was chosen for a number of reasons. South Africa has hosted a number of new barrier 
method trials and urban areas tend to be 'fast' adopters of new goods and ideas; these two 
reasons suggest that urban South Africa is a likely place for early new product introduction. 
HIV-prevalence rates are high in Ekurhuleni (around 27% in pregnant women) [436. There 
is scope for a range of distribution channels, as market segmentation for many goods is the 
norm in urban areas. There are a number of clinical trials of new barrier methods in 
Johannesburg, so a recruitment area was chosen that was geographically distant from the 
sites of these trials. This was to avoid trial participants receiving potentially confusing 
messages about these new products. The Reproductive Health and HIV Research Unit 
(RHRU) had experience working in this location and Ekurhuleni's population was 
sufficiently large to recruit our study participants. 
Within Ekurhuleni, three locations were selected for the quantitative community survey, 
following a discussion with the Metropolitan Municipality Health Department of 
Ekurhuleni: Zonkizizwe, Vosloorus, and Spruitview. These three neighbouring townships 
were chosen to reach populations with diverse socio-economic status' as identified by their 
housing types. 
Vosloorus was the largest community, with a population of 159,525 (4371. Vosloorus 
contributed 73% (742) of participants of the survey. Vosloorus is fairly representative of a 
South African 'Township", with its range of apartheid era municipal housing, newer 
Reconstruction and Development Programme (RDP) housing (built within Nelson 
Mandela's Reconstruction and Development Programme just after the end of apartheid), 
self-built large homes, and patches of informal settlements. It has two shopping complexes, 
three government health clinics, and a large youth centre. Zonkiziswe is a newer 
community, consisting mostly of `site and service stands' and informal settlements. Site and 
service stands are government provided plots (sites) serviced with a toilet and a water tap. 
The residents build accommodation on the plots themselves. It has a population of 32,070 
and one health centre. Twenty-three percent of interviews were from Zonkiziswe. 
Spruitview is the more affluent of the communities in the survey, with primarily self built 
homes. Its population is 11,262. It has one government health clinic and contributed just 4% 
(45) of the interviews. In all communities, most inhabitants are African. Spruitview has a 
very small population of non-African residents. 
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5.4. Ethics 
It was decided to undertake the community survey in a microbicide trial naive population to 
ensure that respondents were not confused by the hypothetical choice scenarios that 
included product efficacy, which has not yet been proven. There was concern that 
microbicide trial community members may be led to believe that the product they were 
using in the trials would provide some level of protection against HIV, STI or pregnancy. 
All participation in the community survey and its supporting qualitative studies (focus 
group discussions and in-depth interviews) was voluntary and subject to completion of an 
informed consent procedure. All information provided by respondents was kept 
confidential. The informed consent forms for the focus group discussions included an 
agreement that participants would not discuss the input of the other participants outside of 
the group. Signed informed consent forms were kept separately from the questionnaires 
and research outputs to protect the identity of the participants. Participants did not need to 
use their real names in any of the interview formats, and names were not written down on 
any study documents. The interviews were held in a private space to facilitate the 
confidentiality of their responses. Participants in all of the interview types were reminded 
before starting that they could stop at any time if they felt uncomfortable or did not want to 
continue. They were also told that if specific questions made them uncomfortable they 
were not required to answer at all, though it would be helpful if they tried to answer to the 
best of their ability. The value of the reimbursement was chosen as a token of thanks for 
their time, not as an inducement to participate. 
Funding for this study was provided through the DFID/MRC Microbicide Development 
Programme. Collaboration with RHRU, who are experienced with research related to 
sexual behaviour, provided additional support to ensure all activities were conducted 
according to ethical guidelines. This study was approved by the Wits Health Consortium 
Ethics Committee and the ethics committee of the London School of Hygiene and Tropical 
Medicine. 
S. S. Overview of data collection 
A private research company, Progressus Research and Development Consultancy, was 
employed to organise the data collection. This resulted in close collaboration between the 
main researcher, who led the data collection team, and participated in all data collection 
activities. Qualitative research, using focus group discussions (FGDs) and in-depth 
interviews (IDIs), was conducted with the aim of developing the community survey 
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instrument. Subsequently, an attribute identification workshop was held to reduce the broad 
range of attributes and levels to a feasible number for the DCE, and to identify their best 
representation for the community survey tool. Within this community survey, data were 
collected on revealed preferences and willingness to pay using contingent valuation, and a 
DCE. The quantitative community survey provided data for objective 2 to objective 4of 
this thesis. 
The sequence of data collection process is summarised in Table 5-2. In 2004, an early 
exploratory focus group discussion was held with participants of the microbicides feasibility 
study (these women were not receiving any product) to generate ideas for the study. This 
was not formally analysed, but used to get a sense of issues and reactions to the types of 
questions we expected to use. Prior to ethics submission, the draft survey instrument was 
tested at LSHTM among five PhD student volunteers. This, along with colleagues' 
comments, provided feedback for initial changes prior to ethics submissions in London 
(LSHTM) and in Johannesburg (University of Witwatersrand) (see Chapter 8). The main 
qualitative research to develop the survey started after ethics approval. 
Tahle 5_2 The data enlletinn aehedole 
Date Interview type # Interviews # participants 
Aug 22,2004 Pre-test focus group at RHRU 2 8+8=16 
2005 
April 22-25 Pre-Test survey LSHTM PhD student volunteers 5 5 
June 18 FGD Male and female condom use and partner types 2 14+14=28 
June 25 FGD Distribution location and promotional messages 2 12+10=22 
July 2 FGD: New technologies 2 12+12=24 
July 9th FGD: New technologies 2 11+11=22 
July 11,12,13 IDI: Contraceptive histories 3 3 
July 18 IDI: New methods 3 3 
July 23 Key attributes workshop 2 11+11=22 
July 25 Pre-test valuation survey 2 2 
Sept 22 Pilot of community survey and evaluation survey 77 77 
Sep 24 Pilot feedback session 1 4 
Oct 4-31 Survey 1017 
Oct 4-31 Evaluation Survey 42 
In the coming chapters (6 to 8) methods used to develop and implement the survey will be 
described. 
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Chapter 6. Qualitative methods to generate attributes 
and levels 
6.1. Introduction 
At the outset of this study, the literature advised the use of qualitative methods to obtain 
attributes and levels that were relevant to the target group. However, further details of 
which methods to use and how remained fairly vague. This chapter describes the process of 
the qualitative data collection and analysis and the various iterations leading to the final 
design of the DCE. This chapter is a methods chapter, but the methods evolved as a result of 
the outcomes of previous iterations. Therefore, intermediate results will be reported and the 
manner in which they fed into the next iteration of methods and the final survey is 
documented. 
The aim of the qualitative research was to inform the design of the DCE survey instruments 
in a number of ways: 
" Identify the appropriate terminology to use to describe the DCE attributes and 
levels; 
" Explore the structure of choice for physical attributes and distribution system 
attributes (joint or independent, i. e. is this a single choice or two separate choices); 
0 Identify key attributes to include within the different attribute categories (physical 
attributes, distribution channel attributes, promotion strategy attributes); 
9 Explore what may be appropriate formats for the presentation of survey questions 
for a population of relatively low literacy. 
Section 6.2 describes the aims of the qualitative research methods used to collect the 
qualitative data, Section 6.3 presents the results of the qualitative interviews and how they 
contributed to the new iteration of data collection. Section 6.4 discusses the qualitative 
methods and findings. 
6.2. Qualitative methods 
The qualitative research was an iterative process, with the initial interviews (focus group 
discussions and in-depth interviews) starting off with a broad question base, and becoming 
increasingly focussed in order to obtain a feasible yet relatively comprehensive survey 
instrument. 
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The qualitative research can be grouped by the topics to be covered: 
9 Determinants of condom use, partner type terminology (includes partner's influence 
on condom/contraceptive use). 
9 Determinants of distribution channel use, promotional messages 
9 New methods (microbicides and the diaphragm) 
9 Identification of key attributes and levels 
The qualitative research started with rounds of focus group discussion on pre-determined 
topics: the use of male and female condoms and their use in different partnership types; 
barrier method distribution types and promotional messaging; and lastly groups on 
microbicides and the diaphragm. However, the topic guides were revised weekly, to allow 
for learning of how to write a topic guide and incorporation of previous weeks' findings. 
The in-depth interviews explored women's decision-making processes in more detail. The 
decisions around contraceptive and condom use within different types of partnerships and 
the interaction between choice of distribution channel and choice of contraception 
technology were discussed in the contraceptive history in-depth interviews. The `New 
methods' (microbicide and diaphragm) in-depth interviews elicited the women's 
impressions of the new methods, and their desirability and feasibility of use, as well as 
factors that might facilitate the use of existing and new methods. Topic guides can be found 
in Appendix 1.1. 
Although there was flexibility in the types of attributes included in the discrete choice 
experiment, the attributes still had to inform the pre-determined questions: 
9 Is substitution between the different barrier methods to be expected? 
9 What interventions are available to influence the use of methods? The demand for a 
good is a function of the good's price, the price of substitute goods, and people's tastes 
and preferences. With this in mind, we aimed to look at the influence of the direct cost 
of the goods and substitutes, the opportunity costs of obtaining them though different 
distribution channels, and how to influence preferences through promotion strategies. 
The search for critical factors influencing the determinants of women's use of barrier 
methods concentrated on identifying which factors could be changed through specific 
interventions. For example, partner type or power relations within a partnership were 
considered likely to have a strong influence on women's ability to negotiate safe sex. 
Though we can adjust promotional messages or distribution channels to facilitate women's 
barrier method use within different types of relationships, changing gender relations is a 
95 
CHAI'7ER 6. QUALITATIVE RESEARCH METHODS 
much greater endeavour necessitating very different types of interventions. Therefore we 
sought to balance these influential factors, which are recorded in the background section of 
the survey, with those factors and trade-offs that provide direct policy lessons. The 
qualitative research aimed to ensure that the most important factors were included in their 
respective sections of the survey instrument. 
6.2.1. Recruitment for the qualitative research 
Eight focus group discussions and six in-depth interviews took place. Participants for the 
qualitative research were recruited from two sources. The first was from the largest primary 
care clinic based in Vosloorus. Every fourth woman entering the clinic was approached by 
the clinic's community organiser and introduced to the study team. The second was from 
the three communities, where a key informant would approach every 10th door. After a 
brief introduction to the study and the aims of the focus group discussions, data were 
collected from those who agreed to participate on their age, home location and contact 
details. Information sheets were provided to the participants (Appendix 1.2), and eligible 
women (based on age and home location) were invited to focus group discussions or in- 
depth interviews the following week. All focus groups were held within a centrally-located 
health clinic in Vosloorus. Four to five women from each community were invited for each 
focus group discussion. Transportation was provided to women from Spruitview and 
Zonkiziswe to the research venue from a central location in their townships. In-depth 
interviews took place with women who were recruited from Vosloorus, and were held in the 
home of one of the recruiters. 
6.2.2. Focus group discussion procedures 
The study team consisted of a field manager, who organised transport for the women, the 
main moderator, and an assistant moderator, who was responsible for tape recording the 
discussions. In addition there was a translator, who translated the proceeding 
simultaneously into notes that could be read by myself and used to keep up with the 
discussion. 
Upon arrival at the location of the focus group discussion, the female moderator welcomed 
the participants. The information sheet and informed consent form (Appendix 1.3) was 
distributed to participants and the moderator read it out loud. This explained the study and 
the importance of their ideas, input and views. They were asked if they had any questions. 
During the first two focus groups the informed consent questions were completed 
individually with a female staff member. However, due to the length of time this took, the 
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questions were completed in a group during the remaining eight focus group discussions, 
with a staff member reading and explaining the questions. If a respondent answered `No' to 
any of the questions, or there were any remaining queries, they were addressed one-on-one. 
If the respondent answered `Yes' to the question about willingness to participate, then the 
signing of the form was done individually. Once the informed consent (both for 
participation, tape recording and to quote participant anonymously) was complete, 
participants were given a letter from the alphabet to use as their name throughout the focus 
group discussion. This was done to allow for linking of quotes to the collected background 
information (though no analysis on this basis was ever undertaken). Background 
information was collected on each participant and is presented in Appendix 2. 
When all consent forms were signed, the tape recorder was switched on, and the discussion 
began. Participants were reminded that the confidentiality of the discussions meant that 
both the views they disclosed and the views of others would not be discussed outside of that 
group. Women were told they could speak in whichever language they were most 
comfortable in; the topic guides were translated on the spot by the moderator. The 
discussion began with an icebreaker; women were asked to use their `letter' to choose a 
word that described them. Then the topic was introduced. The discussions loosely 
followed the discussion guide and lasted two to three hours. After the discussion, the tape 
recorder was switched off and the participants were offered refreshments. They were 
thanked for their time and input and provided with 50 Rand as a token of appreciation 
(Rand 50 = 4.27 in 2005 UK Pounds). 
All participants of the focus group discussions signed the informed consent document 
(Appendix 1.3) in which they agreed not to discuss anything that was talked about during 
the focus group discussion with anyone outside the room. Transcripts and tapes were kept 
in an office away from the study site; nobody other than the primary researcher and the 
survey team had access to these materials. Although individuals did sign that they agreed to 
be quoted in the publication of data, any such quotations will not be attributable to 
particular individuals and identification has been obscured. All tapes will be destroyed after 
the research has been completed. 
6.2.3. In-depth interview procedures 
Upon arrival at the location of the interview, the interviewer welcomed the participant and 
explained the study in general, introduced the specific topic of discussion, and explained 
why we were interested in her views and experiences. The informed consent form was 
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handed to her and read out loud by the interviewer, who then asked if she had any questions 
(the informed consent form used can be found in Appendix 3.1). Questions were answered 
by the main researcher if the participant was sufficiently comfortable with English, and 
otherwise done in the language of her choice by the South African interviewer. The 
participant was told that she could use any name she would like throughout the interview, it 
need not be her real name if it would make her feel more comfortable. The participant was 
reminded of the confidentiality of the interview, that she could decline to answer any of the 
questions if she wants, and that she could stop the interview altogether at anytime. If the 
participant was still interested in participating in the interview then she completed the 
informed consent form on her own or with assistance from the South African interviewer. 
The participant was offered tea, the tape recorder was switched on, and the interview 
started. The interviews loosely followed the discussion guides (Appendix 3.2), allowing the 
interviewer to pursue relevant topics and tended to last one to two hou rs. After the 
interview, the tape recorder was switched off and the participant was provided with a token 
of appreciation / reimbursement of travel costs of Rand 50 (= 4.27 in 2005 UK pounds). 
6.2.4. Qualitative analysis 
Qualitative analysis of the transcripts happened concurrently with qualitative data 
collection, allowing data to feed into subsequent interviews. Each week one topic was 
covered in the focus group discussions. The first four rounds of focus group discussion were 
analysed using an adapted version of framework analysis. This entailed five steps: step 1: 
familiarisation with the data; step 2: identification of themes that are both obtained from the 
data and also predetermined; step 3: coding of the text/data; step 4: organising and 
summarising the data in a table; and step 5: interpretation. Within the same week the first 
three steps of framework analysis were completed. After the first round of focus group 
discussions, a coding frame was developed by a senior researcher with expertise in 
qualitative research (Catherine MacPhail). After the first six focus group discussions and 
the first four in-depth interviews, an interim analysis was performed (completing step 4 
above, organising the data) to determine the attributes and levels to be in the attribute 
identification workshop, which is presented in the next chapter. 
These attributes were also compiled into a draft valuation questionnaire which was tested on 
two participants in the form of in-depth interviews. Further formal interpretation was not 
done within the scope of this thesis, as it was not expected to further contribute towards the 
design of the survey instrument. However analysis of this data using Framework Analysis 
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was later undertaken by Catherine MacPhail; the paper resulting from this analysis can be 
found in Appendix 4. 
The qualitative data also provided insights into the subsequent interpretation of the survey 
data; for example, the meaning of parameters of composite attribute levels such as the 
diaphragm, which embodies a number of implicit attributes and levels. 
6.2.5. Issues regarding recruitment and participation to the focus group 
discussion 
Though most focus group discussions went as planned, a few things should be noted. Two 
of the recruiters decided to participate in a focus group discussion. One woman tried to 
participate in more than one focus group discussion, but was recognised by one of the 
moderators and told that was not possible. At one time it seemed that some of the 
participants had been recruited from a support group for people living with HIV/AIDS. The 
community health nurse from the clinic, who had been involved in participant recruitment, 
was talking about the group to two participants before the focus group discussion started. It 
was felt to be unethical to subject women who were already infected with HIV to 
discussions/interviews about HIV-prevention without their prior knowledge. Following 
discussions about this with the chairman of Wits Ethics Committee, the consent form for the 
community survey was revised to include the statement: "Since this survey is about HIV 
prevention, some women who already know they are HIV-positive have chosen not to 
participate. However, women of all HIV status' are welcome to participate". Qualitative 
results 
This section reports the outcomes of both the focus group discussions and the in-depth 
interviews that took place between June 18,2005 and July 18,2005. As the range of topics 
covered were the same, the outcomes from both types of interviews are reported together to 
allow both to feed into the understanding of women's preferences for product attributes and 
their distribution and promotion. 
6.2.6. Product attributes of importance 
To understand some of the important defining attributes of existing and new barrier 
methods, women were asked: 1. to describe male and female condoms to someone who had 
never heard of them; 2. after being shown a gel filled applicator and diaphragm, 
respectively, what would they want to know before trying it. Below the attributes are 
summarised with associated illustrative quotes on why they were considered relevant. 
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HIV prevention: Partial effectiveness did seem understood once explained and clearly 
affected women's use intentions. After an example describing a 50% effective diaphragm 
relative to a 95% effective condom: 
"1 would use a condom because it has more percentage" (18-29 year old, 
diaphragm discussion). 
Women also acknowledged that even a partial effective method is better than no protection: 
"At least you have that 50% of being protected, it's better than nothing. " (30-45 
year olds microbicide discussion) 
Pregnancy prevention: As current HIV prevention barrier methods also prevent pregnancy, 
it was thought that some women would consider this a negative attribute. However, this was 
only raised once: 
"I still want to fall pregnant ... and there is no way that I can fall pregnant and you 
are scared and you want to protect yourself against HIV. There is no other way is 
either you stay without a child or you risk your life you see that. " (40 year old, new 
methods in-depth interview) 
Among the younger women there was a suggestion to stop using hormonal methods, even 
that they should not be distributed at all, because younger people then would be more likely 
to use condoms, since they are more scared of pregnancy than HIV. Descriptive of how, if 
new products prevent pregnancy, would allow w omen to introduce them with a more 
"acceptable" excuse for using prevention: 
"The thing that can make him change is he is afraid of children, because I said 
that the doctor said I shouldn't drink pills and now I must use condom, because he 
is afraid that I will get pregnant, he says that the support is too much because he 
should buy food he inserts it for that sort time and use it because he is afraid of 
support he says it is too much. " (30-49 year olds, condom discussion) 
STI prevention: This is considered an intrinsic attribute of condoms: 
"This condom makes it possible that we should not get STI's, we protect diseases 
like infectious diseases and burning urine. " (30-45 year olds, condom discussion) 
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Secrecy: The ability to use without their partner's knowledge. This came up over and over 
again as critical. 
When I use a [female] condom as a female, I'm protecting myself from an 
unfaithful partner who pretends to faithful and it will safe me from, as we know 
that people are raped, I wont get sexual infections, and thirdly it will help me not 
to get pregnant, and I will be a happy woman because I know my secret, I have a 
female condom so I'm not afraid of anything I will be free... " (30-45 year olds, 
condom discussion) 
This attribute is discussed in much more depth in the paper in Appendix 4. 
It is interesting to note that there was an expectation of lack of cooperation by men. Men are 
reported to generally oppose the use of contraception, and show an even higher resistance to 
condom use, especially among the older women. 
"We don't use anything with my husband because he is thick skinned he doesn't 
want to know about the condom and he doesn't want me to use contraceptives and 
he doesn't want me to use anything and now we have seven children. " (30-45 year 
olds, microbicide discussion) 
Reliability: Bursting is a problem with condoms, and the diaphragm looked stronger. 
"I think I would use diaphragm because condoms bust at times" (18-29 year olds 
diaphragm discussion) 
"I prefer a diaphragm it is stronger than a condom " (18-29 year olds diaphragm 
discussion) 
Side effects: There were questions about side effects such as rash, damage to self or partner, 
and cancer. 
"I want to know is when they want to introduce this gel, don't they think that it 
might cause some problems in the womb like womb cancer? " (30-45 year olds 
microbicide discussion) 
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Comfort: Issues were raised related to comfort of new products and discomfort associated 
with existing options. Referring to the female condom: 
"I once put it in because I wanted to see if its working and the time I inserted it I 
felt so uncomfortable I just wanted to remove it out. " (40 years old, new methods 
in-depth interview) 
"I want to know is it [the diaphragm] comfortable when walking" (18-29 year olds 
diaphragm discussion) 
Insertion and removal time: There were questions about when to insert a microbicide and 
how long a diaphragm can be worn? One participant counselled another on wearing a 
female condom for extended hours. 
"You know what, if you constantly keep it in your mind that you have something 
in your vagina it won't feel comfortable, but if you don't even consider that and 
you are bold about what you've done you wont feel anything and you'll be fine. " 
(30-45 year olds, condom discussion) 
Ease of use: The female condom was considered complicated to insert. 
"The first time I saw these female condoms I got scared because they are long, 
and I thought that am I suppose to insert that on my vagina, and when I looked at 
those instructions that I must help my partner to insert his penis proper inside 
because of this outside ring, I felt that it was too much for me, I don't want lie to 
you. Every time when I look at this condom I even become frightened of using it, 
I'm really scared but I'll try my best next time. " (30-45 year olds condom 
discussion) 
Sound: The female condom was considered noisy. In response to why she did not want to 
use the female condom again: 
"It's that uncomfortable feeling that I had and it's a little bit noisy it's like... its 
disturbing a bit. " (40 year old, new methods in-depth interview) 
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Initial identification of key physical attributes and potential levels 
From the focus group discussions, a long list of important physical attributes were 
suggested making it difficult to identify the most critical attributes for decision making. 
However, HI V prevention, pregnancy prevention, and secrecy appear the most critical 
issues for women. Knowledge of the current trial expectations and discussion with experts 
then provided the potential levels for these attributes. The microbicide trial related to this 
study is powered to identify a 30% difference in effectiveness over and above condom 
promotion. A diaphragm without gel was estimated to have 55% to 75% effectiveness in 
preventing pregnancy (personal communication, Naomi Lince, Ibis Reproductive Health). 
Secrecy only has two feasible levels. 
HIV prevention: 35%, 55%, 75%, 95% 
2. Pregnancy prevention: 0%, 55%, 75%, 95% 
3. Can be kept secret from my partner: Yes, No 
6.2.7. Distribution channel 
There was a pair of focus group discussions specifically on distribution channels for 
existing barrier methods. The main questions was: "Where do you/ can you get male/female 
condoms"; Such a question really elicits a list, so was then followed up by: "What makes 
you prefer one place over another? ", which was more conducive to discussion. Women 
were further asked if they would like to get female condoms in different places than male 
condoms, and for the new barrier methods they were asked where they would like them to 
be made available. In the contraceptive history interviews, women were asked where and 
why they collected their contraceptives from different sources throughout their lives. 
There were many attributes of clinics that were considered favourable to women. Clinics 
distribute products for free, are often located conveniently in the locations, and women have 
additional reasons for attending clinics. 
"At the clinic when I think everybody will go there because when you take the 
baby for check up you will get it and whatever you are going to do at the clinic 
you will get it. "( 30-45 year olds, microbicides discussion) 
"It is a place around our section where we stay and we go there every time as 
woman because I think as woman it [female condom] should be available for 
woman. " (30-45 year olds, distribution and promotion discussion) 
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"I'll prefer a clinic because it is for free" (18-29 year olds, distribution 
discussion) 
"At the clinic its free you don't have to pay money even when I had medical aid I 
didn't go to a private doctor, beside that the clinic is closer. " (age 41, 
contraceptive history in-depth interview) 
The clinic was also considered trusted, for example to not distribute expired condoms. 
"The clinics won't give you unsafe things like condoms I disagree they wont give 
you unsafe condoms. "(18-29, diaphragm discussion). 
When obtaining products in the consulting rooms the clinic was also associated with 
privacy. 
"Personally I would prefer to get them from the clinic because there is privacy. " 
(30-45 year olds distribution discussion). 
Reliable supply was also considered important. Fir example, referring to male condoms: 
"There are no times when you won't find condoms at the clinic, they are always 
available. " (30-45 year olds distribution discussion). 
However, clinics were not universally preferred. Younger women in particular mentioned 
the nurses could be unfriendly or judgemental. On nurse unfriendliness: 
"In clinics the nurses are too judgmental if you are taking a condom they will ask 
you are you using a condom even if you go to a person you'll be judged" (18-29 
year olds, distribution and promotion discussion). 
Other advantages of non-clinic distribution were time and trust in the product: For young 
people: 
"Clinics are always full and everybody is going to stare at her that she's taking a 
condom" (18-29 year olds, distribution and promotion discussion) 
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"I think those condoms that they are selling they are fine because they are 
available for everybody but for those who are working. Personally I think they 
are stronger than those free ones and they are safe. " (30-45 year olds, 
distribution and promotion discussion) 
"There are people who are very busy working hard then they don't have time to 
go to the clinic [to get microbicide gel]. And the clinic, there are queues and you 
wait for a long time" (30-45 year olds, microbicides) 
This also was highlighted in one of the in-depth interviews that the clinic takes a lot of time, 
whereas private providers are much faster. In deed, this seemed to be the main reason for 
going private (in particular for those with medical aid [health insurance], which means the 
price they face is equal between either location). 
Non-clinical distribution channels were also frequently mentioned, with much more diverse 
opinions. At the chemist, women have to pay for goods, it can be further than clinic, can 
have older people serving which can be unpleasant for younger women. 
`I'll be afraid to buy them in the chemist because I'll find a person who is older 
than me so I can rather get the free one's than buying. "(18-29 year olds, 
distribution) 
The quality perception varied widely, with some indicating that the chemist provided better 
quality products because you pay, and others saying that they might be willing to sell 
expired condoms. Hospitals were identified as helpful distribution outlets because they 
could be visited under the pretense of visiting friends, rather than to access services for 
herself. 
"We were getting injections at Baragwanath [hospital] because we didn't want 
people to know we were on contraceptives so we would pretend as if we were 
visiting one of our friends who is sick in Baragwanath" (33 year old in 
contraceptive history in-depth interview) 
Distribution through family planning clinics was considered a good way to keep men in the 
dark about the existence of these products. 
A number of non-medical outlets were also suggested: 
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" Library: 
"*interviewer: Library and why library? 
*A: Because most of our young stars they utilize the library often then it will be 
easy for them. Some of them they are scared of going to the clinic so may be at 
the library they can get what they want. " (30-45 year olds distribution discussion) 
9 Garage: good because it is anonymous, and: 
"Because of the service hours are okay, " (30-45 year olds microbicides 
discussion) 
9 Hotels in the rooms, and dressing tables: 
"I prefer the once in hotel because that is were I spend most of my time and 
you find them [condoms] there and I think they are not the same as the one in 
the Hospital they can be the same with the ones we buy in chemist so you find 
them there. " (18-29 year olds, distribution discussion) 
This represents both convenience and the type of condom distributed associated with 
better quality. 
" Home delivery: For privacy: 
"If I go to buy in a chemist and I find an older person maybe she's my 
neighbour I'll be afraid to go there and buy a condom or to a person who 
knows me also in clinics I'll be afraid of older people obviously if I take 
condoms that means I'm sexually active that is why I prefer that they should be 
delivered at home. " (18-29 year olds, distribution discussion) 
9 Police station because it is open 24 hours. 
" Taxi ranks are associated with a lack of privacy, but it is also a location where most 
people pass through at some point in the day so is convenient. 
" Shops: There were mixed views on quality of shop bought condoms relative to those 
provided freely in the clinic. 
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"The ones you buy even if they expire the owner won't remove them from display 
because he doesn't want to loose profit. " 
"they stay for long time there and expire" 
"the ones we buy in shops are in good condition the one's in clinics I don't trust 
them" 
"The ones in clinics bust I prefer the one's in shops they are harder. " 
(both age groups, distribution discussion). 
However, shop distribution is not only about quality of condoms, but can also be a 
comfortable way to collect. 
"They can place them at the window, after buying something you can take some 
for yourself. " (30-45 year olds distribution discussion) 
" Public Phones: "because everybody goes there " 
Although less frequent, the participants further suggested the following locations: public 
toilets (at taxi ranks and garages, workplaces, beachfronts); bottle store (liquor store); 
shebeen; hair salon; work places; schools in the classrooms; nightclubs; movies; in large 
gatherings. 
Attribute levels for further consideration 
Proximity to home or work was also considered important, irrespective of the type of outlet. 
Levels could be related to time (e. g. walking distance) or related to the transport costs (e. g. 
1 taxi ride away, 2 taxi rides away). 
Price is important; women reported that if they had no money and or the price was too high, 
they will expose themselves to risky sex. 
"I think the fact that you have to pay for them takes us back to the times where 
women were oppressed I can't get them for free but man can get them for free and 
we are the one's who are most at risk because we know, as we know we you hear 
from your man if he says he wants it today and he'll get it so it's better if you get 
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female condoms because if he wants it and he gets it you are protected! " (18-29 
year olds distribution discussion) 
However, a purchased condom was also associated with having higher reliability, being 
stronger and safer. 
"I prefer the one you buy because as they say you must not put a condom in a 
sunny place and at the clinic sometimes it is hot and there are no air conditioners 
and they are staffed and melting but the one's in shops they are I cool place so 
they are okay so I prefer the one's you buy. " (1 8-29 year olds distribution 
discussion). 
Since distribution channel type are so closely linked to payment and time, with clinic 
always associated with free products and long waits, and chemist and stores with paying for 
products and more rapid service, options to try to disassociate these were explored: 
" How to collect product: from a discrete box or machine, collect from shelf and pay at 
cashier, request from behind counter, need individual appointment. 
" Waiting time, or distance to outlet. 
The need for technology adapted distribution strategies 
The interaction between the different products and how they are distributed is explored 
here. 
Female condom specific issues: For female condoms it was not generally felt that the 
distribution channel would need to differ from male condom distribution locations: 
"how are we suppose to protect ourselves if we can't get an access to condom so 
I would prefer if there [Female condoms] were in clinics and everywhere as 
male condoms. " (18-29 year olds distribution discussion) 
Generally, women expressed concerns about the scarcity of female condoms; in the study 
location, clinic providers rationed the distribution of female condoms to two per woman at 
any one visit and women stated they were expensive from the pharmacy. This led to limited 
use. They also expressed a lack of information on use and re-use of the female condom. 
Additionally the higher price was considered a barrier to use: 
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"But the problem is when it was introduced we were suppose to buy it, only to 
find out that the male condoms was free, I think that if it was introduced like that 
of the males, maybe a lot of women would have adjusted their minds to using the 
female condom, but you find that if a person is unemployed and at home where 
would you find the money to buy the female condom, we always say will lets use 
the male condom, but if the government can sympathize and avail female 
condoms the same as the male ones, maybe it can help to adjust our minds to use 
this condom" (18-29 year olds condom discussion) 
Microbicides specific issues: There was some debate. Many said they should be widely 
available like condoms, others said if they are available at the Spaza shops then men will 
find out what they are and women will loose their secret. 
Diaphragm specific issues: Sharing came up a number of times in one FGD. The group 
thought that the advantage of having to have it fitted is that you would not be able to share 
it: 
"Oh this is not like a condom like you can take any. This one you have to go to the 
doctor and he will measure you and find your size so you won't go around lending it to 
other people. " (30-45 year olds, diaphragm discussion). 
There was also more concern about the implications of a free diaphragm on people taking 
care of theirs since it was a durable product, and the issue that if they pay for it they will 
trust it more. This in contrast to what many women were saying about the price of the 
female condom being a barrier to even trying it. 
The negative impact of too broad distribution channels was mentioned. Women suggested 
only making the diaphragm available at family planning clinics, so that it can be maintained 
as a woman's secret. 
Conclusions on distribution channels 
Respondents were very positive about the clinic as a distribution location, but these 
opinions might have been biased, because the focus group discussions were held in the 
clinic, and some participants were recruited at the clinic and/or recruited by the community 
health worker from the clinic. 
109 
CHAPTER 6. QUALITATIVE RESEARCH METHODS 
Based on these findings, it is clear that it is very difficult to disentangle payments and 
distribution channels: women associate clinics with free products, and stores and pharmacy 
with payments. Distribution channel attributes that were important were: Price (payment or 
free services), privacy, perceptions of quality of products provided by different sources 
(varies widely between women), waiting time, and travel cost/distance. 
Given this, the potential levels for describing distribution could be: 
Type of facility: 
  Medical (e. g. clinic, GP, pharmacy, hospital) 
  Non-medical (e. g. store, public toilet, public phone, taxi rank, library, police station, 
shebeen, hair salon). 
To try to separate out aspects of delivery that were less setting specific, the following 
options for collection were developed: 
  Collect from box or machine 
  Request stock in public from person behind counter (receptionist, pharmacist, 
store owner, etc. ) 
  Request from person in private space. 
6.2.8. Promotional messages 
As the second part of the distribution discussion women were asked to put themselves in the 
position of a nurse or shopkeeper assigned the task to sell either: male condoms, female 
condoms, microbicides, or the diaphragm. They were then asked what the best advertising 
message would be to attract women like themselves to buy each product. The male and 
female condoms were discussed sequentially in the same focus group discussion, the 
microbicide and diaphragms were discussed each in the separate groups. 
Though the vast majority of messages evolved around HIV, STI and pregnancy prevention: 
"*F: Personally I can say diaphragm it is three in one. *INT: Why three in 
one? *F: Because it protects from AIDS, STI's and pregnancy. " (30-45 year 
olds, diaphragm discussion) 
The new methods also drew attention to the possibility to use them without their partner's 
knowledge. It was only after prompting about messaging not related to technical use that 
women suggested other messages. Female condoms are mentioned as stronger than male 
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condoms, they would not tear. Some messages were suggested around: trust, love and 
respect: 
"if you love me respect me use a condom. "(18-29 year olds, distribution 
discussion) 
Only when prompted did women discuss messages around pleasure enhancement or fertility 
protection to make it easier to introduce to their husbands. With microbicides they did say 
just to tell their partners it was medicine prescribed by the clinic suggesting a message 
around vaginal health. The group concluded that, though it would be more difficult to lie to 
their partners about the use of new technologies if they would be advertised, that they 
should nevertheless be advertised. 
Conclusions on promotion 
Though the discussion on promotional messages centred on HIV and STI control and 
pregnancy prevention, women also identified innovative ways to present the gel to their 
partners, specifically around presenting it as a women's medicine. They also mentioned 
that women could either stop using hormonal contraceptives, or lie to their partners that 
they were not using hormonal contraception, to make it easier to introduce condoms or 
other products that are contraceptive as a method of pregnancy prevention rather than HIV 
prevention. In sum, women were innovative in how they present their method for 
protection. 
6.2.9. Price 
In the last four focus group discussions on the new barrier methods, women were asked 
how much they would be willing to pay for: a single use applicator of microbicides or a 
diaphragm that could be used for up to two years. In practice, during the FGDs, the 
responses to these questions seemed to be subject to a strong starting-point bias, where the 
first suggested price set the scene for subsequent suggestions. Table 6-1 shows the first 
price suggestion and the descriptives of the responses within that group. Most stark is the 
difference between the two diaphragm groups. 
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Table 6-1 Proposed prices for new barrier methods by group 
Group First price (in Rand) Descriptives of all suggested prices 
Microbicides (single use), R10 average 7.1 
18-29 year olds median 5 
min 2.5 
max 20 
n= 13 
Microbicides (single use), 30-45 year R6,99 for 10 average 1.1 
olds median 0.9 
min 0.5 
max 2 
n= 4 
Diaghragm (reusable for 2 years), R10 average 16.0 
18-29 year olds median 10 
min 0 
max 50 
n= 15 
Diaghragm (reusable for 2 years), R199 average 136.4 
30-45 year olds median 100.0 
min 5 
max 500 
n= 16 
It was expected that it would be a challenge to find appropriate price levels that could be 
used across technologies. This was reconfirmed by the fact that higher prices were 
suggested for the reusable diaphragm than for single use microbicides. Another challenge 
identified during the London pretest was the presentation of a fixed and variable component 
to the price (applicator plus gel, or diaphragm plus gel). With the idea of having an initial 
cost outlay and a recurrent price being confusing. 
Conclusions on price 
Identifying a single price scale for all products was proving challenging. Women were 
suggesting very different prices for the reusable diaphragm and the single use microbicide. 
This suggests that different price levels between single use and reusable products is needed. 
The other option might be to present the diaphragm as disposable, or present the cost of two 
years supply or a per sex act cost of all products to ensure the price attributes are presented 
in the same units. 
6.3. Discussion: developing an objective process for attributes 
In this first phase of the qualitative research, a broad list of a attributes was identified. 
However the appropriate next steps to select attributes was not clear. Although qualitative 
methods such as contents analysis could be used to identify more and less prominent 
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themes, after completing the first four rounds of interviews it was felt that such an analysis 
of counting mentions of attributes would likely be biased by the more outspoken 
participants' views. A different technique was needed to guide the survey development. It 
was chosen to use these qualitative interviews to generate an inventory of potential 
attributes and levels when appropriate and to then allow a next round of participants to rank 
them. This was thought to provide more objective guidance on what women felt was 
important to them about the product, distribution and promotional attributes. This second 
iteration is presented in the next chapter. 
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Chapter 7. Attribute identification workshop 
7.1. Introduction 
The literature on how to conduct discrete choice experiments (DCEs) generally 
recommends qualitative research methods (focus group discussions and in-depth interviews) 
combined with a review of the literature to identify key factors in people's preferences [273, 
267,268] (see Section 4.4. ) The policy relevance of the attributes can provide guidance on 
which attributes to include 
[342,438,305,276,308,278,340,349,351,350,362] However, there are few 
specific recommendations on how to distil the possible attributes to a reasonable number 
that can be included in a feasible DCE. Two studies have used ranking exercises after 
qualitative research to inform the design of the DCE scenarios. Tanner used a card ranking 
exercise among women to identify key microbicide attributes from those attributes 
suggested in the qualitative interviews [354] De Bekker-Grob asked participants in in-depth 
interviews to complete and rank a list of attributes for osteoporosis drugs that had 
previously been compiled from the literature [27]. This chapter describes the process of 
moving from the qualitative research to a survey questionnaire using a workshop designed 
to allow women to identify the most appropriate attributes and levels for use in the DCE 
and the best was of presenting these. The methods are first described (Section 7.2. ), 
followed by their results. I conclude this chapter by discussing the usefulness of this 
method. 
7.2. Methods 
During the series of focus group discussions and in-depth interviews it became apparent that 
many different factors impact women's choices of product and location of purchase. A 
method was needed to prioritise which dimensions were sufficiently important to warrant 
inclusion in the DCE. I decided to hold an Attribute Identification Workshop. This 
workshop aimed to elicit women's rankings and votes on the best attributes and levels. 
From the qualitative research the lists of attributes and levels were compiled and turned into 
ranking questions. The women were provided with a `priority setting' questionnaires 
(Appendix 5), and each question presented to the full group for discussion. Ex post, 
attribute identification workshop/ questionnaire is considered a more appropriate name. 
The women then filled out their own opinions on the questionnaire, assisted when necessary 
by moderators. Further questions were developed to enable women to express how 
important different attributes/levels might be to them. The worksheets consisted of eight 
sections: 
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1. Background information 
2. Physical attribute rankings 
3. Understanding of representations of effectiveness in preventing HIV and pregnancy 
4. Distribution attributes rankings 
5. Distribution channel rankings 
6. Further questions on distribution attributes 
7. Willingness to pay for single use / disposable diaphragm and microbicides 
8. Promotion 
In many sections there were ranking questions. An example of such a ranking question can 
be found in Table 7-1. In this example women first identified the four most important 
physical product characteristics, then provided a ranking for each of their top four choices: 
first choices were given four points, second choices three points, third choices two points, 
and fourth choice one point (Table 7-1). These were obtained from the analysis of the focus 
group discussions and the in-depth interviews. 
Table 7-1 Physical attribute rankings exercise 
Attributes 4 most important attributes Ranking of importance: 1,2,3,4 
Mark with X 1= most important, 4= least important 
Vaginal wetness: May make the 
vaginal a bit wetter 
Etc. 
In addition to asking women to rank attributes and levels, women were also asked questions 
about their understanding of HIV and pregnancy prevention as presented visually. These 
levels are presented both pictorially and numerically. The first question is shown in Box 
7-1. In the pictures the red dolls represented the HIV infections incurred (in the population), 
and the yellows those that were protected but would have otherwise become infected in the 
absence of the product. In the numeric representation, it is the level of protection that is 
presented, both in terms of percentage protection and numbers remaining HIV-negative. 
This aimed to counter the framing effects (biases introduced by only representing a positive 
[368] or a negative risk), as is suggested by Edwards 
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Box 7-1 Pictorial representation of product effectiveness 
Pl 
8d 
ll HIV 
I 
ease note: o s are -, dolls are HIV+. 
a. If a condom provides 95% protection against HIV, the diaphragm provides 95% protection, and 
using neither provides 0% protection, would you use a condom, the diaphragm, or neither? 
Male condom Diaphragm Neither 
asses Bases *1*1* 
B4 ses asses It*11 
asset asset Stitt 
95% protection 95% protection 0% protect ion 
19 of 20 women 19 of20 women 0 of 20 women 
remain HIV- remain HIV- remain HIV- 
Women were presented with six of such barrier methods scenarios with different levels of 
HIV efficacy. The different product effectiveness' represented in these scenarios can be 
found in Table 7-2. 
Table 7-2 Variations in of product effectiveness 
Neither Condom Diaphragm Microbicide 
A 0% 95% 95% 
B 0% 95% 35% 
C 0% 95% 95% 
D 0% 95% 35% 
E 0% 95% 55% 55% 
F 0% 95% 55% 35% 
Subsequently pairs of visual analogue scale type questions were tested for HIV 
effectiveness to explore women's understanding of the concepts (Box 7-2). 
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Box 7-2 HIV effectiveness scale 
a. What is the lowest level of protection against HIV that you would accept to still choose to use a 
microbicide? Please put aX in the boxes where you would choose to use a microbicide, starting 
from the right side. 
Number of women that would remain HIV negative at different levels of protection. 
If no barrier method were used no women would remain HIV negative, if condoms were used all the time 19 would be 
remain HIV negative 
1 2 3 4 5 6 7 8 9 10 11 2 13 14 15 16 17 18 19 20 
81 81 Z1 81 t, I T ZI S1 8 Percentage rotection against HIV 
5% 10% 15% 20725% 30% 35% 40% 45% 50% 55% 160% 65% 170% 175% 1801/o 185%1900/o 195%1100% 
b. What is the lowest level of protection against HIV that you would accept to still choose to use a 
microbicide? Please put aX in all the boxes where you would choose to use a microbicide, 
starting from the left side. 
Number of women that would become HIV infected at different levels of protection. II 
If no barrier method were used all 20 would be infected, if condoms were used all the time I would be infected 
Additionally women were presented with a series of questions that aimed to assess the 
importance of specific attributes or levels. Box 7-3 shows the question aiming to ascertain if 
reliability of supplied would lead non-use of product or just of seeking the product from 
another sources. 
Box 7-3 The importance of supply reliability 
How important is reliability of supply to your choice of HIV prevention method? 
If I cannot find my preferred method the first time, I If I cannot find my preferred method the first time, I 
will use another method or not use any barrier will go somewhere else to collect it or return 
method for HIV prevention? another day? 
Choice Choice 
Rankings of promotional messages were elicited by the following questions: 
a. If you wanted to use a microbicide or a diaphragm with your most recent partner, 
what would you tell him to make him most willing to accept your use of it? Please 
mark in the column `Best'. Which message would your partner be least likely to 
accept? Please mark in the column `Worst'. 
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b. If microbicides and the diaphragm were advertised on the radio and TV, what 
message would make them most attractive to you and your partner? Please mark in 
the column `Best'. Which of these advertising messages would make them least 
attractive to you and your partner? Please mark in the column `Worst'. 
Product study aids are also used at a number of points during this workshop. The beginning 
women the different barrier methods29 are circulated for women to touch. Later, product 
evaluations of eight existing vaginal products and six condom packages are undertaken. 
These were circulated so women could touch them and consider the products more 
realistically. Women were encouraged to open the vaginal products to feel the products in 
their fingers. In additional to actual product aids, visual aids were also used throughout, 
such as for the presentation of product effectiveness, and in eliciting women's preferences 
for different packaging. 
Women were recruited in the same way as for the focus group discussions and followed the 
same consent procedure presented in Chapter 6, and were grouped in the same way 
(younger and older women). By collecting data from each of the 22 participating women it 
was possible to do a simple descriptive quantitative analysis of the responses. In the next 
section the results are followed presented by a discussion of how the final choices of 
attributes and levels were made. 
7.3. An overview of women's responses 
Two priority setting workshops were held, one with younger women and one with older 
women. Each workshop had 11 participants, resulting in 22 responses for most questions. 
The responses to each of the workshop sections are presented below. 
7.3.1. Participant characteristics 
The average age of the women was 24 years for the younger group and 41 years for the 
older group. On average, women had 1.78 children. Crowding was low, with 1.86 people 
sleeping in each room. Twenty-seven percent of the women had not completed secondary 
school, as opposed to 18% who had. There was high unemployment (36%). Half of the 
women lived with their last sexual partner. Participants had a range of last partner types: 
54% regular partners, 27% husbands, and 18% casual partners. It is noticeable that none of 
the women reported one-off encounters as their last experience, while in the background 
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data from the focus group discussions, which was collected more privately, one-off 
encounters comprised 4% of the total, and casual partners 30%. 
7.3.2. Physical attributes 
HIV prevention came out universally as the most critical physical attribute, with 21 of 22 
women ranking it as the most important (Table 7-3). Interestingly, from the focus group 
discussions the ability to use something without their partners' knowledge was cited as 
quite important, but not a single person ranked this in the top four attributes in the first 
section of the questionnaire. This is where such a ranking exercise can help to identify those 
factors that are most critical to women. 
Table 7-3 Women's rankings of physical attribute importance 
Attribute Rank points 
HIV prevention 85 
Pregnancy prevention 38 
STI prevention 30 
Insertion and removal time 14 
Comfort 13 
Reliability 12 
Ease of insertion 12 
Reusable or disposable 10 
Wetness 8 
Product upkeep (washing requirements) 5 
Sound during sex 4 
Side effects 2 
Secrecy 0 
Insertion time: Women were asked: "How long before sex would you like to insert a 
diaphragm or a microbicide? " The most popular answers were one hour and six hours, 
with six and seven responses respectively. Five women wanted to insert them less than an 
hour before, ranging from three minutes to half an hour. The mean preferred time to 
insertion was 3.5 hours. In response to the somewhat leading question: "Is time of insertion 
important to your decision to use these methods? ", twenty answered "Yes". 
29 Though microbicides do not exist, a real trial applicator filled with lubricant was circulated. 
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Women expressed a preference for a reusable product (17/22). This was unexpected. During 
the in-depth interviews, the reasons for this were explored further. Women explained that 
they expected reusable products to be less expensive. Therefore, the reusability attribute 
seemed to reflect preferences around prices rather than preferences for reusability in itself, 
all else being constant. 
When asked if they would be willing to try a microbicide or a diaphragm if one of their 
friends developed a rash after using one, most women were still willing to try (15/22). At 
the end of the session one woman asked whether toxic shock syndrome, that has been 
associated with the use of tampons, could also occur with the diaphragm. When asked if she 
would try the diaphragm if that was one of the possible side effects, she answered that she 
still uses tampons, so she would still try the diaphragm. 
7.3.3. Understanding of representations of effectiveness in preventing HIV 
and pregnancy 
After an introduction to microbicides and the diaphragm, women were presented questions 
that aimed to identify the best way to present product effectiveness to women (Box 7-1). 
Eight out of the 22 women consistently chose the condom option. Of these eight, two had 
not used condoms in their last sex act. When the diaphragm or microbicides were shown to 
have equal efficacy to the condom (95%), slightly less than half the women switched to a 
new barrier method: 45% chose the diaphragm, and 41% chose the microbicide. Two 
women chose a less efficacious method when presented with this possibility: one chose the 
35% effective microbicide over the condom, and one chose the 55% effective diaphragm 
55% over the condom. However, when all the products were presented together (35% 
effective microbicide, 55% effective diaphragm, 95% effective condom, and 0% effective 
none), all the women chose the condom. The two cases of switching with the addition of the 
forth option, are violations of the assumption of independence of irrelevant attributes, which 
states that adding an alternative will not affect the choices probabilities between the other 
alternatives. Or it might just show unstable preferences. 
Subsequently pairs of visual analogue scale type questions were tested for HIV 
effectiveness to explore women's understanding of the concepts. It was a challenging 
question for women. Firstly the scales were not perfectly consistent (this was not 
intentional), with one running from 5% to 100% protection and the other from 0% to 95%. 
Secondly, providing consistent answers meant looking very closely at what was being 
presented and thinking about what it meant, as the same thing was presented in opposite 
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terms. Although 12 of 21 and 15 of 21 pairs of responses to this question relating to 
microbicides and diaphragm effectiveness, respectively were within 10% of each other, this 
strongly suggested that this type of representation of effectiveness was quite confusing. 
One of the intentions of this workshop was to explore the willingness to accept pregnancy 
prevention among women who wanted to become pregnant; however only two of 20 women 
responded that they did not want a method that also prevents pregnancy. This made the 
group responding to the follow-up question very small. Moreover, it seemed that these two 
women had not understood the adapted visual analogue scale used to represent efficacy in 
preventing pregnancy: they both marked 95% as the lowest they were willing to accept. 
7.3.4. Distribution attributes rankings 
Different types of distribution attributes were presented and can be found in the left column 
of Table 7-4 (for the full description of these attributes see Questionnaire Section 3 in 
Appendix 5). Women were asked to rank the three most important attributes in their 
decision making, with one being the most important and three the least important. These 
were then given a weight of three for the top choice priority, two for the second, and one for 
the third most important attribute. Subsequently an aggregate ranking was obtained. 
"Facility type general" indicated whether or not it was a medical facility. Another question 
explored whether the specific type of facility (i. e. pharmacy versus clinic versus 
supermarket) was important. From this ranking it appears that the more general delineation 
of medical versus non-medical is most important, followed by the characteristics of the 
people who assisted at the facility. Collection method and reliability of supply tied for 
fourth place. A caveat needs to be raised concerning the attributes placed at the top of the 
list, which were often ranked as most important and may therefore be subject to an ordering 
bias. There is less doubt about the importance of type of assistance, because it was near the 
bottom of the list, and still many people ranked it as important. 
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Table 7-4 Women's rankings of distribution attribute importance 
Distribution attribute Votes Rank 
Facility type general (Medical/ non-medical) 42 1 
Facility type specific (e. g. pharmacy, clinic supermarket, etc. ) 17 3 
Collection method 15 4 
Supply reliability 15 4 
Opening Hours 8 5 
Waiting time 0 7 
Distance 8 5 
Privacy 8 5 
Assistant 20 2 
Collection frequency 6 6 
After this general ranking more specific questions were asked relating to these attributes 
and their importance. 
7.3.5. Distribution channel rankings 
Women could vote for the two places where they were most likely to obtain their barrier 
methods, as well as the two least preferred places. Women were most likely to collect from 
the clinic (15/44) and the family planning clinic (10/44) and least likely to collect from 
shabeens (informal township bars) or taxi ranks (Table 7-5). There were very strong 
preferences for clinic and family planning clinics. The votes for the least preferred locations 
were more widespread. Two women marked clinic as their most and least likely locations, 
suggesting the question was not very clear to them. 
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Table 7-5 Women's votes for locations to collect barrier methods 
Most likely locations Nr of votes Least likely locations Nr of votes 
Clinic 15 Shabeen (informal bars) 7 
Family planning 10 Taxi rank 5 
Private GP 5 Garage 4 
Hospitals 4 Supermarket 3 
Awareness campaigns 2 Schools in classrooms 3 
Supermarket 2 Public phone 3 
Home delivery 1 Nightclubs 3 
Library 1 Hair salon 3 
Pharmacy 1 Library 2 
Public phone 1 Clinic 2 
Shops 1 Bottle store 2 
Taxi rank 1 Work place 1 
Shops 1 
Public toilets 1 
Movies 1 
Hotels 1 
Home delivery 1 
Awareness campaigns 1 
TOTAL 44 44 
7.3.6. Further questions on distribution attributes 
Women were asked which was more important: the type of facility or the method of 
collection (e. g. from a box, in a private room, from a person behind a counter); 71% (15/21) 
responded that the type of facility was more important than the collection method. 
Supply reliability: One-third of the women reported that they would resort to another 
method or no method if they did not find a particular product the first time they tried to 
collect it, while two-thirds said they would try to get it somewhere else or return another 
day. 
Opening hours: Two-thirds of the women reported that they could predict when they would 
need their product of choice and could collect them within regular office hours, while the 
remaining one-third needed more flexible hours to ensure that they would use that method. 
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Waiting times: Women reported a willingness to wait a maximum of between four minutes 
and four hours to receive their preferred HIV prevention product, with an average of just 
less than an hour (0.9 hours). 
Travel distance: From the focus group discussions it appeared that distance was expressed 
in walking time or the number of taxis needed to reach a location. Women did not show 
great willingness to go very far to collect their preferred method; 81% said they would not 
be willing to take a taxi ride (Table 7-6). 
Table 7-6 Acceptable travel distances 
Frequency Percent 
30 minutes walk 10 45.5 
1 hour walk 8 36.4 
1 taxi 3 13.6 
2 taxi rides 1 4.5 
Total 22 100.0 
Privac : Although privacy during collection was raised in the focus group discussions, in 
this questionnaire 73% of women reported that they did not care who saw them during 
collection (Table 7-7). Only one would have refrained from collecting the product in the 
presence of others. 
Table 7-7 The importance of privacy 
Frequency Percent 
would not collect it if I might be seen by others. 1 4.5 
do not mind being seen by people like myself, but would not collect if 5 22.7 
there were many different people aroundx. 
do not cane who sees me collect it 16 72.7 
Total 22 100.0 
Assistance: The characteristics of the person providing the product ranked as the second 
most important factor in women's decisions concerning barrier methods. However, when 
'o The four women who defined `people like myself' each had a different definition: people as young as 
me and in the same situation as me; HIV positive; not men and children; young people. 
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presented with the question: "How important is the person giving you your preferred HIV 
prevention method? " Eighteen of the 22 said they did not care who gives them their 
method. It is difficult to reconcile these contradictory responses. It might be slightly 
different wording, or description of the service attribute. On one of the questionnaires, a 
comment in Zulu next to the question about privacy said: `I should not care about other 
people'. This suggests that their response to the later question reflects more what they desire 
to be true, i. e. `I should not care'. 
Collection frequency: How often women were willing to collect their HIV prevention 
products varied a lot from woman to woman, with a small peak at once a month (Table 7-8). 
Table 7-8 Preferred collection frequency 
Frequency Percent 
Twice per month 3 13.6 
Once per month 7 31.8 
Once per 2 months 3 13.6 
Once per 4 months 2 9.1 
Once per 6 months 5 22.7 
Once per year 2 9.1 
Total 22 100.0 
7.3.7. Willingness to pay for single use / disposable diaphragm and 
microbicides 
The willingness to pay question asked women their willingness to pay for products per sex 
act. This question posed a lot of problems because WTP per sex act for both disposable and 
reusable products was being elicited. This meant a jump in reasoning for reusable products: 
i. e. not just asking directly the price but the price divided by the number of times it would 
be used. It seemed women were willing to pay for a single use product (which is then equal 
to a per sex act price), but their total WTP for a reusable product plus supplies was much 
higher (row 2 and 3), while the question had elicited per sex act willingness to pay rather 
than for the full product. This suggests they interpreted the question as their WTP for the 
full purchase of the product, which would have been a more intuitive question for most 
women. 
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The WTP responses were very skewed, which can be seen from the large difference 
between the mean and median WTP values in Table 7-9. The average reported WTPs for a 
single use microbicide arguably seems quite high, as a WTP of almost R15 per sex act is 
about 50% higher than the price of the most expensive condoms on the market, with Durex 
costing R29 for three. The median WTP values seem more reasonable, though still higher 
than one would expect in this population. 
Table 7-9 Willingness to pay per sex act 
In your current situation, what is the maximum you would Mean Median (Min- Max) 
pay per sex act for the following: (in Rand) 
A single use microbicide 14.95 10 (1-50) 
A microbicide in a reusable applicator with a tube of gel 47.50 20 (5- 600) 
A diaphragm with gel that you could use for 2 years 50.77 40 (2- 200) 
A disposable diaphragm 23.52 8 (1- 200) 
7.3.8. Promotion 
Women's preferences for promotional messages were elicited both as the message women 
thought would make it easiest to introduce to their partner and the best way to advertise it 
using mass media. The potential promotional messages women could choose from can be 
found in the left column of Table 7-10. 
Table 7-10 Promotional messaging a: Descriptions of product to make partner most 
willing to accept 
Best Votes Worst Votes 
It prevents HIV 16 It's a cool new sex toy 10 
It prevents pregnancy 4 Its for a fresh vagina 4 
It prevents STI 3 It prevents HIV 3 
Its for a fresh vagina 2 It is for a healthy vagina 2 
It is for a healthy vagina 1 My doctor told me to use it to stay healthy 2 
My doctor told me to use it to stay healthy 1 It increases sexual pleasure 2 
It increases sexual pleasure 1 It prevents pregnancy 2 
It will protect my capacity to have children 1 It will protect my capacity to have children 2 
in the future in the future 
It prevents STI 1 
Its for vaginal hygiene 1 
TOTAL 29 27 
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Most women marked one best and one worst message, but seven women marked two of 
each. In the latter case, their votes were not qualified in terms of I S` and 2nd best/worst 
answers. Therefore these women got two votes (represented by the fact that the totals are 
greater than 22). HIV prevention clearly comes out as a frontrunner in terms of the "Best" 
message, both to tell partners themselves and for public advertising. `It's a cool new sex 
toy', was rated as overwhelmingly unattractive. 
For advertising messages, healthy vagina and sexual pleasure tie for 2nd and P place in 
both the best and worst advertisements (Table 7-11). This suggests that different messages 
appeal strongly to different populations groups; however the sample is very small. 
Table 7-11 Promotional messaging b: Public advertising messages 
Best Votes Worst Votes 
It prevents HIV 14 Its a cool new sex toy 11 
It is for a healthy vagina 3 It is for a healthy vagina 3 
It increases sexual pleasure 3 It increases sexual pleasure 3 
It prevents STI 2 Its for a fresh vagina 2 
Its a cool new sex toy 1 It keeps women healthy 2 
Its for a fresh vagina I It prevents STI 2 
It keeps women healthy 1 It is for a healthy vagina 1 
It prevents pregnancy 1 It prevents HIV 1 
It will protect women's capacity to have 1 
children in the future 
TOTAL 27 25 
Promotional images: In search of a successful image to represent HIV and pregnancy 
prevention, some sample images were presented. The images were not very diverse, and the 
responses were not especially interesting. The LoveLife banner made most women think of 
HIV prevention products (10/22), while a picture of people embracing made them think of 
contraceptives (13/22). Nobody marked the picture of a boy and girl leaning up against each 
other. 
Product evaluation: Women were shown eight pictures of products and asked for their 
impressions. The images are in the left column of Table 7-12. In addition, seven vaginal 
products and six condom brands available in the South African market were circulated for 
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feedback (Table 7-13). Not all the women filled in all the questions; therefore a total of the 
number of votes is also presented. Note that `Healthy Vagina' was the 1St column, which 
may have contributed to its high ranking. Though not collected, it would have been 
interesting to have collected information on actual use of existing vaginal products. 
Table 7-12 Women's reactions to product images 
Increased New Partner 
Healthy Fresh Vaginal Total Willingness Most Least 
Product vagina vagina hygiene 
sex sex 
responses to try 
willing to 
attractive attractive 
pleasure toy try 
tf 6 1 1 1 1 10 9/18 9/18 5 9 
7 3 3 3 16 14/19 12/17 12 3 
4 4 4 2 14 10/16 9/18 9 1 
ý.. 3 1 2 2 8 7/17 4/17 3 10 
eve 
2 3 2 2 2 11 12/18 4/16 6 2 
WPM 
3 2 1 1 1 8 6/17 4/16 0 6 
Vagisil 
4 1 5 2 1 13 12/17 8/16 5 2 
2 4 1 2 9 7/17 5/17 4 11 
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Table 7-13 Women's reactions to some currently available vaginal products 
Increa- New Total Willing- Partner Most Least 
Healthy Fresh Vaginal 
Pmduct vagina vagina hygiene 
sed sex. sex respon- ness to willing to attrac- attrac- 
pleasure toy ses try try tiive five 
A. Intimate Vaginal 
Cleanser: Rooibos & 6 7 3 2 1 19 18/20 17/20 8 9 
herbal extract 
B. Intimate Vaginal 
Cleanser: Tea Tree & 9 8 3 1 21 15/21 14/20 5 8 
herbal extract 
C. Intimate: personal 7 3 6 1 17 14/21 12/21 8 1 lubricant 
D. Regard: lubricating 8 4 2 4 1 19 16/21 17/21 0 8 jelly Glycerine 6% 
E. K-Y Lubricating Jelly 
7 1 5 1 2 16 12/20 12/20 1 8 Glycerine 11,25% 
F. K-Y GEL Personal 
8 3 3 3 1 18 14/20 15/19 5 3 Lubricant 
G. at LAST for Women 7 3 6 1 17 14/19 16/19 7 0 
H. Afrodite libido gel for 5 3 2 7 2 19 20/21 21/21 9 2 
her 
Product Intimate Vaginal Cleanser (A) was rated least attractive by the largest number of 
women, but it also ranked as second most attractive. Afrodite Libido Gel (H) had the 
highest number of women who said they would try it, and all reported that their partners 
would be willing to try it. It was the product that was voted `most attractive' by the largest 
number of women (9). It also resisted the draw of the first column (healthy vagina) with 7 
out of 19 women saying that it made them think of increased sexual pleasure. 
Table 7-14 Women's reactions to some existing condom packages 
Product Willingness 
to try 
Partner 
willing to try 
Most 
attractive 
Least 
attractive 
1. TRUST studded 11/15 10/15 2 4 
J. LoversPlus coloured and flavoured (yellow box) 15/18 15/18 7 3 
K. LoversPlus (purple box) 12/14 10/13 5 3 
L. Durex Performa: for longer lasting pleasure 13/16 13/16 10 2 
M. Contempo Rough Rider studded for extra 
sensation 
8/16 7/17 2 5 
N. Choice 10/16 9/14 2 6 
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Coloured and Flavoured LoversPlus (J) condoms had the highest number of women and 
partner's willing to try. The most expensive condoms, `Durex Performa', were rated most 
attractive, and the free government condoms `Choice' were rated as least attractive. 
However women were more willing to try them than the very explicit `Contempo' with a 
large busted blond woman on the package. 
7.4. Identification of key attributes and levels for the survey tool 
Using simple descriptive statistics of the individual women's responses it was possible 
identify how women rated the importance of for the different product, distribution and 
promotion attributes. 
7.4.1. Physical Attributes 
From these data, HIV prevention rates emerged as much more important than the other 
physical attributes, followed by pregnancy prevention and STI prevention. STI prevention 
was not included in the interest of brevity as it came out as less important than HIV and 
pregnancy prevention. Secrecy did not emerge as important in contrast to women's 
narratives in the focus group discussions. Nevertheless, as this is a much discussed attribute 
in the literature, it is included as an attribute in the DCE. 
7.4.2. Distribution attributes 
Direct comparison of distribution attributes shows that facility type is very important. It is 
unlikely that facility general and facility specific were very clear to people. Though the 
characteristics of the person assisting them when collecting product was ranked second 
most important, further questions do not suggest it would be a major deterrent to accessing 
barrier methods. 
7.4.3. Promotional messages 
Though the results of the questionnaire on promotional messaging is more difficult to 
interpret, a few conclusions can be drawn. The product that women marked as `Pleasure 
enhancing' appeared easiest to introduce to women and their partners (Afrodite libido gel 
for women). However, of the two sexual arousal products presented the product presenting 
the more feminist message (At LAST, for women, developed and manufactured by a female 
medical doctor and homeopath) was less popular. This also held for male condoms: "Durex 
Performa for longer lasting pleasure" was rated by the most women as most attractive. 
"Choice" condoms, the only one that mentions prevention explicitly, was considered least 
attractive by the most women. 
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7.5. Discussion of methodology 
As noted previously, the DCE methodological literature does not provide much guidance on 
how to move from the vast qualitative data obtained through focus group discussions and/or 
in-depth interviews to the final choice of attributes. While Coast et al describes their process 
using constant comparative analysis of in-depth interviews to reach saturation, most studies 
remain vague and thus provide little guidance on the best way to proceed. In this study it 
was felt that the theoretically based qualitative analysis techniques did not provide 
sufficient guidance on how to prioritise attributes for inclusion in the DCE and instead we 
developed a new method to identify attributes. Our experience suggests that a systematic 
approach for allowing women to prioritise what is important to them in a quantitative but 
simple manner. 
However, this method does have limitations. Although the sample size was seemed 
satisfactory for the purpose, it has to be acknowledged that it is small. Moreover, the ideal 
physical layout is a challenge. It was considered advantageous to seat women around a table 
to allow for discussion, however this does limit the amount of privacy that women have in 
noting down their responses. Though each woman had an individual questionnaire to 
complete, women were seated close together and it may have been possible for women to 
see each others' responses. This may have mattered, in particular for reported condom use. 
Another question to which the answers were unexpected was that 68% reported using a 
condom in their last sex act. This question was intentionally placed in a row of questions 
such that it might not be as easy to identify in a glance by neighbours, but this may not have 
been sufficient, or the participants were a selected group of women with very high HIV 
prevention behaviour. If repeating such an exercise, it is recommended to seat women on 
desks with some space in between each other to allow for higher levels of privacy. 
Despite this, the inclusion of the key attribute workshop provided a relatively simple and 
objective way to identify the attributes most important to women. It used rankings of 
attributes and levels that were generated through qualitative research simple choice 
questions to generate quantitative outcomes. Simple descriptive statistics provided objective 
summaries of the different dimensions of women's preferences. This approach may be a 
useful methodological addition to the DCE literature. Further application of this method in 
DCE research will help identify the rules of thumb about the number of participants and the 
process of ranking needed. 
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Following this workshop, the draft survey was pre-test, revised again, piloted and finally 
implemented. The lessons from the intermediate iterations and the community survey 
procedures are presented in the following chapter. 
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Chapter 8. Community survey finalisation and 
implementation 
8.1. Introduction 
After undertaking the qualitative research and an attribute identification workshop, the 
survey was pre-tested, revised, piloted, revised, finalised and implemented. This chapter 
presents this process. 
Section 8.2 describes the methods, Section 8.3 presents the experimental design of the DCE. 
Section 8.4 describes the survey sample and sampling procedures. Section 8.5 gives an 
overview of the final survey instrument. The survey implementation procedures are 
presented in Section 8.6, and Section 8.7 is a discussion. 
8.2. Methods 
Revision of the study instrument was undertaken in a number of steps. 
8.2.1. The pre-test 
A draft questionnaire was developed from the workshop analysis. Two in-depth interviews 
were used to test the proposed attributes and levels 31. These highlighted a number of issues: 
" After the sixth scenario, women start getting bored and tired. When probed into 
why they made their choice, many of the reasons that were put forward were not 
based on attributes present. 
9 Distribution and promotional attributes were rarely (only once) mentioned as critical 
to the women's choices when presented as part of a scenario including physical 
attributes. 
9 The dolls presenting HIV and pregnancy risk did not appear to make much 
difference from risk represented by percentiles. 
" The concept of really thinking back to their last sex act was extremely difficult. 
This is best illustrated by an example. The interview was with an eight-month 
pregnant woman, who had had sex for the last time two months before. When 
probed about how she made her choice, she said it was because of the higher level 
of protection against pregnancy. When probed further, pointing out that in her 
previous sex act she was already 6 months pregnant and already knew she was 
31 A pre-pilot of the very first draft valuation survey was held among volunteers who are members of the 
HIV network, a group of students with an interest in HIV at LSHTM. 
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pregnant and you cannot get pregnant again, she maintained her choice and the 
reason for her choice. 
" Price never seemed to be a limiting factor, even with these young women, out of 
work, who had never used contraception before, and even at a price of RIO per sex 
act. 
It was necessary to make a decision whether to present promotion and distribution within 
the same choice sets as physical attributes. From the pre-test it became clear that physical 
attributes dominated women's choices. The combination of physical and distribution 
attributes together in one large DCE scenario was cognitively too complex. A supporting 
analysis of demographic and health survey (DHS) data from South Africa (1998) was 
undertaken to explore the choice of specific contraceptive method and the choice of 
distribution source. This analysis could not reject the null hypothesis that they were 
independent decisions. Therefore the choice was made to split the two topics and undertake 
two separate, simpler DCEs. 
8.2.2. The pilot 
8.2.3. The pilot implementation and lessons 
The pilot was held in one EA in Vosloorus and one in Zonkiziswe over two days. 
Following the training, each fieldworker was responsible for four interviews. This was not 
fully achieved, resulting in 77 interviews rather than 80. There was a preliminary analysis 
of the pilot data to identify problems, including estimation of a very preliminary utility 
function using a multinomial logit choice model. The pilot provided data on the extent of 
similarities between our participants and the representative sample in the Nelson Mandela 
study [311, and also provided an opportunity to revisit our sampling strategy, described 
above. It was deemed suitable. During the pilot, an evaluation survey was also piloted 
among seven participants. Feedback from the evaluation survey was disappointing; few 
women provided criticism or suggestions for improvements. All pilot participants were 
given information slips, asking if they were willing to participate in a debriefing focus 
group discussion. In contrast to the qualitative focus group discussions, where participation 
was overwhelming, it was difficult to recruit these randomly selected pilot participants for 
this focus group. This suggests differences between the participants of the earlier focus 
group discussions and the sample of women randomly selected from the population. 
However, the team managed to gather four women, two of whom had already participated 
in the evaluation survey. We also had a feedback session with the fieldworkers. 
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The pilot raised a number of issues and, if necessary, how they were subsequently 
addressed in the community survey instrument. 
" There were many households that did not have women of the eligible age group: i. e. 
only grandparents and children, or men. 
9 Some husbands wanted to sit in on the interview. We agreed to discontinue an interview 
if the partner was present. 
9 The question on the number of rooms used for sleeping was interpreted differently by 
respondents. We changed it to two questions: total number of rooms in house, then 
number of rooms used for sleeping. 
9 Some women did not like the questions about asset ownership: `You came to ask me 
about sex; why do you want to know if I have a fridge? ' One woman in the feedback 
session also reported feeling bad because of all the things she did not have. People were 
insulted to be asked if they had a donkey as it is considered a sign of poverty. We did 
not find anyone with donkeys, sheep or cattle in the pilot data, so we removed the 
donkey question. We strengthened the introduction to the asset index question to cover 
the reasons for collecting data on assets. 
9 HIV knowledge was much lower than expected. It was decided to distribute an 
information booklet to participants. 
" Risk reduction pictures were considered easier than pie charts. However, the pictures of 
the dolls were found to be distracting, so they were simplified to exclude the faces and 
outlines (see survey instrument in Appendix 6.1). Respondents reported using the 
percentages in number values more than the pictures in their decision-making. 
9 The distribution attributes worked fine, but a more recognisable image for `chemist' 
was found. 
" The message that microbicides and diaphragms are currently undergoing testing, and it 
is not yet known whether they reduce risk, was difficult to get across. Questions were 
added at the end of the questionnaire to ensure women did understand that their efficacy 
was unknown, and to identify if reiteration was needed. 
9 The scenarios seemed to be well understood. However, some women found the choices 
difficult. 
" The orthogonal design produced a design with 50% of scenarios with product 1, and 
25% with each of the others, resulting in a loss of level balance. 
9 In the pilot the female condom was product 1, which did not have all the attribute 
levels. Product 1 was changed to microbicide, which can take on all the values of the 
other attributes, to reduce the number of scenarios that needed changing for realism. 
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9 Some fieldworkers received complaints about the length of the interview. 
9 The questions on best HIV and pregnancy prevention attributes were too easy and did 
not make women look closely at the images. The question needed to identify whether 
they had understood or not before they were presented with the scenarios. The order 
was changed so values were not consecutive. 
" Both in the evaluation survey and in the pilot feedback, it became clear that people 
considered secrecy as an intrinsic product attribute, and not subject to change. The 
picture accompanying the secrecy attribute was not very self explanatory either. Though 
no solution to this was found, it is considered in the interpretation of the DCE results on 
preferences for product attributes. 
" The evaluation survey contained many of the same questions as Section 4 of the 
questionnaire, but the fieldworkers were getting more critical responses. Participants 
seemed to be protecting fieldworkers, with the impression that we were there to verify 
what they had done. 
Following the pilot, the questionnaire and the evaluation survey were revised. The included 
attributes and levels in the DCE were not changed. 
This completes the discussion of the preliminary work done to develop the quantitative 
survey and the DCE scenarios. The following section describes the final instrument, and the 
survey implementation. 
8.3. The experimental design 
8.3.1. Finalisation of the DCE attributes and levels 
Compilation of the final attributes brought together the priority setting interviews with 
practical considerations raised in the pre-test of the valuation questionnaire, and 
consideration of relevant policy questions identified in the literature. The two most 
commonly cited physical attributes were included: HIV and pregnancy. Despite the fact 
that secrecy did not receive any votes from women in terms of importance, it was included 
because the social science literature defines it as critical to women's ability to use these 
products. 
The most frequently cited distribution attribute (medical or non-medical facility) in the 
attribute identification workshop was considered too vague for people to conceptualise and 
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was suspected to be subject to rank-order bias, therefore a similar concept pin-pointing a 
specific type of facility was chosen (e. g. clinic, pharmacy, supermarket and corner shop). 
The second most importantly ranked choice (the type of person - Assistant - that provides 
the products) was deemed too complicated to properly describe and difficult for policy 
setting because different women considered different characteristics important to them32. 
Moreover, when directly asked whether or not the type of assistant would deter them from 
collecting the product, most women said `no'. The third most important attribute was the 
collection method, in a tie with supply reliability. We chose the former as it would provide 
practical policy lessons, and was fairly easy to conceptualise and put into a picture 
representing its attributes. Promotional messages had been set as one of the attributes 
because of the study objectives. 
Levels for the physical attributes were determined based on the literature and consultation 
with key experts in the technologies. Willingness to pay values from the priority setting 
interviews guided the price attribute. Attribute levels for the distribution channel were 
chosen with women's rankings in mind, and considering their likely distribution sources. 
Collection method attributes were theoretically feasible collection methods, while 
promotion was more guided by expert opinion on the likely range of promotional 
messaging. The final attributes and levels for the DCE are shown in Box 8-1. 
32 This could be a full DCE study in itself. 
137 
CHAPTER H. COMMUNITY SURVEY METHODS 
Box 8-1 Summary of attributes and levels 
Physical Attributes Levels 
1. Product: Female condom, diaphragm, microbicides, Neither (None, Male condom) 3+1 
2. HIV preventive effect: 35%, 55%, 75%, 95%. 4 
3. Pregnancy protection: 0%, 55%, 75%, 95%. 
4. Able to use without partner knowing: Yes /No 
4 
2 
5. Price single use, reusable: Free, low (R5, R20), medium (R10, R40), high (R20, R80) 4 
Distribution Attributes 
1. Distribution outlet types: clinic, pharmacy, super market, comer store 4 
2. Collection method: from a box or dispensing machine, from a person behind a counter, 
from a shelf, from a person in a private room 4 
3. Promotional messages: HIV prevention, pregnancy prevention, more pleasure, 
women's empowerment 
4. Price single use: Free, low (R5), medium (R10), high (R20) 
4 
4 
The physical attributes DCE did not allow for all permutations and had an opt-out 
alternative. In the physical attributes DCE women had three options. They could choose 
between two barrier methods with their accompanying attributes, or select `Neither, I would 
do what I did last time I had sex'. The `Neither' option card had two sides, each 
representing the attribute levels of either having used a condom or not, depending on their 
previous response to that question; so `male condom' is associated with 95% protection 
against HIV and pregnancy, it cannot be used in secret and is available for free. The `no 
barrier method' side was characterised by: 0% protection against HIV, 0% protection 
against pregnancy, could be used in secret and is free (Table 8-1). The pictorial presentation 
can be seen in Box 8-7. 
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Table 8-1 DCE physical attributes and levels 
Alternative 
Attribute 
A, B 
Levels 
C 
Neither, I would do what I did the 
last time I had sex* 
Product Microbicide (MCD), Male No barrier 
Diaphragm (DGM), Condom(MC) method (None) 
Female Condom (FC) 
Effectiveness in preventing HIV 
(MCD, DGM) 35%, 55%, 75%, 95% 95% 0% 
(FC) 75%, 95% 
Effectiveness in preventing pregnancy 
(MCD) 0%, 55%, 75%, 95% 95% 0% 
(DGM, FC) 75%, 95% 
Ability to use without partner's knowledge 
(MCD, DGM) Cannot be used in secret, Cannot be used Can be used in 
Can be used in secret in secret secret 
(FC) Cannot be used in secret 
Price in Rand 
Single use product (MCD, FC) Free, 5,10,20 Free Free 
Reuseable product (DGM) Free, 20,40,80 Free Free 
MCD: microbicide; DGM: Diaphragm; FC: Female condom; *Depending on what they did the last time they had sex, 
a card was placed over the attributes with the appropriate attribute levels for either using a male condom with its 
attributes, or not using a barrier method. 
Further details of the DCE procedures and presentation are presented below. 
8.3.2. Generation of choice sets 
Construction of efficient choice sets for DCE is the topic of a full research area in 
mathematics (see Chapter 4). The final design was a compromise between a behavioural 
model of choice, emphasising realism of choice sets and alternatives, and the statistical 
models. 
The smallest orthogonal design was 120 for the physical attributes and 60 for the 
distribution attributes, which generated 180 choice sets in total. This was obtained using 
the ORTHOPLAN procedure in SPSS, which was recommended at the time the survey was 
designed (SAS is currently considered to produce better and more transparent designs). 
Conventionally DCE's choice sets are created in a two step process, with first the profiles 
generated using a computer package or an existing orthogonal design, secondly the 
alternatives (choices) are generated. The alternatives can be obtained by systematically 
changing the profiles. Most common methods are a randomly pairing another set of the 
profiles and using a fold-over where the levels are replace by their opposite values (e. g. I 
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for -1 in a2 level attribute) [439. As this researcher was finding the creation of alternatives 
from profiles challenging based on the literature available at that time, a ten attribute profile 
was generated in SPSS with a separate attribute for each alternative. Practically this 
generated choice sets rather than the profiles it is intended to create, and so is is likely to 
have resulted in the loss of orthogonality. 
Restricting the choice set alternatives to realistic combinations meant that certain attribute 
levels for the female condom and the diaphragm were limited. Female condoms could offer 
75% and 95% HIV and pregnancy prevention, and could never be used without the partner 
knowing. The diaphragm could not be 0% effective against pregnancy. For the female 
condom, HIV prevention was re-coded from 35% to 75%, and 55% was changed to 95%. 
For pregnancy prevention 0% was re-coded to 75% and 55% to 95%. For the `Ability to use 
without partner's knowledge' question, the 'No' was re-coded to `Yes'. For the diaphragm, 
pregnancy prevention 0% was re-coded sequentially to 55%, 75% and 95%. For the 
distribution attributes, products cannot be collected from shelves in clinics. There were 
eight cases that were changed sequentially into box, person behind counter, and private 
room. Duplicate scenarios were removed. These changes led to an additional loss of 
orthogonality. 
8.3.3. Assessment of design efficiency 
The Huber and Zwerina criteria of orthogonality, level balance, utility balance and 
minimum overlap can be helpful in assessing the efficiency of the design. Orthogonality of 
the applied design was tested using the Street and Burgess website [4391. This showed a d- 
efficiency of 0%, i. e. the design has lost orthogonality, which is likely to result in 
challenges estimating the model parameters. 
Level balance means that each level appears an equal number of times. Frequencies of the 
presence of the different levels were counted in SPSS. In repeated generation of designs in 
SPSS one of the products was always present in double the instances as the other two 
products. It was not clear why this was happening. Because both the diaphragm and female 
condom had restrictions on their feasible pregnancy and/ or HIV effectiveness, and for the 
purposes of this experiment microbicides did not, it was chosen to allow microbicides to be 
the `over-represented' level. However, it is known that this will artificially inflate 
preferences for that level. The remaining attributes were revised to account for realistic 
ranges and thus led to unbalancing of the design (see above comments on the process of 
revising the design for realism). No changes were made to price, or the distribution 
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attributes. These were quite balanced. The largest divergence from equal proportions among 
the distribution attributes occurred in "person behind the counter" and "shelf levels" (Table 
8-2). 
Utility balance aims to generate choice sets that are difficult to choose between, thereby 
forcing the participant to make close choices. This allows for more precise parameter 
estimates [3801. However, this requires a priori knowledge of relative utilities. This can be 
considered using adaptive conjoint analysis or another computer based DCE elicitation 
procedure, but not in a paper-based procedure such as this one. For this reason this was not 
assessed. 
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Table 8-2 Assessment of level balance: frequency of each level in the DCE design 
Attribute Levels Alternative A 
Frequency Percent 
Alternative B 
Frequency Percent 
Product Microbicide 61 50.8 60 50.0 
Diaphragm 30 25.0 31 25.8 
Female Condom 29 24.2 29 24.2 
Total 120 100.0 120 100.0 
Can be used No 72 60.0 72 60.0 
without partner Yes 48 40.0 48 40.0 
knowing Total 120 100.0 120 100.0 
Pregnancy risk Does not prevent pregnancy 14 11.7 14 11.7 
reduction 55% 26 21.7 25 20.8 
75% 38 31.7 42 35.0 
95% 42 35.0 39 32.5 
Total 120 100.0 120 100.0 
HIV risk reduction 35% 21 17.5 21 17.5 
55% 23 19.2 24 20.0 
75% 37 30.8 36 30.0 
95% 39 32.5 39 32.5 
Total 120 100.0 120 100.0 
Price Free 43 23.9 44 24.4 
low 47 26.1 47 26.1 
medium 44 24.4 44 24.4 
high 46 25.6 45 25.0 
Total 180 100.0 180 100.0 
Distribution clinic 13 21.7 14 23.3 
channel pharmacy 15 25.0 14 23.3 
spaza shop 16 26.7 16 26.7 
supermarket 16 26.7 16 26.7 
Total 60 100.0 60 100.0 
Collection method box/machine 15 25.0 14 23.3 
person behind counter 17 28.3 18 30.0 
private room 16 26.7 17 28.3 
shelf 12 20.0 11 18.3 
Total 60 100.0 60 100.0 
Message on HIV prevention 14 23.3 14 23.3 
package pregnancy prevention 16 26.7 16 26.7 
more pleasure 15 25.0 16 26.7 
women's empowerment 15 25.0 14 23.3 
Total 60 100.0 60 100.0 
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Minimal overlap means having as few as possible attributes with the same level across the 
alternatives. The number of potentially overlapping levels in each scenario is equal to the 
number of attributes included, i. e. five for the physical attributes experiment and four for 
the distribution attributes. This is summarised by DCE in Table 8-3, with each scenario in 
the product attributes DCE having potentially five overlapping attribute levels and each 
scenario in the distribution scenario having four potentially overlapping attribute levels. 
Twenty-four percent of all scenarios (=43/180) had no overlapping attribute levels, 39% had 
one overlapping level, and 20% shared two attribute levels, 11% had three overlapping 
attribute levels, and 6% (all in the product attributes DCE) had four overlapping levels. 
Table 8-3 Assessment of level overlap. 
Count of overlapping levels per scenario 
Product 
(5 attributes) 
Distribution 
(4 attributes) Total 
Percent of 
total 
0 21 22 43 24% 
1 42 28 70 39% 
2 28 8 36 20% 
3 18 2 20 11% 
4 11 0 11 6% 
Total 120 60 180 100% 
Because the evaluation of these efficiency criteria are not routinely reported in the literature 
it is not possible to assess the acceptability of the amount of unbalance in the attribute levels 
and the extent of the overlapping levels. However, it may be that more frequently appearing 
levels (such as microbicides) may receive higher values due to the attention that is drawn to 
the attribute during the survey (378,379] in [273]). This will receive further consideration in the 
analysis. 
8.4. The community survey sample 
8.4.1. Sample size 
The literature suggests the need for at least 50 responses to each alternative and 100 
respondents per segment, and argues that the marginal benefit of additional respondents 
declines thereafter 1"01. Segments (stratifications) of interest are: socio-economic status 
(SES) (low/middle), use of condom in last sex act (yes/no), and partner type (cohabitating 
with last sexual partner/ not cohabitating with last sexual partner). The categories are not 
mutually exclusive but each contain two mutually exclusive segments. Because the sample 
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sizes used in empirical studies vary so widely, we decided on a sample of 1000 to allow for 
any contingency and this would generate 3000 observations for the smaller (distribution 
attributes) choice experiment and 6000 for the larger experiment (physical attributes) and 
provide sufficient degrees of freedom to explore preferences within the strata of interest. 
To obtain 1000 completed interviews from eligible women, the number of selected 
households needed to be increased in order to account for: households without adult 
women, failure to find the selected women at home, unwillingness of women to participate, 
and women who were not sexually active. Every household was estimated to have at least 
one woman aged 18-45. Initially, the number of households sampled was equal to the 
number of women needed. However, in the Nelson Mandela study only 74% of the 94% of 
selected individuals agreed to be interviewed [31 L) This meant that the number of 
households/women selected in the randomisation needed to be increased by approximately a 
factor of 1.45. The Nelson Mandela study showed that 23.1% of women, who had had at 
least one partner in their lifetime, had not had sexual intercourse in the past 12 months. As 
the survey sought sexually active women, the sample was again increased by 25%. These 
figures led to a total target sample size of 1,812 adult women (desired sample 1000 x 1.45 
(non-response) x 1.25 (not sexually active). However, the survey team estimated that 20% 
over-sampling would suffice. The randomisation strategy described below allows for 
flexibility in the sampling procedure to allow for this uncertainty. Chapter 8 presents the 
final sample realised. 
Reasons for the necessity of stratified sampling: As mentioned above, the aim was to be 
able to analyse the data by socio-economic status (SES), by condom use, and by partner 
type. The geographical area chosen was a fairly typical township, with a wide range of 
housing types. A random sample in the selected communities was expected to capture the 
diversity of SES present in townships33. However, there were concerns whether a random 
sample would provide sufficient women who had used a condom in their last sex act and 
had had a range of partner types. The Nelson Mandela Survey (2002) found that 24.7% of 
females reported using a condom in their last sex act, while studies done in 1998 and 2000 
showed that only 10%-12% of women used condoms in their last sex act [31 L, 99,182]. The 
pilot data was examined and found that 31% of women reported using a condom during 
their last sex act. If condom use in our sample had been closer to the lower range found in 
the literature, then stratified sampling would have been needed to ensure sufficient numbers 
to do a sub-analysis of condom-use for the last sex act. However, partner-type appeared 
33 Our sample is representative of urban townships, not of South Africa as a whole. 
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more problematic than expected, with only 1 of 77 women reporting a casual partner in 
their last sex act. It was decided that cohabitation was a more helpful categorisation of 
partners. Since 56% lived with their last sexual partner, this categorisation was thus 
expected to provide sufficiently sized segments. Conceptually, this also categorises partner- 
types into relatively discrete groups rather than the more nuanced and subjective distinction 
of long term versus casual partnerships. 
8.4.2. Sampling strategy and realisation 
Sample randomisation was done at three levels: geographical area, household selection, and 
participant selection. In South Africa, towns are divided into enumeration areas (EA) 
consisting of approximately 100 households. Spruitview contained 18 EA, Zonkiziswe 61 
EA, and Vosloorus 225 EA. These 304 EA were given random numbers, and then ordered 
by that number. A self-weighting random sample of 82 clusters was selected, of which 17 
were in Zonkiziswe, five in Spruitview, and 60 in Vosloorus. It was thought that 50 would 
be needed to achieve 1000 interviews. The aim was to complete 20 interviews in each 
cluster. It was estimated that an additional 20% would need to be approached to realise this, 
therefore between 17 and 40 households were selected per cluster. 
Household randomisation: Most EAs had well designated stand numbers, though some of 
the informal settlements did not. Aerial photos of the EA showed that the stands were 
plotted on street maps. A count of the number of stands per EA gave the sampling interval, 
ranging from every 4th to every 9th stand. The supervisors identified the stands. The first 
house to be counted was determined by a random start. If there were multiple households 
on a stand, a fieldworker used a random number chart to determine which household to 
approach. 
Participant randomisation: The fieldworker conducted a random selection of eligible 
participants within a household at the time of first contact with the household. Interviewers 
would first identify themselves and introduce the study briefly; then request permission to 
note down all adult women living in the house in the order of their age. If their ages were 
not between 18 and 45 years they were removed. If more than one eligible woman lived in 
the household, a random number grid was used to identify which woman to select for 
participation. The fieldworkers had date-specific grids containing ten random numbers 
between 1 and 10, generated by the random number procedure in Excel. Once a number 
had been used, it was crossed off and the next number was used if needed. If the woman 
was not present the interviewer would ask for a good time to return. The interviewer would 
145 
CHAPTER ö. COMMUNITY SURVEY METHODS 
return up to three times, and if the woman was still unavailable, a replacement would not be 
selected within the household. 
8.4.3. Sample realisation 
The sample realisation rate was lower than expected. Of the selected EAs, one was an 
empty field and four were men's hostels34. These were removed and replaced by the next 
five on the list. Once in the field it was found that one EA overlapped substantially with the 
pilot EA; it was therefore replaced. Two EA contained two houses from the pilot EA, so 
they were excluded from the household randomisation. Table 8-4 shows the sample 
realisation by cluster and the reasons that selected households did not contribute towards the 
sample. The realisation rate was on average only 12.4 per cluster, ranging from 6 to 22. 
The main reason for the lower realisation was the number of households that did not have 
any eligible women (20%). As we do not have data with which to compare this rate over 
time or by location, it is not clear if this is abnormally high. However, national mortality 
data do show a reversal in the adult mortality rates between men and women in the age 
groups 20-34 years old144'1. In 1997 the excess mortality in males was 1.55 times that of 
women, while in 2003 it had dropped to 0.83 times the female mortality ratet«'3. This is 
quite a dramatic reversal of excess death rates. This suggests death could be the cause of the 
absence of women in some of the sampled households. 
34 Male hostels did not meet the inclusion criteria as they officially do not house women. 
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Table 8-4 Distribution of households, clusters, and interview outcomes by location 
Zonkiziswe Spruitview Vosloorus Total 
Clusters selected 17 5 60 82 
Households selected 429 108 1472 2026 
Complete 230 53% 45 43% 742 50% 1017 51% 
Male only household 54 13% 3 3% 118 8% 175 9% 
No eligible women 75 17% 20 19% 316 21% 411 20% 
Not at home 37 9% 17 16% 155 10% 209 10% 
Postponed 6 1% 7 7% 40 3% 53 3% 
Refused 7 2% 9 9% 52 3% 68 3% 
Partially completed 1 0% 1 1% 7 0% 9 0% 
Other 6 1% 4 4% 27 2% 37 2% 
Missing reason 13 3% 2 2% 15 1% 30 1% 
Incorrect sampling 2 <1% 0 <1% 15 1% 17 1% 
Total households 431 100% 108 100% 1487 100% 2026 100% 
Average number of completed 
interviews per cluster 13.5 9.0 12.4 12.4 
The total number of completed interviews was 1017. An additional 17 questionnaires were 
completed but have not been included in the analysis as the participants were incorrectly 
interviewed, either because they did not fulfil the inclusion criteria or the randomisation of 
the household or woman was incorrect. All questionnaires completed by one interviewer 
were also removed (approximately 40), due to suspicion of consistently fraudulently 
completing the DCE section, which was the last and most challenging section of the 
questionnaire. This interviewer was primarily based in Vosloorus, and had conducted most 
of the interviews that were not in Sotho or Zulu as she was one of the few interviewers who 
mastered other languages. 
8.5. Final instrument 
8.5.1. Overview 
The final community survey questionnaire consisted of four sections (Appendix 6.1). The 
first collected background data on the respondent, including indicators of socio-economic 
status (education level, type of housing, and an asset index). The second section collected 
reproductive histories, including experience with existing barrier methods: what they use, 
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where they obtained it, if they had or had not used a condom in their last sex act. This 
describes the `neither' option. The reproductive histories also included information about 
contraceptives, life-stage questions (current type(s) of sexual partnership(s) and desire for 
pregnancy), and the respondent's perceived HIV risk. The method that was used last time 
reveals preferences for (and/or ability to use) condoms, the existing methods. The third 
section presented an introduction to barrier methods, and elicited preferences of products 
using both contingent valuation and a DCE; this section is described in more detail below. 
A male condom, female condom, a diaphragm, and a microbicide applicator filled with 
lubricant were provided for respondents to inspect as they wish, and ask questions. This was 
included to reduce the hypothetical nature of the products. The last section consisted of 
questions evaluating the interview and eliciting participant feedback on the questionnaire. 
The questionnaire was translated into the two most common non-English languages in the 
recruitment areas (Sesotho and isiZulu); then translated back for validation. 
8.5.2. The description of products and elicitation format for direct WTP. 
Women were given a description of the different barrier methods: male condoms, female 
condoms, the diaphragm and microbicide (Box 8-2). During this description they were 
handed the products (a prototype applicator filled with lubricant representing a 
microbicide). This was followed by an open-ended willingness to pay question on each of 
the products. 
Box 8-2 Presentation of each barrier method to participants 
SECTION 3: STATED PREFERENCES & INTRODUCTION TO FEMALE BARRIER METHODS 
We are going to discuss existing barrier methods for HIV prevention: male condoms, female condoms and 
some that are being developed: microbicides and the diaphragm. I am sure you are all familiar with male 
condoms. They are very effective in preventing HIV infection and pregnancy. They are put on right before 
sexual intercourse, and cannot be used without a male partner's knowledge and participation. We will now 
tell you a bit more about the other products. 
Firstly the female condom: HAND TO PARTICIPANT. The female condom is available in some clinics 
and shops. It provides good protection against HIV, STI and pregnancy. It can be put in for up to 6 hours 
before sex, and can be kept in for a total of 6 hours. It is recommended that a new female condom is used 
for each round of sex, however the female condom is strong and can in some cases be reused if no new 
one is available, and there is no male condom or your partner does not wish to use a male condom. If the 
female condom is re-used, it needs to be washed carefully with soap and water and patted dry between 
each use. It should not be used more than 7 times. The outer ring can sometimes slip inside the vagina, 
and some people say they can hear the female condom move while they have sex. The female condom 
can be used at the same time as using injectable contraceptives or the pill. 
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The Diaphragm, HAND TO PARTICIPANT, is a method that has long been used for pregnancy prevention 
and has shown to prevent some STIs. It is currently being tested to see if it provides any protection 
against HIV infection. The diaphragm can be kept in the vagina for up to 24 hours at a time, so can be 
inserted anytime before sex. It must be left in place for at least 6 hours after sex. The diaphragm you see 
here needs to be fitted by a health worker for the correct size and can be used for up to 2 years if cared for 
properly. This means that care is taken when removing it, not to pierce it with a long fingernail, and to 
wash it with soap and water and store it in its box. Using a lubricant makes the diaphragm easier to insert. 
If lubricant is not available, wetting the diaphragm with a little water can help slide the diaphragm into the 
vagina. Some partners can feel the diaphragm during sex, while others cannot feel it. Scientists are 
developing a single use disposable diaphragm and a one-size fits all diaphragm. The diaphragm can be 
used at the same time as using injectable contraceptives, the pill, and/or condoms. 
Microbicides, HAND APPLICATOR TO PARTICIPANT, are new products that are being tested to see if 
they can reduce women's risk of becoming HIV positive. Microbicides are also being tested to see if they 
can prevent some STI. These products are still being tested, it is not yet known if they provide any 
protection against HIV or whether they may reduce a woman's chance of becoming pregnant. If an 
effective microbicide is found, they may either come in a pre-filled applicator that will need to be thrown 
away after each use, or may be developed for use with a re-usable applicator with a tube of microbicide. 
The re-usable applicator will need to be washed after each use and refilled before each use. It is also not 
known if they need to be inserted directly before sex or if it can be inserted a few hours in advance. The 
gel may make the vagina a little bit more moist (wet). Some partners may notice this, while others may not. 
Microbicides can be used at the same time as using injectable contraceptives, the pill, and/or condoms. 
We would like to remind you that right now we do not know if the diaphragm and microbicides provide any 
protection against HIV. Only male and female condoms have been shown to prevent HIV infection. 
In the open-ended willingness to pay question, female condoms were presented as equally 
effective as male condoms at preventing HIV and the diaphragm and microbicides as half as 
effective as condoms. Women were first asked about their willingness to try the newer 
methods, and if they thought each was something they would want and be able to use 
regularly, then the willingness to pay question was posed. Then women were presented with 
the DCE. 
8.5.3. Participant familiarisation with attributes and level 
To prepare women for the presentation of the attributes and their ranges women were first 
presented with each attribute individually and asked to choose their preferred level. After 
presenting the pictures of the products, women were shown the pregnancy prevention and 
HIV prevention attributes (Box 8-3), then secrecy (Box 8-4) and price (Box 8-5). The 
physical attributes DCE was then done. Then the attributes and levels for the distribution 
DCE were presented one-by-one (Box 8-6) and the DCE implemented. The implementation 
is presented in the next secion. 
To prepare women for HIV and pregnancy prevention attributes portraying partial 
effectiveness, women were presented with visual depictions of choices orr what level of 
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HIV prevention they need, and what level of pregnancy prevention they want from their 
HIV prevention product (Box 8-3)35. These questions also help us to have a sense of how 
well women did comprehend the pictures. Understanding was high, with 94% of women 
choosing the highest level of HIV prevention presented. These were deliberately in mixed 
order: 35%, 95%, 55%, and 75% for male condom, and 55%, 0%, 95%, 75% for the female 
condom, to ensure respondents actually looked at the values before responding. 83.7% 
chose the highest level of pregnancy prevention, and 4% chose no pregnancy prevention. 
Box 8-3 Presentation of each pregnancy and HIV effectiveness to participants 
Vahat kind of pregnancy prevention do you wand from your HIV prevention product? 
55% reduction in 95%reduction in 75%reduction in 
pregnancies Does not prevent pregnancy pregnancies pregnancies 
9 of 20 women Al 20 women 1 of 20 women 5 of 20 women 
become pregnant become pregnant become pregnant become pregnant 
Do you need a product that provides low (POINT TO 1) protection against HIV, very high (POINT TO 2) 
iwotection_ medium protection (POINT TO 31, or high protection (POINT TO 4) against HIV ? 
35%risk reduction 95%risk reduction 55% risk reduction 75%risk reduction 
1'f 1'r 
ý 
1't 1? 1'r TT i'T 7T 
7 of 20 women 19 of 20 women remain HIV 11 of 20 women 15 of 20 women remain HIV 
remain H IV negative negative remain HIV negative negative 
Box 8-4 Is it important to be able to use a product in secrecy? That means without 
your partner knowing. 
-44 X Yes, Can be used without your partner knowing No, Cannot be used without your partner knowing 
35 Please also note that these are the final formats of the risk reduction attribute levels. It can be seen that 
these were simplified from Box 7-1 where the figures have faces and are outlined. 
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The price of a microbicide or a disposable diaphragm is likely to be within the current price 
range of male and female condoms: free at the lowest price and R22.50 at the top end 36 
Women were asked "What is the highest amount you would be willing to pay and could 
afford to pay for any of these single use products to use it every time you have sex? " (Box 
8-5). When presented with the four prices (R0, R5, R10, R20). To represent the price of a 
reusable product (i. e. that is only the diaphragm) women were presented with a higher set of 
prices (R0, R20, R40, R80). 
Box 8-5 Payment scale willingness to pay questions for a single use product and a 
reusable product. 
What is the highest amount you would be willing to pay and could afford to pay for any of these single use products 
to use it every time you have sex? Is it 0 Rand, I would only use it if it were free? Or I would use it every time I had 
sex if it were 5 Rand, 10 Rand, or 20 Rand. You still have the existing other options of collecting male condoms for 
free or paying for them. 
0 Rand, 
ý,,, _.... ý iii( .... ... 
I would only use them 
if they were free -_i 5 Rand 10 Rand 20 Rand 
What is the highest amount you would be willing and able to pay for any of these Reusable products? 
ý ws V 
yy 
,a 
0 Rand, 
I would only use them 
if they were free 
20 Rand 40 Rand 80 Rand 
36 This was the price for two V-Amour female condoms in the private sector, female condoms from the 
Female Health Company were not readily available in the private sector. 
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Box 8-6 DCE distribution attributes and levels and their presentation 
8.5.4. DCE presentation 
The DCE section included a warm-up question to help the respondent understand the 
concept of DCE questions and trade-offs between the attribute levels. During the 
introduction to the DCE, respondents were asked to keep their last sex act in mind when 
making choices between the alternatives. This was supported in the physical attribute DCE 
by a card that was placed over the opt-out option showing on one side the attribute levels of 
having used a male condom and on the other side the attribute levels of not having used a 
male condom (Box 8-7). This aimed to capture not ideal usage but feasible usage. 
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Box 8-7 Presentation of the physical choice sets 
Here are the products and this i s what they do : Would you have used eith er of these products in your last 
sex act or would you have still d one the same as you did the last time you had sex? 
VERSIO N: A 
Neither option card 
CHOICE 
Attribute A B C Front Back 
onto Flesh to Flesh 
Hlahiso Use no barrier 
Ngekengiguquke method 
Product Female condom Microbicide Male Condom 
Ngesese X 
4 kulokhu 4 X 
-. bengikwenýle -W 
Sephiring 
No, Cannot be Yes. Can be used @aikhethin! esedule 
Can be used No, Cannot be used 
secrecy used without your without your without your partner without your partner 
partner knowing partner knowing knowing knowing 
Ukwehlisa 95% reduction in 95% reduction in Does not prevent 95% reduction in 
amathuba pregnancies pregnancies pregnancy pregnancies 
va 
Leletho nka so 
Ho fokots Ho rokotsa 
ý 
rreryeta ya ho ima * * fetal e sea ke so 
Pregnancy risk 1 of 20 woman 1 of 20 women All 20 women 1 of 20 women 
reduction becomes pregnant becomes pregnant entseng kgetlo Is become pregnant become pregnant 
Ukaehlisa 
amathuba 95% risk reducti on 35% risk reduction 
febleng 0 risk reduction 95%nskreduction 
okuwleleka nge 
HIV 
11111 
Ho fokotsa 
h l 
A 
J 
AAA 
1 
me nyel a ya o 
tstr. ýmeis tswa ke HIV 19 of 20 women 7 
RR TT 
7 of 20 women Neither. 0f ZO women remain o 19 of 20 women 
HIV risk reduction remain HIV negative remain HIV negative HIV negative remain HIV negative 
would not change what I 
Intengo 
! :Y 
did last tore 
Free Free 
Hlwehlwe ai r 
Price 20 Rand 20 Rand 0 Rand 0 Rand 
CHOICE 
ID 1 
The distribution attributes experiment was simpler in design. Women were asked their 
preferred barrier method, if not for current use, for possible use in the future. Based on that 
preferred product, they then made a choice between two distribution scenarios, thus 
providing conditional demands. The attributes for the distribution DCE were: distribution 
channel, collection method, advertising message and price. The levels for these attributes 
and how they were represented can be found Box 8-6. 
8.5.5. Axiom testing 
It is good practice in DCE to test the extent to which the respondents' answers are 
consistent with fundamental axioms in economics 
[442,303,443,413,394,444,445,407,446,403,415,29,447- 
450) To test for stability, the same choice set was included at the beginning and at the end of 
the DCE. A hold-out question was included in the questionnaire, but not in the estimation 
procedure to test for predictive/internal validity. Validity was tested using a dominant-pair 
test (monotonicity). Unwillingness to trade was tested, including a second dominant-pair 
test in favour of a different alternative. Given the high quantity of condom promotion 
messages stating that one 'should' always use condoms, there was some concern around 
CHOICE A B C Attributs 
Innto 
Hlahiso 
Ngeke ngiguquke Product Female condom Microbade 
Ngesese x 
4 Wokillu 
-. bengikwenzile 
Sephinng 
No, Cannot be Yes, Can be used osikhathini esedule secrecy used without your without your 
partner knowing partner knowing 
Ukwehfsa 95% reduction in 95% reduction in 
amathub L pregnancies pregnancies 
okukhule 
Leletho nka se 
Ho fokotsa 
rrenyeta ya ho ima * * fetal e sea ke se 
Pregnancy risk 1 of 20 women 1 of 20 wo men 
reduction becomes pregnant becomes pregnant entsengkgetlole 
Ukwehlisa 
amathuba 95%riskreduction 35% risk reduction 
fehl Bfl g 
okusuleleka nge 
HIV 
Hofokotsa 
l h 
i 
fý me nye a ya o 
tstrreaetswa ke HIV 19 of 20 women 
RR TT 
7 of 20 women Nedher, 
HIVrrsk reduction remain HIV negative remain HIV negative 
would not change what I 
Intengo di it asttine 
Hlwehlwe is 
W: 
:r 
Price 20 Rand 20 Rand 
CHOICE 
Front Back 
Flesh to Flesh 
Use no barrier 
method 
Male Condom 
_W4 
x 
Yes, Can be used No, Cannot be used 
without your partner without your partner 
knowing knowing 
Does not prevent 95% reduction in 
pregnancy pregnancies 
All 20 women 1 of 20 women 
become pregnant become pregnant 
0 risk reduction 95% nsk reduction 
11111 ft 0f 20 women remain 19 of 20 women HIV negative remain HIV negative 
Free Free 
0 Rand 0 Rand 
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over-reporting of condom-use during the last sex act. This reporting bias was explored by 
including scenarios comparing existing options and checking for consistency between their 
choice and their reported practice during the last sex act. In order to avoid overloading the 
questionnaire, each of these tests were only included in 20% of the questionnaires, so each 
questionnaire included one extra question. Appendix 7 shows the final design and the 
blocking of the scenarios into choice sets. 
Ten choice sets were considered a cognitively reasonable exercise to present to respondents. 
[373] The 180 experimental choice sets plus 20 test choice sets were blocked into 20 
questionnaire versions. The axiom tests were added on as the last choice task within the 
distributional DCE's, with the exception the reporting-bias choice, which was in the 
physical attributes format. 
8.5.6. Evaluation questions 
After the main interview was completed, participants were asked some additional questions 
about their experiences responding to the questions in the interview, such as which 
questions were difficult, uncomfortable, etc. There was also a short section for the 
interviewer to complete about how the interview had gone that covered interruptions, 
attendance by others, whether the women had difficulty answering questions, and provided 
space for other comments. 
This completes the overview of the survey instrument. The next section covers practical 
issues related to implementing the survey. 
8.6. Community survey procedures 
8.6.1. Recruitment and training of interviewers 
From within the study communities 20 adult women of different ages were recruited to 
implement the survey. Women participated in a week long training in interview methods 
and understanding of the questionnaire that ended with the implementation of the pilot 
survey. Part of this training focussed on how to correctly obtain an informed consent and 
how to maintain confidentiality. A week's break was taken to analyse the data and revise 
the questionnaire. Given the random selection procedure, age matching was not possible, 
but extremely young or old women were not recruited as interviewers. After this week, 
three did not return. 
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8.6.2. Field procedures 
There were five teams of field workers implementing the survey, composed of four to five 
fieldworkers with a supervisor and a vehicle. Interviews were conducted with women in 
Ekurhuleni in their homes. The interviews were face-to-face, and a generic paper 
questionnaire was used. The DCE had 20 versions, which were kept in colour flipcharts. 
Every day the flipcharts were rotated among the fieldworkers following a fixed rotation 
scheme. During the interview the study was first explained, then informed consent 
requested. The questionnaire was administered in a private setting, emphasising that the 
questionnaire could not be completed in the presence of the partner. Participants were 
provided a token reimbursement in the form of a telephone card worth 20 Rand (1.71 in 
2005 GBP), as is common practice with such surveys. 
The interviewers had HIV information booklets containing contacts of available referral 
services to hand out to all participants who were willing to accept them. Debriefing and 
training sessions were held every day with the interview team to give them the opportunity 
to share field experiences in confidence and support any training needs identified. 
The survey instrument and consent form appear in Appendix 6.1 and Appendix 6.2, 
respectively. 
8.6.3. Quality control using evaluation interviews 
A process evaluation was carried out to document the aim of assessing participants 
understanding of the products, particularly that microbicides and the diaphragm were still 
being tested and were not yet known to prevent HIV, and the DCE attributes and levels, 
particularly the understanding of the relative risk profiles. 
A short additional questionnaire was administered after the survey questionnaire to 42 
participants37. This additional questionnaire was administered by the researcher with the 
aid of a South African research assistant, who was involved in this study from the outset. 
The final evaluation survey instrument was a fairly quantitative checklist of a participant's 
understanding of the product attributes and the discrete choice experiment, however most 
evaluation interviews were also recorded as a fallback if needed. Approximately three 
participants were selected daily for this additional questionnaire. Identifying data were 
37 An additional ten participants completed this survey during the first three days; these were used to 
refine the tool and not considered as part of the evaluation survey. 
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collected to enable the evaluation interview to be linked with the valuation survey. After 
the teams had been in the field for about two hours, a team was chosen to visit. Supervisors 
were not told in advance which team would be visited. Participants that were re- 
interviewed were selected by randomising the fieldworkers who interviewed them. The 
monitors were approached to provide the most recently completed interview by a specific 
fieldworker. Sometimes, the fieldworkers themselves were asked to provide the addresses. 
The woman was approached and her participation requested for the brief additional 
questionnaire (Appendix 8). Though not the main aim, the evaluation survey was also a 
monitoring tool that helped to identify problems related to the survey implementation. 
Results from the evaluation survey also contributed to the interpretation and discussion of 
the DCE results but are not formally analysed within this thesis. 
8.6.4. Problems encountered 
Two fieldworkers were fired in two separate incidences of fraud. The first incident occurred 
12 days into the survey, when a fieldworker was found making up answers to missed 
questions, rather than revisiting the interviewee. The second incident occurred during the 
last few days of the survey, when the evaluation survey detected that a fieldworker was 
administering all questions with the exception of the ten DCE scenarios. This was the only 
fieldworker who had not been evaluated earlier, therefore it could not be determined if she 
had been doing it from the start. Therefore all her previously completed questionnaires 
were shredded. 
8.6.5. Data entry 
All questionnaires were checked at least once by the field monitors, the survey monitor or 
myself. Missing responses and inconsistent answers were returned to the interviewee for 
completion/correction. Double data entry was employed: two people entered each 
questionnaire into the database, then the two versions were compared. Where differences 
were identified, the original paper survey was referred to and corrections made. During 
data cleaning there were further checks for infeasible responses and illogical 
inconsistencies. Descriptive statistics and data plots were used to identify outliers. These 
were checked against the paper surveys. During data entry and cleaning, the surveys were 
kept at the main offices of the survey group. They were then couriered to LSHTM, and will 
be destroyed after the end of the study. 
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8.7. Discussion 
This chapter has summarised the design and issues arising in the community survey. To 
collect data on women's preferences for barrier methods and their distribution, a large 
(1017 participants) community survey was implemented in adjacent townships in South- 
East Johannesburg. The community survey instrument was developed based on a series of 
eight focus group discussions, six in-depth interviews, and an attribute identification 
workshop. Specific analysis methods are provided alongside the findings from the analysis 
of the community survey in the in next section. 
157 
CHAPTER 9. SUR VEY SAMPLE AND GENFRALISABIL17T 
SECTION III: SURVEY ANALYSIS AND INTERPRETATION 
This section of the thesis consists of four chapters. Chapter 9 gives an overview of the 
survey realisation and explores the generalisability of the survey population to the broader 
urban South African female population. Chapter 10 explores women's socio-demographic 
characteristics to identify which might be most defining in terms of their preferences. It uses 
a market segmentation analysis and an analysis of women's willingness to pay (as a proxy 
for their preferences) to identify critical women's characteristics to include in the 
subsequent analysis of the discrete choice experiments. Chapters 11 and 12 present the 
analysis of the discrete choice experiments of product attributes and distribution and 
promotion strategies, respectively. 
Chapter 9. Sample generalisability 
9.1. Introduction 
The previous chapter described the design and implementation of the household survey of 
adult sexually active women in Johannesburg, South Africa. This chapter aims to: 
1. Review the household socio-economic characteristics of study participants using 
descriptive statistics, 
2. Develop a household socio-economic status indicator from participants household 
characteristics using factor analysis. 
3. Review women's own socio-demographic characteristics, including reproductive 
health histories. 
4. Assess if the sample of women who participated in this study are representative of 
urban South African women from the general population and consider if results 
from this survey can be generalised to the broader urban female population in other 
locations. 
In the following sections characteristics of the sampled households and women are explored 
using descriptive statistics. Household socio-economic status, women's socio-demographic 
and behavioural characteristics and reproductive health histories are examined. These are 
then compared with data from two nationally representative surveys [30.311 Section 9.2 
provides the methods employed in this chapter. Section 9.3. gives an overview of the 
household characteristics using descriptive statistics. Section 9.4. presents the socio- 
economic indicator. Section 9.5. presents the demographic and reproductive behaviour 
characteristics of the women who participated in the survey. Section 9.6 briefly compares 
the three study locations in terms of the household characteristics and women's own socio- 
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demographic characteristics. Section 9.7 considers the validity of the survey sample. The 
validity of the DCE responses is reviewed in Section 9.8, and 9.9 concludes the chapter. 
9.2. Methods 
Two main methods were used to meet the objectives of this chapter: 
" To understand the comparability between the women in our survey and urban South 
African women from the general population, a range of variables from this survey 
were compared with two recent nationally representative surveys. 
" To represent the variation in household socioeconomic status an index were 
estimated using principal components analysis. 
9.2.1. Review and comparison of descriptive statistics 
A review of the household and individual characteristics of the study participant is 
undertaken using basic descriptive statistics. Generalisability was assessed by comparing 
women's socio-demographic characteristics with those from two recent nationally 
representative surveys in South Africa: the South Africa Demographic and Health Survey 
(DHS) from 2003 [30] and the South African National HIV Prevalence, HIV Incidence, 
Behavioural and Communication Survey, 2005 (known as the Nelson Mandela Survey 
(NMS)) [311. This was a nationally representative survey which included questions on sexual 
behaviour comparable to those included in Ekurhuleni and the 2003 DHS mentioned earlier. 
9.2.2. Estimation of a socio-economic status index 
Principal components analysis was used to operationalise the concept of socio-economic 
status into a uni-dimensional quantitative variable. "PCA is a multivariate statistical 
technique used to reduce the number of variables in a data set into a smaller number of 
`dimensions'. " [4511 as applied by Kline (2000) (452]; Vyas and Kumaranayake (2006) [451], 
and Filmer and Princhett (2001) [453 For the indicator here, variables included were those 
thought to be important to the broader concept of SES. The proxy for wealth included is the 
ownership of ten assets (radio; television; telephone (landline or cell phone); refrigerator, 
computer; washing machine; bicycle; motorcycle; car; and sheep or cattle); if the household 
has electricity; lives in a shack or a room outside; or a self-owned brick house; and the 
number of people per room. Social capital was captured by the variables: number of years 
living in the location and the level of difficulty in accessing R100 if needed in a medical 
emergency38. The statistical technique then computes `principal components' representing 
non-correlated dimensions or indices in the data. Values, representing importance weights, 
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are given to each of the variables. From the presence of the variables in women's homes an 
index is then calculated, representing the relative socio-economic status of each woman's 
household. Some studies proceed to recode this variable into categorical variables such as 
quintiles, or use cluster analysis to identify some natural clustering of the index [4511. As the 
continuous variable provides more information than such a categorical recoding of it, for 
the purpose of this thesis, the continuous form of the variable was used. 
9.3. Survey household characteristics 
The majority of women interviewed reported living in brick homes, either self-built or on a 
bond (mortgaged); 27% lived in municipal, RDP, or RDP extended39 houses, 25% lived in a 
shack. Other types of housing include outside room, inside room and hostel 
accommodation. The houses ranged from one to 13 rooms, of which between one and seven 
were used for sleeping. Most common was a four room house with two bedrooms, and four 
inhabitants (ranging from I to 17). On average there were 2.26 people per bedroom, ranging 
from 0.5 to 10. Accommodation was mostly privately owned, either owned by partners 
(31%), parents (28%), or by the respondents themselves (23%). 
Most homes were relatively well equipped. Table 9-1 shows the percentage of households 
who own each asset; the columns show the differences in asset ownership by the two most 
common and most distinct (from each other) types of housing: bond house and shack, and 
the total for all housing types (including those not shown). Women were asked both if they 
had each asset and if each asset was in working condition. If the asset was broken, the asset 
was treated as not being part of the woman's assets. Only 8% of homes did not have 
electricity, and most had a television, a phone and a fridge (85%, 87%, and 83%, 
respectively). About one-third of households had cars and/or washing machines; in 
households in a bond house this was 49%, and of households living in a shack this was 
14%. Computers were quite rare with only 121 (12%) respondents living in a household 
with one; of these households with computers, six lived in shacks. On the extremes, there 
were 14 (1%) households who owned none of the assets, and 18 households who owned 
nine of the 11 assets on the list. No household had more than nine of these assets. Cattle, 
sheep, bicycles and motorcycles were quite rare in this area. Other indicator of socio- 
economic status is an individual's access to R100 for a family member's medical treatment. 
For 34% of respondents this would be quite difficult, and for 13% very easy. 
38 It could be argued that these are either individual characteristics or household characteristics. 
39 These are the RDP houses which have been extended by residents to include extra rooms. 
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Table 9-1 Household asset ownership by housing type 
Percentage in possession of. Bond house Shack All Housing types DHS 2003-Urban 
Electricity 99% 73% 92% 90% 
A radio 94% 72% 84% 81% 
A television 98% 64% 85% 79% 
A telephone/cell phone 96% 70% 87% 70% 
A refrigerator 98% 54% 83% 75% 
A personal computer 22% 2% 12% 14% 
A washing machine 58% 8% 37% n/a 
A bicycle 18% 11% 14% 16% 
A motorcycle or motor scooter 0% 0% 1% 2% 
A car 49% 14% 31% 33% 
Sheep or cattle 1% 1% 1% 2% 
Total number of households 381 256 1017 4502 
(% of all households) (37%) (25%) (100%) 
9.4. The household socio-economic status indicator 
Now the household data has been explored, this can be used to constructs a variable of 
household socio-economic status, which then summarises a number of the dimensions of 
household characteristics above, into a uni-dimensional composite index. A review of the 
concept of socio-economic status and poverty can be found in Appendix 9. Following an 
overview of the method used to construct the household socio-economic status index, a 
description of the variable is briefly presented. 
9.4.1. The results of composing a socio-economic status index 
The PCA generated 16 components. The first represents the socio-economic status index of 
interest. The first component accounted for 25% of variation in the data. The component 
scores represent the weight of each variable in the index, shown in Table 9-2. 
40 This includes categories not shown' to the column heading `All housing types 
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Table 9-2 Wealth and social capital proxy weights in socio-economic status indicator 
Inputs Factor score 
Wealth indicators: 
Lives in a shack or a room outside -0.71 
Lives in a self owned brick home 0.63 
Crowding index (people per sleeping room) -0.39 
Household ownership of: 
Electricity 0.59 
A radio 0.51 
A television 0.67 
A telephone/cell phone 0.51 
A refrigerator 0.68 
A personal computer 0.39 
A washing machine 0.58 
A bicycle 0.21 
A motorcycle or motor scooter -0.00 
A car 0.48 
Sheep or cattle 0.01 
Social capital indicators 
Years lived in location 0.27 
Ease of access to R100 0.54 
The absolute magnitude of these weights indicates the strength of association with being of 
higher or lower socio-economic status. This can also help to consider the theoretical validity 
of the index. It can be seen that the largest weight (in absolute size) is for the variable `lives 
in a shack or room outside'. As it is negative, it indicates that it is a strong identifier for 
those of low socio-economic status. The second most important asset is refrigerator, 
followed by owning a television and living in a home owned by one of the occupants. A 
couple of variables contributed little to the index: owning sheep or cattle and a motorcycle. 
By definition, the mean of the index is 0, and a standard deviation of 1. However, the 
median of 0.22 shows the skewdness of the index. This can also be seen in Figure 9-1. 
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Figure 9-1 Distribution of socio-economic status variable 
Using the "two-step cluster" procedure in SPSS, three clusters are identified. It would be 
expected that the lowest socio-economic status group would be represented more in 
households living in Zonkiziswe and that more of the households in Spruitview would be in 
the highest category. 
Table 9-3 Descriptives of socio-economic clusters 
Average socio- Number of households in 
Cluster economic status Zonkiziswe Vosloorus Spruitview Total 
1 -1.72 86 88 0 174 
2 -0.17 126 275 11 412 
3 0.87 16 376 34 426 
Total 228 739 45 1012 
In Table 9-3 it can be seen that Cluster 1 has the lowest socio-economic status and cluster 3 
the highest. Cluster I contains 38% of households from Zonkiziswe, 11% of households 
from Vosloorus and no households from Spruitview; cluster 3 on the contrary contains 7% 
of households from Zonkiziswe, 51% of households from Vosloorus and 76% of 
households from Spruitview. This is consistent with expectations. 
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9.5. Women's characteristics 
Women could be included in the study if they were between 18 and 45 and had been 
sexually active in the past six months. The average age of participants was 31.5 years 
(Figure 9-2). 
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Figure 9-2 Age distribution of participants 
The most common languages spoken in women's homes were Zulu (52%) and Sotho 
(24%). Few women (3%) women never had any formal schooling; 45% started but did not 
complete secondary school, and 27% completed secondary school; 9% completed tertiary 
education (Table 9-4). 
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Table 9-4 Participants' languages, religions and educational attainments 
Home language What religion do you belong to? 
What is the highest level of 
education you gained? 
IsiZulu 52% Christian -unspecified 37% None 3% 
SeSotho 24% Zionist 25% Incomplete primary 6% 
ZiTsonga 8% Catholic 11% Completed primary 3% 
IsiXhosa 6% None 10% Incomplete secondary 45% 
SePedi 5.0% Bom Again 8% Incomplete secondary & 1% 
SeTswana 3% Other 3% some vocational training 
SiSwati 1% Shembe 2% Completed secondary 27% 
English 1% Protestant 2% Incomplete tertiary 5% 
TshiVenda 1% Jehovah's Witness 1% Completed tertiary 9% 
isiNdebela <1% Traditional African 1% 
Afrikaans <1% 7th day Adventist 1% 
Other <1% Muslim <1% 
Total % 100% Total % 100% Total % 100% 
Total responses (1017) Total responses (1016) Total responses (1016) 
Twenty-eight percent of women had moved to the area within the past five years. Most 
were from other areas in Gauteng (57%) and Kwazulu-Natal (19%). New movers came 
from other large cities (36%), towns (37%) and rural areas (27%). Just over half the women 
(51%) were unemployed, 26% worked full-time, and 10% part-time, the remaining were 
students (8%), housewives (5%), retired (<10/o), and undefined (1%). The most common 
sectors of work were sales and services (72%) and domestic work (14%). 560 women 
(55%) were living with a sexual partner (of which 84% considered their partner as the head 
of household); 25% lived with their parents, and only 8% lived by themselves; about 77% 
of cohabitating women reported that their partners contributed more financially to the 
household then they did themselves. 
Reproductive health histories 
The median age at sexual debut was 18 years old, ranging from 10 to 30 years old. Women 
had an average of 1.8 children, with 80% having at least one child. About a quarter (24%) 
of women would be happy if they became pregnant in the next couple of weeks, 14% would 
be indifferent, and 63% would be unhappy. 
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Figure 9-3 Histogram of age at sexual debut and number of children 
Most women (73%) had used contraceptives (Table 9-5). Mean age to start using 
contraceptives for the first time was 20 years old, ranging from 12 to 41. Only 40% of 
women were using contraceptives at the time of the interview. Among ever users of 
contraceptive, injectables were the most common first contraceptive (62%) followed by 
pills (18%). Condoms appear to have increased in popularity for contraceptive purposes. 
Condoms were reported to have been used in 10% of protected first sex acts, while they 
make up 24% of current contraceptive use. 
Table 9-5 Types of contraceptives used 
What was the first method you ever What method are you currently using? 
used? (among ever users) (among current users) 
Injectables 62% 43% 
Pills 18% 25% 
Condoms 10% 24% 
IUD-Copper T 10% 3% 
Sterilised >1% 4% 
Other >1% 
Total 100% 100% 
Of the women who had ever used contraceptives, almost half never changed method, 
another 47% switched once or twice and six women had used five or six different types of 
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contraceptive methods. The main reasons for discontinuation of methods were side-effects 
(53%) and wanting to get pregnant (26%). By far the most common source of first 
contraceptives is the public clinic (83%) followed by private GP (6%) and government 
hospital (4%). For current contraceptive use, the clinic remains highly frequented, with 
74% having collected their last contraceptive method from there. However, the use of other 
sources was slightly more frequent. 
Table 9-6 Sources of current contraceptives by source 
Where did you get that method 
the last time you collected it? 
What method are you currently using? 
Injectables Pills Condoms IUD Other 
Total % of 
Total 
Clinic 154 83 59 6 2 304 75% 
Government hospital 9 3 0 0 14 26 6% 
Youth Centre 0 0 1 0 0 1 >1% 
Other public source 0 0 4 0 0 4 1% 
Private hospital 3 1 0 2 1 7 2% 
Pharmacy-chemist 0 4 16 0 0 20 5% 
Private GP 9 9 1 5 0 24 6% 
Supermarket 0 0 2 0 0 2 0% 
Spaza shop 0 0 1 0 0 1 0% 
Other 0 0 13 0 1 14 3% 
Total 175 100 97 13 18 403 100% 
% of total 43% 25% 24% 3% 4% 100% 
Contraceptive switching was more common than switching sources: 85% of women had 
only obtained contraceptives from one type of outlet, the highest number of outlet types 
used by a woman was three. 
Familiarity with male condoms was high, with 63% having ever used a male condom with a 
partner. With their last partner with whom they used a condom, almost half (48%) 
suggested using a condom themselves, 39% of partners suggested condom use, and 13% 
both suggested using a condom. Many women who had used condoms with a partner had 
also collected condoms themselves (68%), most commonly from the clinic for free (64%), 
or paid for them from a chemist (11%). The three main reasons for their choice of condom 
source were convenience, price and location. The most common reason for collecting from 
the clinic was price; `chemist' stands out for the number of women reporting getting their 
condoms there because `it has the brand they like' (Table 9-7). Collected them `from a box 
or machine' was popular (78%) and `from a person behind a counter' less so (18%). The 
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free government condoms were quite common (77% of condoms collected by women were 
free), followed by LoversPlus (14%), the upmarket social-marketing condom. The lower 
priced social marketing condom, Trust, contributed 5%, and only 13 women (1%) reported 
buying private sector brands. 
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Table 9-7 Male condom sources, method of collection and reasons 
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Although 77% of women had heard of the female condom, just 39.2% had ever seen one, 
and only 3% (28 women) had ever tried one. The most common reason for not trying a 
female condom, among those who had seen one, were: that they never thought about it 
(29%); they did not like the way they looked (18.2%); they expected discomfort/pain 
(16%); they could not find one (14%); couldn't afford one (8%) and they didn't know how 
to use it (4%) (Table 9-8). 
Table 9-8 Reasons for not trying the female condom 
Reasons for not trying a female condom Frequency % of total 
Never thought about it 108 29% 
Do not like the way they look 68 18% 
Expect discomfort/pain 58 16% 
Couldn't find one 51 15% 
Couldn't afford 30 8% 
Did not know how to uses it 15 4% 
Does not need HIV or pregnancy prevention 14 4% 
wanted to but my partner refused 12 3% 
Afraid to use/doesn't look safe 6 2% 
was using a male condom 2 1% 
Married 2 1% 
Don't know 2 1% 
Other 4 1% 
Total 372 100% 
Note: there were 27 missing reasons for not trying a female condom from 399 women 
who had heard of it. 
Of the women who had ever used a condom and had ever collected one themselves, most 
collected their last condoms for free (65%), from a person behind the counter (55%), at a 
clinic (30%), or a chemist (30%). The reason for this choice was mostly the convenience of 
already being at the source (40%). 
The vast majority of women reported that their last sex act was either with their husband 
(43%) or a regular partner (56%); only 6 of 1017 women interviewed reported that their last 
sex act was with a casual acquaintance. No women reported that their last sex act was with 
someone they just met, or with a paying partner. Thirty-eight percent of women had ever 
experienced difficulty in negotiating condom use. In their last sex act, 31 % reported using a 
170 
CHAPTER 9. SURVEY SAMPLE AND GENERALISABILITY 
condom. Table 9-9 shows the main reasons women gave for using or not using a male 
condom. 
Table 9-9 Main reasons for using and not using a condom in women's last sex act 
Main reason a condom was used? Frequency Percent 
Dual protection 173 55% 
HIV prevention 70 22% 
Pregnancy prevention 43 14% 
STI prevention 16 5% 
Other (not specified) 5 2% 
Because it was that time of the month 3 1% 
Breast feeding 2 1% 
HIV positive 1 >1% 
There was a misunderstanding 1 >1% 
Lack of trust 1 >1% 
Health workers told me to use it 1 >1% 
We use it every time 1 >1% 
I feel like using it 1 >1% 
Total 318 100% 
Main reason a condom was not used Frequency Percent 
I did not want to41: 279 40% 
l am not worried about HIV or STI 114 16% 
They trust each other 101 14% 
do not like condoms 64 9% 
My partner refused/ partner doesn't like, afraid of partner 226 32% 
Never thought about it 54 8% 
want to get pregnant 52 7% 
We did not have one at the time 47 7% 
Use other method to prevent pregnancy 22 3% 
Cultural norms (married, Christian, age) 8 1% 
Did not know how to use it 5 1% 
Side effects/pain 4 1% 
Condoms cause AIDS 3 >1% 
I use it only when I am sick 2 >1% 
It was rape 1 >1% 
Total 703 100% 
The main reason for using a condom was dual protection (54%) followed by HIV 
prevention (22%). The main reason for not using a condom was because they did not want 
41 The following three actual responses fall into this general category. 
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to (40%), either because they were not worried about HIV/STI, they trusted their partner, or 
they don't like condoms. Almost a third did not use a condom because their partner either 
refused or she did not dare ask. 
HIV knowledge and risk perceptions: HIV knowledge was relatively high, 40% knew the 
correct answer to all eight of the questions, and only 13% had five or less correct answers. 
Women's own perception of their risk was very equally distributed between the four risk 
categories: no (26%), low (23%), medium (26%) and high (22%). 
9.6. Comparison of the study locations 
The profiles of the three locations reflect the targeted differences in socio-economic status 
(Table 9-10). Generally it can be seen that Zonkiziswe is the poorest of the three areas. It 
has the highest number of participants living in shacks and the highest crowding index. On 
average participants had the lowest social capital, number of assets owned, age, education, 
and level of employment. Their age at sexual debut was the youngest, with the lowest 
proportion of women who had ever used a condom and the lowest HIV knowledge scores. 
Spruitview is on the other end of the spectrum with the highest: portion living in self owned 
brick homes, level of social capital, number of assets owned, age, education, level of 
employment, age at sexual debut, ever use of a male condom, and HIV knowledge. 
Whether the head of household is the participant herself or considered her husband as head 
and the number of children are similar between Spruitview and Zonkiziswe, while the 
statistics for Vosloorus were lower. 
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Table 9-10 Comparison of statistics from the three study areas 
Zonkiziswe 
Location 
Vosloorus Spruitview All 
Lives in a shack or a room outside 76.5% 13.3% 2.2% 27.1% 
Lives in a self owned brick home 11.7% 50.1% 91.1% 43.3% 
Crowding index (people per sleeping room) 2.6 2.2 1.9 2.3 
Social capital 1.7 2.4 2.6 2.3 
Speaks Sotho at home 13.9% 25.6% 40.0% 23.6% 
Speaks Zulu at home 67.0% 47.7% 35.6% 51.5% 
Number of assets owned 4.4 5.5 6.4 5.3 
Household head - Husband 50.4% 46.1% 53.3% 47.4% 
Household head - Self 21.3% 15.5% 20.0% 17.0% 
Age 30.5 31.8 33.2 31.5 
Education in Years 8.1 10.6 11.5 10.0 
Employed part-time or full-time 18.7% 39.5% 46.7% 35.1% 
How many children do you have? 1.9 1.8 1.9 1.8 
Age at sexual debut 17.3 18.0 18.2 17.8 
Male condom ever use 40.1% 59.4% 59.5% 55.2% 
HIV knowledge score (on a scale of 0-8) 6.4 7.1 7.3 6.9 
n= 230 742 45 1017 
9.7. Generalisability 
9.7.1. Representativeness of study participants' households 
The last column in Table 9-1 shows asset ownership in urban South Africa in 2003. 
Though the proportions who own each asset type appear similar, the ownership of a 
telephone (70% DHS and 87% in Ekurhuleni) is the largest difference. In the DHS 3% 
reported having none of the assets, while in Ekurhuleni this was 1%. These may indicate 
Ekurhuleni being slightly better off in terms of household wealth. In addition Table 5-2 
reiterates how South African inequalities within small geographic areas are easily masked 
by averages. 
9.7.2. Representativeness of study participants' own characteristics 
It is interesting to note the high presence of Zulu speakers in the sample. In the urban South 
African adult female population in the DHS, Zulu speakers only represent 14% of 
respondents, and among women living in informal urban areas, they represent 30%, and 
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among this group in Gauteng, it is 26% (Table 9-4). This may highlight a dimension of the 
sample that could suggest less generalisability due to the overrepresentation of Zulu 
speakers, relative to other language (ethnic) groups. However, Ekurhuleni was chosen in as 
a township with no obvious reasons to consider it different from other townships 
surrounding Johannesburg. The survey team, who ran this survey, is encountering the same 
high levels of representation of Zulu speakers in their current Orange Farm survey. This 
could have three explanations: 1. a bias originating in the sampling methods, 2. true high 
presence of Zulu speakers in townships surrounding the Johannesburg relative to other 
townships in Gauteng. 3. Changes in the population composition between the 2003 DHS 
survey and this survey. If Zulu women's preferences are different from non-Zulu women's 
preferences then the sample estimates will be biased at some level of extrapolation (up to 
Gauteng for the first two, and beyond Gauteng for the third). 
Table 9-11 Women's languages by household location: comparison of Ekurhuleni 
sample with DHS 2003 
DHS 2003 Informal, Gauteng, 
Urban women Urban Informal, Urban Ekurhuleni 
English 25% 5% 2% 1% 
Afrikaans 18% 13% 0% <1% 
IsiXhosa 11% 19% 11% 6% 
IsiZulu 14% 30% 26% 52% 
SeSotho 16% 15% 28% 24% 
SeTswana 8% 7% 8% 3% 
SePedi 5% 7% 16% 5% 
SiSwati 2% 3% 2% 1% 
TshiVenda 0% 0% 1% 1% 
ZiTsonga 1% 1% 5% 8% 
isiNdebela 0% 1% 1% <1% 
Other 0% 0% 0% 0% 
Total 100% 100% 100% 100% 
n 4095 535 125 1017 
In the 2003 DHS, 3% of urban women age 15-49 years had no formal schooling, 47% had 
started but did not completed secondary school, and 24% had completed secondary school. 
In Ekurhuleni (age 18-49) this was 3%, 45%, and 27% respectively. In the 2003 DHS 36% 
and 6% of urban women were employed full-time or part-time, respectively, totalling 42% 
in either type of employment; in Ekurhuleni, this was 25% and 10%, in full and part-time 
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employment, and 35% in either type of employment. It appears that Ekurhuleni, at least on 
these two variables, is fairly representative of urban South African women, with slightly 
more completing secondary school, l but less in full-time employment. 
9.7.3. Representativeness of study participants' reproductive histories 
The mean age at sexual debut was 17 in the NMS, 20 in the DHS, and 18 years in 
Ekurhuleni. The average number of children is only available in the DHS. This was 1.6 for 
urban women in the DHS and 1.8 in Ekurhuleni. In the NMS 75% of women had ever used 
contraceptives, 73% had in the 2003 DHS, compared with 72% in Ekurhuleni. Age at first 
contraceptive use was the same in the NMS and Ekurhuleni (20 years). Injectables were the 
most popular contraceptive to start out with, 54% of contraceptive users (ever users) used 
injectables first, compared with 62% in Ekurhuleni. Of urban women in the DHS 51% were 
currently using contraceptives, while this was 40% in Ekurhuleni. The use of condoms for 
among contraceptive users was much lower with 12% urban women in the DHS, while this 
is 24% in Ekurhuleni. Reported condom use at last sex act in the NMS was 26% among 
urban women, 29% among urban women in the DHS and 31 % here. 
Table 9-12 shows the sources of current contraceptives in the 2003 DHS, comparable with 
Table 9-6 above. A popular source in the 2003 DHS was the family planning clinic, which 
was not mentioned in our Ekurhuleni sample. Clinics were the most popular source for 
both, however the DHS shows government hospital more commonly used (23% versus 7% 
in Ekurhuleni), and GPs less often used (4% versus 8% in Ekurhuleni). 
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Table 9-12 DHS 2003 Source of supply for modern contraceptive methods 
Last source for current 
users 
Injectables Pill 
Current contraceptive method 
Male IUD Female 
condom sterilisation 
Other Total 
Clinic 976 265 185 9 31 8 1474 44% 
Government hospital 262 76 51 8 380 7 784 23% 
Family planning clinic 226 126 57 2 0 1 412 12% 
Mobile clinic 177 37 14 1 0 0 229 7% 
Private hospital 14 16 9 4 130 9 182 5% 
Pharmacy-chemist 0 66 37 0 0 2 105 3% 
Private GP 62 44 9 14 12 0 141 4% 
Other 0 13 28 1 4 0 46 1% 
Total 1717 643 390 39 557 27 3373 100% 
51% 19% 12% 1% 17% 1% 100% 
Male condom use: 33% of women in the NMS reported using a condom at their last sex act, 
in Ekurhuleni this was 32%. Free condoms were most popular in both surveys, with 70% 
accessing free condoms in the NMS and 77% in Ekurhuleni. Brand popularity was slightly 
different with 18% accessing LoversPlus, 8% Durex, and 3% Trust in the NMS; in 
Ekurhuleni these shares were 14%, 2%, and 5%, respectively. This corresponds to higher 
popularity of the free and low price brand (Trust) and lower popularity of the more 
expensive condoms LoversPlus and Durex. Although the questions were posed slightly 
differently, it can be seen that in both the NMS and Ekurhuleni, the most popular source of 
condoms was the clinic, followed by the pharmacy. 
Overall, there seems to be high correspondence between the characteristics of the study 
participants and those in the general adult urban female population in South Africa. 
9.8. Validity and other data issues 
9.8.1. Introduction 
This section reviews the responses to the axiom testing questions to assess the quality of the 
survey and the validity of the responses and provides a further review of other data issues 
that arose. As the last choice in the questionnaire, an additional choice set was added to test 
axioms of dominance and stability. In six of the DCE versions, respondents received one 
extra physical attribute question exploring reporting bias. 
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9.8.2. Version rotation 
By having 17 fieldworkers and rotating the questionnaire daily, the aim was to achieve an 
equal number of responses to each questionnaire version, and distribute any interviewer 
effects equally over the versions. On average 50.8 questionnaires of each version were 
completed, ranging from 42 (version M) to 59 (versions L and H). 
9.8.3. Respondent fatigue 
Although there was only one questionnaire with one missing response to the product 
attribute DCE's, there were 27 (2.7%) questionnaires with one missing DCE-distribution 
response and one with two missing responses. In all cases these occurred at the last (or last 
two) DCE questions. This suggests the presence of respondent fatigue among women (or 
interviewers) towards the end of the questionnaire. 
9.8.4. Orthogonality 
At the time the study was designed, SPSS ORTHOPLAN procedure was considered an 
acceptable method for generating designs. However, when testing the design for 
orthogonality using the software on the diagnostic website by Street and Burgess [439], it 
became clear that there was a loss of orthogonality. The diagnostic programme would not 
converge for the physical attributes design and showed low levels of design efficiency for 
the distribution attributes. This leads to much noise in the estimates, and reduces the 
possibilities of estimating more sophisticated models with this data (such as attribute 
interaction effects and random parameters logit model with correlations) because of 
correlations in the data causing the models to not converge. 
9.8.5. Dominance and stability42 
Of the 155 responses to the test of dominance (also referred to as internal consistency) 26 
women (17%) chose the dominated alternative (price choices in Table 9-13). In the choice 
sets there happened to be a number of sets in the product attribute experiment where the 
alternatives differed on one attribute only, but had not intentionally been set up to test for 
dominance. Here the non-dominant alternative was chosen in 21% of choices. There were 
also a number of scenarios where the alternatives differed on pregnancy prevention 0% 
versus higher pregnancy prevention, but 0% pregnancy prevention may be the dominant 
alternative for women who do desire pregnancy. 
42 These questions were part of the distribution attribute DCE, but is discussed here most of the other 
validity tests relate to the product attribute DCE. 
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Table 9-13 Test for dominance 
Choose dominant alternative Violations 
N(chose dominant alternative) /N(choices) % 
Consistency test 
Low - high price (R5- R20) 51/57 90% 
Medium - high price (R10-R20) 78/98 80% 17% 
Part of design 
Secrecy (Yes) 37/62 60% 
Pregnancy prevention (55%-75%) 34/41 83% 
Pregnancy prevention (75%-95%) 126/146 86% 21% 
Total 326/404 81% 
To test for stability of preferences, the first of the distribution scenarios was presented again 
at the end. Nineteen percent changed their response to the same scenario when it was 
presented after 3 questions. 
Therefore, in 1% to 21% of responses there were violations of the axioms of monotonicity 
(dominance) and stability. This will lead to noise in the utility estimates. However we have 
not removed them from the analysis as they were only administered on sub-samples of the 
study population. These estimates are well within the range of internal consistency 
identified in the literature. For comparison with the literature on internal consistency, 
studies report ranges between I% and 27% J407' 394' 398,408,4K 303,4W, 410] 
9.8.6. Non-trading and non-switching behaviour 
There are two reasons people have been observed to not make trade-offs between the 
attributes levels. Firstly if choices are difficult, respondents use simplifying heuristics to 
make choices easier 1405,3661 . This means that they may choose the attribute most 
important 
to them and make their choice solely by comparing the levels of that attribute. The other 
reason for observing such behaviour is that the range of the other attributes is not wide 
enough to induce trading, which is a design flaw rather than reflecting inconsistent 
responses [405j In this study assessment of non-trading behaviour is undertaken with 
reference to the HIV effectiveness attribute. Table 9-14 shows the number of choice where 
participants were faced with different HIV effectiveness levels in the rows and the number 
of choices they made in favour of the highest HIV effectiveness level. 
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Table 9-14 Dominant attribute choices 
Possible number of choices with different HIV 
Nr. Of HIV dominant choices made effectiveness' per participant 
356 Total 
0 1 2 38 41 
1 4 11 52 67 
2 5 20 90 115 
3 9 37 110 156 
4 0 16 122 138 
5 0 49 162 211 
6 0 0 289 289 
Total 19 135 863 1017 
The number of people always choosing alternative with hgherst HIV effectiveness: 9(3 out of 3 possible) + 
49 (5 out of 5 possible) + 289 (6 out of 6 possible) = 347 
In this study 347 (34%) people always chose the alternative with the highest HIV 
effectiveness, suggesting quite strong dominant attribute preferences. Forty-one (4%) 
always chose the alternative with the lower HIV effectiveness. The remaining 629 (62%) 
chose some of each43 
Figure 9-4 shows the distribution of respondents' choices between A, B and C. There were 
104 (10%) respondents who never switched their response. Ninety-four (9%) respondents 
said they would never switch from doing what they did the last time they had sex. Five 
respondents always chose A and 5 always chose B in the product attribute choices. 578 
(57%) said they would always switch to one of the choices and not do what they did last 
time they had sex. The remaining 344 (34%) respondents changed their responses between 
one of the product alternatives and `neither' depending on the product attributes. 
43 In Table 9-14 attribute levels of the neither option are included, i. e. if Neither represented using a 
condom and was chosen over A, and B with for example 55% and 75% HIV effectiveness, this was 
considered a dominant choice. When all HIV effectiveness levels were equal (only possible when 0.95) 
no dominant choice was possible based in HIV effectiveness, and were thus not part of the analysis. 
Alternatively, it could be argued that Neither is a different kind of choice and should be excluded. 
179 
CHAPTER Y. J URVEY SAMPLE AND GENERALISABIL17T 
Percentage of a respondent's choices to each choice option (A, B, Neither) 
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Figure 9-4 distribution of respondents' physical attribute choices over alternatives 
9.8.7. Reporting bias 
To explore reporting bias, one scenario was presented with the choice between male 
condom, female condom, and `neither'. This is analysed with cross tabulation and presented 
in Table 9-15. 
Table 9-15 Reporting bias: cross tabulations of choice among male and female condom 
and neither, and reported use in last sex act. 
Would you have used one of these The last time you had sex, was a condom used? 
products the last time you had sex or 
would you have still done what you did 
the last time you had sex? No Yes Total 
Male condom 71 40% 51 59% 122 46% 
Female condom 84 47% 28 33% 112 42% 
Neither 23 13% 7 8% 30 12% 
Total 178 100% 86 100% 264 100% 
Of women who reported using a condom in their last sex act, 59.3% said they would have 
used a condom in response to the DCE scenario, 12.9% of women who did not use a 
condom said they would not have used a condom. This gives ((23+51)/264)= 28% of 
responses which were representative of their last sex act. It is a bit complicated to interpret 
the responses of women who said they would use the female condom, since though they 
180 
0% 17% 20% 33% 50% 60% 67% 83% 100% 
% of responses 
CHAPTER 9. SURVEY SAMPLP AND GENERALISABILI7Y 
exist, access is quite limited; it is for this reason it is not purely a discrepant result. Fully 
discrepant results are considered when a condom using woman chooses `neither' or a non- 
condom using woman chooses `male condom'. This occurred in ((7+23)/264)=30% of 
responses. In particular, among those who reported not using a condom the last time they 
had sex, only 13% said they would not have used a condom in the DCE scenario. Consistent 
with the findings of the evaluation survey, this suggests that people answered the scenarios 
with what they would like to do the next time they have sex more than what would have 
been feasible to do the last time they had sex. Women's choices should be interpreted as 
what they would have liked to do in their last sex act rather than what they would have liked 
and been able to do in their last sex act. 
9.8.8. Conclusions on validity issues 
This section has considered a number of dimensions that could potentially undermine the 
validity of the estimation results: respondent fatigue; orthogonality; dominant preferences; 
stability of preferences; non-trading behaviour. The issue non-trading behaviour observed 
with the HIV effectiveness attribute, raises the tension on how to design DCEs when 
realistic ranges of attributes are not wide enough to induce trading behaviour in favour of 
other attribute levels. Though, violations of the other axioms were observe, the literature 
suggests the levels are acceptable. 
9.9. Conclusions 
This chapter has provided an overview of the sample obtained, and a description of the 
women's socio demographic backgrounds, their reproductive histories, and their reported 
sexual behaviour. These were compared with data from larger nationally representative 
surveys in South Africa, specifically the South African Demographic and Health Survey 
2003 and the Nelson Mandela Survey containing sexual behaviour data from 2005. 
Generally the sample from Ekurhuleni did not appear to be very different from urban 
women in the national surveys, though the ownership of some assets, such as phones, was 
higher and the percentage of people owning none of the assets in Ekurhuleni was lower than 
in the general South African urban population. Reproductive histories and sexual behaviour 
were also strikingly similar between the women in this survey and women from the general 
population of urban South African women. 
This chapter has also considered a number of issues related to the validity of women's 
responses, the trade-offs they make and ultimately the estimation results. Though violations 
of many of the key axioms were observed, the rates of these violations were generally 
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within the range of the literature. The next chapter explores women's directly elicited 
preferences to identify market segments. 
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Chapter 10. Exploration of preferences and market 
segments 
10.1. Introduction 
As in the methods section, where a number of iterations were undertaken to develop the 
final survey tool, this chapter presents the iterative process used to develop an estimate-able 
discrete choice model that includes a succinct number of socio-demographic characteristics. 
Although socio-demographic variables are included in discrete choice models, such 
unlabelled discrete choice models quickly become unwieldy due to the fact that they are 
included as cross products of the attributes, rather than as single variables [430] This makes 
them unsuitable for broad exploration of potential variables representing different women's 
characteristics. This chapter presents women's directly elicited preferences for products, 
their attributes and their distribution and subsequently explores the relationship between 
socio-demographic characteristics and women's directly elicited preferences. This chapter 
aims to answer the following questions : 
1. Which attribute levels are preferred when presented one by one? 
2. What are the demographic characteristics of the market segments identified using a 
three step approach? 
3. What are the determinants of women's willingness to pay values for the different 
women's barrier methods? How do they differ across products? 
Together, these supporting analyses provide guidance on which socio-demographic 
variables to carry forward into the analysis of the choice experiments. 
Section 10.2 describes this chapter's methods. Section 10.3. presents an overview of 
women's preferences for each of the attributes, when presented on its own. Section 10.4. 
presents an overview of the willingness to pay questions. Section 10.5. looks at grouping 
women into market segments using different types of preference data. Section 10.6. 
analyses the determinants of willingness to pay. The last section suggests some key 
variables to carry forward into the analysis of women's preferences. 
10.2. Methods 
This chapter uses three methods to address its aims. Firstly basic descriptive statistics are 
used to explore women's directly elicited preferences and their willingness to pay values for 
the different products and analysis of variance (ANOVA) is used to consider interactions 
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between the importance of secrecy and women's characteristics and preferences for 
distribution strategies. Secondly a market segmentation analysis is used, and thirdly 
regression analysis is used to identify key socio-demographic determinants of their product 
preferences as represented by their directly elicited willingness to pay. The last two 
methods are described in more detail below. 
10.2.1. Identification of latent product profiles and market segments: 
methods 
Identification of the demographic characteristics of market segments ws done in four steps 
(Figure 10-1). 
Step 1. Identify latent product profiles represented by factors using principal components analysis 
Step 2. Group individual factor scores to identify natural market segments using cluster analysis 
Step 3. Explore differences in product profile scores and attribute choices by market segment using ANOVA 
Step 4. Explore demographic characteristics of market segments using ANOVA 
Figure 10-1 Steps in identification of characteristics of markets segments 
In the first step, principal components analysis is used to identify those product/distribution 
attributes that define latent product profiles (represented by the factors that are generated) 
[452,451] Included in the analysis are all of the expressed preferences (left column in Table 
10-5). Most variables are categorical. Variables entered as continuous variables are product 
effectiveness in preventing HIV (35%-95%) and pregnancy (0%-95%) and willingness to 
pay for a single use and reusable product. Because of this combination, we use the 
correlation matrix rather than a covariance matrix to estimate the principal components [ast] 
The output of principal components analysis is a number of factors which we can call 
product profiles. These profiles contain weights for all of the product/distribution attributes, 
based on their underlying correlations. These weights represent their importance in defining 
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that profile. Product profiles can be interpreted as attributes that are often chosen together, 
if positive and large, or tend not to be chosen together, if negative and large. 
From the product profiles, we can group consumers into market segments by their product 
attribute choices (step 2). Based on the attribute weights from the principal components 
analysis, a variable can be generated containing summary profile scores for each participant 
for each product profile. These represent the strength of each woman's preference for each 
profile. Based on these product profile preference scores, cluster analysis is then used to 
identify natural groupings of these preferences. These clusters represent different market 
segments. Step 3 uses analysis of variance (ANOVA) to identify statistically significant 
differences in the mean product profile scores and their product/distribution attribute 
choices between the different clusters. This is primarily to see if the empirically generated 
clusters have are consistent with our a priori expectations (if they are intuitive). 
Step 4: The demographic and behavioural characteristics of each of these market segments 
can then be identified using a one-way ANOVA. The demographic characteristics and 
responses from reproductive health histories of women are entered as the independent 
variables into the ANOVA to test for a difference in the means of the characteristics 
between the different clusters. The most significantly different demographic characteristics 
will then be included as variables in the analysis of determinants of willingness to pay for 
the barrier methods. 
10.2.2. Estimation of determinants of willingness to pay 
Three main regression models were used to estimate determinants of willingness to pay: 
ordinary least squares (OLS), Tobit, and interval regression (also called grouped data 
regression [4541). This section describes the estimation models and their specification. 
The OLS models were estimated with the dependent variable in three functional forms. The 
first with the actual WTP values, the second as logarithms of the WTP values, and the third 
as logarithms of WTP value+l. The logarithmic transformation was undertaken because the 
data are highly skewed (See Figure 10-2 and Table 10-4). However ln(0) is not defined, so 
this would lead to the exclusion of all observations with WTP values of 0. This is between 
50% and 87% of the responses for the different products. To address this problem, 
Donaldson et al. (1998) suggest taking the logarithm of the WTP value +1, in which case 
the 0 values are included in the estimation sample (as ln(1)= 0). 
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Tobit was developed to correct for biases that occur in OLS estimation that are introduced 
when using censored data 1419,4551. When an open-ended WTP question is asked the lowest 
amount that one can respond is 0. Zero-values then generally capture both real `0' values 
(willing to use if free), and those who dislike the product and would thus have to be paid to 
use it (negative WTP). In the open-ended WTP questions, women were given the choice to 
opt out, and therefore 0 values should reflect willingness to try but only at a0 price. It is 
not expected that these data are censored in the same manner as most WTP responses are. 
The payment scale questions for single use and reusable products are censored, however, 
both at the lower end, at 0, and at the upper end, at Rand 20 and Rand 80, respectively. Two 
Tobit models were estimated with the open-ended WTP responses. The first with the data as 
unchanged (thus including only those willing to try in the sample) and the second 
transforming those who opted out to have a0 WTP value, which is the form of data in 
which Tobit models are generally applied. The open-ended WTP questions were then left 
censored at 0, and the payment scale WTP questions were considered both left and right 
censored. These estimates can then be compared with the estimates generated using the 
OLS and interval regression. 
Interval regression is used when the data are grouped, either because the data are collected 
in intervals rather than exact numbers or because people's responses heap at rounded 
numbers [asa] An example of the first is when using a payment scale, as we did when we 
limited the WTP responses for a single use product to 0,5,10 and 20 Rand, and for a 
reusable product to 0,20,40 and 80 Rand, the second type of grouping can be seen by the 
peaks in response frequencies at round numbers in the open-ended willingness to pay 
responses presented in Figure 10-2. Specification of the intervals for the payment scale data 
for the single use product is presented in Appendix Table A10-1. 
The basic models are estimated using a number of functional forms (see Table 10-1). The 
models were first estimated in full in an initial exploratory analysis. Stepwise regression is 
then used to obtain the most parsimonious model for each product with significant variables 
only. Stepwise regression is used with an entrance criterion of a p-value of 0.2 or less for 
each variable. This provides guidance on which variables are not significant in any of the 
different product regressions. The reduced model is then discussed and variables for 
inclusion in de DCE are suggested. 
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Table 10-1 Models and functional forms estimated for determinants of WTP 
WTP for .... 
Diaphragm Microbicide Female Single Reusable 
Long (variables from Eq. 10-1) condom use 
OLS- Values x x x x x 
OLS- Logarithms x x x x x 
Tobit x x x x x 
Interval regression, with 0 as =0 [0,0] x x x x x 
Interval regression, with 0 as <0[.... 0] x x x 
Reduced (variables from Eq 10-2) 
* OLS Values x x x x x 
OLS-logarithms x x x x x 
OLS-Ln (WTP+1) x x x x x 
* Tobit Values x x x x x 
Tobit logarithms x x x x x 
Tobit on Log(WTP+1) x x x x x 
Tobit with opt- out as WTP=O x x x x x 
Interval regression, with 0=[0,0] x x x x x 
* Interval regression, with 0=[ .., O] x x x 
Reduced (excluding outliers ) 
OLS x x x 
Tobit x x x 
Interval regression x x x 
* Estimates from these models are presented in Table 10-7, all other results only presented in Appendix 10 
10.3. Women's preferred attribute levels 
10.3.1. Physical attributes 
The level of HIV protection desired had little to do with women's perception of their own 
risk: cross tabulation of `self-perceived HIV risk', and `level of HIV protection required' 
(Table 10-2), did not show any particular pattern. 
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Table 10-2 Cross tabulation of self perceived HIV risk and needed HIV protection 
Do you need a product that provides very low, low, 
medium protection, or high protection against HIV 
Do you consider yourself at high, medium, low, Very low Low Medium High 
no risk of getting HIV or becoming re-infected 35% 55% 75% 95% Total 
1 High risk 1 5 9 208 223 
2 Medium risk 2 0 13 245 260 
3 Low risk 0 1 6 226 233 
4 No risk 2 4 13 242 261 
Total 5 10 41 921 977 
For protection against pregnancy, of the few women (40) who said they did not want their 
HIV prevention product to prevent pregnancy, 74% wanted to get pregnant. However, of 
those wanting to get pregnant, 64% still chose a product with 95% pregnancy prevention. 
These findings suggest that most women who chose a non-pregnancy preventing product 
were expressing preferences consistent with their previously expressed desire to get 
pregnant. However, the majority of women who wanted to get pregnant did not give 
consistent responses in their preference for pregnancy prevention effectiveness of product 
(i. e. it would be expected that they would prefer products with low effectiveness against 
pregnancy, but many still stated they wanted a product that would provide high levels of 
pregnancy prevention). However, this could also mean that such a product would 
`normally' be most useful to them, rather than relating the question to their current 
situation. 
When presented with the four single use prices (R0, R5, RIO, R20), 50% choose free 
distribution; 27% said they would pay up to R5,15% would pay up to R10, and 9% said 
they would pay up to R20. Although these values were chosen to cover the range of prices 
of male and female condoms current available, it can be seen that these also happen to be 
the most frequently response values in the open-ended WTP question and can therefore be 
deemed quite appropriate. The open-ended willingness to pay responses were quite a bit 
higher than payment scale responses. For a reusable product, women were willing to pay 
more: 26.5% reported they would only use it if free, 44% reported being willing to pay up 
to R20,17% would pay up to R40, and 13% would pay up to R80. 
Women were asked if it was important to be able to use a product without their partner 
knowing (Box 8-4). Just under half (43%) said it was important, and 57% did not think this 
was important. 
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10.3.2. Distribution attributes 
The preferred distribution channels were clinic (49%) and chemist (40%), while 
supermarket (7%) and corner store (5%) were rarely chosen. Distribution `in a private 
room' was most preferred (38%), followed by `from a dispensing machine or box' (28%); 
`from a person behind a counter' (17%) and `from a shelf (16%) were less preferred. Thus 
those collection methods that were most private were preferred. Of the four advertising 
messages presented 'HIV prevention' (45%) had the largest preference, followed by 
`women's empowerment' (30%), `pregnancy prevention' (17%) and `extra pleasure' (8%). 
This was counter to expectations that HIV prevention would have a negative association 
and HIV prevention messaging would make the product least attractive for women and their 
partners. 
10.3.3. Interactions between the importance of secrecy and women's 
characteristics and preferences for distribution strategies 
Table 10-3 shows the analysis of variance (ANOVA) of characteristics and preferences that 
were significantly different between women who did and did not consider secrecy 
important. Women were more likely to say that it is important to be able to use the product 
without their partner knowing if they: considered themselves at high risk for HIV 
(RiskHigh); preferred collection from the chemist, spoke Sotho at home, and thought 
microbicides or the diaphragm would be the most suitable HIV prevention product for 
them. Characteristics" of women who did not think secrecy was important were: considered 
male or female condoms their preferred HIV prevention product; considered themselves at 
no risk of becoming infected with HIV; lived in higher socio-economic status households; 
preferred the clinic as place for product collection; preferred promotion for extra pleasure; 
preferred collection from a person behind the counter or from a shelf; and older age. 
44 which a significantly higher percentage said it was not important than did say it was important 
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Table 10-3 Characteristics and preferences of women who do and do not consider 
secret product use important 
Group means Variables with 
Characteristics and preferences 
significant difference 
Secrecy Secrecy not between groups P- 
important important value (ANOVA) 
Considers themselves to be at HIGH risk 27% 18% 0 001 
of becoming infected with HIV . 
Male condom suits their reproductive 6% 12% 0 001 health needs best . 
Female condom suits their reproductive 10% 15% 006 0 health needs best . 
Collection from chemist preferred 44% 36% 0.007 
Considers themselves to be at NO risk of 22% 29% 0 008 becoming infected with HIV . 
Household SES -9% 7% 0.009 
Collection from clinic preferred 45% 52% 0.024 
Sotho speaking at home 27% 21% 0.039 
Promotion for extra pleasure preferred 6% 9% 0.040 
Microbicides suit their reproductive health 53% 46% 043 0 
needs best . 
Diaphragm suits their reproductive health 32% 26% 0 054 
needs best . 
Collection from person behind counter 15% 19% 0.084 
preferred 
Age 31.1 31.9 0.094 
Collection from shelf preferred 19% 15% 0.104 
Other characteristics were not significant at a 10% level. 
This section has now provided a descriptive overview of women's directly elicited 
preferences for barrier methods and distribution strategies and their attributes. Generally, 
acceptability was highest for microbicides, followed by the diaphragm. Women showed less 
enthusiasm for the male and female condomas 
10.4. An overview of the open-ended willingness to pay responses 
Willingness and ability to try the products differed with the most women willing to try 
microbicides (74%), followed by 60% of women willing and able to try the diaphragm, and 
56% willing to try the female condom. If a woman stated that she was willing to try a 
product but it was not something she thought she would use regularly it was categorised as 
45 In the next chapter the ordering of these preferences will be further explored. 
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"novelty use". Novelty use was highest for the female condom, with 22% of women who 
would be willing to try it also reporting it was unlikely to be something they would want to 
or be able to use regularly; this was 14% for the diaphragm, and only 5% for microbicides. 
For the willingness to pay question, the diaphragm was presented as reusable, and 
microbicides as single use. Women who thought they would use a product regularly were 
willing to pay on average R37.58 for a reusable diaphragm, R17.44 for a single use 
microbicide, and R10.33 for a female condom (Table 10-4). Novelty values were lower for 
a diaphragm at R18.67 and for a microbicide (R12.95). Novelty value for the female 
condom was just slightly higher than its regular use value (RI 0.97). For comparison, social 
marketing condoms are also available in South Africa for R2 and R5 per packet of three. 
However, these responses were highly skewed, with median values far below their means. 
Table 10-4 Willingness to pay for the diaphragm, microbicides and female condoms 
Mean Mean Mean Median Minimum Maximum Std Deviation 
In 2005 Rand Novelty use* Regular use All All All All All 
Diaphragm 
Microbicides 
19 
13 
38 
17 
35 
17 
20 
10 
0 
0 
450 
300 
46 
27 
Female condom 11 10 10 50 250 18 
"A WTP value is considered a novelty use value when a woman states she is willing to try a product but it is not 
something she thinks she would use regularly. 
Figure 10-2 plots the WTP values. It shows the skewedness of the WTP responses and that 
the values are lumped together, with peak frequency of responses at round numbers (e. g. 0, 
5,10,20, etc. ). 
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WTP reusable diaphragm - open ended 
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WTP microbicide - open ended 
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WTP female condom - open ended 
Note: very high values were excluded to make the figure more readable at the lower end. The values excluded were: 
for the diaphragm R300*1, R400*1, R450*1; for microbicides R150*5, R200, R300*2; for the female condom R250*1. 
Figure 10-2 Count of open-ended willingness to pay values for the diaphragm, 
microbicides and the female condom 
Consistent with the high `willingness to try' and `willingness to use regularly' of 
microbicides, 50% stated that microbicides would best suit their reproductive health needs, 
followed by the diaphragm (9%), the female condom (13%), and the male condom (9%). 
10.5. Product/distribution categories and market segmentation 
The analysis seeks to explore the existence of market segments to guide which variables to 
include in the analysis of the determinants of willingness to pay in Section 10.6. 
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10.5.1. Product profiles based on hypothetical preferences 
Table 10-5 shows results of steps 1-3. Eleven latent product profiles were identified using 
principal components analysis. 
Profile 1 represents a strong positive preference for distribution from a chemist off the 
shelf at higher prices, with a strong dislike for clinic distribution in a private 
room. 
Profile 2 represents strong product preferences, with a positive preferences for the male 
condom in particular and a dislike of microbicides. Distribution for HIV 
prevention has a positive association, and women's empowerment a negative 
association. A dispensing machine or box at a supermarket distribution all 
contribute to this product profile. 
Profile 3 represents a favourable attitude towards the female condom that would be 
promoted for woman's empowerment, with a strong dislike for promotion for 
HIV prevention. Distribution from a dispensing machine or box at spazas 
(cornershops in townships) contribute to this profile, while distribution from a 
chemist in a private room is negatively associated with this profile. 
Profile 4 This profile is dominated by a very strong positive weight for the diaphragm, 
preferably distributed for pregnancy prevention in a private room at a chemists, 
and negative weights for microbicides and the male condom distributed for HIV 
prevention on a supermarket shelf. 
Profile 5 shows a strong dislike for promotion for pregnancy prevention, the female 
condom and shelf distribution in supermarkets, with strong positive value for 
high levels of HIV prevention to be collected from a box or machine and 
promoted for women's empowerment or HIV prevention. 
Profile 6 portrays a compilation of attributes as follows: male condom distributed for sale 
at clinics or the supermarket, but not the clinic, collected off a shelf and 
promoted for extra pleasure or women's empowerment. Promotion for HIV 
prevention has a negative weight. 
Profile 7 places strong positive values on promotion for extra pleasure and is associated 
with higher prices, the female condom, but values promotion for women's 
empowerment and distribution from a supermarket shelf negatively. 
Profile 8 has very strong dislike for collecting a product from a person behind the counter, 
and is associated with a preference for a product that can be used secretly. More 
appropriate distribution for a discreet product would thus be a shelf or a 
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dispensing machine or box. The only promotional message with a positive 
weight is extra pleasure. 
Profile 9 This profile revolves around the female condom distributed from a spaza or a 
private room for women's empowerment. 
Profile 10 Product attributes are most important for this profile: critical are high pregnancy 
and HIV efficacy and ability to use it in private, it also has a positive weight for 
collection from a person behind a counter. 
Profile 11 This profile is dominated by higher pricing and supermarket distribution, with 
negative weights for the male condom, high levels of pregnancy efficacy, 
chemist distribution and promotion for extra pleasure. 
Each latent product profile can be described by the larger weights of the attribute inputs. 
Higher values (in absolute value) represented variables with strong preference weights. To 
facilitate viewing, weights with an absolute value above 0.4 are presented bold, weights 
with an absolute value of less than 0.2 (not very important) are faded. 
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Table 10-5 Latent product profiles, differences in market segment valuations between 
the product profiles, and differences in attribute preferences between market 
segments 
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10.5.2. Market segments 
Applying cluster analysis to these product profiles (limiting to a maximum of five clusters) 
generates three market segments (clusters). Market Segment 1 contains 64% of the 
participants, 20% fall into Market Segment 2, and 16% into Market Segment 3. 
The bottom part of Table 10-5 shows the results of the market segments analysis, as tested 
for significant differences in their preferences for the different product profiles using 
ANOVA. The first three rows represent the average profile value of each market segment 
and the 4t' row is the p-value of the null hypothesis that the market segment means are the 
same (using ANOVA). With the exception of Profile 11, the market segments have different 
scores for each of the product profiles. Market Segment 1 has the least strong profile 
preferences and captures the preferences of the majority of participants. Market Segments 2 
and 3 tend to have different groupings of their choices and more extreme scores. The 
highest positive scores for Market Segment 1 are for Profiles 4,5, and 8; Market Segment 2 
scores Profiles 2,3,7,9, and 11 the highest; and Market Segment 3 gives highest scores to 
Profiles 1,6, and 10. The last column of Table 10-5 tests for significant differences in 
women's choices for the different attributes by cluster. The columns `Market segment 
means' show the average choices made by women in each cluster. Again most were 
significantly different from each other (as tested in an ANOVA at a 5% level), with the 
exception of willingness to pay for a single use product, supermarket collection and the 
promotional messages of women's empowerment, pregnancy prevention, and HIV 
prevention. 
" Market Segment 1 (64%) had a higher preference for being able to use a product 
secretly and collect it from the clinic. 
" Market Segment 2 (20%) differed most from the other two clusters on preferred 
product, with 55% of women in Market Segment 2 reporting that the female 
condom would be the product that suited their reproductive health needs most. They 
also chose lower levels of HIV and pregnancy efficacy necessary for them and gave, 
on average, the lowest willingness to pay values. Women in Market Segment 2 
chose Spaza distribution more often than women in did in the other market 
segments and extra pleasure less often. 
" Market Segment 3 (16%) had the strongest divergence from the other two in their 
preferences for collection methods, with all women having chosen from a person 
behind the counter. They also had the highest preference for chemist collection 
(50% chose collection from a chemist). 
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10.5.3. Demographic profile of market segments 
Table 10-6 shows the descriptive statistics of the demographic characteristics ranked by the 
p-values test of differences between the three market segments. The market segments were 
significantly different at the 5% level for the first 15 variables. The greatest differences 
were found in level of social capital, the level of education, having paid for condoms the 
last time they collected them, the number of rooms in their house (but not the crowding 
index), their household socio-economic status and their asset index. 
Market Segment I appears to be market segment with average personal characteristics, with 
Market Segment 2 representing women of generally lower socio-economic status and 
empowerment, and Market Segment 3 are those on the other end of the spectrum with 
higher socio-economic status and empowerment. These women are higher educated, more 
likely to be employed (45% versus 34% and 30%), more likely to have ever used a female 
condom, to have initiated condom use themselves the last time a condom was used, and to 
have purchased it46. However, the strong preferences of Segment 2 for female condoms 
make this picture less clear. 
Conceptually, these also form intuitive target groups for introducing new barrier methods 
with different introduction strategies. However, what would this mean in practice for 
developing targeting strategies for a variety of barrier methods? The marketing literature 
suggests four criteria for evaluating the usefulness of market segments [456,225,4291 : 
" Measurability: Does the segment description provide sufficient information to 
identify and measure the size of the population in the segment? 
" Substantiality: Are the segments large enough (in marketing think: profitable 
enough) to matter? 
" Accessibility: Can they be reached with the product? 
" Actionabilty: Can a marketing strategy be developed to reach the groups? 
In brief, this study has measured relative sizes of the groups through the cluster analysis. 
The smallest cluster is 16%. It is not clear how demand for new barrier methods may vary 
between the groups as there does not seem to be one group with much higher unmet need 
(e. g. condom use was not significantly different between the three clusters). However the 
smallest group (cluster 3) did have much higher condom purchasing behaviour. As all of the 
clusters are urban, it is likely they can be reached both with targeting and promotion 
46 However they were not more likely to have used a condom in their last sex act. 
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strategies. However, one potential problem with these clusters might be that they do not 
have a sufficiently clear identity to provide actionable guidance to marketing. 
Table 10-6 Demographic profile of market segments based on hypothetical preferences 
Market segment means 
123 P-value 
Variables that were significantly (p-value <0.05) different between clusters 
Social capital 2.27 2.04 2.57 <0.01 
Education in years 10.04 9.31 10.92 <0.01 
Did you pay for condoms the last time you collected them? 0.19 0.16 0.38 <0.01 
How many rooms are there in your house? 4.29 3.85 4.64 <0.01 
SES 0.00 -0.17 0.22 <0.01 
Asset ownership score (from factor analysis) 0.02 -0.19 0.16 <0.01 
Zonkiziswe resident 0.24 0.26 0.13 0.01 
Lives in a shack or a room outside 0.28 0.32 0.18 0.01 
Employed 0.34 0.30 0.45 0.01 
Vosloorus resident 0.71 0.71 0.83 0.01 
Have you ever used a female condom? 0.02 0.02 0.06 0.02 
Does not want to become pregnant 0.59 0.48 0.60 0.02 
How old were you the first time you had sexual intercourse? 17.85 17.51 18.17 0.03 
Years living in location 13.10 14.28 15.65 0.03 
Initiated condom use - Self 0.47 0.42 0.58 0.04 
Variables that were not sianificantlv (at o-value <0.05) different between clusters 
Age 31.12 32.35 32.25 0.06 
Risk of becoming HIV infected - High 0.22 0.26 0.16 0.09 
Risk of becoming HIV infected - Low 0.24 0.28 0.28 0.18 
Initiated condom use - Partner 0.14 0.13 0.08 0.23 
Are you currently pregnant? 0.04 0.06 0.02 0.29 
Have you ever collected or bought a condom yourself? 0.67 0.66 0.74 0.30 
Many women find it difficult to get their partners to use 
condoms, has this ever happened to you? 0.39 0.38 0.33 0.40 
Religion -Zionist 0.25 0.27 0.21 0.46 
Risk of becoming HIV infected - None 0.24 0.28 0.28 0.47 
Do you live with the last person you had sex with? 0.55 0.59 0.53 0.49 
Sprufiriew 0.05 0.03 0.04 0.51 
HIV knowledge score 6.94 6.85 6.99 0.53 
Crowding index (persons per bedroom) 2.29 2.25 2.19 0.57 
Have you ever seen a female condom? 0.50 0.51 0.55 0.57 
Household head - Self 0.17 0.18 0.14 0.61 
Household head - Husband 0.46 0.50 0.49 0.64 
Risk of becoming HIV infected - Medium 0.26 0.23 0.27 0.66 
Owns home 0.43 0.43 0.46 0.69 
The last time you had sex, was a condom used? 0.32 0.31 0.29 0.71 
What proportion of the household expenses does your partner 
contribute? 4.07 3.99 4.01 0.80 
Ethnicity - Zulu 0.51 0.51 0.52 0.95 
How many children do you have? 1.83 1.79 1.81 0.96 
Ethnicity - Sotho 0.24 0.23 0.23 0.98 
N= 650 199 166 
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From this analysis, we however, can identify the significant demographic variables to be 
included in our exploration of the determinants of directly elicited willingness to pay. 
However, since the asset index and access to social capital are part of the household socio- 
economic status variable, they will not be included together. Also, though locations 
Zonkiziswe and Vosloorus appear in the list of significant demographic variables, though 
they may indicate some kind of location fixed effect, they are of little use for drawing 
generalisable conclusions and will not be included. 
10.6. Determinants of directly elicited willingness to pay 
In this section determinants of respondents' willingness to pay values are explored to 
identify key socio-demographic characteristics. Of interest is what determines the relative 
values that women give to the different products (microbicide, diaphragm and the female 
condom), rather than to estimate the demand curve or changes in welfare by estimating 
consumer surplus, as is more frequently the aim of willingness to pay surveys (also known 
as contingent valuation surveys) ýasý a6a, 390, abs-aý1 ] 
10.6.1. The model specification 
In 10.5. , an exploratory analysis of market segments and preferences was undertaken using 
principal components analysis. It suggested a number of key demographic factors that are 
likely to determine choices: household socio-economic status (seshh) and individual 
demographics (age (age), level of education (EducYrs), and employment status (employd), 
Years living in location (YrsinLoc)) and a number of behavioural characteristics: whether they 
had ever paid for condoms (PaidMCSCens); ever use of a female condom (FCEvUs), desire not 
to get pregnant (DontWantPreg), age at sexual debut47 (SexDeb), the last time they used a 
condom if they had initiated condom use themselves (InitiateMC), if they are living with a 
sexual partner, and their self perceived risk of HIV (RiskHigh, RiskMed, RiskNo, relative to 
RiskLow). These will be the explored as variables in the analysis of determinants of WTP. In 
addition, we are interested in probing into the issue of how cohabitation (Cohab), the ability 
to use condoms (having ever experience difficulties negotiating condom use (DiffMC) and 
condom use at last sex act (MCLastS)) affect the WTP for the different products. Male 
condom ever use (MCEvrUse) is included to avoid the omitted variable bias. 
47 Of course this may not be a choice variable 
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SEShh, Age, Education, Employment, Years living in location, Cohabitating, 
f 
Don't want pregnancy, Age at sexual debut, Male condom-ever used), 
WTP,,, o, = Male condom-paid for, Condom initiated-self, Female condom ever used, q. 10-1 
Experienced difficulties getting a partner to use condom, Used condom last sex act, 
Self perceived HIV risk. 
There are three main regression models used to estimate determinants of willingness to pay: 
ordinary least squares (OLS), Tobit, and interval regression (also called grouped data 
regression E4M1). This section estimates and compares the results of these three models. 
The models were first estimated in full (as above in Eq. 10-1) in an initial exploratory 
analysis. These results are presented in Appendix Table A10-2. Stepwise regression was 
then used to obtain the most parsimonious model for each product with significant variables 
only. Stepwise regression was used with an entrance criterion of a p-value of 0.2 or less for 
each variable. This provides guidance on which variables are not significant in any of the 
different product regressions. The reduced model includes the following variables: 
SESnh (seshh), Age (age), Employment (employd), Female condom ever used 
WTP r 
(FCEvUs), Male condom-ever used (MCEvrUse), Male condom-paid for 10-2 °ý J (PaidMCSCens), Condom initiated-self (InfiatMCSCens), Cohabitating (Cohab), 
Eq. 
Self perceived HIV risk- None (RiskNo). 
The full set of estimations can be found in Appendix Table A10-3. These are OLS and 
Tobit with the dependent variable in values, logarithms and logarithm (WTP+1), Tobit with 
those who stated they would not try a product being included in the sample with a WTP 
value of 0 rather than as a missing value, and the interval regression with the interval 
specified as 0 and as less than 0 to 0. Also in this appendix are the estimates of WTP for 
single use and reusable products. The payment scale questions were designed to get people 
accustomed to the presentation of the prices that would occur in the DCE; there was a set of 
prices (0-R20) for single use products (the female condom and microbicides) and a different 
set for the reusable diaphragm (0-R80). In the payment scale question, these values were for 
a generic single use or reusable product. 
10.6.2. Model estimates of the determinants of willingness to pay 
To gain some insights into which factors influence women's valuations (as measure through 
WTP) and their differences between the different barrier methods, the three reduced models 
(OLS, Tobit, Interval regression) are estimated for each product using the actual WTP 
values (Table 10-7). The estimates are then compared between products. However, it should 
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be noted that this does not formally test for differences in determinants of WTP among 
products. To do so would require estimation of a pooled model with dummy variables and 
interaction terms which allows testing for differences in intercepts and slopes between the 
products. 
Table 10-7 Regression estimates of WTP for the diaphragm, microbicides, the female 
condom, using reduced OLS, TOBIT and Interval regression models 
Reduced-OLS Diaphragm 
Values Coef. P>jtj 
seshh 8.37 <0.01 
age -0.56 0.03 
employd 9.17 0.04 
FCEvUs -13.14 0.07 
MCEvrUse -4.57 0.3 
PaidMCS 5.12 0.46 
IntatMCS 3.57 0.42 
Cohab 6.16 0.08 
RiskNo 9.45 0.07 
cons 45.78 <0.01 
n= 606 
r"2 0.07 
RESET p-value 0.03 
Tobit Diaphragm 
Coef. P>ItI 
seshh 9.98 <0.01 
age -0.75 0.02 
employd 9.72 0.04 
FCEvUs -15.72 0.2 
MCEvrUse -5.12 0.33 
PaidMCS 5.69 0.46 
IntiatMCS 4.19 0.4 
Cohab 6.49 0.14 
RiskNo 11.23 0.02 
cons 47.40 <0.01 
n= 606 
pseudo-r"2 0.01 
Microbicide 
Coef. P>Itl 
Female condom 
Coef. P>Itl 
4.30 <0.01 1.88 <0.01 
-0.51 <0.01 -0.31 0.01 
7.44 0.01 4.25 0.01 
-5.16 0.13 -2.08 0.39 
4.73 0.03 0.33 0.86 
-1.51 0.74 -4.35 0.14 
4.17 0.17 0.33 0.86 
4.31 0.08 -1.57 0.32 
4.47 0.11 2.52 0.25 
23.23 <0.01 18.98 <0.01 
745 514 
0.08 0.04 
<0.001 0.69 
Mlcrobicide Female condom 
Coef. P>Itl Coef. P>Itl 
5.54 <0.01 
-0.61 <0.01 
8.72 <0.01 
-6.73 0.38 
5.78 0.06 
-2.18 0.6 
4.83 0.09 
4.30 0.09 
4.83 0.07 
21.07 <0.01 
745 
0.01 
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2.37 0.03 
-0.49 <0.01 
5.17 0.02 
-1.60 0.78 
1.18 0.65 
-5.13 0.17 
0.24 0.92 
-1.48 0.49 
1.78 0.42 
20.66 <0.01 
514 
0.01 
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Table 10-7 continued 
Interval regression 
When 0=[., 0] 
Diaphragm 
Coef. P>Izl 
Microbicide 
Coef. P>Izl 
Female Condom 
Coef. P>Izl 
seshh 8.76 <0.01 4.39 <0.01 2.11 <0.01 
age -0.75 <0.01 -0.35 <0.01 -0.35 <0.01 
employd 7.91 0.05 4.13 0.01 3.48 0.03 
FCEvUs -12.67 0.18 -1.27 0.63 0.29 0.93 
MCEvrUse -2.21 0.61 3.55 0.03 0.50 0.77 
PaidMCS 8.23 0.23 -2.25 0.63 -4.30 0.07 
IntiatMCS 1.94 0.65 2.47 0.22 0.35 0.83 
Cohab 5.68 0.12 1.69 0.1 -0.50 0.74 
RiskNo 5.53 0.14 1.39 0.1 0.33 0.83 
cons 52.44 <0.01 20.12 <0.01 18.98 <0.01 
n= 606 745 514 
pseudo R12' 0.06 0.07 0.03 
* RESET p-value tests the Ho: that there are no omitted variables. This test is not available in Stata for TOBIT 
and interval regression models. "" pseudo RA2 is calculated as average of the correlations between the 
predicted values and the upper and lower limits of the intervals 1474 
Seshh: household socio-economic status; age: age; EducYrs level of education; employd: employment 
status; FCEvUs: ever use of a female condom; MCEvrUse: male condom ever use; PaidMCS: whether they 
had ever paid for male condoms; InitiateMC: if they had initiated condom use themselves the last time they 
used a condom; Cohab: if they are living with a sexual partner. DontWantPreg: desire not to get pregnant; 
SexDeb: age at sexual debut; RiskHigh, RiskMed, RlskNo, relative to RiskLow their self perceived risk of 
HIV- high, medium, or none, relative to low; DiffMC: having ever experienced difficulties negotiating condom 
use; MCLastS: condom use at last sex act YrslnLoc; Years living in location. 
A number of variables maintain consistent signs and significance in the different models for 
all products. Household socio-economic status and if the women is employed are 
consistently positive and significant. This is important as it shows that WTP is related to a 
woman's ability to pay, consistent with economic theory, if, as expected, these products are 
normal goods. If this was not found we would have a strong basis to doubt the remaining 
estimates. Age is consistently negative and significant. This is also expected as younger 
women are generally expected to be quicker to adopt new technologies. 
The estimated coefficients of the different models of WTP for the diaphragm maintain their 
signs, but do not remain consistently significant at conventional levels. In the OLS women 
who `have ever used a female condom' (FCEvUs) have lower estimated WTP values for the 
diaphragm, and cohabitating (Cohab) women and women who consider themselves at no 
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risk of becoming HIV infected (RiskNo) show higher WTP values. With the exception of 
RiskNo in the Tobit model, all of the coefficients of these variables lose their significance 
in the Tobit and Interval regression models. 
The estimated coefficients for the WTP for microbicides are more robust than those of the 
diaphragm. All three estimators show a positive and significant relationship between 
women's WTP for microbicides and `having ever used a male condom' and for 
cohabitating. Having initiated condom use herself and considering herself at no HIV risk 
were both positive and significant in the Tobit and Interval regressions. 
The reduced models do not appears to fit the WTP for a female condom data very well, the 
the only variable that was significant (other than the household socio-economic status 
variables) is having paid for a male condom, which is significantly negative; the R-squared 
was also consistently lower for this group. In the full models, the different self-perceived 
HIV risk categories appear to have an effect on WTP for the female condom, with women 
who consider themselves at High, Medium and No HIV risk, reporting lower values than 
women who consider themselves at Low risk (see Appendix 10). However, there is no 
further clear explanation for this result. 
10.6.3. Comparison of determinants for the different products 
Comparison between the three products show that the signs of: household socio-economic 
status, employed, age, initiated male condom use self, and considering oneself at no risk of 
HIV are the same for all products. There were a number of interesting differences. The 
diaphragm has a negative sign for ever male condom use, while microbicides and the 
female condom have consistently positive signs. This suggests that those women who have 
never used a condom before value the diaphragm higher than women who have, while 
women who have used a condom before value microbicides and the female condom higher 
than women who have never used on. 
The most interesting difference between women's valuation of the products is the difference 
in sign between cohabitating and non-cohabitating women: for the female condom cohab 
is negative and highly insignificant, and for the diaphragm cohab is positive and significant 
in the OLS model and just insignificant if using a p-value cut-off of 10% in the Tobit 
(p=0.14) and interval regression (p=0.12), respectively and for microbicides it is significant 
and positive in all models. This suggests that cohabitating women value the more discreet 
products (diaphragm and the microbicides) more than non-cohabitating women, but that 
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there is no difference in their valuations of the female condom, which cannot be used in 
secret. These conclusions remain largely intact under alternative model specifications and 
removal of outliers (Appendix 10). 
10.7. Discussion 
In this chapter, women's directly elicited preferences have been presented and suggest that 
women were most willing to try microbicides, followed by the diaphragm, and then the 
female condom. There appeared to be good comprehension of the presentation of the 
effectiveness concepts, both around HIV and pregnancy prevention. 
The analysis of potential market segments that allow for identification of some key 
differences in socio-demographic and `behavioural' characteristics identified three groups 
of women with different product and distribution preference. When examining their 
characteristics, there appear to be a central large group of `average' women. The two 
smaller clusters represent a less empowered poorer group of women and more empowered 
better off group of women. 
Section 10.6.2 used the willingness to pay values to draw conclusions about differences and 
similarities of preferences between the three women's barrier products. As expected, socio- 
economic status was consistently shown to influence the monetary values given, reflecting 
higher willingness to pay values by women with higher abilities to pay. Younger women 
were willing to pay more than older women for all products. The key differences in 
women's valuations between the products were between cohabitating and non-cohabitating 
women: cohabitating women had higher values for the discreet products (microbicides and 
diaphragm) but not for the female condom, which can never be used without a partner's 
participation. The next chapter analyses women's preferences for the product attributes 
elicited through the discrete choice experiment. 
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Chapter 11. Analysis of a DCE 1: preferences for physical 
attributes 
11.1. Introduction to the DCEs 
Policymakers and academics have raised the possibility that introducing new barrier 
methods for human immunodeficiency virus (HIV) prevention could lead to the substitution 
of condoms for potentially less effective microbicides [473,162,474,4751 This chapter explores 
how preferences for products and their attributes vary by women's risk/need profiles and 
looks at which women are most likely to change from what they did last time they had sex. 
This allows exploration of how different groups of women may react to different types of 
products, more specifically how. 
More specifically, indirect preference for products and distribution strategies are explored 
to answer the following questions: 
9 What are women's preferences for barrier methods and their attributes? 
9 How do women's preferences for the new products vary by their own characteristics 
and situations? 
" How is uptake of new products likely to differ by: 
oa woman's current capacity to protect herself 
o having had difficulties using condoms in the past 
o living with her partner? 
The general methods of the analyses are described in Section 11.2. A description of the 
women's choices is provided in 11.3. Women's preferences for physical attributes are 
presented in 11.4. The last section discusses results. 
I1. Z. Methods: estimation approach and model specification 
11.2.1. The model 
The general theoretical model has been presented in Chapter 4. In this section we present 
the specific estimation approach and model. 
The outputs of the discrete choice models are relative utilities. The simplest form of the 
models incorporate only product attributes in the utility function. The way in which 
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preferences for the products and their attributes vary among women can be explored by 
including interactions with women's socio-demographic characteristics (SDC). 
The utility functions of main effects for the existing methods (no barrier method or male 
condom (MCLastS)), Vnot switch-main ' and the new barrier methods, 
'new-main' 
are: 
Vnot switch-main Nochange * NoChange + ßMCLast 
* 
1Y1CLast 
"new-morn 
- /3dgm * DGM + ß., d* MCD + (-1 * (ßdgin + ßmcd) * FEMC) 
+, 8,,,. * SECR + ßp,, eg 
* PREG + ßH, v * HIV + ßtn(pnce) * LN(PRICE) 
It is hypothesised that: 
9 the choice to switch to any of the new barrier methods could be affected by the utility of 
their current practice (use of a male condom in last sex act (MCLastS)), having had 
difficulties using a male condom in the past (DifvIC), cohabiting (Cohab). 
"not 
switch-SDC 
= Vnot switch-main 
+ /3Di, BMC 
* Dl C+ ßcý). 
b9 * Cohab 
It is hypothesised that the preference for: 
" products is different for women who used a condom relative to those who did not 
(DGM MCLastS, MDC MCLastS , FEMC MCLastS 
), 
" being able to use a product in secret or not is different for women who had and had not 
experienced difficulties using a male condom in the past (SECR DifMC 103) 
" pregnancy prevention effectiveness is different for women who are living with their 
partners (PRG Cohab) than those who are not because of their life stage/circumstances 
relating to the consequence (positive or negative) of conception. 
" HIV prevention effectiveness is different for women who consider themselves at higher 
risks of becoming HIV infected (HIVRISK). 
9 HIV prevention effectiveness is different for women who are cohabiting (HIV_Cohab). 
Vnew-soc = Vnew-male + 
/3DGM 
_ 
MCLaatS 
* (DGM 
_ 
MCLastS) +, 8mcD_mcLms * (MCD_MCLastS) 
+ (-1 * (ßDGM McL,, cs + ßMm Mc s) * FEMC) +ß ei103 
* SECR 
_ 
DyJMC 
+ ßp, G comb * PRG _ 
Cohab + ßP, ß cw * PRG _ 
Cohab + ßfJv k* RISKHJV 
+ I3HIV coupe * (HIV - 
Cohab) 
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For generic experiments such as these, adding SDC will quickly expand the number of 
variables that need to be estimated and thus the degrees of freedom. This is because each 
SDC included results in adding a cross-product of the SDC with the attribute variables to 
obtain an estimate of how the SDC changes women's' preferences for a specific attribute. 
In the next sub-section the appropriate functional form for price and pregnancy is explored, 
then the appropriateness of the NL versus MNL models is tested. The hypotheses above are 
tested in 11.4.48. LIMDEP 8.0/NLOGIT 3.0 was used for estimation. 
11.2.2. Model specification 1: functional forms for price and 
pregnancy 
This section aims to test the appropriate functional form of price and pregnancy 
effectiveness, specifically to: 
1 test if the price attribute is better represented by `partworths', which allow for a 
non-linear response to changes in price, or if a continuous linear variable suffices. 
2 test if the linear specification of pregnancy represents preferences correctly: i. e. 
That `No pregnancy prevention' is not preferred to some medium levels; 
Functional form of price 
There are a number of different functional forms the price variable may take. These are 
presented in Table 11-1. 
Table 11-1 Potential functional forms of price 
Partworths by price level Free Low Medium High 
Partworths by price values - female condom & microbicide 
- diaphragm 
0 5 10 
40 
20 
80 
Price values in Rand - female condom and microbicide 
-diaphragm 
0 
0 
5 
20 
10 
40 
20 
80 
Price values in Ln(Rand+1) - female condom & microbicide 
-diaphragm 
0 
0 
1.792 
3.045 
2.398 
3.714 
3.045 
4.394 
Linear transformation: price/ 5 and price/ 20, respectively 0 1 2 4 
Ordinal values for categories 0 1 2 -7 M 
48 In addition, an RPL model was estimated but did not prove more appropriate than the current models 
have therefore not been presented in the main body of the text. For the RPL estimates and a brief 
discussion, see Appendix 12. 
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The marginal utility may not be consistently decreasing. As mentioned above there is much 
talk of the distrust of free products. This can be tested by specifying the different prices as 
categorical variables (partworths), using either dummy variable coding or effects coding. 
This could be a 4-level categorical variable (free, low, medium, high), or a 6-level 
categorical variable for each Rand value. These could be in natural units (Rands). 
Economic theory tells us that there is a decreasing marginal utility of money. This suggests 
a non-linear but decreasing response to price. A number of functional forms would allow 
for this. Commonly used is a logarithmic transformation. However, as 0 Rand is also one of 
the levels, and we cannot take the log of 0,1 is added to all values. This could also be taken 
into account by a transformation such as dividing the prices by 5 for the disposable products 
(female condom and microbicide) and 20 for the reusable diaphragm (generating codes: 
0,1,2,4), or using ordinal values (0,1,2,3). 
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Table 11-2 Testing for functional forms for price and pregnancy 
3 NL simple - price 4 NL simple - pregnancy 
1 MNL simple 2 NL simple partworths effectiveness partworths 
Coeff. P-value Coeff. P-value Coeff. P-value Coeff. P-value 
DG2 0.085 0.03 0.140 <0.01 0.128 0.02 0.0723 0.08 
MD2 0.226 <0.01 0.256 <0.01 0.248 <0.01 0.289 <0.01 
FEMC -0.311 <0.01 -0.396 <0.01 -0.376 
SECR 0.043 0.10 0.047 0.14 0.050 0.12 0.051 0.11 
HIV 3.397 <0.01 4.305 <0.01 4.284 <0.01 4.290 <0.01 
PRG 1.187 <0.01 1.375 <0.01 1.427 <0.01 
PRG0% - 0.699 <0.01 
PRG55% -0.110 0.02 
PRG75% 0.257 <0.01 
PRG95% 0.552 
PRICE -0.007 <0.01 -0.009 <0.01 -0.134 <0.01 
P=R5 -0.092 0.23 
P=R10 -0.214 <0.01 
P=R20 -0.424 <0.01 
P=R40 -0.731 <0.01 
P=R80 -0.556 <0.01 
C 3.043 <0.01 0.712 <0.01 0.646 <0.01 0.3653 0.03 
C*McLastS 0.690 <0.01 0.660 <0.01 0.660 <0.01 0.6602 <0.01 
Inclusive value 
SWITCH 0.338 <0.01 0.329 <0.01 0.3276 <0.01 
NOSWITCH 1.000 - 1 0 1 0 
LL -5680 -5606.4 -5593.5 -5596.1 
n 6,101 6,101 6,101 6,101 
Adj. pseudo 
R-2* 0.141 0.152 0.1537 . 1534 
*Based on current model over a constants only model 
Figure 11-1 shows the estimates of changes in utility at the prices in the data (0-80 Rand) 
generated from a simple nested logit model. The broken straight line shows a linear 
specification, the unbroken pointed line shows a partworth specification by price values 
(using dummy coding not effects coding), and the smooth unbroken curve is the logarithmic 
specification. Partworths for R5 and RIO are based only on values occurring for 
microbicides and the female condom. Partworths for R40 and R80 are based only on values 
occurring only for the diaphragm. It appears that the partworth values show a stronger 
disutility for price than the linear specification. The value of p=40 in the partworth 
specification shows an unexpected value, having a lower utility than the higher price of 80. 
This goes against economic theory. Interestingly, at p=80, the functional forms predict very 
similar relative utilities. 
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We can also use the LR test to test between the linear and partworth model. The linear 
functional form is the restricted model and the partworth functional form the unrestricted 
model: -2*[ LLr-LLur] =-2*[-5606.4- -5593.5]=22.2 with a x2 distribution with 3 degrees 
of freedom (number of additional parameters). This shows that we can reject the hypothesis 
that there is a linear response to price. 
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Figure 11-1 Price, linear versus partworth specification 
An alternative way to specify price is categorically. Figure 11-2 shows the relative utilities 
of price by product. Using effects coding, these are relative preferences. The prices 
represented by Free, Low, Medium and High for the female condom and microbicides are 0, 
R5, RIO, R20; for the diaphragm they are 0, R20, R40, R80. The price attribute was 
designed to account for the reusability of the diaphragm. The diaphragm shows the dip in 
utility at medium price (R40) seen above. The expected very negative utility of something 
price at R80 is not seen. In fact it has a higher utility than a R20 female condom. 
Microbicides have a peak in utility at RIO, rather than free or low as expected. It is only the 
female condom that is showing a consistently negative curve that is predicted by economic 
theory. In fact this figure shows that the greatest disparity in utility between the products is 
at medium price, otherwise they are fairly close together. This could suggest that high has 
similar utilities be it for the diaphragm with the high price of R80 or for the microbicide or 
female condom with the high price of R20. The thicker line is for all products together, and 
interestingly shows a remarkably linear relationship. 
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Figure 11-2 Relative utilities for price by product 
However, it is difficult to actually use a non-linear (partworth) specification. So given 
diminishing marginal utility, we explored using price represented by an ordinal scale: first 
in proportions to the prices in rand: where for the female condom and microbicides R0=0, 
R5=1, R10=2, R20=4 and for the diaphragm R0=0, R20=1, R40=2, R80=4 (the pink line 
with square markers). And for a more simple ordinal scale of 0,1,2,3 for free, low, medium 
and high (the yellow line with triangles) (Figure 11-3). Then we compare the slope of these 
with the slope of the partworths. The continuous linear function using 0,1,2,3 values leads 
to estimates with almost exactly the same utility values as when unrestricted using 
partworths for all products together (the dark line mostly behind the light (yellow) line). 
This suggests this would be a good functional form with which to estimate price as a linear 
function. However, this makes retrieval of relative WTP values quite complicated with the 
X's taking on different values depending on the product. 
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Figure 11-3 Price ordinal value specification 
The functional form of the price variable is important as it affects some of the key outcomes 
such as potential WTP values and price elasticity of demand. 
Pregnancy functional form 
This analysis aims to understand if no pregnancy prevention better than some intermediate 
levels of pregnancy prevention? Model 4 in Table 11-2 shows the partworth coefficients. 
Pregnancy effectiveness =0 is not larger than any of the other coefficients for pregnancy 
effectiveness. Effects coded partworths impose the mean at 0, while the linear specification 
imposes 0 at 0%, otherwise their slopes are almost identical. We will therefore use a linear 
specification for pregnancy effectiveness. 
0.5 , 
Z 
Ir 0 o 10% 20% 30% 4°0 60% 70% 809/o 90% 100 
0 
Pregnancy effectiveness (%) 
-0 Partw orth -- Linear 
Figure 11-4 Relative utilities for pregnancy, linear and partworth specification 
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11.2.3. Model specification 2: MNL versus NL model 
This section focuses on testing for violations of IIA by examining the inclusive values in a 
simple NL model. The models estimated to test for violation of IIA are presented in Table 
11-3 49 The specific parameter values will be discussed in the next section in a model with 
SDCs. We test if the variance of the error terms of the "not-change" option is different 
those in the "change" branch. Inclusive values (IV) are generated which are sometimes 
called dissimilarity parameters. In estimation, one inclusive value is normalised to 1, then 
the inclusive values of the remaining parameters must be significantly different from I for 
the nesting to be valid (the Wald test). If it is valid, the distribution of the error term is 
significantly different from those of the normalised branch. Here the IV of `Not-change' is 
set to 1. If IVs for `Change' is significantly different from 1, the branch is valid and the 
error structure of A and B are different from C. 
Table 11-3 Estimation of preferences for barrier methods and their attributes: MNL 
and NL without interactions. 
MNL NL 
Coeff. p-value Coeff. p-value 
Diaphragm 0.019 0.58 0.058 0.15 
Microbicide 0.255 <0.01 0.283 <0.01 
Female Condom -0.274 <0.01 -0.341 <0.01 
Secrecy 0.041 0.11 0.051 0.11 
Pregnancy effectiveness 1.177 <0.01 1.366 <0.01 
HIV effectiveness 3.370 <0.01 4.290 <0.01 
LN (Price+1) -0.094 <0.01 -0.134 <0.01 
Neither (average) 2.942 <0.01 0.615 <0.01 
Neither. If condom 0.691 <0.01 0.66 <0.01 
IV-CHANGE 0.327 <0.01 
NOTCHANGE fixed 
N= 6101 
LR -5676.65 -5597.96 
49 Violations of IIA are also tested using a random parameters logit model with correlations. These 
estimates are shown in Appendix 12. Such a specification allows for identifying attributes with correlated 
preferences. However, as this is not able to feed into product development, it is not further explored. 
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We find that the parameters for CHANGE are significantly different from 1. This means 
that the two levels are valid. If the IV was not significantly different from 1, the model 
would have collapsed into a single level (equivalent to the MNL model). 
The other test that could be applied is the likelihood ratio test. The MNL model is a 
restricted form of the NL model. The computed test statistic for this is 
-2* [-5676.65 -- 5597.96] = 157.38 which has a chi-squared distribution with 2 degrees 
of freedom, which has a p-value of less than 0.01. Again we are justified in rejecting the 
hypothesis that the NL model is not an improvement to the MNL model. From here 
onwards the analyses and interpretation will all relate to the NL model. 
Here, the nested logit model will only be applied to the physical attributes DCE, because the 
distribution attributes DCE has only two choices and can therefore not be partitioned. 
Generally, the final tree structure is found through trial and error in the search for the lowest 
log-likelihood at convergence. However, in this application there should be no difference in 
the variance of the error term between A and B as they are designed to be exactly the same, 
but C represents different attributes and levels (i. e. condom and no condom). Although the 
NL is designed purely to accommodate violations of IIA, it is not designed to model the 
decision making processes, and in this application these are closely linked. Therefore, there 
will be no exploration of the tree structure. The structure to be tested is depicted in Figure 
4-2. 
11.3. Descriptive analysis of choices 
Table 11-4 provides an overview of the choices made according to women's characteristics 
that are hypothesised to have an effect on women's choice behaviour. Each woman was 
given six choice sets with three alternatives. Of the 6101 choices possible50, if left to 
chance, two-thirds would have been to change and one-third would have been not to 
change. Seventy-four percent of choices were in favour of a new barrier method, 26% were 
for what the person did last time. Of the responses by women who had not used a condom 
in their last sex act, only 17% opted to `not change'. Of responses by women who had used 
a male condom in their last sex act, 44% were `Not change' (which meant use a male 
condom). Women who used a male condom were less likely to change to one of the new 
barrier methods: in 56% of choices they chose one of the new barrier methods versus 83% 
of women who did not use protection. This suggests that preferences for the new barrier 
S0 6 choice sets*1017 women and 1 missing response 
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methods are likely to differ between women who were and were not able to use a male 
condom in their last sex act. Other groups of women whose choice to change was 80% or 
higher were: those currently using contraceptives (80%), those who experienced difficulties 
using condoms (82%), and those who perceive themselves at high risk of HIV. 
Table 11-4 Switching responses by women's characteristics 
Change Not-change 
Count % Count % 
All 4,539 74% 1562 26% 
Condom used at last sex act (MCLastS) No 3,466 83% 727 17% 
Yes 1,073 56% 835 44% 
Cohabiting with sexual partner (Cohab) No 1,926 70% 810 30% 
Yes 2,613 78% 746 22% 
Ever experienced difficulties getting No 2,624 69% 1156 31% 
partner to use condoms (DiffMC) Yes 1,890 82% 401 18% 
Employed (emplyd) No 2,902 73% 1058 27% 
Yes 1,637 76% 504 24% 
Self-perceived risk of HIV* (RiskH) High 1,105 83% 232 17% 
(RiskM) Medium 1,198 77% 362 23% 
(RiskL) Low 1,043 74% 361 26% 
(RiskNo) None 1,019 65% 547 35% 
Means Means 
Household SES (SEShh) -0.006 0.018 
Age (age) 31.86 30.58 
Years of education (EducYrs) 10.00 10.14 
Risk is an ordinal variable that we will be using as cardinal in the model estimates, valued as 0 for No risk to 3 for 
High Risk. This functional form was chosen by model fit and consistency of parameters with theoretical expectations. 
** The original variable was ordinal in terms of level of education attended and completed. This was transformed into 
an average number of years in education to obtain a continuous variable, however this represents more an interval. 
An overview of these characteristics, their coding and the descriptive statistics for the 
participants can be found in Appendix Table All-1. Correlations of these variables are 
presented in Table Al 1-2. This has provided a general description of the choice data. The 
following section will describe the estimation procedures. 
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11.4. Estimation results 
Table 11-5 shows the results of the MNL and NL models with interactions. The non- 
interacted variables allow for the testing of the importance of products and their attributes in 
women's choices. The interacted terms test for differences in women's preferences by 
women's socio-demographic characteristics. 
Table 11-5 Estimation of determinants of preferences for barrier methods for HIV 
prevention and their attributes with interactions 
MNL 
Coeff. 
NL 
Coeff. 
Diaphragm (DGM) 0.071 * 0.126 *** 
Microbicide (MCD) 0.235 0.257 "** 
Female condom (FEMC)t -0.307 *** -0.383 
Ability to use in secret (SECR) 0.064 0.071 
Pregnancy efficacy (PRG) 1.195 **" 1.383 **" 
HIV efficacy (HIV) 3.016 3.605 
LN(Price) (LNP) -0.086 *** -0.121 *** 
DGM*Used condom last sex act (MCLastS) 0.125 *** 0.146 *** 
MCD*MCLastS -0.047 -0.048 
FEMC*MCLastS -0.079 -0.098 ** 
SECR*ever difficulties negotiating condoms (DiffMC) 0.092 **" 0.101 **" 
PRG* cohabiting -0.091 -0.144 
HIV* self perceived risk of HIV 0.290 *"* 0.496 *** 
HIV*Cohab -0.157 -0.334 ** 
LNP*employed (EMP) 0.037 *"* 0.044 *** 
Choose'do the same as last time' (C) (NOSWITCH) 2.859 *'* 0.904 *** 
C*MCLastS 0.633 *** 0.614 *** 
C*DiffMC -0.268 *"* -0.251 *** 
C*Cohab -0.165 * -0.136 ** 
Inclusive values -Change 0.412 
Not Change 1.000'** 
n 6065 
Lifunction -5555.18 -5490.54 
* is significant at a P-value<0.1. "' is significant at a P-value<0.05. "" is significant at a P-value<0.01. 
tretrieved parameter by swapping the omitted category. 
11.4.1. Main effects 
Of the different products, the microbicide has the highest relative utility (. 257) and female 
condom the lowest (-. 383). These results are consistent with a priori expectations and the 
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directly elicited preferences for products, where microbicides appear most popular, 
followed by the diaphragm. Secrecy has a significant but small effect on choice probability. 
HIV effectiveness has a very large marginal effect: for 1 percentage point increase in HIV 
effectiveness an increased utility of (3.605/100 percentage points=) 0.036 is predicted. The 
levels used have differences of 20% points, so this would translate into an increase in utility 
of 0.72 for each level of increased effectiveness. Effectiveness in preventing pregnancy is 
also important with a coefficient of 1.383. This translates into an increased utility of 0.28 
for each 20% increase in pregnancy effectiveness. The highest utility obtainable from these 
new products would be from: a microbicide that is usable in secret with 95% efficacy in 
preventing pregnancy and 95% efficacy in preventing HIV provided for free. This would 
provide a relative utility of 5.07. The least attractive feasible alternative would also be a 
microbicide, but one which cannot be used in secret, has 0% efficacy in preventing 
pregnancy and 35% efficacy against HIV and is sold at R20 (relative utility 1.08). 
Although the diaphragm and the female condom have lower product attributed valuations, 
they are restricted to 75% and 95% effectiveness against pregnancy and HIV, and thus 
putting a floor on the relative utilities associated with them. 
80% 
75% 
70% 
ät 65% 
60% 
55% 
50% 
45% 
= 40% 
35% 
30% 
0% 20% 40% 60% 80% 100% 
Pregnancy effectiveness 
--*-Base (U=2.40) 
-. - DGM (U=2.52) 
MCD (U=2.65) 
FEMC (U=2.01) 
w SECR+MCD (U=2.72) 
-ý Not SECR+FEMC 
(U=1.94) 
DGM: Diaphragm; MCD: microbicide; FEMC: female condom; SECR+MCD: usable in secret and a microbicide; 
Not SECR+FEMC: not usable in secret and female condom 
Figure 11-5 Effectiveness trade-offs 
Figure 11-5 shows the trade-off between different levels of product effectiveness against 
pregnancy and HIV. The slope of the lines shows the marginal rate of substitution between 
HIV effectiveness and pregnancy effectiveness. This is the ratio of their coefficients 
(=3.605/1.383 = -2.61). The base line shows the average for all products. If it was a 
diaphragm, relative utility would be 0.12 higher (=2.52), if it was a microbicide, relative 
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utility would be higher still (2.65). As we saw above the female condom is least preferred 
with a relative utility of 2.01. If the microbicides were usable in secret, the marginal utility 
would increase by 0.07, and if the female condom was not usable in secret (as in reality), its 
relative utility would be just 1.94. The lines are linear as we have not allowed for increasing 
or decreasing marginal utilities or synergies (interactions) between HIV and pregnancy 
effectiveness. 
11.4.2. Interactions 
A number of interactions are included to explore the effect of women's characteristics on 
their product valuations (Table 11-5). Firstly, we examine how women's values for these 
products are affected by their current HIV prevention options/choices51. The effect of 
having used a condom in their last sex act (`MCLastS') has an opposite effect on women's 
marginal valuations of the female condom and the diaphragm. Women who used a condom 
last time have higher marginal valuations of the diaphragm than women who did not use a 
condom, and women who used a condom had lower marginal valuations of the female 
condom than women who had not. As may be expected secrecy was significantly more 
important to women who had ever experienced difficulties getting a partner to use a 
condom, with their marginal utility obtained from a secret product being 1.5 times greater 
than the average. 
Women who were living with their partners had lower marginal utilities for pregnancy and 
HIV prevention efficacies, potentially reflecting that cohabiting women were not as worried 
about pregnancy and HIV. Consistent with observed behaviour, women who were currently 
using contraception had higher marginal utilities for pregnancy prevention efficacy. Women 
who considered themselves at higher risk of acquiring HIV had higher preferences for HIV 
efficacy. And lastly employed women had higher coefficients for price, which implies 
higher willingness to pay. Figure 11-6 shows the impact of women's self perceived risk of 
HIV and their cohabitation status on their marginal valuations of HIV effectiveness. 
Women who were both not cohabiting and who perceived themselves at high risk of 
acquiring HIV valued HIV effectiveness the highest, 66% higher than women who were 
cohabiting and perceived themselves at no risk of HIV (Figure 11-6). 
51 Having used a condom in the last sex act implies using a condom is a feasible option, however having 
not used one may mean that it is not an option or that it is an option but the choice was not to use one. 
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Figure 11-6 Utilities for HIV prevention effectiveness by women's self perceived risk of 
HIV and cohabitation status 
11.4.3. The choice to not switch 
The following section interprets the NL results in Table 11-5. The choice to switch from 
what a woman did last time she had sex represents either newly protected sex acts, if the 
woman had not used a condom in her last sex act, or it represents substitution away from 
the condom, if she had used a condom. The value of not switching is allowed to differ if the 
last sex act was or was not protected by a condom. If the woman used a condom, her 
relative utility is C+C_MCLastS, and if she did not it is C-C_MCLastS. There appears to 
also be high utilities related to not changing (. 904) especially for women who used a 
condom in their last sex act (1.518). For women who did not use a condom, the relative 
utility is 0.29. Having had difficulties in negotiating condoms (DiffMC), living with a 
partner (Cohab), and currently using contraceptives (Contr) decreases the relative utility of 
not-changing and thus also its probability. A woman with these characteristics and who did 
not use a condom in their last sex act is predicted to have a relative utility of -0.34. In 
contrast, a single woman, who has never had a problem using condoms, and indeed used 
one in the last sex act and is not using contraception has a relative utility of 1.96. These are 
shown in Figure 11-7. 
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Figure 11-7 Relative utilities for not switching to a new barrier method from having 
used a condom or not having used a condom by women's SDCs 
Figure 11-8 shows the probability of switching to a microbicide with different levels of HIV 
efficacy, pregnancy efficacy and price, according to whether she had used a condom or not 
in her last sex act. The choice is between the microbicide and a female condom sold at 10 
Rand or Neither. The light bars on the left are the probabilities for women who reported 
having used a condom in their last sex act and on the darker bars on the right are the 
probabilities for women who had not used a condom in their last sex act. On the very left it 
can be seen that an expensive microbicide with low prevention efficacy would have a low 
probability of being chosen. As the product characteristics improve (towards the right of the 
figure), women find the product becomes more and more attractive relative to the female 
condom or what they did last time. 
From these choice probabilities, it can be seen that the HIV effectiveness of product clearly 
played an important role in women's choices, with a low projected uptake of microbicide 
with poor effectiveness. Pregnancy prevention was also important to women and would 
enhance the attractiveness of a microbicide and facilitate its use. This shows that th e 
effectiveness of microbicides will be a major determinant of their uptake by women. For all 
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levels of the product attributes, women who had not used a male condom considered 
microbicides a more attractive choice than women who had used condoms. 
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Figure 11-8 Probability of choosing a microbicide with different characteristics over a 
female condom or neither for women who had and had not used a condom in their last 
sex act. 
11.4.4. Comparison between the NL and MNL 
Both the simple model (Table 11-3) and the model with SDC interactions (Table 11-5) 
show fairly similar results to the MNL models in the same tables, maintaining the ordering 
of relative preferences. The major difference is in the coefficient for Neither (C). In MNL 
with SDC interactions this is 2.806 and in NL it is 0.8 10. In addition, the coefficients of the 
interactions with HIV (HIVRISK and HIV_Cohab) in the NL model are almost twice as 
large as those in the NL. This shows that the MNL is relatively robust to the violations of 
IIA, if the interest is merely in identifying influential factors and their relative importance. 
11.4.5. Predictive validity 
Predictive validity can be explored by analysing the responses to the hold-out questions. 
This is done using the percentage of correctly predicted responses (here done using the 
simple model with no interactions) and are presented in Table 11-6. 
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Table 11-6 Predictive validity 
Predicted Observed # correctly 
Choice % correctly 
probability of Choice Choice Probability predicted 
sets choices 
choosing A Choice A B of A choices 
C 51% A 7 39 15% 7/46 15% 
G 18% B 14 31 31% 31/45 69% 
K 62% A 27 18 60% 27/45 60% 
0 48% B 11 34 24% 34/45 76% 
Total 55% 
The choice sets show that the marginal utilities of the alternatives were very close together 
for choice C, and only correctly predicted 15% of the actual choices. If we consider all the 
responses, the predictive validity is 55%, only slightly better than chance. However, this 
method of evaluating predictive validity purely looks at correctly predicted choices, 
regardless of the disparity in the choice probabilities. As pointed out by Train [420), this 
approach ignores the richness of the discrete choice models that present a far more nuanced 
picture of choice by estimating probabilities. 
I1. S. Discussion 
This chapter has focussed on identifying how women value different physical product 
characteristics using a nested logit model. This is a two step approach where the choice to 
use one of the women's barrier methods (substitution from what they did last time) is 
modelled separately from the choice among the women's barrier methods. 
The results provide several important insights. When choosing among the women's barrier 
methods, microbicides and the diaphragm were generally preferred to the female condom. 
HIV prevention effectiveness was the most important characteristic to women and seemed 
to dominate most choices. Although pregnancy prevention effectiveness. HIV was more 
than twice as important as pregnancy prevention, and was especially important to women 
who considered themselves at higher risk of becoming HIV infected. Although secrecy was 
not found to be a critical factor to uptake, women who had experienced difficulties using 
condoms found it most important for a product to be usable in secret. 
Women who used a condom were less likely to try alternative methods. Women who had 
ever experienced difficulties getting their partner to use a condom, and were living with 
their partners were more likely to try the women's methods. 
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The key policy lesson from the physical attributes analysis is that although all women 
expressed interest in trying microbicides, those who are in greater `need' of new methods of 
protection were more likely to choose the new methods. Given these results, some self 
selection is expected to occur, with microbicide uptake higher among women who are 
unable to use male condoms. This should be reassuring for those who have expressed 
concerns about substitution away from male condoms towards possibly less effective 
microbicides. 
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Chapter 12. Analysis of a DCE 2: preferences for 
distribution and promotion strategies 
12.1. Background and aims 
Chapter 11 focussed on predicting the impact of physical product attributes on product 
uptake and how this might differ between different women. This chapter aims to assess how 
best to promote and distribute new barrier methods to facilitate their access. More 
specifically it aims to answer the following three questions: 
" What are women's relative preferences for distribution strategies? 
" Are preferences for distributing new products (microbicide and diaphragm) different 
from those for distributing existing methods (female condom & male condom)? 
9 How do preferences vary by women's socio demographic characteristics (cohabiting, 
household socio-economic status, employment status)? 
Section 12.2 describes the methods used in this analysis, Section 12.3 present the results 
and Section 12.3 Discusses the polic implications of these results. 
12.2. Methods: Model specification 
The general methods for estimating discrete choice models have been described previously. 
This section describes the specific models used to answer the three study questions. In the 
first section we describe the variables included in the three models estimated. In the second 
section we describe the method for choosing between estimators (multinomial logit (MNL) 
versus random parameters logit (RPL). 
12.2.1. Model specification 1: Variables included 
To answer this chapter's study question, it was necessary to estimate three separate models, 
differing in the interaction terms. 
The base model without interactions answers the first question and estimates the probably 
of choosing a given alternative as a function of the: 
9 distribution sources: clinic (CLIN); pharmacy (PHARM); spaza (SPAZ); supermarket 
(SPKT); 
" collection methods: box (BOX); from a person behind the counter (CNTR); from a 
person in a private room (PVTRM); or off a shelf (SHLF); 
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" message used to advertise the product: for HIV prevention (ADHIV); pregnancy 
prevention (ADPREG); for enhanced pleasure (ADPLS); women's empowerment 
(WEP); 
" Price: Free, 5 Rand, 10 Rand, 20 Rand 
Main effects equation: 
VDisnib 
main -A ciin 
* CLIN+I3PHARM* P R- /3SPAZ * SPAZ+(-I * ýcfln +YPHAPM+! 'SPAZ) * SPK`J + 
ßBox*BOX+ßc v*CNTR+/33Vrxw*PVTRMf(-1*(86ox+QcNrR+QPVrx) *SHLJ3+ 
ßADyry* ADHIV+ flADP, EG* ADPREG, 6ADPLs* ADPLS-(-1 *(ß+ 
ßADPREG+f 
ADPI) *WE! )+ 
/P,, 
n 
* PRICE 
Interaction terms are used to test if preferences for distribution strategies may vary by some 
key factors (variables). In contrast to the model presented in chapter 11, there were not clear 
expectations that the interacted variables needed to answer study questions 2 and 3 would 
only affect specific attributes. This meant that all interaction terms (preferred products and 
variables describing women's characteristics) needed to be multiplied with each attribute. 
This became an unwieldy model. It was therefore chosen to estimate a separate model for 
each study question. 
To explore if the new barrier methods are better distributed using different strategies from 
the existing barrier methods, interaction . Before starting the 
distribution strategies section 
of the DCE, women were asked: of the four barrier methods (including male and female 
condoms) what you think would suit your needs best? That product was then used in each 
of the distribution scenarios: where would you prefer to get your .... e. g. "Female condom"? 
The omitted category was male and female condoms52. 
To see if women's socio demographic characteristics affect their valuations of distribution 
systems, interaction terms were included for: women's employment status (either part- or 
full-time versus not employed at all); the socio-economic status of women's households; 
and whether or not women are cohabiting. 
sZ We first estimated the difference of distribution preference relative to preferences for distributing the 
male condom (e. g. women expressed that male condom was their preferred product and thus the 
distribution strategies all referred to collection of the male condom). However the regression results were 
counter-intuitive, with many of the main effects losing significance. 
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12.2.2. Model specification 2: Test for appropriate estimator 
To test for the appropriate model, a number of estimations were needed. First, we estimated 
the main effects model using MNL and RPL to test for violations of IIA and preference 
heterogeneity (Appendix Table A13-1). The RPL model estimates distributions around the 
parameter estimates. All main effects parameters were tested for having a distribution. The 
shape of the distribution of the categorical variables was set as uniform, while for price a 
triangular distribution was chosen after exploration of the normal and lognormal 
distributions (presented in Appendix Table A13-2). In an iterative approach, in which 
parameters with insignificant distributions are subsequently not included in the specified 
random parameters (i. e. modelled as fixed parameters) in the next iteration, no random 
parameters were left. This resulted in the model collapsing to a standard MNL model. 
Therefore only MNL estimates are presented in the main text. 
12.3. Estimation results 
12.3.1. a. What are women's relative preferences for distribution 
strategies? 
In the MNL model (Table 12-1) box, shelf and advertised for pregnancy prevention do not 
influence choice probabilities, otherwise all attributes and levels are significant. Strongest 
preferences were around distribution source (largest relative utility coefficients), though 
advertising for enhanced pleasure also reveals strong negative preferences. Women had 
large positive utilities for the clinic and the pharmacy, and relatively disliked the 
supermarket and the spaza. The private room was the most valued collection method. 
Contrary to conventional wisdom, both HIV prevention and women's empowerment had 
positive associations, while pleasure was quite unattractive to most women in our study. 
This was supported by the qualitative work, where women said that if it was advertise too 
sexually "it would be like bringing home pornography" (30-45 year olds, attribute 
identification workshop). 
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Table 12-1 Estimation of distribution strategy preferences 
MNL 
Coeff. p-value 
Source 
Clinic 0.29 <0.01 
Supermarket -0.20 <0.01 
Pharmacy 0.33 <0.01 
Spaza (comer store) -0.43 <0.01 
Collection method 
Box or dispensing machine 0.04 0.38 
A shelf 0.02 0.65 
A person behind a counter -0.18 <0.01 
In a private room 0.11 0.01 
Advertising message 
HIV prevention 0.10 0.02 
Women's empowerment 0.13 <0.01 
Enhanced pleasure -0.30 <0.01 
Pregnancy prevention 0.06 0.15 
Price -0.04 <0.01 
IIr -1951.17 
12.3.2. b. Are preferences for distributing new products (microbicide 
and diaphragm) different from those for distributing existing methods 
(female condom & male condom)? 
Table 12-2 shows MNL results testing for differences in preferences by their preferred new 
barrier method. 
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Table 12-2 Utilities for distribution strategies for new and existing products -MNL 
estimates 
Main effect 
Interactions 
Diaphragm Microbicides 
Coeff. p-value Coeff. p-value Coeff. p-value 
Source 
Clinic 0.31 <0.01 -0.04 0.60 -0.08 0.25 
Supermarket -0.22 <0.01 0.00 0.99 0.07 0.27 
Pharmacy 0.33 <0.01 0.07 0.37 0.03 0.70 
Spaza (comer store) -0.42 <0.01 -0.03 0.70 -0.02 0.81 
Collection method 
Box or dispensing machine 0.05 0.26 0.12 0.07 -0.08 0.16 
A shelf 0.03 0.64 0.01 0.87 0.02 0.83 
A person behind a counter -0.21 <0.01 -0.18 <0.01 0.14 0.02 
In a private room 0.13 <0.01 0.04 0.56 -0.08 0.22 
Advertising message 
HIV prevention 0.11 0.03 -0.16 0.03 -0.02 0.71 
Women's empowerment 0.14 <0.01 0.14 0.03 -0.01 0.71 
Enhanced pleasure -0.29 <0.01 -0.10 0.15 -0.01 0.83 
Pregnancy prevention 0.05 0.34 0.12 0.07 0.05 0.42 
Price -0.04 <0.01 0.01 0.21 0.00 0.52 
LIr -1934.94 
Preferences for different distribution strategies were different for those women who chose 
the diaphragm as their preferred product, with higher preferences for collection from a box 
and for advertising for women's empowerment and pregnancy, and lower preferences for 
collection from a person behind a counter and promoting diaphragms for HIV prevention. 
For microbicides there was a less negative preference for collection from a person behind a 
counter. More generally, distribution of new methods through a person behind the counter 
was the least attractive collection method, and with this being especially the case for the 
diaphragm (relative utility -0.39 (=-0.21-0.18)). 
In the next section we explore how women's characteristics affect their preferences for 
distribution strategies. 
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12.3.3. c. Do preferences vary by women's socio demographic 
characteristics? 
Table 12-3 shows the results of testing for the impact of women's characteristics on their 
preferences for distribution strategies. Women who were cohabitating had less negative 
preferences for promoting microbicides for `pleasure' (though still negative: -0.312+0.102 
= -0.210), and were less positive about women's empowerment (0.04). They also had 
greater price sensitivities. 
Employed women had less negative preferences for the spaza (-0.36) and liked distribution 
from a box or machine. They also were more enthusiastic about women's empowerment 
messaging. Household socio-economic status had a significant impact only on preferences 
for private room collection, with women from higher socio-economic status households 
finding private room collection less important. 
Table 12-3 Estimates of Distribution preferences by socio demographic characteristics 
Main effects 
Interactions 
Cohabit SES Employed 
Coeff. p-value Coeff. p-value Coeff. p-value Coeff. p-value 
Source 
Clinic 0.295 <0.01 0.049 0.34 -0.061 0.30 0.000 0.99 
Supermarket -0.201 <0.01 0.018 0.69 0.018 0.71 0.004 0.93 
Pharmacy 0.363 <0.01 -0.056 0.26 0.043 0.41 0.085 0.12 
Spaza (comer store) -0.457 <0.01 -0.012 0.81 0.043 0.38 -0.089 0.09 
Collection method 
Box or dispensing machine 0.007 0.882 -0.013 0.77 0.006 0.89 -0.093 0.05 
A shelf 0.009 0.874 -0.037 0.52 0.052 0.38 -0.046 0.44 
A person behind a counter -0.158 <0.01 0.041 0.37 0.028 0.55 0.060 0.23 
In a private room 0.142 <0.01 0.008 0.86 -0.086 0.08 0.079 0.12 
Advertising message 
HIV prevention 0.116 0.017 -0.024 0.60 -0.025 0.60 0.019 0.71 
Women's empowerment 0.161 <0.01 -0.118 0.01 0.070 0.16 0.102 0.05 
Enhanced pleasure -0.312 <0.01 0.102 0.03 -0.034 0.50 0.019 0.72 
Pregnancy prevention 0.034 0.475 0.024 0.39 0.025 0.82 -0.139 <0.01 
Price -0.034 <0.01 -0.011 <0.01 0.003 0.41 0.006 0.17 
(Ir -1916.94 
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The relative impact of significant women's characteristics on preferences was greatest for 
box collection by employed women (8 times greater than average: 0.06 versus 0.007) 
followed by the preferences for advertising for women's empowerment, where a non- 
cohabiting employed woman's preferences were twice the average preferences for women's 
empowerment (0.33 versus 0.16). 
Model summary 
To summarise the impact of products and women's characteristics on distribution strategy 
preferences, their significant interactions are presented in Table 12-4. Household socio- 
economic status and microbicide as preferred product appear to have little impact on 
preferences. 
Table 12-4 Impact of preferred product and women's characteristics on distribution 
strategy preferences 
Interactions None Products Women's characteristics 
Diaphragm Mic robicide Cohabiting SES Employed 
Coeff. p-value Sign. Sign. Sign. Sign. Sign. 
Source 
Clinic 0.29 <0.01 
Supermarket -0.2 <0.01 
Pharmacy 0.33 <0.01 
Spaza (comer store) -0.43 <0.01 + 
Collection method 
Box or dispensing machine 0.04 0.38 ++ 
A shelf 0.02 0.65 
A person behind a counter -0.18 <0.01 -- ++ 
In a private room 0.11 0.01 - 
Advertising message 
HIV prevention 0.10 0.02 - 
Women's empowerment 0.13 <0.01 +_ ++ 
Enhanced pleasure -0.3 <0.01 ++ 
Pregnancy prevention 0.06 0.15 + +++ 
Price -0.04 <0.01 --- 
-1+ is significant at p<0.1, -l++ at p<O. 05, --1+++ at p10.01 
Note: From 3 separate regressions 
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Though distribution source remains the attribute with the strongest influence on women's 
choices, it is preferences for advertising messages that have the greatest variation, shown by 
the number of significant interactions. In fact, despite the significant interactions with other 
attributes it is only advertising where their relative ordering changes by product or women's 
characteristics (Figure 12-1). Advertising for women's empowerment is most frequently the 
most desirable advertising message followed by HIV prevention. In most cases enhanced 
pleasure was not considered desirable. However, there were a number of exceptions to this. 
Pregnancy prevention was the second most attractive message for the diaphragm. 
Cohabiting women's choices were least influenced by advertising strategy, but preferred 
HIV prevention and pregnancy prevention to women's empowerment. The greatest 
difference in preferences for advertising messages can be identified among employed 
women. They had far greater preferences for HIV prevention and most interestingly had 
positive preferences for enhanced pleasure. 
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Figure 12-1 Relative advertising preferences by product and women's characteristics 
12.4. Summary of results and key policy lessons 
This chapter has explored women's preferences for different distribution and promotion 
strategies. A random parameters logit model was initially estimated to test for violation of 
IIA and allow for preference heterogeneity (i. e. different people having different 
preferences). However, this was found to be unwarranted and the MNL model was 
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subsequently used to answer the study questions. The most popular distribution outlets were 
clinic and pharmacy, with spaza and supermarket less so. In line with expectations the more 
discreet collection methods were preferred, in particular from a private room, with from a 
person behind a counter being least discreet and least preferred, particularly so for the 
diaphragm. Preferences for advertising products for women's empowerment showed the 
greatest variation by women's characteristics. 
These findings have very interesting policy implications. Firstly to facilitate women's 
access to products, distribution through pharmacies should complement health clinic 
distribution. The study also showed that different products do not need to be distributed 
through different distribution sources or adopt varying collection methods to reach different 
groups of women. Additionally, it showed that advertising strategies can be used to 
stimulate demand for different products or differentiated products by different women. This 
is a very convenient finding because advertising messages are the easiest to adapt to the 
different products and used target different groups of women. This approach, commonly 
part of a social marketing approach to commodity distribution, can be applied to encourage 
use of a variety of HIV prevention products by a wider range of women. 
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SECTION IV: CONCLUSIONS 
Chapter 13. Determinants of women's uptake of new 
barrier methods for HIV prevention in urban South Africa 
13.1. Overview 
The fight against the HIV epidemic has taken some very positive turns in recent years, with 
great increases in funding for and access to HIV treatment [2). However, for the long term 
sustainability of such efforts, prevention cannot be over-emphasised. In particular, women 
still lack HIV prevention strategies they can initiate discreetly 151. Although female condoms 
are an important addition to prevention options for women, they do not seem to address all 
women's needs, and are still not widely available. At the onset of this PhD research both 
microbicides and diaphragms were potentially important prevention options whose 
effectiveness was being explored. Although diaphragms have not been shown to be 
effective, there is ongoing analysis of trial data to explore whether some protection may 
have been obtained among consistent diaphragm users. And though the recent microbicide 
trial of Pro2000 has shown this product not to be effective, further trials of other 
compounds are underway. 
This thesis set out to explore what factors may influence the uptake of future female 
initiated methods for HIV prevention, with the aim of learning lessons that can be used to 
inform future introduction and distribution strategies. Multiple complementary research 
methods have been used. Primary data collection has used focus group discussions, 
individual interviews, attribute identification workshops, and a community survey applying 
a discrete choice experiment (DCE) among a representative sample of urban South African 
women. This data was then analysed for women's preferences for barrier methods and their 
distribution and promotion. 
This chapter reviews the extent to which the thesis has addressed the key empirical and 
methodological questions it set out to answer, and discusses the caveats and limitations of 
these findings. This chapter further reflects on the general approach to the questions and 
identifies some priorities for future research. 
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13.2. Key empirical findings and lessons for new product introduction 
13.2.1. Market segmentation 
The analysis of potential market segments that allow for identification of some key 
differences in socio-demographic and `behavioural' characteristics identified three groups 
of women with different product and distribution preference. When examining their 
characteristics, there appears to be a central large group of `average' women. The two 
smaller clusters represent a less empowered poorer group of women and more empowered 
better off group of women. 
Analyses using the contingent valuation data showed that the key determinants in women's 
preferences for the different products were household socio-economic status, age, 
employment status, cohabitation status and their self-assessed HIV risk status. As expected, 
socio-economic status was consistently shown to influence the monetary values given, 
reflecting higher willingness to pay values by women with higher abilities to pay. Younger 
women were willing to pay more than older women for all products. The key differences in 
women's valuations between the products were between cohabitating and non-cohabitating 
women: cohabitating women had higher values for the discreet products (microbicides and 
diaphragm) but not for the female condom, which cannot be used without a partner's 
participation. 
13.2.2. Determinants of women's demand for barrier methods and 
their attributes 
Analysis of the DCE showed that, ceteris paribus, microbicides were generally the most 
attractive among the barrier methods presented, followed by the diaphragm. Female 
condoms were considered less preferred by most women. Despite much qualitative research 
focussing on the importance of secrecy of use, this was considered far less important than 
product effectiveness in preventing HIV and pregnancy. However, this masks the 
underlying heterogeneity in preferences. 
HIV effectiveness came out as being very important to women. A highly HIV effective 
(95%) microbicide is predicted to be chosen by 56% of women (who had not used a 
condom) over the female condom or use nothing, while if it was only 35% effective, only 
13% of these women are predicted to choose it. Women who had used a condom were far 
less likely to switch, 32% would switch if the product was highly effective (95%) and 6% 
would switch to a product moderate effectiveness (35%). This suggests that a microbicide 
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with moderate effectiveness is unlikely to have widespread appeal, but may nevertheless 
address an important prevention gap, being twice as likely to be used by women who were 
unable to protect themselves with existing methods, than women who could use condoms. 
Women who had ever experienced difficulties getting their partner to use a condom, and 
were living with their partners were more likely to try the new methods. Cohabiting women 
also had higher WTP values for the diaphragm and microbicides in the CV study. Women 
who had experienced difficulties using condoms found it most important for a product to be 
usable in secret. 
13.2.3. Determinants for women's demand for distribution strategies 
The analysis of distribution strategies to facilitate women introducing barrier methods into 
their relationships and to support continued use showed greatest preferences for the clinic 
and pharmacy. It is reassuring to know that even if products are restricted to prescription 
only distribution, these distribution channels would satisfy the largest segment of women. 
Conveniently these could provide an distribution for both free and priced products. Women 
had preferences for the more discreet collection methods over those less private, i. e. the 
private room was generally preferred and collection from a person behind the counter was 
disliked, in particular for collection of the diaphragm. These preferences were relatively 
stable across women. However, there was more variation between women in their 
preferences for the advertising messages, in particular for enhanced pleasure, which was 
generally disliked except among employed women. HIV prevention was the most widely 
accepted message. 
13.2.4. Lessons for new product introduction 
There are a few important policy lessons that can be learned from this study. Firstly, there 
do appear to be some identifiable market segments, with women who were cohabiting 
expressing higher preferences for the more discrete products (microbicides and the 
diaphragm). 
Secondly, from the analysis of women's preferences for products and their attributes, we 
learned that although all women expressed interest in trying microbicides, those who are in 
greater `need' of new methods of protection were more likely to choose the new methods. 
Given these results, some self selection is expected to occur, with microbicide uptake higher 
among women who are unable to use male condoms. This should be reassuring for those 
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who have expressed concerns about substitution away from male condoms towards possibly 
less effective microbicides. 
Thirdly, to facilitate women's access to products, distribution through pharmacies should 
complement health clinic distribution. The analysis also showed that different products do 
not need to be distributed through different distribution sources or adopt varying collection 
methods to reach different groups of women. Additionally, it shows that advertising 
strategies can be used to stimulate demand for different products or differentiated products 
by different women. This is a very convenient finding as advertising messages will be the 
easiest to adapt to the different products and can be used to target different groups of 
women. This approach, commonly part of a social marketing approach to commodity 
distribution, can be applied to encourage use of a variety of HIV prevention products by a 
wider range of women. 
13.3. Key methodological findings 
The study used a discrete choice experiment to investigate women's preferences for 
physical attributes of products and their distribution strategies. This methodology has rarely 
been applied in health economics studies to study uptake of new products/services in sub- 
Saharan Africa. Methodologically there are a number of important findings. 
13.3.1. The attribute identification workshops 
To date the most commonly recommended and applied method for identifying attributes to 
be used in DCEs are focus group discussions (FGDs) and in-depth interviews (IDIs) [292.273, 
257x. Because a very large number of attributes and levels were suggested in the qualitative 
interviews, a further step was necessary to obtain a concrete prioritisation of the importance 
of the attributes and levels in women's decision making. Twenty-two women participated in 
the attribute identification workshops to rank the vast range of product and distribution 
attributes suggested during the qualitative research. This collected all the suggested 
attributes and levels and allowed women to consider them together and express what was 
most important to them. While the questions were presented to the group and could be 
discussed, each woman completed their own questionnaire, generating rankings that could 
be analysed quantitatively. This was very helpful for rationalising the choice of attributes 
and levels for inclusion in the DCE tool. 
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Though this method is recommended for future studies using FGDs and IDIs to identify 
DCE attributes, if I was to repeat this study I would have configured the fieldwork 
differently, by seating women at individual desks in a circle rather than around a big table. 
This would have still encouraged discussion among women while providing them with 
more privacy in noting down their responses. 
13.3.2. The interpretation of product effectiveness 
This study also explored women's capacity to evaluate risk in the context of DCEs. A 
question received repeatedly while presenting this research in various meetings is whether 
women were able to interpret the level of protection provided by the different products. In 
general, these findings suggest that women were able to interpret what was being presented. 
Women's interpretation of the potential level of risk reduction presented was explored using 
a range of methods. In the evaluation interviews and in the community survey, women were 
asked to identify the product that would provide the most protection against HIV. In both, 
this was almost universally answered correctly (>95% in both). The analysis of the DCE 
showed that improvements in the effectiveness of products preventing HIV had the greatest 
impact on switching choices, followed by improvements in pregnancy prevention. Although 
none of these approaches can be used to conclusively establish women's precise 
interpretation of the absolute effectiveness numbers, this does suggest a good understanding 
of relative effectiveness. Indeed, this study suggests that women, even of little education, 
can evaluate the relative risks and benefits of different choices, and factor this into their 
decision making. Indeed, the challenge may be more that, even with such knowledge and 
understanding, they may not always be able to enforce their preferences for protecting 
themselves. 
13.3.3. `Evaluation' interviews 
The evaluation interviews identified that the DCE segment of the survey was challenging, 
not only to participants, but also to the fieldworkers. By including a post survey interview 
it was possible to identify areas of misinterpretation of the scenarios and allowed for their 
immediate correction. It also showed how well women did understand the characteristics of 
the products. This was likely increased by allowing women to view and handle the different 
products under consideration during their interview. 
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13.3.4. Validity of using DCE in low and middle income countries 
Although well established in health economics in industrialised countries, there are few 
(though growing numbers of) studies that have undertaken DCEs in low and middle income 
countries and their remains ongoing question about its applicability in different settings. 
The findings from this research suggest that, in this urban South African context particular, 
DCE methods can provide valid and meaningful findings, athough there were also some 
emerging issues. 
Women's strong preferences for high HIV effectiveness may have caused bias in the 
results. Thirty-five percent of women always chose the DCE alternative with the highest 
HIV effectiveness. This may indicate a violation of the axiom of monotonicity (more is 
better). Possible explanations for this are: that it truly is the only attribute women found 
important; that the ranges of the other attributes were not wide enough to compensate for 
the reduction in HIV effectiveness [4021; or that women were applying simplifying heuristics, 
where they use the most important attribute to simplify the difficult choices with which they 
are being presented E405'1. Although it is not possible to uncover the true explanation for 
these women's choice behaviour, we found that the estimates largely held when estimated 
excluding the respondents who displayed non-trading behaviour. The main difference, as 
would be expected, was in the magnitude of the coefficient for HIV effectiveness. It is 
possible that this is biased upward. 
The DCE generated results that are consistent with the relative rankings from the priority 
setting workshop and the directly elicited preferences. However, there is some question 
about the complexity of the scenarios and if women had applied simplifying heuristics. If so 
this may have led to upwardly biased coefficients for the HIV effectiveness attribute. 
Further comparison with the literature shows the results to generally be externally 
consistent. Kleinschmidt et al (2003) shows the importance of personal and partner 
characteristics in male condom use in South Africa [9 9]. From our analysis, important 
motivations for trying new products are: cohabiting, having had difficulties negotiating 
condom use, and women's own risk perceptions. Similarly, focus groups from Mexico ["] 
showed secret use of the female condom was not essential but probably useful to some 
women. Women in ongoing microbicide trials are also reporting that products need to be 
discreet rather than secret per se [155j This study shows that secrecy is generally the least 
essential of the attributes included, but is important to women who have experienced 
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difficulties negotiating male condom use. The Mexico study also suggested that the female 
condom would be as unacceptable as the male condom to many women [121; in this study the 
female condom was rated more negatively than the microbicide was rated positively. 
13.4. Reflections on the approach 
13.4.1. The theoretical framework 
Chapter 1 identified a number of critical steps between producing new barrier methods and 
having a successful product that women can use consistently when they need them. The 
demand by the end user is only one of the key bottlenecks to achieving this. 
WHO's Strategic Approach to Contraceptive Introduction was used to conceptualise 
important dimensions affecting successful product introduction [681. This aims to move 
beyond the product characteristics to understand broader constraints to uptake such as 
attributes of the service and women's characteristics. This framework appeared to identify 
key dimensions to include in the DCE. It also directs attention to broader societal, political 
and economic factors, which were outside the scope of this analysis. 
13.4.2. Applicability of diffusion theory to barrier method 
preferences 
Diffusion theory (reviewed in Chapter 2) suggests five broad attributes that account for the 
adoption of innovations [271: relative advantage, compatibility, complexity, trialability, 
observability. This research highlights the difference in preferences for new barrier methods 
between women who had and had not used a condom in their last sex act and the 
significance of the `self-perceived risk of HIV variable' which suggests that relative 
advantage is likely to play an important role in uptake. Compatibility appears only to be 
important to preferences for the diaphragm. The positive interaction term between having 
used a male condom in the last sex act and preferences for the diaphragm53 suggests that the 
diaphragm is perceived as more compatible among condoms users. Perceptions of 
complexity of product use are likely both reflected in the preferences for the products and 
their ability to be used in secret. These variables have very different magnitudes of 
importance which make commenting on the relevance of complexity difficult. All of the 
products have high triability at the technical level. 
s' Those who had used a condom in their last sex act had higher preferences for the diaphragm than those 
who had not used a condom 
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However, my research also highlights that a number of other dimensions will affect 
women's actual ability to try the product, such as how accessible the distribution system 
makes the products. Additionally, partners' attitudes are likely to constrain a products' 
triability; triability of microbicides is likely to be higher than that of the other new products 
if they can be used without the partners' active consent. Observability of benefits was very 
important, reflected by the importance of the HIV and pregnancy effectiveness coefficients. 
When the effectiveness is lower, the observability of benefits is reduced: prevention of 
pregnancy or HIV infection becomes less likely. These dimensions can also be considered 
at a broader level in terms of accessibility of products. 
13.4.3. Generalisability of results 
The comparison of the survey with comparable surveys of South African women shows 
high generalisability in the urban South African context. 
This is an important country for new product introduction; it has hosted numerous HIV 
prevention trials (trial communities are the first to receive products if found effective) and 
has very high HIV prevalences. However, it must be acknowledged that urban South Africa 
is different from rural South African from many other African country contexts. Firstly, the 
structure of South Africa's economy is different. Though it is a middle income country, it is 
better characterised by high income and a low income economies existing in parallel. Being 
urban, communication networks are good and diffusion of innovations is quick. The speed 
of uptake of new products may be slower in other countries, where mass media is not as 
accessible or widespread. 
Exposure and uptake of contraceptives has been very high in South Africa and reported 
condom use is also high, leading to the expectation of more rapid uptake of new prevention 
methods than in places where contraceptives are not as widespread and condom use is still 
low or where the public sector is week. 
Comparing women's preferences for distribution outlet types with those presented in DHS 
analysis on where women collected their contraceptives presented (Chapter 9), we found, 
holding all else constant, that women had very positive and close preference for the clinic 
and pharmacy, were not in favour of the supermarket and strongly dislike the spaza shop. 
However, in reality, a critical difference between the clinic and the pharmacy is in the prices 
of their services and drugs, which makes it impossible to disentangle women's revealed 
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preferences for price and source. In the 2003 DHS the majority (73%) of urban women 
obtained their condoms from the clinic or other public sources [30]. If we look at condoms, 
which is probably a more fair comparison as condoms allow for non-clinic distribution, 
63% of women collected them from the clinic, 16% from a pharmacy and 2% from 
supermarket and spaza each. The rankings are similar, though express a larger difference 
between clinic and pharmacy and less difference between supermarket and spaza than we 
found. We do not have comparators from the literature for collection method or advertising 
strategy. 
Although the messages of the importance of the different attributes are likely generalisable, 
the specific preferences for the attribute levels, in particular relating to distribution 
strategies, are likely to be specific to the urban South African context. 
It is also worth considering the lessons from this study for other new HIV prevention 
products such as ARV based microbicides, HIV vaccines and pre-exposure prophylaxis 
(PREP). Some of the key differences to consider are the need for continual supplies in the 
case of microbicides and PREP, relative to a one off intervention (could be with a sequence 
of boosters, but a relatively discrete intervention). In such we would expect there to be more 
in common between vaccines and male circumcision. Both (would) require a series of 
contacts with a service provider; once completed, the effectiveness of the intervention does 
not require continued behaviour change / product use. 
An important lesson for all HIV prevention products is the large synergistic impact of 
intervention/product effectiveness and uptake will likely contributing to an even larger 
impact on the epidemic, if highly effective products are found. On the other hand, 
projections of impact need to take into account the dynamic effects of a modestly effective 
product likely resulting modest uptake and thus modest epidemiological impact. 
13.4.4. Caveats and areas for improvement for future research 
Reflecting back on this research, there are a number of limitations that need to be 
recognised. 
In practice, not all concepts are very easily captured in words or pictures. The concept of 
"secrecy" was not always clear in people's minds, and the picture of secrecy did not speak 
to the imagination of respondents. We were also not satisfied with our picture representing 
advertising for pregnancy prevention. The result of unclear presentation of attribute levels is 
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likely to underestimate the true value of such an attribute. Women also found it difficult to 
incorporate into their choices the concept of "in the last sex act". Many women responded 
based on best intentions in the possible future, rather than realistic and feasible option in 
their last sex act. The result of this is potentially an overestimate of new product uptake, in 
particular by women who did not use a condom in their last sex act. In future research, it 
would be very helpful to have better representations of these concepts, possibly through 
collaboration with anthropologists or sociologists. In replicating this study, these would 
need refining. 
Secondly, in experimental design there is a trade off between a strictly orthogonal 
experimental design and not presenting unrealistic scenarios. In this study, it led to the loss 
of orthogonality. In estimation this led to non convergence of more sophisticated models. 
This was especially disappointing when it came to estimating the RPL model with 
correlations, which wou Id have allowed for identification of a package of distribution 
strategy attributes that were correlated and would have guided the composition of 
distribution strategy packages. If repeating such an exercise, I would consider it important 
to consult with DCE design experts and test the design prior to the survey. However, the 
thanks to a large sample size, it was possible to estimate the appropriate models to answer 
our study questions. 
We developed the scenarios as a generic experiment because we thought that would 
facilitate valuation of products and distribution sources independent of their attributes. In 
practice, it appeared that many of the women did have fuller associations related to both the 
product and distribution source beyond the attributes included in the experiment. Although 
the results do appear plausible, future DCEs of barrier methods would be more suitable to a 
labelled experiment. This would also this save on degrees of freedom in estimation as the 
socio demographic characteristics can be included directly into the model rather than as 
interaction terms as we had to do here. 
However, despite these caveats, the models appear to generate intuitive results and the 
policy recommendations. 
13.5. Areas for future research 
This analysis aims to contribute to facilitating women's access to HIV prevention products, 
but clearly could not identify all critical bottlenecks to ensuring access in all countries. This 
study has raised a number of further questions: 
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Four other key players are likely to play an important role in the "success" of new barrier 
methods. First, once an effective product is identified, the international funding bodies will 
need to put their full weight (both support for product and financing to back this up) behind 
the product without hesitation. Second, country regulatory authority support is necessary to 
approve products. The International Partnership for Microbicides is very active in 
identifying and working on facilitating the regulatory processes in countries that are likely 
to be frontrunners in introducing new barrier methods due to their willingness to host 
existing trials on the products. Many of these countries also have advocacy groups that are 
working on mobilising political support for these products. Third, the female condom 
experience showed that providers' preferences against the female condom caused 
stigmatisation. Lastly, men's preferences are likely to have a strong impact on the 
consistency of women's use. 
Other studies of uptake, using DCE, are warranted in those countries where early 
introduction is expected, such as India, and other African countries which have hosted 
microbicide trials, such as Tanzania, Uganda and Zambia. 
Modelling studies are looking at the optimal strategies for microbicide introduction could 
use the information on preferences to model the speed of uptake under various scenarios 
and understand how the product characteristics and distribution and promotion strategies 
adopted will impact on the HIV epidemic. 
There is also the need to refine the research methods to reflect the characteristics of 
products in the microbicide/ HIV prevention technology pipeline. First generation 
microbicides are all coitally dependent gel based products. The future generations of 
microbicides are likely to be antiretroviral drug based. This would change the scenarios 
considerably. Such products may not be coitally dependant, with products being inserted 
daily or even monthly (in a vaginal ring); and they are unlikely to have any pregnancy 
prevention effectiveness. With active antiretroviral ingredients, provision will need to be 
linked to routine HIV testing to ensure that use is only among HIV negative women, and it 
is highly unlikely that they will be provided over the counter in the foreseeable future. This 
implies there will be limited scope for non-medical distribution or mass product promotion 
with product differentiation in the short term. 
However, this study has shown that this may not be as detrimental to access as initially 
thought because the clinic and pharmacy were by far the most preferred access points for 
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women anyway. Critical attributes of new products are likely to be more around the 
physical attributes and frequency of insertion (or consumption in the case of pre-exposure 
profylaxis products in the pipeline (see Box 1-1). These factors which would need to be 
reflected in future demand studies for new HIV prevention products. 
This study can also contribute to the consideration of uptake of HIV vaccines. A recent 
large scale phase 3 vaccine trial in Thailand showed it significantly decrease the risk of HIV 
infection by 31.5% [4761. However, such a low effectiveness provides policymakers with a 
great dilemma due to concerns about disinhibition and recipients understanding of the level 
of protection the vaccine would provide to the individual. This study suggest that South 
African women are able to make appropriate choices for themselves based on 
represenatations of relative risk. Such representations may be helpful in project uptake of 
partially effective vaccines, once discovered. 
13.6. Final conclusion 
In this thesis I have developed, implemented and analysed a DCE study on the uptake of 
new HIV prevention technologies for women. From this study we learned that hierarchical 
messages including information on HIV effectiveness can be part of an effective HIV 
prevention intervention. Women can use this information to make choices about the best 
and most feasible way to protect themselves in their situations. In general, women valued 
the choice of outlets, in particular being able to collect products from both health clinics as 
well as pharmacies. Importantly, this study showed that distribution systems do not per se 
need to be different for new products or to reach different groups of women. This study 
shows that product positioning and advertising is likely to be quite effective in 
differentiating the market, and may contribute toward making the product appeal to a wider 
range of women than would be achieved from a single marketing strategy. 
These broad lessons are likely to hold-outside of the context of urban Johannesburg. 
However the precise manner in which hierarchical messaging and the precise type of 
product promotion is likely to vary by location, as is commonly acknowledged in the 
marketing world. 
Methodologically also, we show that DCE studies can be a useful approach to better 
understanding women's preferences. In depth qualitative research and a focussed workshop 
can help focus the DCE research to key issues. 
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To date there has been substantial investment in finding methods that can help women 
protect themselves from HIV. There has been far less research to inform future product 
introduction and distribution. This is an important omission. 
A good understanding of the determinants of women's preferences and the demand for 
barrier methods will play an important role in facilitating women's access to new methods 
when they become available. This work showed that a combination of appropriate personal 
information, appealing promotion, and free or very low priced products distributed through 
clinics or pharmacies is likely to encourage substantial new product uptake by women who 
need it. 
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Appendix 1. FGD tools 
Appendix 1.1 Topic guides FGDs 
Hi my name is .......... Thank you for agreeing to have this group discussion with us. There are studies testing 
the effectiveness of new products in preventing HIV and sexually transmitted diseases. 
These products that are being tested will be inserted vaginally. Today we are gathered to 
understand your opinions of these products. These focus group discussions are asking 
women to help us describe: 
" these different products to different people, 
" where women would like to get them and why, 
" how they should be advertised and why, and 
" the types of partners they might use them with. 
We will not cover all of these questions today though. Today we are going to discuss 
why women use or do not use male and female condoms, and discuss the different ways 
we can describe our male partners. 
Your comments are confidential and will be analysed together with the contributions 
from other groups. Please do not discuss other people's comments out of this group. 
Remember there are no right or wrong answers. We are not here to judge you. All the 
deliberations of this discussion will be treated with our utmost confidence. 
FGD Topic A (2): Determinants of condom use and partner types 
Lets first talk about using male and female condoms: 
1. Condom use: 
Male 
a. To someone who has never heard of male condoms how would you describe 
them and the experienced using them? 
b. Why do women use male condoms with their partners? 
c. Why do they not use male condoms? 
d. What kind of problems might be encountered to use male condoms? 
Female condoms: 
e. To someone who has never heard of female condoms how would you 
describe them and the experienced using them? 
f. Why do women use female condoms? 
g. Why do they not use female condoms? 
h. What kind of problems might be encountered to use female condoms? 
Now let's talk about partner's 
2. What kind of partners can you have throughout your life? 
a. How do these types of partners differ? 
b. How are these types of partners the same? 
c. How do these different types of partners affect women's willingness and 
ability to use condoms to protect themselves from HIV? 
FGD Topic B (2): Determinants of distribution channel use, Promotional messages 
3. Where do you get male condoms (make list) 
a. Are there other places women can get male condoms from? 
b. What makes you prefer one place over another? 
PROMPT of not raised spontaneously 
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c. How are these places different? 
d. How are they the same? 
e. What kind of problems might women encounter to access male condoms? 
Here we are looking for the main characteristics of the different distribution channels that effect women's 
choices of where they go. We want a description of the different distribution channels focussing on what 
are the most important reasons for going to a specific provider/distribution source. This can include 
things like, price, transport access, opening time access, attitudes of staf etc etc 
4. For Female condoms, do women prefer to get them in different places than male condoms? 
a. Where? (list) 
b. Why? 
c. Now if female condoms could be obtained from anywhere, where would 
you like to get them and why? (for example hair salon and other non 
conventional placess? ) 
Here we interested to see if different characteristics of distribution channels are important for female 
condoms relative to male condoms, and to generate distribution channel ideas outside of the standard 
health system distribution. 
Promotional messages 
5. If you were a nurse or shop keeper and your task was to sell male condoms, what message 
would you use to advertise them so that people like yourself would buy them? 
6. If you were a nurse or shop keeper and your task was to sell female condoms, what message 
would you use to advertise them so that people like yourself would buy them? 
This question aims to generate different advertising messages that people might find attractive to 
themselves and their partners and might make the products easier to use. This may include messages 
about HIY/STI/pregnancy prevention, female control, specific physical attributes of the product, image 
(pleasure, being cool, etc etc 
FGD Topic C (2): New Methods- microbicides 
Now lets discuss these new products that are being tested. 
The microbicides that we are going to test will be a gel that women insert into their vaginas 
before having sex. We are trying to understand which things women find important in wanting 
to use them and being able to use them. 
1. From looking at these this microbicide, how would you describe it? 
a. What would you want to know about them to decide to try them? 
Now try to answer these questions -> Fern to answer groups questions 
b. Now we have given you some more information, how would you feel about trying 
it? 
c. What about using them in the longer term, every time you have sex? 
d. What do you think your partners would think about them? 
e. Could they be used without your partners knowledge? 
f. Where would you like them to be available to you? 
2. If microbicides were available, do you think you would use some kind of HIV protection 
more often? 
3. If these were available, do you think you would use condoms less? 
a. What if they only provide'/ the protection that condoms provide? 
4. How much do you think you would be willing to pay for a single use applicator of 
microbicides? 
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5. What is the highest amount you can imagine anyone being willing to pay for such a 
microbicide for a single use dose of a microbicides? 
6. If you were a nurse or shop keeper and your task was to sell Microbicides, what message 
would you use to advertise them so that people like yourself would buy them? 
a. How about messages to make them easier to introduce to your partners? 
7. Now that you have described these new methods, what would be the four most important 
things for you to try a microbicide? 
Write them on a blackboard or paper, then give people a pen and a response card to hand in to 
the moderator. Then hold a show of hands vote. 
FGD Topic C (2) : New Methods-diaphragm 
Now lets discuss these new products that are being tested. 
The diaphragm is a physical barrier method that covers the cervix (show prototypes). There are 
many ways of describing them. We are trying to understand which things women find important 
in wanting to use them and being able to use them. 
1. From looking at these this diaphragm, how would you describe it? 
a. What would you want to know about them to decide to try them? 
Now try to answer these questions -> Fern ??? 
b. How would you feel about trying it? 
c. What about using it in the longer term, every time you have sex? 
d. What do you think your partners would think about them? 
e. Could they be used without your partners knowledge? 
f. Where would you like them to be available to you? 
2. If the diaphragm was available, do you think you would use some kind of HIV protection 
more often? 
3. If these were available, do you think you would use condoms less? 
a. What if they only provide'/2 the protection that condoms provide? 
4. How much would you be willing to pay for a diaphragm that you could use for up to 2 
years? 
5. What is the highest amount you can imagine anyone being willing to pay for a reusable 
diaphragm used with spermicide? 
6. If you were a nurse or shop keeper and your task was to sell Diaphragms, what message 
would you use to advertise them so that people like yourself would buy them? 
a. How about messages to make them easier to introduce to your partners? 
7. Now that you have described these new methods, what would be the four most important 
things for you to try a diaphragm? 
Write them on a blackboard or paper, then give people a pen and a response card to hand in to 
the moderator. Then hold a show of hands vote. 
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Appendix 1.2 Information sheet FGDs 
Hello, my name is ..... I am working on a project for the Reproductive Health and HIV Research Unit and 
the London School of Hygiene and Tropical Medicine. I would like to invite you to participate in a 
research study on women from Ekurhuleni. 
Whv are we conducting this study? 
Many women in South Africa are infected with HIV every day. In many cases it is because women find it 
difficult to persuade their partners to use condoms during sex. At the moment, the condom is the only 
reliable method of preventing HIV. Researchers are now trying to develop new methods of preventing 
HIV, called microbicides and the diaphragm, which can be used and controlled by women. 
What is this study about? 
This study aims to understand the reason that women use or do not use male or female condoms and the 
reasons they may decide to the use these newer methods, if they are found to be effective. We are 
interested in what women think about these new methods, where women would be interested in obtaining 
them, and how women think they should be advertised. This study will provide us with important 
information necessary to facilitate access to barrier methods which women can use to protect themselves 
from HIV. 
REMEMBER: WE ARE NOT PROVIDING ANY PRODUCTS FOR THIS STUDY 
Who can take Dart? 
You can take part if you: 
  Are willing to participate in a focus group discussion 
  Are between the age of 18 and 45 
  Have had sexual intercourse at least once in the past 6 months 
What do you have to do if you agree to take Dart? 
Attend focus group discussions. 
You have been asked to participate in focus group discussions. The focus group discussion will take 
approximately two hours of your time. 
All focus group discussions will be recorded on audio tape. This is to ensure that the information we 
collect is accurately recorded. Later we will write down the information and store this on a computer. All 
tapes will be kept in a locked cabinet. No one except program staff will be able to listen to the tapes or 
view the material. After the research has been completed all audio tape recordings will be destroyed. 
This information will be used by us to gain more insights into how to ask women where they get male and 
female condoms and what women think about microbicides and the diaphragm. By participating you are 
helping us decide on how to do research on microbicides. 
Will the information from these focus ¢roun discussions be confidential? 
As researchers we guarantee your confidentiality. You will not be identified by name on any 
documentation. No one will have access to any tape recordings and all tapes will be destroyed at the end 
of the study. We cannot, however, guarantee that other participants in the focus group discussion maintain 
your confidentiality but will encourage confidentiality through a discussion of this issue with all 
participants before the FGD starts. We will attempt to ensure that all participants maintain one another's 
confidentiality by requesting that you, or any of the participants, do not discuss the content of what any of 
the participants said during the focus group discussion with any people outside. This is to ensure your 
opinion and other people's opinions and experiences are kept confidential. 
Will the study benefit You? 
There is no immediate benefit to you by participating in this part of the study. However, you will be 
compensated for your transport costs and will be given R50.00 for this. 
What are the risks? 
The focus group discussions may discuss some personal issues. You will also be asked to discuss your 
experiences in a group setting but you may chose not to tell what you consider private information in the 
company of others. Although all participants are requested to not to discuss what has been said during 
these discussion with anyone else, we cannot guarantee full confidentiality. 
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What happens if you change your mind about taking part? 
You can choose not to answer any of the questions that you do not want to answer. You can withdraw 
from the focus group discussion at any time without giving a reason. Not answering specific questions or 
withdrawal from the discussion will not negatively affect you. 
What hanaens if I have any problems during the focus group discussion? 
If you have a problem resulting from your participation in this focus group discussion, assistance is 
available from: 
Fern Terris-Prestholt Dr Catherine McPhail 
Visiting Research Fellow Director: Adolescent Health 
Reproductive Health and HIV Research Unit Reproductive Health and HIV Research Unit 
11th Floor Nurses Home 11th Floor Nurses Home 
CH Baragwanath Hospital CH Baragwanath Hospital 
Soweto Soweto 
Tel: 011 933 1228 Tel: 011 933 1228 
Cell: 072 9350393 (24 hours accessible) Cell: 083 441 5415 (24 hours accessible) 
Fax: 011 933 1227 Fax: 011 933 1227 
Prof Helen Rees Dr Lilani Kumaranayake 
Principal Investigator Principal Investigator 
Reproductive Health and HIV Research Unit Health policy unit 
11th Floor Nurses Home London School of Hygiene and Tropical Medicine 
CH Baragwanath Hospital Keppel Street 
Soweto WC1E 7HT 
Tel: 011 933 1228 Tel: 001-902 431-3686 (24 hours accessible) 
Cell: 083 572 2057 (24 hours accessible) Fax: 001-902 431-3689 
Fax: 011 933 1227 
You may also discuss any concerns you might have regarding your participation with any of the nurses, 
counsellors or community health workers involved in the study. 
This study is conducted in accordance with the Department of Health Guidelines for the Good Practice 
in the Conduct of Clinical Trials in Human Participants in South (2000), and has received ethical 
approval from the University of the Witwatersrand, Human Research Ethics Committee: (Medical). If 
you have complaints about how you were treated or feel that the study has caused you harm please 
contact: 
Prof Peter Cleaton-Jones 
Chairperson for the Committee for Research on 
Human Subjects 
University of the Witwatersrand, Human 
Research Ethics Committee: (Medical) 
Tel: 011 717 2229 
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Appendix 1.3 Informed consent form FGDs 
Statement of INFORMED Consent' 
The participant must complete the following questions herself/with a staff member who did not 
administer the consent 
Have you had an opportunity to read the consent form/have it read to you? YES NO 
Have you had an opportunity to ask questions and discuss this study? YES NO 
Have you received satisfactory answers to all of your questions? YES NO 
Have you received enough information about the study? YES NO 
Do you understand the benefits of the study? YES NO 
Do you understand the risks of the study? YES NO 
Do you agree to not discuss what other participants have said during the focus 
group discussion outside of this group? 
YES NO 
Which study staff member have you spoken to about the study? 
PLEASE PRINT HIS/HER NAME: 
Do you understand that you are free to not answer any of the questions at any 
time without having to give a reason for not wanting to answer the question? 
YES NO 
Do you understand that you are free to withdraw from the discussion at any 
time without having to give a reason for withdrawing? 
YES NO 
Do you agree to take part in this study? YES NO 
If the participant answers NO to any of the above questions then she may not be enrolled in the study. 
Printed name of Investigator Date 
Signature of participant Time 
Do you agree to the focus group being tape recorded? YES NO 
Printed name of Investigator Date 
Signature of participant Time 
Do you agree that some of your responses be quoted in a manner in which 
you cannot be identified? 
YES NO 
Printed name of Investigator Date 
Signature of participant Time 
Always given with an information sheet 
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Appendix 2. FGD participant's background information 
Younger 
(18-29 years) 
Older 
(30-45 years) Total 
Col % Col % Col % 
Location 
Spruitview 25.0 31.0 27.9 
Vosloorus 46.9 31.0 39.3 
Zonkizizwe 28.1 37.9 32.8 
100.0 100.0 100.0 
Partner type 
husband 2.1 48.0 25.8 
Regular 53.2 28.0 40.2 
casual 42.6 18.0 29.9 
one-off 2.1 6.0 4.1 
100.0 100.0 100.0 
House type 
RDP 12.8 16.0 14.4 
bond house 27.7 24.0 25.8 
room outside 4.3 6.0 5.2 
shack 25.5 26.0 25.8 
municipal 17.0 18.0 17.5 
big house 12.8 8.0 10.3 
missing 2.0 1.0 
100.0 100.0 100.0 
Employment status 
employed full time 4.3 14.0 9.3 
emplyed part time 6.4 6.0 6.2 
self employed 6.0 3.1 
student/scholar 23.4 11.3 
unemployed 61.7 54.0 57.7 
housewife 18.0 9.3 
other 4.3 2.0 3.1 
100.0 100.0 100.0 
Educational attainment 
primary incomplete 8.0 4.1 
primary complete 2.1 1.0 
secondary incomplete 48.9 76.0 62.9 
secondary incomplete + vocational 6.4 6.0 6.2 
secondary complete 36.2 8.0 21.6 
tertiary incomplete 6.4 3.1 
tertiary complete 2.0 1.0 
100.0 100.0 100.0 
means means means 
age 22.8 39.2 30.9 
# of children 0.8 2.7 1.8 
# of rooms used for sleeping 4.0 3.4 3.7 
# of inhabitants 4.9 4.4 4.6 
Crowding 1.5 1.7 1.6 
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Appendix 3. IDI tools 
Appendix 3.1 Information sheet and informed consent form IDIs 
Hello, my name is ..... I am working on a project for the Reproductive Health and HIV Research Unit and 
the London School of Hygiene and Tropical Medicine. I would like to invite you to participate in a 
research study on women from Ekurhuleni . 
Whv are we conducting this study? 
Many women in South Africa are infected with HIV every day. In many cases it is because women find it 
difficult to persuade their partners to use condoms during sex. At the moment, the condom is the only 
reliable method of preventing HIV. Researchers are now trying to develop new methods of preventing 
HIV, called microbicides and the diaphragm, which can be used and controlled by women. 
What is this study about? 
This study aims to understand the reason that women use or do not use male or female condoms and the 
reasons they may decide to the use these newer methods, if they are found to be effective. We are 
interested in what you think about these new methods, where you would be interested in obtaining them, 
and how you thing they should be advertised. This study will provide us with important information 
necessary to facilitate access to barrier methods which women can use to protect themselves from HIV. 
REMEMBER: WE ARE NOT PROVIDING ANY PRODUCTS FOR THIS STUDY 
Who can take Dart? 
You can take part if you: 
" Are willing to participate in an in-depth interview 
" Are between the age of 18 and 45 
" Have had sexual intercourse at least once in the past 6 months 
What do you have to do if you agree to take Dart? 
Participate in an in-depth interviews 
You have been asked to participate in an in-depth interview. The interview is expected to take between 1 
and 2 hours of your time. 
All in-depth interviews will be recorded on audio tape. This is to ensure that the information we collect is 
accurately recorded. Later we will write down the information and store this on a computer. All tapes will 
be kept in a locked cabinet. No one except program staff will be able to listen to the tapes or view the 
material. After the research has been completed all audio tape recordings will be destroyed. 
This information will be used by us to gain more insights into how to ask women where they get male and 
female condoms and what women think about microbicides and the diaphragm. By participating you are 
helping us decide on how to do research on microbicides. 
Will the study benefit you? 
There is no immediate benefit to you by participating in this part of the study. However, you will be 
compensated for your transport costs and will be given 850.00 for this. 
What are the risks? 
The interview may ask some personal questions, but because these interviews are confidential there are 
no risks to you in giving this information. 
Will the information from these in-dent interviews be confidential? 
Yes, all results of the in-depth interviews will be confidential. You will not be identified by name on any 
documentation. No one will have access to any tape recordings and all tapes will be destroyed at the end 
of the study. 
274 
APPENDICES 
What hauuens if you chance Your mind about taking Dart? 
You can withdraw from the in-depth interview at any time without giving a reason. You can also choose 
not to answer any of the questions that you do not want to answer. Withdrawal from the interview or not 
answering specific questions will not negatively affect you. 
What happens if I have any problems during the in-death interview? 
If you have a problem resulting from your participation in this in-depth interview, assistance is available 
from: 
Fern Terris-Prestholt Dr Catherine McPhail 
Visiting Research Fellow Director: Adolescent Health 
Reproductive Health and HIV Research Unit Reproductive Health and HIV Research Unit 
11th Floor Nurses Home 11th Floor Nurses Home 
CH Baragwanath Hospital CH Baragwanath Hospital 
Soweto Soweto 
Tel: 011 933 1228 Tel: 011 933 1228 
Cell: 072 9350393 (24 hours accessible) Cell: 083 441 5415 (24 hours accessible) 
Fax: 01 1 933 1227 Fax: 011 933 1227 
Prof Helen Rees Dr Lilani Kumaranayake 
Principal Investigator Principal Investigator 
Reproductive Health and HIV Research Unit Health policy unit 
11th Floor Nurses Home London School of Hygiene and Tropical 
CH Baragwanath Hospital Medicine 
Soweto Keppel Street 
Tel: 011 933 1228 WC 1E 7HT 
Cell: 083 572 2057 (24 hours accessible) Tel: 001-902 431-3686 (24 hours accessible) 
Fax: 011 933 1227 Fax: 001-902 431-3689 
You may also discuss any concerns you might have regarding your participation with any of the 
nurses, counsellors or community health workers involved in the study. 
This study is conducted in accordance with the Department of Health Guidelines for the Good Practice 
in the Conduct of Clinical Trials in Human Participants in South (2000), and has received ethical 
approval from the University of the Witwatersrand, Human Research Ethics Committee: (Medical). If 
you have complaints about how you were treated or feel that the study has caused you harm please 
contact: 
Prof Peter Cleaton-Jones 
Chairperson for the Committee for Research on 
Human Subjects 
University of the Witwatersrand, Human Research 
Ethics Committee: (Medical) 
Tel: 011 717 2229 
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STATEMENT OF INFORMED CONSENT 
The participant must complete the following questions herself/with a staff member who did not 
administer the consent 
Have you had an opportunity to read the consent form/have it read to you? YES NO 
Have you had an opportunity to ask questions and discuss this study? YES NO 
Have you received satisfactory answers to all of your questions? YES NO 
Have you received enough information about the study? YES NO 
Do you understand the benefits of the study? YES NO 
Do you understand the risks of the study? YES NO 
Which study staff member have you spoken to about the study? 
PLEASE PRINT HIS/HER NAME: 
Do you understand that you are free to not answer any of the questions at 
any time without having to give a reason for not wanting to answer the 
question? 
YES NO 
Do you understand that you are free to withdraw from the interview at any 
time without having to give a reason for withdrawing? 
YES NO 
Do you agree to take part in this study? YES NO 
If the participant answers NO to any of the above questions then she may not be enrolled in the 
study. 
Printed name of Investigator Date 
Signature of participant Time 
Do you agree to the interview being tape recorded? YES NO 
Printed name of Investigator Date 
Signature of participant Time 
Do you agree that some of your responses be quoted in a manner in which 
you cannot be identified? 
YES NO 
Printed name of Investigator Date 
Signature of participant Time 
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Appendix 3.2 Topic guides IDIs 
Hello, my name is ................... Thank you for agreeing to have this interview with us. We have requested this interview to understand 
how you make your choices about HIV prevention, your use of condoms and contraceptives and where 
you go to obtain these products. This will help us learn about how best to distribute new methods for HIV 
prevention specifically made for women's use. There are studies testing the effectiveness of a microbicide 
and of the diaphragm in preventing HIV and sexually transmitted diseases. These product to be tested 
will be inserted vaginally, and might not be noticed by your partner. 
We would like to let you know that your comments are confidential and will be analysed together with the 
contributions from other interview. Remember there are no right or wrong answers. We are not here to 
judge you. All the deliberations of this discussion will be treated with our utmost confidence. You have 
the right to skip any questions that you do not want to answer and the right to discontinue the interview at 
any time you wish. 
We would like to start off with some background information about you. You are welcome to use another 
name if that makes you feel more comfortable. 
1. Interview date: // 
Day / Month / Year 
2. Interviewer name: 
3. Interview start time: 
Section 1: generic background information 
Can you tell me a bit about yourse 
Section checklist: 
4. QAge 
5. QLanguage spoken at home 
6. QHi et level of education gained? 
Tell me a bit about where you live: 
7. Q Years lived in area 
8. Q Where lived before moving here 
9. Q Type of house they live in 
10. Q Number of rooms used for sleeping 
11. Q Number of people living there? 
12. Q Relationship to head of household 
Tell me a bit about what you do for work? 
13. Q Employment status? 
14. Q Type of work 
15. Q How paid 
16. Q Where the work took place 
Can you tell me a bit about what the head of household does? 
17.13 Employment status? 
18. Q Type of work 
19. Q How paid 
20. Q Where the work took place 
Can you tell me a bit about your last sexual encounter 
21.13 Partner type 
22.0 Barrier method used? 
23.0 Contraception used? 
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Section 2 In-depth interviews specific questions/ topics 
Topic 1: Contraceptive histories 
3 interviews by age group: 23-28 ; 33-38 ; 43-48 
Aim: To understand the determinants of contraceptive use and influences of partner, 
distribution channel and information source, using a contraceptive history timeline, with 2 
lines: contraceptive methods and partners. Aim to get stories from beginning of sexual debut on 
partners, technologies, channels, and information sources and understand choices made. 
Now I would like to move on to the main section of this discussion and I would like to hear 
about your experiences from when you first started using contraception until your current 
contraceptive method. 
1. Can you tell me about the first time you used contraception? 
a. Type of method used first 
b. reason for using specific type of contraceptive/barrier method, 
c. what was already known about the method before trying it, 
d. from where/whom this knowledge was obtained 
2. What type of channel was visited to receive the method 
a. why channel was chosen, 
b. experience at that channel 
3. Did you know which method you wanted before going to that channel, or did you first 
choose to go there, then decide which method to use? (Was the choice simultaneous or 
in 2-steps? ) 
4. Types of partnerships while using that method 
5. Reason for stopping/changing/adding method. 
a. Probe also for dual method use and reasons, Risk of HIV 
Can you tell me about your first boyfriend......, did you have sex with him? Had you already 
had sex before that? Can you tell me about the first time you had sex? Where, when, why, with 
whom, using any protection for HIV or pregnancy? 
Put years on time line, then next to the contraceptive timeline, put the partnership history, probe 
for one-offs and use of any method. Also probe for duration between switching methods within 
partnership types (common to 1" use condoms then move to a hormonal contraceptive) 
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Section 2 In-depth interviews specific questions/ topics 
Topic 2a: New Methods and critical attributes (Female Condom, Microbicides and 
Diaphragm) 
Now lets discuss these new methods that are being tested. 
You may already be familiar with the female condom. The microbicides that we are going to 
test, will be a gel that women insert into their vaginas before having sex. The diaphragm and the 
cervical caps are physical barrier methods that cover the cervix (show prototypes). There are 
many ways of describing them. We are trying to understand which things women find important 
when choosing to use barrier methods and how they might choose between the different 
methods. 
1. From looking at these three methods how would you describe them? 
2. What would you want to know about them to decide to try them? Why? 
3. What about longer term use every time you have sex? 
4. What do you think your partners would think about you using each of these methods? Why? 
5. Could they be used without your partners knowledge? How important is this? 
6. Are they something you would try? Why? Why not? 
a. If yes, Where would you like them to be available to you? And why? 
b. Would where they can be obtained have a strong influence on women's ability to use 
these methods? 
7. If these were available, do you think you would use condoms less? Why, Why not? 
a. What if they microbicides and the diaphragm only reduce your risk of HIV infection by 
50% while condoms provide 95% protection? 
8. If you were a nurse or a shopkeeper selling Female condoms, what message would you use 
to advertise them so that people like yourself would buy them? Why? 
a. What message would you use to make them attractive to your partner? 
9. If you were a nurse or a shopkeeper selling Microbicides, what message would you use to 
advertise them so that people like yourself would buy them? Why? 
a. What message would you use to make them attractive to your partner? 
10. If you were a nurse or a shopkeeper selling the Diaphragm, what message would you use 
to advertise them so that people like yourself would buy one? Why? 
a. What message would you use to make it attractive to your partner? 
11. Do you think advertising messages are important in influencing people to use a method? 
12. How much do you think you would be willing to pay for a single use applicator of 
microbicides, in your current situation? 
13. What is the highest amount you can imagine anyone being willing to pay for such a single 
use dose of a microbicides? 
14. How much do you think you would be willing to pay for a Diaphragm that you could use 
for 2 years with a tube of gel which would last 4 months in your current situation? And a 
single use disposable diaphragm? 
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15. What is the highest amount you can imagine anyone being willing to pay for such a 
diaphragm with gel? 
16. For female condoms what are the most important things that would make you choose them 
and make it possible for you to use them in your current situation and why? 
a. After that which is most important and why? 
b. And then? 
c. Which of these is least important to you? 
17. For Microbicides what are the most important things that would make you choose them 
and make it possible for you to use them in your current situation and why? 
a. After that which is most important and why? 
b. And then? 
c. Which of these is least important to you? 
18. For Diaphragm which are most the 3 most important attributes? 
a. After that which is most important and why? 
b. And then? 
c. Which of these is least important to you? 
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Section 3: closing section 
Asset index 
24. Would you say that the money that you bring into the family/household is more than what your 
husband / partner contributes, less that what he contributes, or about the same as he contributes. 
Q More Q Less Q About the same 
25. Does your household have: 
Q Electricity 
Q A radio 
Q A television 
Q A telephone 
Q A refrigerator 
Q A personal computer 
Q A washing machine 
26. Does an y member of your family own: 
QA bicycle 
QA motorcycle or motor scooter 
QA car 
QA donkey or a horse 
Q Sheep or cattle 
27. In the last 12 months, have you or any members of this household been prescribed medicine that 
you didn't obtain because you couldn't pay? O Yes 
0 No 
28. If a person became ill in your home and R100 was needed for treatment or medicines, would you 
say it would be very easy, easy, quite difficult or very difficult to find the money? 
Q Very easy Q Easy Q Quite difficult Q Very 
difficult 
We have now come to the end of the interview. Thank you very much for your participation and 
your openness. Do you have any comments or questions about the interview? 
Interview end time: 
281 
APPENDICES 
Appendix 4. Managing men: women's dilemmas about overt and covert 
use of barrier methods for HIV prevention. 
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15 Women in sub-Saharan Africa are at high risk of HIV infection and may struggle to 
16 negotiate condom use. 
This has led to a focus on the development of female-controlled 
barrier methods such as the female condom, microbicides and the diaphragm. One of 
the advantages of such products is their contribution to female empowerment through 
is attributes that make covert use possible. We used focus groups to discuss covert use of 
19 barrier methods with a sample of South African women aged 18-50 years from Eastern 
«0 Johannesburg. Women's attitudes towards covert use of HIV prevention methods were 
21 
influenced by the overarching themes of male dislike of HIV and pregnancy prevention 
methods, the perceived untrustworthiness of men and social interpretations of female 
:2 faithfulness. Women's discussions ranged widely from overt to covert use of barrier 
23 methods for HIV prevention and were influenced by partner characteristics and 
yt previous experience with contraception and 1V prevention. The discussions indicate 
25 that challenging gender norms for HTV prevention can be achieved in quite subtle ways, 
26 
in a manner that suits individual women's relationships and previous experiences with 
negotiation of either HIV or pregnancy prevention. 
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. 31 Introduction 
32 In South Africa, as is the case inmost sub-Saharan African countries, HIV prevalence levels 
33 are high particularly among women. A nationally representative survey conducted in 2005 
34 indicated a prevalence of 20.2% among women and 11.7% among men aged 15-49 years 
35 (Shisana et al. 2005). There is evidence that women's greater susceptibility to HIV is the 
36 result of the physiology of the female genital tract (Mayer and Anderson 1995; Morrison 
37 et al. 2005). Also, their status in society, inability to discuss sexual issues with partners and 
38 the social unacceptability of female autonomy may play a role in increasing women's risk of 
39 HIV infection (Amaro 1995; Meekers and Calves 1997; Pulerwitz et al. 2002). 
40 The initial focus on male condoms as an effective HIV prevention tool has been 
41 challenged as real-world experience has shown that significant challenges exist to ensuring 
42 consistent protected sex, especially among women in developing countries (Gollub 2006). 
43 The potential for cervical barrier methods to protect women from HIV infection is 
44 currently being explored with a range of products and in a variety of settings (Moench, 
45 
46 
47 
48 
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50 Chipato, and Padian 2001). As well as the protective potential that these cervical barriers 
51 may deliver, the fact that they are female-initiated is believed to contribute to enhancing 
52 safe sex for women, increasing women's bargaining power and enhancing women's 
53 control over their bodies. 
54 Given that women's limited relationship power increases their risk of 1 1V infection 
55 (Dunkle et al. 2004; Pettifor et al. 20(4; Pulerwitz et al. 2002; Zierler and Krieger 1997), 
56 there has been a focus on the development of female-initiated barrier methods for HN 
57 prevention. The female condom is already available for use in South Africa after a national 
58 roll out scheme, but access remains limited for most women (Mantell, Scheepers, and 
59 Karim 2000; Warren and Philpott 2003). Many current HIV prevention trials therefore 
e0 focus on new female-controlled methods such as diaphragms and candidate microbicides 
61 (Minnis and Padian 2005; Rosenberg and Gollub 1992). A diaphragm is a shallow, dome- 
6 shaped rubber disk with a flexible rim that fits within the vagina to cover the cervix. 
63 Although traditionally used for pregnancy prevention, the diaphragm is also being 
64 potentially considered for protection against 111V (Moench, (hipato, and Padian 2001). 
65 Microbicides are compounds formulated as gels, creams, foams or tablets that are inserted 
nn into the vagina (often with an applicator) to provide HIV protection (Ramjee et al. 2001). 
67 Female-initiated methods of HIV prevention have been particularly emphasised for women 
68 in long-term relationships in which the use of male condoms is acknowledged to be 
tic) challenging (Lansky, Thomas, and Earp 1998; Macaluso et al. 2000). The use of all female- 
70 initiated barrier methods allows for women to instigate method use while the ability to use 
71 some of these methods covertly has been highlighted as a particular advantage for women. 
72 This paper reports on findings from focus group discussions (FGDs) held with South 
73 African women aged 18-50 years to establish their understanding and feelings about 
74 attributes of female-initiated barrier methods for Hi: V prevention, with specific attention to 
75 the ability to use these methods covertly. 
76 
77 Methods 
78 
79 Recruitment 
so Focus group discussions were conducted with women aged 18-50 years from three areas 
81 in Eastern Johannesburg, South Africa. The areas were selected to represent different 
levels of socio-economic stratification in South African society: one consists primarily of 
93 site and service schemes' and informal settlements (Community A in Table 1), the second, 
84 an area with a mix of public housing, private housing and informal settlements 
ss (Community B) and the third with mainly upmarket private housing (Community Q. 
86 We followed a three-stage process of (1) preparation; (2) contact and (3) follow-up in 
87 conducting the research (MacDougall and Fudge 2001). This involved making contact 
ss with local community representatives prior to the research and culminated in a report back 
89 of findings from the broader research study, which included administration of a 
90 questionnaire as well as the qualitative data collection reported here. For this qualitative 
91 component of the study, women were purposively sampled to ensure representation by age 
92 group, language and socio-economic status and asked to participate in a study about 
93 methods for HN prevention. Selection by socio-economic status was made by selecting 
94 across all communities and constructing groups that cut across socio-economic status. 
95 Women were approached in a local clinic and contacted door-to-door, where they were 
96 invited to participate in FGDs at a local community facility. Female field staff conducted 
97 the recruitment and accommodated working women by recruiting in the evenings when in 
98 the community. 
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Table 1. Overview of study participants by age group. 
Younger 
(18-29 years) n=46 
Older 
(30-50 years) n= 51 
Total 
n=97 
Mean age (years) 23 39 31 
Mean number of children 1.0 3.0 2.0 
(%) (%) (%) 
Location 
Community A 28 38 33 
Community B 47 31 39 
Community C 25 31 28 
Partner type 
Husband 2 48 26 
Regular 53 28 40 
Casual 43 18 30 
One-off 2 6 4 
House type 
RDP 13 16 14 
Privately owned house 41 32 36 
Outside room 4 6 5 
Shack 26 26 26 
Municipal house 17 18 18 
Missing 2 1 
Employment status 
Employed full time 4 14 9 
Employed part time 6 6 6 
Self employed 6 3 
Student/scholar 23 11 
Unemployed 62 54 58 
Housewife 18 9 
Other 4 2 3 
Educational attainment 
Primary incomplete 8 4 
Primary complete 2 1 
Secondary incomplete 49 76 63 
Secondary incomplete + vocational 6 6 6 
Secondary complete 36 8 22 
Tertiary incomplete 6 3 
Tertiary complete 2 1 
Focus group discussions 
Women who agreed to participate were stratified into two age bands: 18-29 years and 
30-50 years. This age stratification aimed to capture differences in women's life stages 
and to facilitate open discussion among women of the same generation. Four topics around 
preferences for barrier methods and their potential distribution were discussed: the manner 
in which products could be described to others; potential product distribution points; and 
potential promotional messaging and use with different types of partners. Condoms 
(female and male), microbicides and diaphragms were each discussed in separate groups. 
Eight FGDs (condoms n=4; diaphragms n=2; microbicides n= 2) were held with 
between 10-15 women and were conducted in one of two local languages spoken in the 
area (either IsiZulu or SeSotho). More groups were conducted on condoms as these are 
available barrier methods of HN prevention and to cover both male and female condoms. 
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148 The FGDs were conducted at a central community venue, were between two and three 
149 hours long and participants were reimbursed ZAR50.00 and refreshments for 
150 participation. Focus group discussions enable a process of participant reflection in the 
151 discussion, such that each individual's views and opinions become sharpened and refined 
152 through interaction with the opinions and beliefs of other participants. Thus, the focus 
153 group is a reflection of a natural environment in which participants are influenced by one 
154 another (Finch and Lewis 2003; Kreuger and Casey 2000). 
155 The difficulties associated with FGDs in developing countries are outlined by Maynard- 
156 Tucker (2000); namely lack of moderator experience, lack of moderator research 
157 background and poor language skills of transcribers. These issues were addressed through 
158 the use of moderators experienced in the collection of sexual and reproductive health data in 
159 South African settings. The second author oversaw all discussion groups with the assistance 
160 of a translator. To further ensure accuracy, the FGDs were tape recorded with participants' 
161 permission and later translated and transcribed into English by group moderators. Only 
162 female, local African language speaking moderators were used and notes were taken during 
163 each discussion group. After each discussion group moderators were debriefed to capture 
164 their impressions of the discussion, to highlight areas in which the discussion topics could 
165 be improved and to provide support to field workers if required. At either the start or end of 
166 the discussion groups, women completed a brief questionnaire to provide study staff with 
167 basic demographic information and limited information on their relationship status. In 
168 discussions particularly focused on microbicides and diaphragms, information about the 
169 products was provided, participants were shown prototypes and questions were fielded. This 
170 was to provide the women with some degree of product familiarity before the discussions, 
171 given that microbicides are not yet publicly available and that diaphragms are no longer 
172 provided as contraceptive measures in South African public clinics. Participants were 
173 informed of this and asked to discuss hypothetical products with HIV prevention efficacy. 
174 Informed consent was obtained from all participants prior to beginning the discussions 
175 and the study was approved by the Human Research Ethics Committee (Medical), 
176 University of the Witwatersrand, South Africa and by the London School of Hygiene and 
177 Tropical Medicine Ethics Committee. 
178 
179 
180 
Analysis 
181 All FGDs were transcribed and translated into English in a single step for analysis using 
182 Atlas. ti. Translation and transcription was conducted by the group moderators and 
183 checked against the FGD notes by an additional field worker. The analysis was also 
184 conducted through frequent discussions between the first two authors and through the field 
185 worker debriefing process described above. The analysis was conducted using framework 
186 analysis (Pope, Ziebland, and Mays 2000). Essentially five steps were followed in analysis 
187 of the FGDs: (1) familiarisation; (2) identification of a thematic framework; (3) indexing; 
188 (4) charting; and (5) mapping and interpretation. 
189 
190 Results 
191 
192 Participant characteristics 
193 Ninety-seven women participated in the eight FGDs. The size of focus groups ranged from 
194 10 to 15 individuals, with a mean of 12 participants. Participants were equally recruited 
195 from the three participating communities. Women had a mean age of 31 years and a mean 
196 of 2 children each (range 0-7). Just under two-thirds of the women reported having started 
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197 but not completed secondary school, while an additional 22% reported having completed 
198 secondary education. Only one woman reported having completed tertiary education. 
199 In keeping with unemployment statistics for South Africa, 58% reported being 
200 unemployed and a further 11 % reported being students. Less than 20% of women were 
201 employed in any capacity (full-, part-time or self-employed). The small number that were 
2202 employed were largely engaged in domestic or service industry occupations or were 
203 volunteer health counsellors. Most women reported a regular sexual partner (40%) and 
2011 slightly more women reported a casual partner than a husband (30 versus 26%), with large 
205 differences between the younger and older women. Only 4% of women reported one-off 
206 sexual partners (see Table 1). 
207 
208 Overarching themes 209 
10 The discussion groups with women were characterised by three main themes that ran 
211 through all groups with women of all ages. First, the notion that partners generally dislike 
212 contraceptive and disease prevention methods; particularly where they believe that the 
213 method may alter their sexual experience. Women reported their unsuccessful or difficult 
214 experiences with getting their partners to use condoms and their perception that this dislike 
215 would be the same for other barrier methods: 
216 They won't accept it easily because even the condom they haven't accepted it. (30-50 years 
217 old, microbicide discussion) 
218 Most women had some experience of attempting to engage partners in decision-making 
2219 about condom use. Their discussions of other barrier methods were coloured by these 
220 experiences and informed by strategies they had used in negotiating condom use. Second, 
221 all discussion of men (and all partner types) was characterised by the assumption that men 
222 are unfaithful and untrustworthy. In most instances, women classified men as untrustworthy 
2223 because of extra-relationship partners they were assumed to have. The phrase `you don't 
224 know what this person is doing when you are not there' was the most common means of 
2225 expressing the disquiet women feel about their partners' sexual behaviour. In keeping with 
226 this, women frequently blamed men for HIV and other sexually transmitted diseases. 
227 Other illustrations of the untrustworthiness of partners included fears that they would hide 
228 sexually transmitted diseases from their partners, deliberately infect women with HIV and 
229 other sexually transmitted infections and purposively sabotage barrier method use: 
'. 10 
231 When I use a condom as a female, I'm protecting myself from an unfaithful partner who 
232 pretends 
to faithful. (30-50 years old, condom discussion) 
233 I'll use it so that it can protect me from a disease that he brought with him. (30-50 years old, 
234 
diaphragm discussion) 
235 You get into the climax feeling and ... you don't feel a thing. Because you're in that situation 
236 all he is thinking about is pushing to the side. He will end up pushing the condom aside and 
237 you won't even feel that it's been moved. (18-29 years old, female condom discussion) 
238 A third thematic element was present in all groups; the perception that, within 
239 relationships and the broader community, requesting the use of protection was seen as 
240 being synonymous with being untrustworthy oneself. Numerous statements by women 
241 during discussions highlighted the social and relationship pressure they feel that they have 
242 to overcome to request condom or other prevention method use: 
243 Then another thing is that, let me talk about me. At first I didn't use a condom, but I got to a point 244 whereby I also realised that I should use a condom, because I now know about the HIV/AIDS 
245 . virus. And when you're supposed to tell your partner it gets bard, berme he will ask why we 
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246 should use a condom now and that maybe you're cheating on him and that there is no more trust in 
247 the relationship, do you see such things? (18-29 years old, condom discussion) 
248 In the groups, women discussed strategies for using barrier methods in different 
249 relationships, access to barrier methods, attitudes towards new barrier methods and 
250 messages for promoting them. The covert use of barrier methods was raised by women in 
251 all discussion groups, although it was an insignificant part of the discussion in one of the 
252 condom discussion groups and was more likely in discussions focusing on diaphragms and 
253 microbicides, particularly since the possibility for covert use was one of the product 
254 attributes specifically addressed in terms of these products (see Table 2). From the 
255 discussions, attitudes about the covert use of HIV barrier methods could be divided into 
25 three distinct areas: support for complete covert use; advocating for delayed or inaccurate 
257 overt use; and full disclosure of method use. During all the discussions, it was common for 
258 women to conflate the HIV preventive ability of products to include pregnancy prevention. 
259 This was likely based on their experience with male condoms where dual protection is 
260 provided and reflects women's desire for products that address more than one reproductive 
261 health issue at a time. 
262 
263 
264 Support for complete covert use 
265 
266 Complete covert use was raised in all discussion groups 
barring three of the four groups 
267 
focusing on condoms. We hypothesise that the overt character of condoms (explicitly raised 
263 
by women) may have prevented their contemplation of covert use in these particular 
269 
discussions. Additionally, women were most likely to frame discussions of the advantages of 
270 covert use 
in their previous negative experience with requesting partners to use condoms. 
271 
Advocating for complete secrecy was most frequently premised on two factors: the 
272 belief that male partners would not 
be open to the use of new methods; and generalizations 
273 about male 
dislike of all or most HIV prevention devices: 
274 They won't accept it easily because, even the condom, they haven't accepted it. But if you 
275 know that you need to be safe you have to hide it from him because even the condom they 
276 haven't accepted it. They say it is the one that spreads AIDS. (30-50 year old, microbicide 
277 
discussion) 
278 
279 
280 
281 
282 
283 
284 
285 
286 
287 
288 
289 
290 
291 
2_92 
293 
294 
There are silly men out there and you wouldn't know what he is doing but he wants you to be 
with him alone. It's better if this can be my own secret alone because when I tell him he will 
refuse using it. (18-29 year old, microbicide discussion) 
Table 2. Topics on covert method use by different focus group discussion categories. 
Condom Diaphragm Microbicide 
Topics (n = 4) (n = 2) (n = 2) 
Full disclosure of use xx 
Relationship doesn't require covert use x x 
Value of covert use x xx 
Women's options for managing covert use xx 
Educating men for buy-in x xx 
Half truths for male buy-in x xx 
Characteristics of method making covert use impossible x x 
Characteristics of method making covert use possible x 
Negative potential outcomes of covert use x 
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295 Women noted an appreciation for the potential to use female-initiated barrier methods 
296 (diaphragm and microbicide) as covert back up should their attempts to initiate condom 
297 use fail. In discussions of covert use, women suggested that this method of managing 
298 barrier methods might be dependant on the character of each individual partner, indicating 
299 that they might chose covert use if their partner was known to be `stubborn' or `silly' about 
300 HIV or pregnancy prevention methods. Women liked the idea of having a back up method 
311 that they could control and which would still offer them protection should condom 
302 negotiations be unsuccessful: 
303 
301 
I think it is better if you don't tell him. As long as you know that you are using this, even when 
he says he wants a baby and you don't want one then you can use this. If the day you feel like 
305 you want a baby you can stop using it. (30-50 year old, diaphragm discussion) 
306 
307 Personally I feel the gel is right because some of our partners, we don't know what they are doing when they are not home. For men it is not easy to use a condom and for me, I will be 30 able to hide it from him and protect myself while I am using a condom. (30-50 year old, 
309 microbicide discussion) 
310 In contrast to women advocating covert use as a means of overcoming particular partner 311 
characteristics, a small number of women expressed reservations about the need to discuss 312 
such matters with men at all. These women expressed the opinion that disease and 
313 
pregnancy prevention were female issues and that it was therefore not necessary to have 3 14 discussions about method use with male partners. Additionally women noted that 315 disclosure of barrier method use could potentially be associated with social harms, which 316 
women felt might be avoided by maintaining covert use: 317 
318 Personally I don't see the need for them to know about this because I am protecting my life and 
319 if he went outside [the relationship] and did something, he doesn't tell you about it. (30-50 
320 year old, microbicide discussion) 
321 I don't think you should tell a boyfriend because if you tell him and he walks out on you and 
322 never comes back, what then? (30-50 year old, diaphragm discussion) 
323 Women were generally positive about their ability to use the methods covertly, 
324 particularly noting that men could be easily duped with lies to cover product use. They 
31-5 noted that there were numerous opportunities during sexual encounters for them to insert 
326 diaphragms and apply or reapply microbicide gels. Given that many of the women either 
327 lived apart from their partners or were at home while their partners were employed, it was 
328 common for women to discuss inserting barrier methods just prior to when their partners 
329 were expected home so that they were prepared for potential sexual encounters without 
330 having to disclose or negotiate time for product insertion. Acceptability of covert use was 
331 not particularly influenced by women's recognition of the potential for social and physical 
332 harms that might result from discovery. Indeed, these issues were only raised in a single 
333 diaphragm discussion group in which being abandoned or physically abused for deception 
334 were highlighted as the potential consequence of partners discovering that women had 
335 covertly used barrier methods: 
336 
337 
I think you should tell him because if he finds out he can even beat you for not telling him. So 
it is better if he knows, even if be beats you he will know [that you are using the method]. 
338 (18-29 years old, diaphragm discussion) 
339 
330 
While acknowledgement of the usefulness of the potential for covert use was the 
ý1 most common response to 
discussions of microbicides and diaphragms, some participants 
342 were not comfortable with, or uncertain of, covert use. 
These participants were more likely 
34, E to advocate considered covert use with some element of 
disclosure to partners. 
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344 Half-truths and overt use after the fact 
34$ The content of most FGDs (bar two) reflect women's discomfort with complete covert use 
346 but reflects the realities of assuring their own HIV protection in the face of male resistance. 
347 Women reported three distinct strategies they might consider using for wresting the power 
349 of HIV prevention decision-making from men without their full knowledge. 
349 At one end of the scale of responses, women indicated their willingness to inform their 
350 partner of method use, but not to discontinue use if their partners disapproved. Here the 
351 potential for covert use was seen as serving women well when men were unreasonable or 
352 `stubborn': 
353 
354 
You will have to tell him and listen what is his response then if he refuses you can use it 
355 
without his knowledge. (18-29 years old, microbicide discussion) 
356 Given that women's experiences of initiating condom use had been largely negative due to 
357 men's dislike of the method, many expected the same arguments with regard to new 
358 female-controlled barrier methods. To counteract the expectation of immediate negative 
359 male reaction some women advocated covert use as an initial strategy to gather evidence 
360 against male arguments of discomfort or excessive vaginal lubrication. To this end, some 
361 women suggested that covert use might offer an opportunity to test men and then argue for 
362 method use based on evidence from this experience: 
363 I would tell him after sex ... I would ask him if he 
felt something different and if be says no 
364 then I'll tell him about it and I'll say we must use it because you didn't even feel it is inside. 
365 (18-29 years old, diaphragm discussion) 
366 Finally, drawing on the notion of men as easily duped, women across most discussion 
367 groups discussed the potential for using half-truths to explain the use of female-controlled 
368 methods, rather than disclosing their true purpose. To this end they discussed providing 
369 male partners with incomplete or inaccurate information that men were unlikely to 
370 dispute. Some participants spoke of previous experience with informing men that they are 
371 unable to use hormonal contraceptive methods and thereby getting their partners to use 
372 condoms (many men were reported as being against the costs of further children). The 
373 suggestion was made that diaphragms and microbicides could also be promoted as family 
374 planning methods, thereby ensuring that men who didn't want more children would be 
375 open to their use: 
376 The thing that can make him change is he is afraid of children. I said that the doctor said I 
377 shouldn't drink pills and now I must use condoms, because he is afraid that I will get pregnant. 
378 He says that the support [of children] is too much because he should buy food. He ... uses it 
379 [condom] because he is afraid of support. He says it is too much. (30-50 years old, condom 
380 discussion) 
381 Other women suggested using men's discomfort with `women's health issues' to inform their 
382 partners that methods were for treatment of mysterious gynaecological health issues and to 
383 thereby provide a medically sanctioned justification for the use of new barrier methods: 
384 I think if we make our secret what if he finds out. I think as this it is our secret we have to lie 
385 about it and say that the doctor said you should use this tube because you have a womb 
386 problem. So when he sees it he won't be angry or shocked. (30-50 years old, microbicide 
387 discussion) 
388 
389 
390 Full disclosure of barrier method use 
391 Across all discussion groups there were a small number of women who expressed their 
392 discomfort with any covert use of female-initiated barrier methods. In both diaphragm and 
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393 microbicide discussion groups, a minority of women argued against covert use. Reasons 
394 for informing partners ranged across discomfort with lying or omitting to inform partners 
395 about method use, acknowledgement of good relationships in which communication about 
396 such matters and joint decision-making were the norm and more overt feelings of the need 
397 for women to protect themselves against HIV in spite of potential relationship 
398 consequences such as abandonment or violence: 
399 I think if you talk to each other and he tells you to prevent you'll introduce that gel to him and 
400 he will like it because you won't fall pregnant and you won't get diseases. (18-29 years old, 
401. microbicide discussion) 
402 I would tell my partner because most of the time I tell him everything. You have to 
403 communicate. So if he likes it or not as long as you told him and it's up to him whether he 
404 accepts it or not. (18-29 years old, microbicide discussion) 
405 [addressing partners Listen here, I don't beg you and I'm not scared of you. There are girls 
who are in a relationship that is abusive, I don't stick around for nonsense, I don't beg. So it's 
407 like that, I would tell him. I tell it like it is, I don't beg. It should end if it's time for our 
408 relationship to end ... So I'm talking on behalf of others who are scared of dumping their 
409 boyfriends, she's even afraid of saying I don't love you anymore. So, what more to tell him 
410 that 
I'm scared that you might infect me with HIV/AIDS and it's like that. (18-29 years old, 
condom discussion) 
411 
412 Such statements were not uncontested in the discussions; other women in their groups 
413 argued strongly against the need for full disclosure. In such instances women were likely to 
414 acknowledge that disclosure of method use was only possible with particular types of 
415 men/partners or among women who were particularly empowered, as illustrated by the 
416 quote above. Indeed, the response to the comment above showed that many participants in 
417 these groups felt unable to advocate strongly for their health and admired women who had 
418 such ability. 
419 
420 
421 Discussion and condusion 
422 Discussions with women in Johannesburg, South Africa showed that many women have 
423 had negative experiences with negotiating HIV and pregnancy prevention methods with 
424 their partners. This is particularly true of methods that men believe will affect their sexual 
425 experience. Women we spoke with expected to have many of the same difficulties with 
426 using new female-initiated barrier methods, such as microbicides and diaphragms, but 
427 there were mixed responses to covert use of such methods. Despite the opportunity for 
428 women to use female-initiated barrier methods covertly, a growing body of evidence from 
429 clinical trials suggests that women demonstrate a desire to inform their male partners of 
430 their method use (Mantell et al. 2005; Weeks et al. 2004; Woodsong 2004). Although 
431 women often choose to disclose method use to their partners, partner dislike of female 
432 initiated methods has been linked to discontinuation of use in a range of studies (Beksinska 
433 et al. 2001; Ramjee et al. 1999; Rustomjee at al. 1999) and partner acceptability has been 
434 shown to affect product use (Jones et al. 2008). A study in Zimbabwe noted that consistent 
435 diaphragm use was associated with secret or discrete use (van der Straten et al. 2005), 
436 although women's desire for secret use varies considerably (Barnett 2000). While men 
437 frequently support the use of female initiated methods, in Uganda and Zimbabwe these 
438 methods have been found to cause male partners some degree of anxiety (Moon et aL 
439 2002; Pool et al. 2000). 
440 There has been limited opportunity to study issues of covert use outside of clinical 
441 trials, given that both microbicides and diaphragms are not generally available. There is 
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442 some evidence from discussions of general use that women are able to practice some 
443 degree of covert female condom use, specifically when partners are drunk or high. 
444 Among these South African women, discussions of covert barrier method use were 
445 framed in a context of: male partner dislike of existing barrier methods and an expectation of 
446 the same dislike fornew methods; concerns aboutmale partner fidelity; and a fear ofappearing 
447 untrustworthy when raising concerns about H1V prevention. Women's preference for overt or 
4" covert use of female-initiated methods was mediated by three specific factors: (1) the ability 
a49 they had within relationships for open communication about family planning and disease 
450 prevention; (2) the attitudes of specific partners; (3) and their experience with men not taking 
451 responsibility for children and therefore, a belief that they would not take responsibility for 
452 disease. One would expectthere to be some paradox in introducing methods for covertuse into 
453 long-term relationships characterised by trust - although this was not found to be the case 
454 among these women. Women acknowledged that requesting the use of such a method might 
455 be construed as indicating their lack of trustworthiness, although there was a generally 
456 accepted theme of men being untrustworthy. 
457 While the introduction of new female-initiated barrier methods for HIV prevention are 
458 developed in a context of limited female autonomy, their use and acceptance by women is 
459 a first step in challenging existing gender norms (Mantell et al. 2006). However, given that 
460 challenging existing gender norms and societal structures that increase women's HfV risk 
461 are long-term strategies and that many women may lack the motivation, opportunity or 
462 resources to challenge such norms, female barrier methods must be accommodated, at 
463 least initially, within existing norms. The strategies outlined by women in these discussion 
464 groups provide concrete examples of the manner in which women manage the patriarchal 
465 bargain (Kandiyoti 1988) in their pursuit of 1.11V protection, recognising that each woman 
466 may have a different mix of relational, socio-cultural, structural and prevention factors 
467 (Gollub 2006). Rather than challenging gender norms overtly, these women discussed 
468 strategies that are more subtle in their challenge to the patriarchal bargain but which have 
469 the potential to allow women control over their own sexual health. 
470 There is the expectation that challenging gender roles is an overt expression of female 
471 power (Yoder and Kahn 1992), yet these discussions with women show that challenging 
472 gender norms may be more subtle. While the information generated from these discussions 
473 with women in Johannesburg are not generalisable to all women, they illustrate the need to 
474 think innovatively about assisting women with strategies that help them use new female- 
475 initiated barrier methods, rather than concentrating on covert use as one of these methods' 
476 most important attributes. It is apparent from these discussions with women that the ability 
477 to use female-controlled barrier methods covertly will have varying importance for 
478 different women in different relationships. For some women the potential for adverse 
479 outcomes when disclosing product use may overwhelm the potential for similar adverse 
480 outcomes should they fabricate a reason for product use or use the method covertly. This is 
491 part of each woman's individual decision-making for HIV prevention. Whatever the 
482 strategies that women choose to use once new female-initiated barrier methods such as the 
483 microbicide or diaphragm are available, healthcare providers need to provide support to 
484 women across a range of decisions about disclosure of method use to partners. 
485 
486 Note 
487 1. The South African Reconstruction and Development Plan makes provision for a range of public 488 housing schemes. Site and service schemes allocate land an which residents initially construct 
489 shack dwellings with the proviso that permanent dwellings are constructed within a stipulated 
490 time period. 
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566 Resume 
567 En Afrique sub saharienne, lea femmes sont fortement expos6es aux risques de contamination par 
568 le VIM et peuvent avoir du mal ä nbgocier ]'usage du prEservatif. Cette situation a poussb ä Is 
569 focalisation sur le developpement de m6thodes de barriere ä l'initiative des femmes, telles que le 
570 pr6servatif feminin, les microbicides et le diaphragme. L'un des avantages de ces produits est 
571 leur contribution an renforcement de 
Is capacitb ä agir des femmes, grace ä ceataines de leurs 
caracteristiques qui facilitent lour utilisation secrete. Nous avons employb la methode des groupes 
572 de discussion tl matique pour aborder l'usage secret des m6thodes de barriere dann un 
573 bchantillon de femmes sud africaines ägees de 18 ä 50 ans vivant ä Johannesburg Est. II ressort 
574 des discussions quo lea attitudes de ces femmes par rapport ä l'usage secret des m6thodes de 
575 prevention du VIH sent influencbes par la question fcrasante de 1'aversion des hommes pour ces 
576 mbthodes, ainsi quo celles de Is prevention 
des grossesses, la perception d'un faible niveau de 
577 
fiabilite des hommes et les interpretations sociales de Is 6d6lite feminine. Les opinions parmi ces 
femmes sont ties diverses en cc qui concern l'usage manifeste on secret des m6thodes de 
578 b ee pour la prevention du VIII, et subissent l'influence des caractEristiques des partenaires et 
579 des experiences pr6c6dentes de contraception et de prevention du VIM. Les discussions indiquent 
580 quo la remise en question des normes de genre dann le champ de Is pr6vention du VIM eat 
581 possible de maniere assez subtile pour prendre en compte 
lea relations individuelles des femmes 
S82 et 
leur experience de Is n6goeiation de la prevention, ä la fois du V IH et des grossesses. 
583 
584 
585 
586 
587 
598 
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Appendix 5. Attribute identification workshop tool 
Worksheets for Focus Group Discussion 
23 July 2005 
Prioritising Attributes 
Participant Identifier: 
Session: 
Letter: 
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Introduction: 
Today we will be working through some exercises to help us understand how you make 
decisions about using or not using products to prevent HIV infection. We will first work 
through many pages of exercises individually, then we will discuss some of the questions in a 
group. Please remember, there are no right or wrong answers, we are interested in your 
opinions, and please ask any questions you have. 
Today we are going to discuss all types of barrier methods: male condoms, female condoms, 
microbicides and the diaphragm. I am sure you are all familiar with male condoms. We will 
tell you a bit more about the other methods. 
Firstly the female condom: pass around The female condom exists and is available in some 
clinics and shops. It provides good protection against HIV, STI and pregnancy. It can be put in 
for up to 6 hours before sex, and can be kept in for a total of 6 hours. Although it is 
recommended that a new female condom is used for each round of sex, the female condom is 
strong and can be reused for up to 7 times with the same partner. Then it needs to be washed 
carefully with soap and water and patted dry. The outer ring can sometimes slip inside the 
vagina, and some people say they can hear the female condom move while they have sex. 
The Diaphragm, pass around, is a method that has long been used for pregnancy prevention and 
has shown to prevent some STIs. It is currently being tested to see if it provides any protection 
against HIV infection. The diaphragm can be kept in the vagina for up to 24 hours at a time, so 
can be inserted anytime before sex. It must be left in place for at least 6 hours after sex. A 
diaphragm can be used for up to 2 years if cared for properly. This means that care is taken 
when removing it, not to pierce it with a long finger nail, and to wash it with soap and water and 
store it in its box. However lubricant is needed each time it is used. They are also developing a 
disposable diaphragm and a one-size fits all diaphragm. The diaphragm you see here needs to 
be fitted by a health care worker. 
Microbicides are a gel that are being tested to see if they can reduce women's risk of becoming 
HIV positive. They are also being tested to see if they can prevent some STI. A number of 
different types of microbicides are being tested. Some might reduce a woman's chance of 
becoming pregnant, some may not. Some will come in a pre-filled applicator, that will need to 
be thrown away after each use, others will come as a re-usable applicator with a tube of 
microbicides. The re-usable applicator will need to be washed after each use and refilled before 
each use. Some formulations will need to be inserted right before sex, some will last for an 
295 
APPENDICES 
hour, and some will last for 24 hours. The gel may make the vagina a little bit more moist 
(wet). Some women like this effect, while others do not. 
We are here today to understand the best way to introduce these new methods. We want to 
know how you decide to use a method, which factors make it easier or more difficult to use 
them with your partners. We will be looking at characteristics of the product, ways to make 
them accessible to you, and ways to advertise and promote them. 
There is a lot to cover, so please do not get tired, and we hope you enjoy the exercises. 
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Background information 
a. Where do you live? Q Spruitview Q Vosloorus Q Zonkizizwe 
b. How old are you? 
c. How many children do you have? 
d. What is the highest level of education you have obtained? 
Q None 
Q Went to school but did not complete primary 
O Completed primary 
O Incomplete secondary 
O Incomplete secondary but some vocational training 
Q Completed secondary 
Q Incomplete tertiary 
Q Completed tertiary 
C. What is your employment status: 
Q Employed full time 
Q Employed part-time 
Q Self employed 
Q Student/scholar 
Q Work seeker / unemployed 
Q Housewife 
Q Other Specify 
f. What kind of partner was the last person you had sex with? 
Q Husband 
Q Other regular 
Q Casual 
Q One-off 
g. Does this person live in the same house as you do? Q Yes 13 No 
h. What kind of house do you live in? 
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QRDP 
Q Municipal house (ama 4 rooms) 
Q Big house 
Q Room inside 
Q Train house (attached) 
Q Double house 
Q Hostel 
Q Hostel - family unit 
Q Flat 
Q Townhouse 
Q New house (bond house) 
Q Room outside 
Q Shack 
In your house, how many rooms are used for sleeping? 
j. How many people sleep in your house? 
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HIV efficacy levels 
Please note: Yellow dolls are HIV-, Red dolls are HIV+. 
a. If a condom provides 95% protection against HIV, the diaphragm provides 95% protection, 
and using neither provides 0% protection, would you use a condom, the diaphragm, or 
neither? 
Male condom- Diaphragm 
ISS888 
Bess 
SUBS 
Bassi 
95% protection 
19 of 20 women 
remain HIV- 
Bases 
Bases 
Bases asset 
95% protection 
19 of 20 women 
remain HIV- 
Neither 
*1*8 
*111* 
*111* 
*111* 0% protection 
0 of 20 women 
remain HIV- 
b. If a condom provides 95% protection against HIV, the diaphragm provides 35% protection, 
and using neither provides 0% protection, would you use a condom, the diaphragm, or 
neither? 
Condom Diaphragm 
ýu"un"IIO"ud'uo` 
ý 
ýo"un` `ud fin` 
4ýd 5zd ýd 
111 *1 
95% protection 35% protection 
19 of 20 women 7 of 20 women 
remain HIV- remain HIV- 
Neither 
*811 
1*111 
1111* 
1111* 0% protection 
0 of 20 women 
remain HIV- 
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c. If a condom provides 95% protection against HIV, a microbicide provides 95% protection, 
and using neither provides 0% protection, would you use a condom, a microbicide, or 
neither? 
Condom Microbicide Neither 
Bases AAaA 844 4 ttttt 
Bases Bases 188 
Bases Bases 1111* 
Beast asset 11111 
95% protection 95% protection 0% protection 
19 of 20 women 19 of 20 women 0 of 20 women 
remain HIV- remain HIV- remain HIV- 
d. If a condom provides 95% protection against HIV, a microbicide provides 35% protection, 
and using neither provides 0% protection, would you use a condom, a microbicide or 
neither? 
Condom Diaphragm Neither 
Bases Bases ttttt 
Bases SaUt 818 
asses 11111 11111 
asset 11111 11111 
95% protection 35% protection 0% protection 
19 of 20 women 7 of 20 women 0 of 20 women 
remain HIV- remain HIV- remain HIV- 
e. If a microbicide provides 55% protection against HIV, and the diaphragm provides 55% 
protection, would you use a microbicide, a diaphragm, a condom or neither? 
Microbicide 
Bases 
Bases 
ZHU 
*111.1 
azalea 
a8ass 
18& 
*88 
Condom 
8AAA 8444 
BUSS 
BUBB 
Bazat 
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11111 
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55% protection 
11 of 20 women 
remain HIV- 
55% protection 
11 of 20 women 
remain HIV- 
95% protection 
19 of 20 women 
remain HIV- 
0% protection 
0 of 20 women 
remain HIV- 
f. If a microbicide provides 35% protection against HIV, and the diaphragm provides 55% 
protection, would you use a microbicide, a diaphragm, a condom or neither? 
Microbicide 
a4n. 
gun`zs `ýd 
SaUt 
1181 
11111 
35% protection 
7 of 20 women 
remain HIV- 
Diaphragm 
Bases 
Bases ZHU 
ItUt 
55% protection 
11 of 20 women 
remain HIV- 
Condom Neither 
Bases 
Bases 
Bases Beast 
95% protection 
19 of 20 women 
remain HIV- 
*1*1* 
*18* 
*1*1* 
*1*11 
0% protection 
0 of 20 women 
remain HIV- 
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g. What is the lowest level of protection against HIV that you would accept to still choose to 
use a microbicide? Please put aX in the boxes where you would choose to use a 
microbicide, starting from the right side. 
Number of women that would remain HIV negative at different levels of protection. 
It no barrier method were used no women would remain HIV ne five, if condoms were used all the time 19 would be remain HIV ne ative 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
Percentage protection against HIV 
5% 10% 15% 120%125% 30% 35% 140%145% 50% 155%160% 65% 70% 76% 180%185% 90% 95% 100% 
h. What is the lowest level of protection against HIV that you would accept to still choose to 
use a microbicide? Please put aX in all the boxes where you would choose to use a 
microbicide, starting from the left side. 
Number of women that would become HIV infected at different levels of protection. 
If no barrier method were used all 20 would be infected, if condoms were used all the time 1 would be infected 
12 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
Percentage protection against HIV 
95 
% 
90 
% 
85 
% 
80 
% 
75 
% 
70 
% 
65 
% 
60 
% 
55 
% 
50 
% 
45 
% 
40 
% 
35 
% 
30 
% 
25 
% 
20 
% 
15 
% 
10 
% 
5% 0% 
What is the lowest level of protection against HIV that you would accept to still choose to 
use the diaphragm? Please put aX in the all boxes where you would choose to use a 
diaphragm, starting from the right side. 
Number of women that would remain HIV negative at different levels of protection. 
If no barrier method were used no women would remain HIV n five, if condoms were used all the time 19 would be remain HIV ne ative 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
Percentage protection against HIV 
5% 10% 15% 20% 25% 30% 35% 40% 45% 50% 55% 60% 65% 70% 75°x6 80% 85% 90% 95% 100% 
What is the lowest level of protection against HIV that you would accept to still choose to 
use the diaphragm? Please put aX in all the boxes where you would choose to use a 
diaphragm, starting from the left side. 
Number of women that world become HIV infected at different levels of protection. 
If no barrier method were used all 20 would be infected, if condoms were used all the time 1 world be infected 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
Percentage protection against HIV 
95%6 90% 86% 80% 75% 70% 65% 60% 55% 50% 45% 40% 35% 30% 25% 20% 15% 10% 5% 0% 
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k. How long before sex would you like to insert a diaphragm or a microbicide? 
1. Is time to insertion important to your decision to use one of these methods? Yes 
- 
No 
m. Do you prefer a product that you throw away after 1 single round, or one that is reusable 
that would need to be washed and refilled? Single use Reusable 
n. Did you use a male or female condom the last time you had sex? Yes 
_ 
No 
o. If you heard that one of your friends developed a rash after using the microbicide or the 
diaphragm, would you still try it? Yes No_ 
Pregnancy prevention levels: 
Do you want a method that also prevents pregnancy? Yes No 
If No: How much prevention against pregnancy would you accept to still use a method to 
prevent HIV? Please mark with an X all the levels that you would accept to use a method of 
HIV prevention. 
Number of women out of 20 that would become pregnant. 
If no barrier were used all 20 women would become pregnant, if condoms were used all the time I woman 
would be become pregnant 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
Urr -vu 
Percentage protection against pregnancy 
95 
% 
90 
% 
85 
% 
80 
% 
75 
% 
70 
% 
65 
% 
60 
% 
55 
% 
50 
% 
45 
% 
40 
% 
35 
% 
30 
% 
25 
% 
20 
% 
15 
% 
10 
% 
5 
% 
0 
% 
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Distribution attributes 
What are the 3 most important things that influence your decision to get barrier methods? 
3 Most Ranking of 3 
important most 
Place X important (I- 
3) 
1= most 
important 
Type of facility general: Medical facility or not medical 
facility: 
  Medical (clinic, GP, Pharmacy, hospital, etc.. ) 
  Not medical (shop, hairsalon, supermarket, public toilets, 
bottle store, hotel, taxi rank) 
Type of facility (specific): Clinic, hospital, shop, pharmacy, 
hair salon, garage, pharmacy, supermarket, public toilets, 
bottle store, shabeen, hotels, private GP, home delivery, 
police station, taxi rank, spaza shop, etc.. 
Method for collecting product: 
  From a box / machine in a discrete location 
  In public from a person behind a counter (clinic 
receptionist/ shopkeeper/ pharmacist/ etc.. ) 
  In a private room from a person. 
Reliability of supply: When I get to the facility I can Always, 
Sometimes, Rarely find my product. 
Opening times 
Waiting times 
Distance: walking distance'/2 hour, 1 hour, 1 taxi, 2 taxis 
Privacy: 
Characteristics of person to assist you : Age, sex, 
friendliness, expertise. 
Frequency of having to collect product supplies: 
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Channel preferences 
What are the 2 most likely place for you to collect your barrier methods? What are the 2 least 
likely places for you to collect your barrier methods? 
2 most likely places to go to 
get barrier methods 
2 least likely places to go 
for barrier methods 
Clinic 
Private GP 
Family Planning 
Library 
Garage 
Pharmacy 
Supermarket 
Public toilets 
Public Phones: 
bottle store: 
Shaheen: 
Hair salon: 
Work places: 
Schools in the classrooms: 
Hotels: 
Hospitals: 
Nightclubs 
Home delivery: 
Police station : 
Taxi ranks: 
Shops: 
Movies: 
In large gatherings: 
Awareness campaigns 
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other distributional attributes 
a. What is more important in your choice of HIV prevention method? 
Type of facility: Method of collection 
Clinic, hospital, shop, pharmacy, hair salon,   From a box / machine in a discrete 
garage, pharmacy, supermarket, public 
location 
  In public from a person behind a 
toilets, bottle store, shabeen, hotels, private counter (clinic receptionist/ 
GP, home delivery, police station, taxi rank, shopkeeper/ pharmacist/ etc.. 
) 
  In a private room from a person. 
spaza shop, etc.. 
b. How important is reliability of supply to our choice of HIV prevention method? 
If I cannot find my preferred method the first If I cannot find my preferred method the first 
time, I will use another method or not use any time, I will go somewhere else to collect it or 
barrier method for HIV prevention? return another day? 
Choice Choice 
c. How important are opening hours to your choice of lily prevention method? 
I can predict when I will need my product and I need to be able to collect my product at 
be able to collect them within regular working different hours of the time and days of the 
hours? week or I will not use that method? 
Choice Choice 
d. What is the longest you are willing to wait in line for your preferred HIV prevention 
product? 
minutes hours 
e. What is the furthest you are willing to travel for your preferred HIV 
prevention roduct? 
308 
APPENDICES 
30 minutes walk 1 hour walk 1 taxi ride 2 taxi rides 
f. How important is privacy when requesting your preferred HIV prevention method? 
I would not collect it I do not mind being seen by people like myself, I do not care who 
if I might be seen by but would not collect if there were many different sees me collect it. 
others. people around. 
Choice Choice 
Choice Please specify `people like me': 
How important is the person who would ive you your preferred HIV prevention method? 
I would not collect it if I do not feel I do not care who gives me my preferred 
comfortable with the person method 
Choice Choice 
h. What is the most frequent you are willing to collect new product supplies? 
Twice per month _ once per month _ once per 
2 months 
once per 4 months _ once per 
6 months _ once per year _ 
i. In your current situation, what is the highest amount you would be willing to pay for a 
single use microbicide? 
Rand per protected sex act 
j. In your current situation, what is the highest amount you would be willing to pay for a 
microbicide in a reusable applicator with a tube of gel? 
Rand per protected sex act 
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k. In your current situation, what is the highest amount you would be willing to pay for a 
diaphragm with gel that you could use for 2 years? 
Rand per protected sex act 
1. In your current situation, what is the highest amount you would be willing to pay for a 
disposable diaphragm? 
Rand per protected sex act 
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Promotional messaging 
a. If you wanted to use a microbicide or a diaphragm with your most recent partner, what 
would you tell him to make him most willing to accept your use of it? Please mark in the 
column `Best' Which of these messages would he least likely to accept? Please mark in the 
column 'Worst'. 
Best Worst 
It prevents HIV 
It prevents pregnancy 
It prevents STI 
It is for a healthy vagina 
Its for a fresh vagina 
Its for vaginal hygiene 
It increases sexual pleasure 
It's a cool new sex toy 
It will protect my capacity to have children in the 
future 
My doctor told me to use it to stay healthy 
Something else: 
b. If microbicides and the diaphragm were being advertised on the radio and TV, what 
message would make them most attractive for you and your partner to use? Please mark in 
the column `Best' Which of these advertising messages would make them least attractive 
for you and your partner? Please mark in the column `Worst'. 
Best Worst 
It prevents HIV 
It prevents pregnancy 
It prevents STI 
It is for a healthy vagina 
Its for a fresh vagina 
Its for vaginal hygiene 
It increases sexual pleasure 
It's a cool new sex toy 
311 
APPENDICES 
It will protect women's capacity to have children in 
the future 
It keeps women healthy 
Something else: 
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Promotional images 
a. HIV prevention: Which of the images below make you think of a product that prevents HIV 
and do you like best? 
_ý. Choice 
D 
ýý ý 
R 
Choice 
Choice 
Choice 
Choice 
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b. Pregnancy prevention: Which of the images below make you think of a product that 
prevents pregnancy? 
c. Can you think of any other images that would bring pregnancy prevention to your mind 
(think of a picture to advertise a contraceptive)? 
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Appendix 6. Community survey tools 
Appendix 6.1 Survey Instrument 
Determinants of women's demand for barrier methods for HIV prevention MC RHRU likagiii 
1 a. LOCATION 
Zonkiziswe 1 Vosloorus 3 
Spruitview 2 
b. CLUSTER NUMBER [] 
c. HOUSEHOLD NUMBER 
PLACE 
2 FLIPCHART VERSION FLIPCHART VERSION STICKER 
HERE 
3 SURVEY LANGUAGE ISIZULU 
4 INTERVIEWDATE day [] 
month [] 
5 INTERVIEWER NAME [] 
6 INTERVIEW START TIME Hour [] Min. [] 
7 HAS THE CONSENT FORM BEEN SIGNED? No 0 Yes 1 
8 FIELD MONITOR WHO CHECKED SURVEY NAME OR INITIALS [] 
9 FIELD EDITED BY: NAME [] 
10 FIELD EDITED ON day [] 
month (] 
10 b. WAS THIS A PERFECT INTERVIEW? No 0 Yes 1 [] 
11 OFFICE EDITED BY NAME [] 
12 OFFICE EDITED ON day [] 
month [] 
13 is' DATA ENTRY COMPLETED BY NAME [] 
14 i' DATA ENTRY COMPLETED ON day 
m onth [] 
15 2"0 DATA ENTRY COMPLETED BY NAME [] 
16 2nd DATA ENTRY COMPLETED ON day 
m onth 
COMMENTS: 
ZULU-1 Other 96 
Survey 18-10-2005 Don't know/ Don't remember 98 
Refuse to answer 99 
APPENDICES 
Determinants of women's demand for barrier methods for HIV prevention 
MTw RHRU 
ubona igama lami ngingu ............................................................. bonga ngokusiwmela ukuthi sikhulumisane nawe. Sicele ukukhuluma nawe ngoba sithanda ukuqonda ukuthi 
atha kanjani izinqumo zokuvimbela i-HIV, ukusebenzisa kwakho ama-condom nezindlela zokuhlela nokuthi 
ola kuphi lama-products. Lokhu kuzosisiza kakhulu ukuthi sazi kangcono ngokuthi zingasatshalaliswa kanjani 
lela ezintsha zokuvembela iHIV ikakhulukazi ezenzelwe abantu besifazane. Okwamanje kunocwaningo 
nziwayo ekuhloleni ukusebenza kwama-products amasha, imicrobicides ne diaphragm; inikeza abesimame 
Akelekeni kwi-HIV nezifo zocansi. Lama-product ahlolwayo azokwenzelwa abesimame ukuba afakwe 
weni sabo sangasese, kanti futhi ingeke yabasobala kumlingani wakhe. Kodwa akukaginiseki ukuthi 
npela ziyavikela. kwi-HIV nasezifweni zocansi. Kant kuyo lengxoxo yethu sizochaza kabanzi 
amaproduds. 
Lengxoxo yethu inezigaba ezine: Esokuqala sizothathanda ukwazi kabanzi ngawe nangomndeni wakho, esesibili 
sizothanda ukwazi kabanzi ngomlandu wakho ekusebenziseni ama-condom nezindlela zokuhiela umndeni 
nangenkathi owagcina ngayo ukuya ocansini. Isigaba sesithathu kunezimo okucatshangelwa kuzo lapho 
sizokucela khona ukuba ucabange ngezinqumo obungazithatha umangabe lama-products besetholakala. Emva 
kwengxoxo yethu sizocela uvo Iwakho mayelana nalokhu esikuxoxile. 
17 
Sithanda ukukwazisa ukuthi konke okushoyo kuzogcinwa kuyimfihlo kanti futhi kuzocubungisiswa nokunye 
okuzoshiwo abanye ababandekayo kulolucwaningo. Khumbula ukuthi ayikho impendulo eqondile nenga qondile. 
Asikho lapha ukukwahlulela. Konke ozokusho kuzogcinwa kuyimfihlo. Unelungelo lokwega nanoma yimuphi 
umbuzo ongathandi ukuwuphendula kanti futhi unelungelo lokungamula Iengxoxo nanoma isiphi isikhathi 
Hello, my name is ................... Thank you for agreeing to have this interview with us. We have requested this interview to understand how you make your choices about HIV 
vention, your use of condoms and contraceptives and where you go to obtain these products This will help us learn about how best to distribute new 
(hods for HIV prevention specifically made for women's use. Currently, there are research studies testing whether these new products, microbicides 
1 the diaphragm, provide women any protection against HIV and other sexually transmitted diseases The products that are being tested will be made 
women to insert into their vagina before sex, and so might not be noticed by her partner. However, it is not yet known if they provide any protection 
3inst HIV and STD transmission Further on in this interview we will tell you much more about these products. 
This interview has 4 man parts: the first will ask some background questions about you and your household, the second part will ask about your 
! ory of using condoms and contraceptives and about the last time you had sex. The third part presents some imagined scenarios in which we ask you 
think about the choices you might have made if these new products were already available. After the main survey questions we will ask for your 
dback on what you thought of the interview. 
would like to let you know that your comments are confidential and will be analysed together with the contributions from other interviews. Remember 
re are no right or wrong answers. We are not hereto fudge you. All that you say will be kept secret. You have the right to skip any questions that you 
not want to answer and the right to discontinue the interview at any time you wish 
Q lQuestions I Codes I Responses I saps 
SECTION 1: BACKGROUND INFORMATION 
18 Ngizothanda ukubuza ngomdeni wakho kanye nawe. 
I would like to start asking some general questions about your famiy and your own background. 
19 
Iingabe uzaiwe ngayiphi inyanga nonyaka? I Unknown 98 Month a. 
l 
[1 
198-021 
In which month and year were you bom? Year b. 
0 a. WAS SHE BORN BEFORE OCTOBER 19597 No 0 Yes 1 [] 1-. ineligible 
1-+ineligible 
b. WAS SHE BORN AFTER OCTOBER 1987? No 0 Yes 1 
+Q23 
21 Uneminyaka emingaki namhlanje? How old are you today? 
122 b. IS SHE BETWEEN 18 AND 45 YEARS OLDS No 0 Yes 1 (1 0-ineligible (INCLUSIVE)? 
English 1 SePeti 7 
Afrikaans 2 SiSwati 8 
23 Nikhuluma luphi ulimi ekhaya? IsiXhosa 
3 TshiVenda 9 
What language do you speak at hone? IsiZulu 4 ZiTsonga 10 
SeSotho 5 isiNdebela 11 
SeTswana 6 Other 96 
Bom Again 1 Traditional African 7 Hindu 8 Catholic 2 9 
24 Ningabayiphi inkoko? Protestant 3 Shembe 10 What religion do you belong to? Christian -unspecified 4 Zionist 11 
Jehovah's witness 5 None 12 7th day Adventist 6 Other 96 
ZULU-2 Other 96 
Survey 18-10-2005 Don't know/ Don't remember 98 
Refuse to answer 99 
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Manje sengizokubuza imibuzo embalwa None 1 
ngezinga lakho lemfundo nokuthi yimiphi Incomplete primary 2 imithombo eletha imali ekhaya lakho. Completed primary 3 
Incomplete secondary 4 
25 Ufunde wagcina kweliphi ibanga Incomplete secondary & some [] 
ngokwemfundo? vocational training 5 
I am now going to ask you some questions about your Completed secondary 6 
level of education and what sources of income there are Incomplete tertiary 7 
coming into your household What is the highest level of Completed tertiary 8 
education you gained? 
Uneminyaka engakanani uhlala kulendawo? >5 Yrs 26 [THIS TOWNSHIP) Always 95 
years Q29 How many years have you lived in this area? 
Gauteng I Northern Cape 6 
Bewuhlala kuphi phambi kokuba uzohlala Eastern Cape 2 Northern Province 7 
27 kulendawo? Free State 3 North West 8 (] 
Where did you live before moving here? Kwazulu Natal 4 Western Cape 9 
Mpumalanga 5 Other Country 96 
Kwakuyidolobhakazi, idolobhana noma Large City 1 
28 emakhaya noma ipulazi? Town 2 [] 
Was this a large city, a town or a rural area/form? Rural areal farm 3 
Ungasichaza kanjani isimo sakho Employed full time I 
maqondana nokuqashwa? Ingabe uqashwe Employed part-time 2 
okwesikhashana noma ngokuphelele; Student/scholar 3 
29 bewungumfundi, usafuna umsebenzi Homo Work seeker /unemployed 4 
1--+Q31 
umgcini khaya. 
Housewife 5 2--Q31 
How would you define your employment status? Are 
Retired 6 
Other 96 you employed full-time or pan-time, were you a student, a 
warkseeker. a housewife? Specify 
Ukhona umsebenzi oke wawenza onyakeni 
30 odlule? No 0 Yes 1 [] 0-034 
During the past year, did you do any kind of work? 
Chaza kafuphi uhlobo lomsebenzi omkhulu 
(a) 
owenzayo noma obuwenza. (b) Sales, services 1 
31 WRITE RESPONDENTS ANSWER in (a) THEN 
Unskilled manual 2 
Household/domestic 3 ] b[ 
CODE IN OFFICE (b) Menufsct 4 Describe briefly the main work or job that you do/did? er 96 Other 
Kulowo msebenzi ukhokhelwa noma 
bewukhokhelwa kanjani? Ingabe iholo 
olithola njalo, uyazisebenza, ukhokhelwa Regular paid I 
32 ngenani olukhigizile, noma awuzange Self-employed 2 Paid per piece 4 
wakhokhelwa? Casual labourer 3 
Unpaid 5 
In your man job, how areMrere you paid? Is this based 
on a regular salary, self-employed, as a casual labourer, 
paid by the amount you produced, or unpaid? 
Uwenzephi/ uwenzaphi lo msebenzi? At own home 1 
Ekhaya lakho, endlini yomcashi, emgwaqeni, 
At employers house 2 
estolo, efemini, engadini, emayini noma 
On the street 3 
Shophnerks 
kwenye indawo? Office 5 33 
Where does/did this work take place? Is this at your 
' 
Industry/factory 6 
Plantation/farm/garden 7 home, at your employer s house, on the street, in a 
shop/marketAaoek, in an office, in an industry/factory, in a Construction/rrines/quarrying sites 8 
plantatioNfarnVgaden. in a construction/minel quarrying Other 96 
site or somewhere else? Specify 
ZULU-3 Other 98 
Survey 18.10-2005 Don't know! Don't remember 98 
Refuse to answer 99 
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Manje sengizokubuza imibuzo embalwa maqondana nekhaya lakho. Ngekhaya sichaza umuzi qobo kanye nabantu 
ohlala nabo (ungaba wedwa noma ube nomndeni kanye nezihlobo). Kungaba yindlu noma ikhaya elinezindlu 
eziningi zandawonye, ngisho noma ngabe azisondelene kakhulu. Ikhaya lineqembu labantu, ekuvame ukuba 
34 yizihlobo, ababelana ngezinto ezahlukene futhi abavamise ukudla ndawonye. 
I am now going to ask you some questions relating to your household. By household we mean the physical and social unit in which you live (either by 
yourself or with family and relatives). This could be a house or a compound consisting of dfferent buildings that belong together, even though they may 
not be very close together A household consists of a group of people, usually relatives, who share resources and regularly share meals 
Ungathi ngubani inhloko yekhaya lakho? Self I Son/daughter in law 6 
35 
Husband/partner 2 Mother/father in law 7 Child 3 1 1-'Q42 PROBE: Lomuntu uhlobene kanjani nawe? Other- relative 8 
Who would you say is the head of your household? 
PROBE What is this person's relationship to you? 
Parent 4 Other-rid a relative 96 Sibling 5 
36 Sizothanda ukukubuza imibuzo embalwa ngenhloko yekhaya osanda kuyisho 
We would like to ask you some questions about the heed of household who you just identified. 
Ungasichaza kanjani isimo sokuqashwa e Employed full time 1 
senhloko yekhaya? ld part-time 2 Employed 
Studenttschdar 3 
Ingabe uqashwe okwesikhashana noma Work seeker / unemployed 4 1-. Q39 37 ngokuphelele; ingabe ungumfundi, usafuna Housewife 5 2-Q39 
umsebenzi noma umgcini khaya. Retired 6 
How would you definee the head of household's Other 96 
employment status? Is the head employed full-time or part- Specify 
time, is the head a student, a workseeker, a housewife? 
Inhloko yekhaya ike yasebenza onyakeni 
38 odlule? No 0 Yes 1 [] 0-ºQ42 
During the pastyear, dd the head of household do any 
kind of work? 
Chaza kafuphi uhlobo lomsebenzi (a) 
obuwenziwa/owenziwa yinhloko yekhaya. 
(b) Sales, services 1 b 39 WRITE RESPONDENTS ANSWER IN (a) Unskilled manual 2 
I 
THEN CODE IN OFFICE (b) Household/domestic 3 
Describe briefly the main work or job that the head of Manufacturing 4 
household doesldid? Other 98 
Ikhokhelwa noma beyikhokhelwa kanjani 
inhloko yalapha ekhaya? 
40 
Ingabe yiholo alithola njalo, uyazisebenza, Regular paid 1 Paid per piece 4 Selaemployed 2 
ukhokhelwa ngenani olukhiqizile, noma Unpaid 5 Casual labourer 3 
awuzange wakhokhelwa? 
How is/was the head of household paid? Is this based 
on a regular salary, self-employed, as a casual labourer. 
paid by the amount you produced, or unpaid? 
At own home 1 
At employers house 2 
On the street 3 
Shoplmarket/kiosk 4 
Ubuwenziwaphi/wenziwakkuphi lo Office 5 
41 msebenzi? Industry/factory 6 I] 
Where does/did this work take place? Plantation/farm/garden 7 
Construction/mines/quarrying sites 8 
Other 96 
Specify 
42 a. Mangakhi amagumbi endlini yakho? How many rooms are there in your house? 
b. Mangaki amagumbi eniwasebenzisela 
ukulala ekhaya Iakho? 
How many rooms in your household are used for sleeping? 
Bangaki abantu abavame ukulala ekhaya 
43 lakho? How many people usually sleep in your 
I 
household? 
ZULU-4 Other 96 
Survey 18-10-2005 Don't know! Don't remember 98 
Refuse to answer 99 
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RDP 1 Bond house 7 
RDP extended 2 Municipal/council house 8 
44 Nihlala endlini ewuhlobo olunjani? Hostel 3 Shack 9 What type of housing do you stay in? Hostel family unit 4 Room inside 10 
Double house 5 Room outside 11 
New house 6 Other 96 
Ngubani ongumnikazi wendlutwendawo 
Parent/parent-in-law 1 Self 5 Partner 6 
45 ohlala kuyona? 
Private landlord 2 
Government/council 3 Sibling 7 [ 
Who owns the houselplace you live in? Company 4 Other relative 8 Other-not a relative 96 
Sithanda ukwazi ngesimo sakho sempilo, ngoba sidinga ukuqondisisa ukuthi ngabe lokhu kukwama 
kanjani izinqumo zakho. Khumbula ukuthi lolwazi onikela ngalo luyimfihlo kanti futhi 
luzosetshenziswa kulenhlolomvo ukukubeka esigabeni sesimo sempilo. 
46 Ingabe ninazo lezinto ezilandelayo kulendlu enihiala kuyo: 
We want to find out about your secio-economic standard, because we need to understand how this effects your choices Please 
remember this information is confidential and will only be used by this study to place you in a socio-economic category 
Does your household have 
a. Ugesi Electricity No 0 
Yes, working I a[ Yes, but not working 2 
b. lwayilense A radio No 0 
Yes, working 1 b[ Yes, but not working 2 
.... ...................... 
c. Umabonakude A television No 0 
Yes, working 1 c[ Yes, but not working 2 
d. Ucingo/ Umakhala ekhukhwini No 0 Yes, working I d[ A telephone/ cell phone Yes, but not working 2 
e. Ifiliji A refrigerator No 0 
Yes, working 1 
Yes, but not working 2 
---- ----------------- 
f. Ikhompyutha A personal computer No 0 
Yes, working 1 
Yes, but not working 2 
g. U mshinl woku washy A washing machine No 0 
Yes, working 1 g[ Yes, but not working 2 
47 Ingabe lekhaya linazo lezinto ezilandelayo: Does any member of your household own 
__....... ..... ........ _..... _. _ .... __... __.. _.. _ ..... ................... _. _.. ... ..... ..... _.. _.. ...... _. ................. ...... .... _. _. _. T.... __... 
a. Sondombili A bicycle No 0 
Yes, working 1 
Yes, but not working 2 a[ 
b. lsithuthuthu noma iskutha No 0 Yes, working 1 b[ 
A motorcycle or motor scooter Yes, but not working 2 
C. Imoto A car No 0 
Yes, working 1 
Yes, but not working 2 c[ 
d. Izimvu noma izinkomo sheep or cattle No 0 Yes 1 d[ ] 
Unna kukhona omunye endlini ogulayo 
kufuneka i-R100 yamakhambi noma 
yokumelapha, ungasho ukuthi kulula 
kakhulu, kuludlana, kunzinyana noma Very easy 1 
48 kunzima kakhulu ukuthola imali? 
Easy 2 
Quite difficult 3 [ 
If a person became ill in your home and R100 was 
Very difficult 4 
needed to pay for treatment or medicines, how easy would 
it be for you to find the money very easy, easy, quite 
difficult or very difficult? 
ZULU-5 Other 96 
Survey 18-1 0.2005 Don't know! Don't remember 98 
Refuse to answer 99 
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Ingabe nihlala ndawonye nomlingani wakho 
49 wezocansi? No 0 Yes 1 [] O-"Q52 
Are you currently living with a sexual partner? 
Ungasho ukuthi imali oyiletha endlini noma 
emdenini iningi ukwendlula umlingani wakho 
ozwana naye noma incane noma icishe More 1 
50 ilingane? Less 2 [] 
Would you say that the money that you bring into the About the same 3 
family/household is: more than what your partner 
contributes; less than what he contributes, or about the 
same as he contributes 
Umlingani wakho ukhipha imali engakanani 
ukukhokhela izindleko zasendlini? Lutho, 
Uhalufu nesigamu, Okulingene, Ingxenye None 1 Three quarters 4 51 nohaful, Konke? One third 2 All 5 
What proportion of the household expenses does your Half 3 
partner contribute? None, about one third, about half, about 
three quarters, all? 
SECTION 2 REPRODUCTIVE HISTORY 
Manje ngithanda ukubuza imibuzo mayelana nokusebenzisa kwakho izindlela zokuhlela umndeni nobuhlobo bakho 
52 ngokwezocansi. Ngithanda ukukukhumbuza ukuthi lolulwazi ozosinika Iona Iuzogcinwa Iuyimfihlo. Kanti futhi 
luzosentshenziswa ukuqonda ngezidingo zempilo zabesifazane. 
Now I need to ask you some questions aboutyour use of contraceptives and sexual relationships. I would like to remind you that this information will 
be kept secret and will only be used to better understand women's heath needs. 
Ubuneminyaka emingaki ngenkathi uqala 
53 ukuya ocansini? age in years [] How old were you the first time you had sexual 
intercourse? 
Wake wasebenzisa indlela yokuhlela 
54 umndeni? No 0 Yes 1 [] 0-+Q68 
Have you ever used any contraceptives? 
lyiphi indlela yokuqala owayisebenzisa? 
Injectables IUD / Copper T4 
55 
Whatwas the first method you ever used? 
Pills 22 Other 96 
Condoms 3 Specify 
[] 
Clinic 1 Pharmacy/chemist 6 
Govemment hospital 2 Private GP 7 
56 Wayithdaphi leyondlela yokuhlela umndeni? Y- centre 3 
Supermarket 8 
Where did you get that method? Other public source 4 
Spaza shop 9 
Private hospital 5 Specify 
Other 96 
Hlawumbisela ukuthi buneminyaka emingaki 
ngenkathi uqala ukusebenzisa indlela 
57 yokuhlela? age in years [] 
Roughly how old were you when you started using that 
method? 
Hlawumbisela ukuthi buneminyaka emingaki 
ngenkathi ugcina ukusebenzisa indlela 
yokuhlela? 
58 Never stopped 95 age in years [] 95-+Q67 IF NEVER STOPPED, PROBE IF THEY EVER 
TOOK A BREAK? RECORD THE BREAK 
Roughly how old were you when you stopped using that 
method? 
Bekusiphi isizathu esenza ukuthi uyeke 
Wanted to get pregnant 1 
Side effects 2 
59 ukusebenzisa lendlela okuhlela y No longer in a sexual relationship ship What was the main reason you stopped using that Other 96 
method? Specify 
ZULU-6 Other 96 
Survey 18-10-2005 Don't know/ Don't remember 98 
Refuse to answer 99 
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Okwamanje ikhona indlela oyisebenzisayo 
60 yokuhlela umndeni? No 0 Yes 1 [] 0--Q64 
Are you currently using any contraceptives? 
Ingabe iyiphi leyondlela yokuhlela umndeni Injectables I IUD! Copper T4 
61 oyisebenzisayo? Pills 2 Other 6 
What method are you currently using? Condoms 3 Specify 
Clinic 1 Pharmacy/chemist 6 Wayithola kuphi indlela yokuhlela umndeni Government hospital 2 Private GP 7 
62 ngenkathi ugcina? Y -centre 
8 
-centre 3 Where did you get that method the last time you SSpý shop 9 Other public source 4 collected it? Other 96 Private hospital 5 Specify 
Hlawumbisela ukuthi ubuneminyaka 
emingaki ngenkathi uqala ukusebenzisa 
63 lendlela yokuhlela? age in years [] 
Roughly how old were you when you started using that 
method? 
Ingabe ukewasebenzisa enye yezindlela 
64 zokuhlela umndeni? No 0 Yes 1 [] 0--+Q67 
Did you ever use any other types of contraceptives? 
Bekuyiziphi? Kukhona ezinye? Injectables 1 IUD/ Copper T4 a[ ] 
65 
MARK ALL 
Pills 2 Other 96 b[ ] 
C[ ] 
Whatwerethey? Any others? 
Condoms 3 Specify d[ ] 
Yiziphi izindawo okewazisebenzisa 
ekutholeni ezinye izindlela zokuhiela 
Pharmacy/chemst 6 Clinic 1 a[ ] 
umndeni? Kukhona ezinye? 
Pate GP 7 Government hospital 2 Supermarket 8 b[ ] 66 Y-centre 3 Span shop 9 c[ 
] 
MARK ALL Other public source 4 Other 96 d[ ] 
What places have you used to collect these other Private hospital 5 Specify e [] 
methods? Any others? 
MALE CONDOMS 
HAS THE RESPONDENT REPORTED HAVING L L7 
EVER USED CONDOMS? No O Yes 1 [] 
CHECK Q55, Q61, AND 065 ýQ 
Uke wasebenzisa ijazi lomkhwnenyane 
68 nanoma yimuphi umlingani? No 0 Yes 1 [] O-+Q$0 
Have you ever used a male condom with any partner? 
Kumuntu ongcine okuya naye ocansini, 
ngubani oweza nombono wokuthi 
nisebenzise ijazi lomkhwenyane: nguwena Me 1 69 noma ohlekisana naye? My partner 2 [] 
The most recent person with whom a condom was Both 3 
used, who suggested to use a condom: you or your 
partner? 
Uke wathenga noma wamkele ijazi 
70 lokhwenyane ngobuwena? No 0 Yes 1 [] 0-ºQ80 
Have you ever collected or bought a condom yourself? 
Days a [J 
Kwakukunini mhla ugoina ukuzilandela OR Weeks b [J 
71 amajazi ngokwakho? 
How long ago was the last time you collected a condom OR Months 
yourself? 
OR Years d [] 
Clinic 1 Pharmacy/chemist 6 Esikhathini esendlule, uwathathe kuphi Private GP 7 Government hospital 2 
72 amajazi omkhwenyane? Y-centre 3 Supermarket 8 
The last time you collected condoms: Other public source 4 
Spaza shop 9 
Where did you get them? Other 96 Private hospital 5 
Specify 
ZULU-7 Other 96 
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I happened to be there anyway 
(convenience) 1 
It was the closest place (location) 2 
It was an anonymous place (privacy) 3 
It was cheap or free (Price) 4 
73 Yini eyakwenza ukuba uwalande lapho? I knew I would find them there Why did you collect them from there? (reliable supply) 5 
Shorter wait 6 
Friendlier service 7 
Has the typelbrand of condom I like 8 
Other 96 
Specify 
Unikezwe ngubani noma uwatholephi? From a box or machine 1 Ingabe uwathole ebhokisini noma emshinini From a person behind the counter 2 
74 ofakwa 
imali? Emuntwini egumbini From a person in a private room 3 
efihlakele? Eshelufini noma ngenye indlela? Off a shelf 4 How did you collect them? From a box or machine? Other 96 
From a person behind a counter? From a person in a Specify 
private room, off a shelf, or some other way? 
75 Kwakunhloboni yamajazi? 
Choice 1 Durex 4 
Trust 2 Other 96 What brand of condom were they? Lovers Plus 3 Specify 
76 Uwakhokhele noma awuwakhokhelanga na? Free 0 Paid 1 0 -+ý80 Did you pay for them or were they free? 
Ukhokhe malini ukuthola ibholdsi lamajazi 
77 omkhwenyana? Don't remember 98 
[ 
Rand 
] 
How much did you pay for the package of condoms 
78 Bemangaki ngaphakathi ebhokisini? How many were in that package? 
a. Ube nayo yini inkinga ngokuthola ijazi 
79 lomkhwenyane? No 0 Yes I I] 
Did you have any problems getting the condoms? 
FEMALE CONDOMS 
80 Wake wazwela nge-condom yabesimame? No 0 Yes I [I ý'Qý Have you ever heard of the female condom? 
81 Uke wayibona i-condom yabesimame? No 0 Yes 1 (] 0-, 094 Have you ever seen a female condom? 
Wake wayisebenzisa i-condom 
82 yabesimame? No 0 Yes 1 (] 1-. Q84 
Have you ever used a female condom? 
Never thought about it 1 
Expect discomfort/pain 2 
Do not like the way they look 3 
Kungani? I do not need HIV prevention or pregnancy 
83 Why not? prevention 4 Could not find one 5 -'Q94 
Couldn't afford 6 
I wanted to but my partner refused 7 
Other 96 
Specify 
Ubani oqalile ukuze nisebenzise i-condom 
84 yabesimame, nguwena noma umlingani Me 1 Both 3 [] 
wakho? My partner 2 
Who initiated female condom use, you or your partner 
Wake wanikwa noma wathenga ama- 
85 condom abesifazane ngobuwena? No 0 Yes 1 (] 0-+094 Have you ever collected or bought female condoms 
yourself? 
ZULU-8 Other 96 
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Clinic 1 Pharmacy/chemist 6 Ukugcina kwakho ukulanda i-condom Private GP 7 Government hospital 2 
86 yabesimane, wayitholaphi? Y- centre 3 
Supermarket 8 
The last time you collected a female condom, where did wer public source 4 
Spaza shop 9 
you get it? Other 96 Private hospital 5 Specify 
happened to be there anyway 
(convenience) I 
It was the closest place (location) 2 
It was an anonymous place (privacy) 3 
87 Yini eyakwenza ukuba uyilande lapho? 
It was cheap or free (Price) 4 
I knew I would find them there [] Why did you collect it from there? (reliable supply) 5 
Shorter wait 6 
Friendlier service 7 
Other 96 
Specify 
Uyilande kanjani? Ingabe uwathole From a box or machine 1 
ebhokisini noma emshinini ofakwa imali? From a person behind the counter 2 
88 
Emuntwini egumbini elfihlakele? Eshelufini From a person in a private room 3 
noma ngenye indlela? Off a shelf 4 
How did you collect them? From a box or machine? Other 96 
From a person behind a counter? From a person in a Specify 
private room, off a shelf, or some other way? 
89 Uwakhokhele noma uphiwe? Free 0 Paid 1 [] 0-+Q94 Od you pay for them or were they free? 
Ukhokhe malini ukuthola ibhokisi lama- 
90 condom abesimame? Don't remember 98 
[] 
How much did you pay for the package of female Rand 
condoms? 
91 Bemangaki ngaphakathi kwebhokisi? How many were in that package? 
Uye wahlangabezana nenkinga ukuwathola 
92 lama-condom abesimame? No 0 Yes 1 [] O--. Q94 Did you have any problems getting the female 
condoms? 
Yiziphi izinkinga oyewahlangabezana Specify 
93 nazo ekuwatholeni 
What problems did you have getting them? 
Manje ngizothanda ukubuza mayelana 
94 ngezingane. Ingabe unazo izingane 
eziphilayo na? No 0 Yes 1 [] p_ggß 
Now I would like to ask you about children. Do you 
have any children that are alive now? 
Zingaki izingane onazo? 
95 CHECK IF CONSISTENT WITH CONTRACEPTIVE [] 
HISTORY, IF NOT PROBE AND CORRECT. 
How many children do you have? 
96 Ukhulelwe okwamanje? No O 
Yes 1 
' I] ýQ Are you currently pregnant? Don t know 98 
Ungathanda ukuba nengane noma izingane 
97 ezinyangeni ezingu-12 ezizayo? No 0 Yes 1 I1 
Would you like to have any/ more children in the next Maybe / not sure 3 
12 months? 
Uma ungakhulelwa emavikini ambalwa 
azayo ungajabula noma ungejabule noma Happy 1 
98 ungambaxambili? Unhappy 2 
If you became pregnant in the next couple of weeks, Indifferent 3 
would you be happy, unhappy, orindfferent? 
ZULU-9 Other 96 
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Imibuzo elandelayo imayelana nokokugcina kwakho uya ocansini. Ngokocansi ngichaza ukuthi ohiekisana naye 
99 angene ngaphakathi kwesingezansi sakho. 
The next questions are about the very last time you had sex. By sex I mean when your partner put his penis in yourvagina. 
Isikhathi esingakanani wagcina ngaso ukuya Days a [] 
100 ocansini? OR Weeks b [] >6months -" 
How long ago was the last time you had sex? i neligible 
OR Months [] 
Husband 1 
Ungabuchaza kanjani ubuhlobo onabo 
Regular 
in 
partn 
tan 
er 2 
Casual one 3 
101 nomuntu woku cina owa ocansini na e? 9 Ya Y One-off/ someone I just ust met met 4 Can you describe your relationship with the last person Client/ paying partner 5 you had sex with? Other 96 
Specify 
102 Uhlala naye lowomuntu? No 0 Yes 1 [] Do you live with this person? 
Abesimame abaningi bahlangabezana 
nobunzima ekutheni abalingani babo 
103 basebenizise amajazi. Sekuke kwakwe No 0 Yes I [] 
nzakalela wena lokho na? 
Many women find it difficult to get their partners to use 
condoms. Has this ever happened to you? 
Ukugcina kwakho ukuya ocansini, 
104 ulisebenzisile ijazi lamkhwenyane? No 0 Yes 1 (] O--. Q106 
The last time you had sex, was a condom used? 
Isiphi isizathu esasibalulekile esenze HIV prevention 1 Dual protection 4 
105 usebenzise ijazi lomkhwenyane? Pregnancy prevention 2 Other 96 [] - 0107 
What was the main reason a condom was used? STI prevention 3 Specify 
I want to get pregnant 1 
Isiphi isizathu esibalulekile esikwenze ukuba I am not worried about HN or STI 
ungasebenzisi ijazi lomkhwenyane? I do not like condoms 3 
106 1 wanted to but my partner refused 
IF ANSER IS'PARTNER REFUSED, AND 0103 We did not have one at the time 
IS 'NO' PROBE INTO WHICH IS CORRECT. I never suggested because I was afraid 
What was the main reason a condom was not used? Other 96 
Specify 
Nogizokufundela ezinye zezitatimende ezimayelana nokuzivikela kusandulela ngculaza. Kusitatimende ngasinye 
ngicela usho ukuthi ucabanya ukuthi kuyiqinso noma akulona. 
107 
Abantu bangazivikela ekutholeni isandulela ngculazi, ... I am going to reed out some statements about protection against HIV. For each statement please tell me whether you think it is true or not. People 
can protect themselves from becoming infected with HIV by........... 
a. Ngokudla ukudla okulungele umzimba. Having a good diet No 0 Yes 1 ' a( Don t know 98 
b. Ngokuba nom Iingani oyedwa othembekile. Staying with onefaithful No 0 Yes 1 ' b[ ] partner Don t know 98 
c. Ngokugwema izindlu zangasese zomphakathi. Avoiding public toilets No Yes 1 0 ' (] c 
.. _ ....... .... ..... ........... - -.............................. 
Don t know 98 
---- d. Ngokusebenzisa ijazi uma uya ocansini. Using condoms during sexual Yes 1 No 0 ' d[ ] intercourse t know 98 Don 
e. Ngokugwema ukuthintana nomuntu onesifo sesandulela Yes 1 No 0 ' (] e ngculazi. Avoiding touching a person who has HIV/AIDS 
. _.. _. _........ 
t know 98 Don 
f. Ngokugwema ukudla nomuntu onesifo sesandulela ngculazi. No 0 Yes 1 ' ] Avoiding sharing food with a person who has HIV/AIDS t know 98 Don 
g. Ngokugwema ukulunya umndozolwane noma izilwanyana No 0 Yes 1 ' g[ ] ezifana nazo. Avoiding being bitten by mosquitoes or similar insects t know 98 Don 
In. Ngo kuginisekisa ukuba umjovo osetshenziswayo uhlanzekile. No 0 Yes 1 ' h[ ] Making sure any injection they have is done with a clean needle t know 98 Don 
ZULU-10 Other 96 
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Uzibona usencuphekeni enkulu, noma 
elingene, noma encane, noma lingekho 
108 kwasantlobo ithuba lokuba ne -HIV noma High risk 1 Low risk 3 
usuleleke futhi ngegciwane? Medum risk 2 No risk 4I 
Do you consider yourself at high, medium, low, no risk 
of getting HIV or becoming re-infected? 
SECTION 3: STATED PREFERENCES & INTRODUCTION TO FEMALE BARRIER METHODS 
zoxoxa ngezindlela ezahlukahlukile esinazo zokuvikelwa kwe-HIV okungamajazi omkhwenyane kanye nalawo 
etshenziswa ngabesimame kanye nezinye ezisacutshungulwa noma ezisenziwa okungama-microbicides kanye 
ma-diaphragm. Ngiyethemba ukuthi unoiwazi ngejazi lomkhwenyane Iobaba. Asebenza kakhulu ekuvikeleni 
induleli ngculazi nokukhulelewa. Afakwa nje ngaphambi kokuya ocansini futhi angeke asetshenziswa owesilisa 
gazi futhi azibandakanye. Manje sizonitshela kabanzi ngezinye zezindlela ezikhona. 
ala nge-condom yabesimame. HAND TO PARTICIPANT. I-condom yabesimame ikhona kanti futhi 
lakala emitholampilo kanye nasezitolo. Ikunika ukuvikeleka okuthembekile kwizifo ezifana no-HIV, STI 
nasekukhulelweni. Ingafakwa isikhathi esingaba amahola ayisithupha (6 hours) ngaphamb' kokuya 
i, kanti futhi ingagcineka amahola ayisithupha (6 hours). Kuyangxuswa ukuthi usebenzise i-condom 
lame entsha njalo uma uya ocansini ngezigaba, kodwa i-condom yabesimame iqinile kanti futhi ngesinye 
i ingabuye isetshenziswe futhi uma ngabe entsha ingekho ngalesosikhathi, Iingekho nalo ijazi 
enyane noma ohlekisana naye engathandi ukusebenzisa ijazi Iomkhwenyane. Uma ngabe i-condom 
name ibuya isetshenziswa futhi, kudingeka ukuba igezwe ngobunono ngensipho namanzi bese 
shenziswa izihlandla iziyisikhombisa noyedwa olala naye. Kwesinye isikhathi lomlomo uyaye ungene 
kathi kowesimame, kanti abanye bathi bayaye bezwe i-condom yabesimame ihamba uma beya ocansini. 
)mu yabesimame ingasetshenziswa kanye nemijovo yoku\ikela noma amapeni wokugoma. 
I-Diaphragm, HAND TO PARTICIPANT, indlela beyisetshenziswa kudala ukuvikela ukukhulelwa kwabesimame 
kanti futhi isikuvezile ukuthi iyakwazi ukuvikela i-STI. Isacutshungulwa ukubona ukuthi ingakwazi ukuvikela 
ukusuleleka kwe-HIV. I-diaphragm ingagcineka ngaphakathi kwesingezansi sowesimame amahora angu-24 (24 
hours) ngesinye isikhathi, okusho ukuthi ingafakwa noma ngasiphi isikhathi ngaphib' kokuya ocansini. Kufanele 
ingcinwe amahola ayisithupha (6 hours) emva kokuya ocansini. I-diaphragm oyibonayo lapha idinga ukuba ifakwe 
abasenzi bezempilo (health worker) ukuze ibe ngelingene ngokwanele kanti futhi ingasetshenziswa ukuya 
eminyakeni emibili (2 years) uma inakekelwe ngokwanele. Loku kusho ukunakekela uma ikhishwa ingagqobhozwa 
ngezinzipho ezide, igezwe ngamanzi nensipho bese igcinwe ebhokisini layo. Ukusebenzisa i-lubricant kwenza 
109 
kube ukuyifaka. Uma i-lubricant ingekho ukumanzisa i-diaphragm ngamanzi kancane kunganceda ukuthi ishelele 
ingene kalula kwisitho sangasese. Abanye besilisa bangayizwa i-diaphrgm ngenkathi aya ocansini kanti abanye 
bengayizwa. Noma kunjalo uketshezi luyadingeka njalo uma izosetshenziswa. Ocwepheshe basungula i- 
diaphragm engasetshenziswa kanye ilahlwe futhi ezobanobukhulu obubodwa, bulingane wonke owosimame. I- 
diaphragm ingasetshenziswa kanye nemijwo yokuvikela noma namapeni okugoma noma namacondom. 
Microbicide, BONISA ISISETSHENZISWA kobuzwayo, yizisetshewziswa ezisahlolisiswa ukuze kubonwe 
ingabe zinganciphisa incupheko yabesimame ekusulelekeni ngesanduleli ngculaza. Kunemihlobo 
ahiukene yamaMicrobicide ehlolisiswayo, eminye inganciphisa amathuba wabesimame okukhlelwa, eminye 
. iphise. Namuhla sizokhuluma ngamafutha we-microbicide. Wona angeza agcwaliswe kwisisetshenziswa, 
dingakalaka ukuba silahlwe emuva kokuba sisetshenziswe kanye, noma angeza njengesisetshenziswa 
3setshenziswa kaningi kanye nesiphatho samafutha we-Microbicide. Lesi sisetshenziswa sidinga 
ishwa emva kokuba sisetshenziswe, sigcwaliswe ngaphambi kokuba sisetshenziswe futhi. Ezinye izinhiobo 
nga ukufakwa nje njaphampi kokuya ocansine, eminye ifakwe kusele i-awa elilodwa lokuya ocansini, ezinye 
iikela ukuya kuma-awa angamashumi amabili nane (24) emva kokufakwa. Amafutha angenza owesimame 
de ukubamanzi kancane ngaphansi. Abanye abalingani bangakunaka lokhu kanti abanye bangeke. I- 
bicide ingasetshenziswa kanyekanye nemijovo yokuhiela, amapililisi okuhiela kanye namakhondomu. 
a ukukukhumbuza ukuthi, okwamanje asazi ukuba i-diaphragm nama-microbicide ayanika uvikeleko 
ngculaza. Ama-condomu wabesilisa nabesimame aseke abonisa uvikeleko Iwesandelelo ngculaza. 
We are going to discuss existing barrier methods for HIV prevention: male condoms, female condoms and some that are being developed, 
obicides and the diaphragm I am sure you are all familiar with male condoms. They are very effective in preventing HIV infection and pregnancy. 
V are put on right before sexual intercourse, and cannot be used without a male partners Imowledge and participation. We will now tell you a bit more 
ut the other products. 
Firstly the female condom. HAND TO PARTIOPANT. The female condom is available in some clinics and shops. It provides good protection 
nst HIV, Si] and pregnancy. It can be put in for up to 6 hours before sea, and can be kept in for a total of 6 hours. It is recommended that a new 
ale condom is used for each round of sex, however the female condom is strong and can in some cases be reused if no new one is available, and 
eis no male condom or your partner does not wish to use a male condom. If the female condom is re-used, it needs to be washed carefully with 
p and water and patted dry between each use. It should not be used more than 7 times The outer ring can sometimes slip inside the vagina, and 
ie people say they can hear the female condom move while they have sex. The female condom can be used at the some time as using injectable 
traceptives or the 01 
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The Diaphragm, HAND TO PARTIaPANT, is a method that has long been used for pregnancy prevention and has shorn to prevent some STIs. It 
is currently being tested to see if it provides any protection against HIV infection. The diaphragm can be kept in the vagina for up to 24 hours at a time. 
so can be inserted anytime before sex. It must be left in place for at least 6 hours after sex. The diaphragm you see here needs to be fitted by a health 
worker for the correct size and can be used for up to 2 years if cared for properly. This means that care is taken when removing it, not to pierce it with a 
long finger nail, and to wash it with soap and water and store it in its box. Using a lubricant makes the diapragm easier to insert. If lubricant is not 
available, wetting the diaphragm with a little water can help slide the diaphragm into the vagina. Some partners can feel the dapragm during sex, while 
others cannot feel it. Scientists are developing a single-use disposable diaphragm and a one-size fits all diaphragm. The daphragm can be used at the 
some time as using injectable contraceptives, the pil, and/or condoms. . Microbicides, HAND APPLICATOR TO PARTICIPANT, are new products that are being tested to see if they can reduce women's risk of becoming 
HIV positive. Microbicides are also being tested to see if they can prevent some STI. These products are still being tested, it is not yet known if they 
provide any protection against HIV or whether they may reduce a woman's chance of becoming pregnant. If an effective microbicide is found, they may 
either come in a pre-filled applicator that will need to be thrown ovay after each use, or may be developed for use with a re-usable applicator with a tube 
of microbidde. The re-usable applicator will need to be washed after each use and refilled before each use. It is also not known if they need to be 
inserted directly before sex or if it can be inserted a few hours in advance. The gel may make the vagina a little bit more moist (wet). Some partners may 
notice this, while others may not. Microbicides can be used at the same time as using injectable contraceptives, the pill, and/or condoms. 
We would like to remind you that right now we do not know if the diaphragm and microbicides provide any protection against HIV Only male and 
female condoms have been shown to prevent HIV infection. 
WILLINGNESS TO PAY 
Ngizothanda ukwazi ukuthi ingabe uzithandile lezindlela lezi esesikhulume ngazo. Sicela ucabange zonke 
izinkinga zakho eziphathelene nemali kanye nomuntu oya naye ocansini okwamanje. Unazo ezinye izindlela 
110 zokuthola ama-condom wabesilisa ungakhokhile noma kumele uwakhokhele. Khumbula azikho izimpendulo 
eziqondile, sifuna ukwazi umbono wakho. 
Now I would like to ask you about your general interest in these new methods we have just discussed. Please think of your own financial situation at 
the moment and your most recent sexual partner when you answer the questions. You still have the existing other options of collecting male condcsns for 
free or paying for them. Remember there are no right answers, we are interested in your opinions. 
Ungafisa ukuzama i diaphragm le ezoyehlisa izinga lokuthola i 
hiv ngesigamu. 
Loku kusho ukuthi kubantu besifazane abangamashumi amabili 
(20) bangaba (HIV) bengasebenzisi izindlela zokuzivikela, 
111 abayishumi(10) babo bangaba neleligciwane (HIV) mangabe No 0 Yes 1 [] O-aQ114 
besebenzisa i diaphragm ngaso sonke isikhathi uma beya 
ocansini. 
Would you be interested and able to try a Diaohrarsn that would reduce your risk 
of gelang HIV by half? This means that if 20 women would become HIV-positive if they 
used no barrier method, about 10 would be come HIV positive if all women used a 
diaphragm each time they had sex. 
I diaphragm ubona kuyindlela ofuna ukuyisebenzisa noma uhiale 
112 uyisebenzisa kulesimo okuso. No 0 Yes 1 
Is the diaphragm something you think you would want to use and be able to use 
regularly in your current situation? 
Ukube i diaphragm le okhona ukuyisebenzisa izikhathi eziningi 
(re-usable) umabeyikhona futhi ufuna ukuyithenga kuleviki, 113 ungazimisela ukuyithenga ngemalini. Rand 
If the reusable diaphragm was available and you wanted to buy it this week what 
is the highest price it could be for you to still want to buy it and still be able to buy it? 
Ungakuthokozela ukuzama i microbicid le eyehlisa amazinga 
okuthola I (HIV) ngesigamu(halt)? 
Loku kusho ukuthi kubesifazane abangu (20) bangaba (HIV) 
114 benga sebenzisanga izivikelo, abangu (10) babe (HIV) mangabe No 0 Yes 1 O--sQ117 
bonke besebenzisa im icrobicid sonke isikhathi mabeya ocansini. 
Would you be interested and able to try a Microbicide that reduces your risk of 
getting HIV by half? This means that if 20 women would become HIV-positive if they 
did not use a barrier method, about 10 would be come HIV-positive if all women used 
microbicides each time they had sex. 
Ubona ukuthi i microbicid yiyo indlela ofuna ukuyisebenzisa 
115 ngaso sonke isikhathi? No 0 Yes 1 [] 
Are microbicides something you think you would want to use and would be able to 
use regularly? 
Mangabe le microbicide oyisebenzisa kanye beyitholakala ufuna 
116 ukuyithenga kuleviki, kade uzimisele ukuthenga ngemalini? 
[] 
If this single-use microbicide was available, what is the highest price it could be for Rand 
you to still want to buy it and still be able to buy it this week? 
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Ubungathanda yini ukuzama i-condom yabesimame eyehlisa 
incupheko yokusuleleka ngesandulela ngculazi ngo 95% 
(phesenti) 
17 117 ukuthi abesifazane abangu 20 baba (H IV) No 0 Yes 1 [1 Q12Q bengasebenzisanga le ndlela, oyedwa eba (HIV) mangabe bonke 
besebenzise i condom ngaso sonke isikhathi mabeya ocansini. 
Would you be interested and able to try a Female Condom that reduces your risk 
of getting HIV by 95%? This means that if 20 women would become HIV-positive if 
they did not use a barrier method, about 1 would be come HIV-positive if all women 
used a female condom each time they had sex. 
Ngabe i condom yabesiiazane yiyo ofuna ukuyisebenzisa 
118 ngasosonke isikhathi? No 0 Yes 1 
Is the female condom something you would want to use and be able to use 
regularly? 
Mangabe ubufuna ukuyithenga kuleliviki, ubungayithenga 
11g ngamalini ongakhona ukuyithenga ngayo futhi? [] 
This week, what is the highest price a female condom could be for you to still want Rand 
to buy it and still be able to buy it? 
INTRODUCTION TO ATTRIBUTES AND LEVELS 
Sihlangene la namhlanje sifuna ukuthola indlela esingenza ngayo ukuthi lezindlela zokuvikela zitholakale 
kwabesimame. Sifuna ukwazi yini ekwenza ufune ukuzisebenzisa, yini into eyenza kube lula noma kube nzima 
ukuzisebenzisa nomuntu ozwana naye? Sizobheka ukusebenza kwazo, indlela yokuthi ukhone ukuzithola, 
120 nokwazisa abantu ngazo. Sizothanda ukuthi ucabange ngezinto ezisetshenziswayo ukuvikela i (HIV) 
nangokuhlukana kwazo. 
We are here today to understand the best way to introduce these new products to women. We want to know how you decide to use a product, which 
things make it easier or more difficult to use them with your most recent partner. We will be looking at characteristics of the product, ways to make them 
accessible to you, and ways to ad ertise and promote them. First we would like you to start thinking about these HIV prevention products and their 
differences. 
Eziphi phakathi kwalezi ocabanga ukuthi ungakhona ukuzisebenzisa kahle njalo. Ngicela ucabange 
ngokuhlela kwakho umdeni? 
121 DISPLAY IMAG 
vnnich of these products do you tluk w;. uld s,., c , x. + iaprociuc.... nealm clads bas;. I-Ioa. o Lenk &WUt which of these products 
you would be most likely to use regularly. 
Male condom Female condom Diaphragm Microbicide 
Mark answer 
in 0141 
lyiphi indlela yokuvikela ukukhulelwa oyifunayo kulezinto zokuvikela i (HIV)? 
Ezinye (POINT TO 1), Ayikho (POINT TO 2), Kakhulu kakhulu (POINT TO 3), Kakhulu (POINT TO 4), 
Umangabe sivtmbela isisu ngo 55%, abangu 9 bangakhulelwa. 
Umangabe usisetshenziswa asMmbeli isisu kwasantlobo, abesimame abangu 20 bangakhulelwa. 
122 Umangabe sMmbela isisu ngo 95%, abangu 1 bangakhulelwa. 
Umangabe slwmbela isisu no 75%, abangu 5 bangakhulelwa 
Wnat kind of pregnancy prevention do you want from your HIV prevention product? None (POINT TO 1), Some (POINT TO 2), 
gh (POINT TO 3), Very high (POINT TO 4) If the product does not prevent pregnancy at all, 20 women would get pregnant. If it 
revents pregnancy by 55% then 9 women would get pregnant. If it prevents pregnancy by 75% 5 women would get pregnant. If it 
revents pregnancy by 95%, 1 woman would get pregnant. 
55% None (0%) 95% 75% 
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Ingabe kubalulekile ukusebenzisa lezindlela zokuzMkela ngasese. Lokhu kusho ukuthi ngaphandle 
123 kokuthi umlin lani 
wakho azi? 
is it important to be able to use a product in secrecy? That means without your partner knowing? 
Yes No 
Ufuna le evikela kancane (POINT TO 1) noma le ekuvikela ku HIV, noma yezinga eliphakeme 
kakhulu (POINT TO 2), noma ngokulingene (POINT TO 3), noma yezinga eliphakeme (POINT TO 
4) ukuvikela I HIV? 
Umangabe akusetshenziswa isMkelo sesandulela ngculaza abesimame abangu 20 
bebangasuleleka. 
Umangabe bonke besimame basebenzise isivikelu sesandulela ngculaza esinciphisa incupheko 
35%, 13 wabesimame bangasuleleka abangu 7banga sinda. 
Umangabe bonke besimame basebenzise isivikelu sesandulela ngculaza esinciphisa incupheko 
124 95%, 1 wabesimame bangasuleleka abangu 19 banga sinda. 
Umangabe bonke besimame basebenzise isivikelu sesandulela ngculaza esinciphisa incupheko 
55%, 9 wabesimame bangasuleleka abangu 11 banga sinda. 
Umangabe bonke besimame basebenzise isivikelu sesandulela ngculaza esinciphisa incupheko 
75%, 5 wabesimame bangasuleleka abangu 15 banga sinda. 
Do you need a product that provides low (POINT TO 1) protection against HIV, veryhigh (POINT TO 2) protection, medium 
protection (POINT TO 3), or high protection (POINT TO4) against HI V? 
If no HIV protection is used 20 women would become infected. If all women used a product that reduced the risk of HIV infection 
by 35%. 13 women would become HIV infected and 7 would remain HIV negative If all women used a product that reduced the risk 
of HIV infection by 55%, 9 women would became HIV infected and 11 would remain HIV negative. If all women used a product that 
reduced the risk of HIV infection by 75%, 5 women would become HIV infected and 15 would remain HIV negative. It all women used 
a product that reduced the risk of HIV infection by 95%. 1 woman would become HIV infected and 19 would remain HIV negative. 
35% 95% 55% 75% 
Uzimisele ukukhipha noma ungakwanzi ukukhipha malini ngalezi ozisebenzisa kanye ngaso sonke 
isikhathi mawuya ocansini? [KHOMBA IMALI USAKHULUMA]. Kungaba 0 Rand Bengingakhona 
ukuzisebenzisa umazingakhokhelwa? bengingazisebenzisa ngaso isikhathi umangiya ocansini 
umaziza 5 Rand, 10 Rand noma 20 Rand. Unazo ezinye izindlela zokuthola ama-condom wabesilisa 
125 ungakhokhile soma kumele uwakhokhele. 
dvhat is Lr e highest amount you would be willing to pay and could afford to pay for any of these single use products to use it 
every time you have sex? [POI NT TO AMOUNTS AS YOU SAY: ] Is it 0 Rand, I would only use it if it were free? Or I would use it 
every time I had sex if it were 5 Rand, 10 Rand. or 20 Rand. You still have the existing other options of collecting male condoms for 
free or paying for them. 
0 Rand, 
I would only use them 5 Rand 10 Rand 20 Rand 
if they were free 
1-129 
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GET RESPONSE 0100: HOW LONG AGO WAS LAST SEX ACT? Days a [1 
126 IF 7 DAYS OR LESS SPEAK OF'L4ST WEEK' 
Weeks b I1 
I1 skips 
. IF BETWEEN 8 DAYS AND I MONTH AGO- SPEAKOF'LAST N7N' Months c 
" IF MORE THAN 1 MONTH AGO -. SKIP TO 0129 
washo ngaphambilini ukuthi ungakhona ukukhokha imali engadluli ku - 
_Rand 
[FROM Q125] ukusebenzisa enye yalezindlela zinkathi zonke uya 
isini. Manje masibale. ukuthi Iokho kungasho ukuthi yimalini ngeviki noma 
iyanga. Lelithebula libonisa ukuthi yimalini ongayisebenzisa ezintweni ezivimbela 
kuya ngenani oye ngalo ocansini. 
iumbula ukuthi uyekangakhi ocansini emavikinWezinyangeni ezedlule. (SEE 
Ngicela ukhombe inani lemali obungabe uyisebenzisile kwizindlela 
nbela kwizinto ezivinbela iHIV kwiviki noma inyanga edlule, uma usebenzisa 
a zokuvimbela nkathi zonke uya ocansini. 
ubuye ocansini kayishumi evikini noma enyangeni edlule, ubuzodinga ukuchitha Rand 
Uma ubuye ocansini kayisishiyagalolunye ubuzondinga ukuchitha 
e ... 
JETC. UNTIL SHE INDICATE:, THE CORRECT AMOUNT 
You just said you would be auo I, I. ry nn i. nv,: n .t ]FRuNl t 125] Hand to use One of these 
products each time you have sex L, t, I . >i ul,, t ýY. it th, It would mean per week or month. This table shows how much you would be spending on HIV prevention products depending on the number of 
times you had sex. 
Can you remember the number of times you had sex in the last WeeWMonth? [see 126] . 
Please point to the 
amount you would have spent on barrier methods for HIV prevention products in the past weeWmonth, if you use a 
barrier method each time you had sex. 
[YOU MAY NEED TO ASSIST, START WITH 10 ROUNDS AND WORK DOWN TOWARDS 1] If you had 10 
rounds of sex in the last wee dmonth, you would have needed to spend 
_ 
[50 Rand` 100 Rand' 200 Rand]; If 
you had 9 rounds, you would have needed to spend ....., 
ETC, ETC 
127 Yyo ima[i ongakhona ukuyi khokhela? No 0 Yes 1 Is that an amount you can afford? T 
Ungakwazi ukukhokha imal[ en akani kulezinto ongazisebenzisa kan e 
128 r, `. SPLA? OE 5B 
What is the highest amount you could afford for any of upese Single use [e atu.: t? 
0 Rand, 
Bengingakhona 
ukuzisebenzisa 
umazingakhokhelwa 5 Rand 10 Rand 20 Rand 
I would only use them rf 
they were free 
Ungakwazi ukukhokha imali engakanani kulezinto on a hinda uzisebenzise njalo? 
129 
What is the highest amount you would be willing and ade to pay for any of these Reusable use products? 
0 Rand, 
Bengingakhona 
ukuzisebenzisa 20 Rand 40 Rand 80 Rand 
umazingakhokhelwa 
I would only use them if 
they were free 
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Usitholile isikhathi sokuthi ucabange ngezinto ongazisebenzisa ukuziAkela mayelana nempilo yakho: 
Imibuzo elandelayo sizobuza ngezinto ezahlukene ongacabanga ukuthi ungakhona ukuzisebenzisa futhi 
ongazikhetha ukuzisebenzisa ekuAkeleni i (HIV). Okokuqala uzonikwa ukuthi ukhethe indlela kanye noku 
sebenza kwayo ekuvikeleni i (HIV). Sithanda ukuthi ubhekisise kulezindlela ezimbili ubheke ukuthi kungaba 
khona ongayi khetha noma ayikho. Kubalulekile ukuthi ucabange ngesimo okuso futhi ubheke ukuthi eyiphi 
indlela ongayisebenzisa ezobancono kuwe. Sifuna ukwazi ukuthi ukhetha kanjani cabanga ukuthi iyiphi indlela 
encono We simo okuso. Ukugcina kwakho ukuya ocansini indlela owayisebenzisa ucabanga ukuthi 130 ungashinthsa ukhethe kelezi esesikhulume ngazo. Bowuzobe ukhethe i MICROBICIDE, i condom yabisimame 
noma ungashintshi lutho? Akukho zimpendulo ezicondile noma ezingacondanga, sidinga ukwazi okungasebenza 
ngcono kwabesimame. 
Now you have had a chance to think about differences between the product benefits and prices. we will move on to the final set of questions that ask 
about whether or not you might have been able to use these different products if they were all available now. Please look at the two options and think 
back to the last time you had sex. Would you do the same thing you dd last time you had sex, or would you have used one of the two options provided? 
Please tell is which option you would have done: Option A, Option B. or Nether. Neither means 'do what you did in your last sex act (use a condom or 
not)' It is important to think about your own situation and consider which of the three options you are most likely to have used. Please remember, there 
are no right or wrong answers. we are only interested in learning what may work best for women like yourself in the future. 
Ukugcina kwakho ukuya ocansini indlela owayisebenzisa ucabanga ukuthi ungashinthsa ukhethe ku[ezi 
esesikhulume ngazo? . Bowuzobe ukhethe i microbicide, i condom yabisimame noma bewungeshintshe lutho. Lokhu kusho ukuthi bewuzosebenzisa i-condom noma bewungesebesizise lutho ukuvimbe[a isandulela 
131 n cu[aza. [BHEKA 01044 
Imagine you ri ad nad the choices below the last time you had sex, would have charged from what you actually did lest time you had sex? Would 
you have chosen Choice A (use a microbicide), Choice B( use a Female condom) or Choice C, no change from what actually happened. This means 
you would: use a condom / not use any barrier method for HIV prevention [SEE 0104] 
WARM UP QUESTION Choice A Choice B Choice C: Do what I did last time I had 
sex. 
CHOICE 
Manje ngizocela ukuba ukhethe phakathi kwezinh[obo zokuvike[a ezinezinzuzo ezahlukene futhi ezibiza 
ngokwah[ukah[ukene. Akulula ukukhtha, kodwa kubonisa izindlela ezahlukene abesifazane abangahlanyabezana 
nazo ekukhetheni izinhlobo ezintsha zokuvikela ezingaba khona. (Abanga ngenkathi ugcina ukuya ocansini ngazo 
132 zonke izinkathi kwnzaka ngicela ugitshaele iyiphi indlela obungayikhetha. Ngicela ungitshele uma ufuna 
ngikuchazele kabanzi. 
I an now going to ask you to make choices between products with different benefits and prices. They are not easy choices, but represent the range 
of choices women may face if these new products become available. Thinking about the very lasttime you had sex, in each case please tell me which 
choice you would have made. Please let me know if you need me to explain anything further to help you choose 
Nazi izinhlobo zokuvike[a, futhi zisebenza lokhu: ubungathanda ukusebenzisa enya yalezizinhlobo ngenkathi 
ugcina ukuya ocansini noma ubungenza ngend[e[a obuwnze ngayo ekuqaleni? 
Indlela yokuqala yi [PRODUCT A] (engasetshenziswa) OR (noma ongeke ukwazi ukuyisebenzisa) (SECRECY A 
YESINO] ngasese umlingani wakho engazi, yehlisa amathuba akho wokukhu[e(wa [PREGNANCY PREVENTION Al 
%, futhi yehlisa incupheko yakho yokusuleleka ngesanduleli ngculaza [HIV PREVENTION A] %, yona ibiza [PRICE A] 
randi. Noma bawungathanda ukusebenzisa indlela yesibili, (PRODUCT B] (ongayisebenzisa) OR (noma ongeke 
ukwazi ukuyisebenzisa) [SECRECY B YESJNO] ngasese umlingani wakho engazi, ukwaz[ ukuyisebenzisa ngasese 
umlingani wakho engazi, yehlisa amathuba akho woku khu[e[ewa ngamaphesenti [PREGNANCY PREVENTION B] 133 %. Futhi yehlisa incupheko yakho yokusuleleka ngesandule[i ngculaza [HIV PREVENTION B] %, yona ibiza (PRICE 
B] randi. Ubungasebenzisa enye ya[ezizindlela ngenkathi ugcina ukuya ocansini noma ubungeke usebenzise 
int[obo okuzMke[a/ ikhondomu n'en oba uye wenza ngenkathi ugcina ukuya ocans[ni? 
DISPLAY IMAGE 8 
Here are the products and this is what they do'. Would your ;., " ý. -[i .at:. "- products in your last sex actor would you have still done the 
same as you did the last time you had sex? Option A is a [PRODUCT Al hit -n [IF SECRECY A IS YES] cannot OF SECRECY A NO] be used 
without your partner knowing, it reduces your chance of getting pregnant by [PREGNANCY PREVENTION A] %, and reduces your risk of HIV by [HIV 
PREVENTION A], and will cost you [PRICE A], or would you have used Option B. This is a [PRODUCT B] that can [IF SECRECY B IS YES] cannot [IF 
SECRECY B NO] be used without your partner knowing, it reduces your chance of getting pregnant by [PREGNANCY PREVENTION B]%, and 
reduces your risk of HIV by [HIV PREVENTION B], and will cost you [PRICE B]? Would you have used either of these the last time you had sex or would 
you have used a condom! not used a barber method like you did last time you had sex? 
Choice A B C: Neither 
Attribute 
CHOICE 
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Nazi izinhlobo zokuvikela, futhi zisebenza Iokhu: ubungathanda ukusebenzisa enya yalezizinhlobo ngenkathi 
igcina ukuya ocansini noma ubungenza ngendlela obuwnze ngayo ekuqaleni? 
Indlela yokuqala yi [PRODUCT A] (engasetshenziswa) OR (noma ongeke ukwazi ukuyisebenzisa) [SECRECY A 
YES/NO] ngasese umlingani wakho engazi, yehiisa amathuba akho wokukhulelwa (PREGNANCY PREVENTION Al 
%, futhi yehlisa incupheko yakho yokusuleleka ngesanduleli ngculaza [HIV PREVENTION A] %, yona ibiza [PRICE A) 
randi. Noma bowungathanda ukusebenzisa indlela yesibili, [PRODUCT B] (ongayisebenzisa) OR (noma ongeke 
ukwazi ukuyisebenzisa) [SECRECY B YESMO] ngasese umlingani wakho engazi, ukwazi ukuyisebenzisa ngasese 
umlingani wakho engazi, yehlisa amathuba akho woku khulelewa ngamaphesenti [PREGNANCY PREVENTION B] 
134 %. Futhi yehlisa incupheko yakho yokusuleleka ngesanduleli ngculaza [HIV PREVENTION B) %, yona ibiza [PRICE 
B] randi. Ubungasebenzisa enye yalezizindlela ngenkathi ugcina ukuya ocansini noma ubungeke usebenzise 
riere are the proaucts ano mis is was may ao: wouia you nave uses eimer or these proaucts in your last sex act or wouia you nave son none the 
e as ycu dd the lest time you had sex? Option A is a [PRODUCT A] that can [IF SECRECY A IS YES] cannot OF SECRECY A NO) be used 
out your partner knowing, it reduces your chance of getting pregnant by [PREGNANCY PREVENTION Al %, and reduces your risk of HIV by [HIV 
VENTION A], and will cost you [PRICE A]. or would you have used Option B. This is a [PRODUCT B] that can [IF SECRECY B IS YES] cannot (IF 
RECY B NO] be used without your partner knowing. H reduces your chance of getting pregnant by (PREGNANCY PREVENTION B]%, and 
ices your nsk of HIV by [HIV PREVENTION B], and will cost you [PRICE B]9 Would you have used either of these the last time you had sex or would 
have used a condom I not used a barrier method like you did last time you had sex? 
C: Neither 
CHOICE 
III 
Nazi izinhiobo zokuvikela, futhi zisebenza Iokhu: ubungathanda ukusebenzisa enya yalezizinhlobo ngenkathi 
ugcina ukuya ocansini noma ubungenza ngendlela obuwnze ngayo ekuqaleni? 
Indlela yokuqala yi [PRODUCT A] (engasetshenziswa) OR (noma ongeke ukwazi ukuyisebenzisa) [SECRECY A 
YESRJO] ngasese umlingani wakho engazi, yehlisa amathuba akho wokukhulelwa [PREGNANCY PREVENTION A] 
%, iuthi yehlisa incupheko yakho yokusuleleka ngesanduleli ngculaza [HIV PREVENTION A] %, yona ibiza [PRICE A] 
randi. Noma bowungathanda ukusebenzisa indlela yesibili, [PRODUCT B] (ongayisebenzisa) OR (noma ongeke 
ukwazi ukuyisebenzisa) [SECRECY B YESINO] ngasese umlingani wakho engazi, ukwazi ukuyisebenzisa ngasese 
umlingani wakho engazi, yehlisa amathuba akho woku khulelewa ngamaphesenti [PREGNANCY PREVENTION B] 
135 %. Futhi yehlisa incupheko yakho yokusuleleka ngesanduleli ngculaza [HIV PREVENTION B] %, yona ibiza (PRICE 
B] randi. Ubungasebenzisa enye yalezizindlela ngenkathi ugcina ukuya ocansini noma ubungeke usebenzise 
Here are the products and this is whet they do' Would you heue u'. ý I thor ref these products in your last sex ad or would you have still done the 
e as you dd the last time you had sex? Option A is a [PRODUCT A] th, jt can [lF SECRECY A IS YES] cannot OF SECRECY A NO] be used 
out your partner knowing, it reduces your chance of getting pregnant by [PREGNANCY PREVENTION A] %, and reduces your risk of HIV by [HIV 
VENTION A], and will cost you [PRICE A], or would you have used Option B This is a PRODUCTS] that can [IF SECRECY B IS YES] cannot [IF 
32ECY B NO] be used without your partner knowing, it reduces your chance of getting pregnant by [PREGNANCY PREVENTION B]%, and 
ices your risk of HIV by [HIV PREVENTION 8], and will cost you [PRICE B]? Would you have used either of these the last time you had sex or would 
have used a condom I not used a barrier method like you did last time you had sex? 
C: Neither 
CHOICE 
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Nazi izinhlobo zokuvikela, futhi zisebenza lokhu: ubungathanda ukusebenzisa enya yalezizinhlobo ngenkathi 
, igcina ukuya ocansini noma ubungenza ngendlela obuwnze ngayo ekuqaleni? 
Indlela yokuqala yi [PRODUCT A] (engasetshenziswa) OR (noma ongeke ukwazi ukuyisebenzisa) [SECRECY A 
YES/NO] ngasese umlingani wakho engazi, yehlisa amathuba akho wokukhulelwa [PREGNANCY PREVENTION A] 
%, futhi yehlisa incupheko yakho yokusuleleka ngesanduleli ngoulaza [HIV PREVENTION A] %, yona ibiza [PRICE A] 
randi. Noma bowungathanda ukusebenzisa indlela yesibili, [PRODUCT B] (ongayisebenzisa) OR (noma ongeke 
ukwazi ukuyisebenzisa) [SECRECY B YESMO] ngasese umlingani wakho engazi, ukwazi ukuyisebenzisa ngasese 
umlingani wakho engazi, yehlisa amathuba akho woku khulelewa ngamaphesenti [PREGNANCY PREVENTION B] 
136 %. Futhi yehlisa incupheko yakho yokusuleleka ngesanduleli ngculaza [HIV PREVENTION B] %, yona ibiza [PRICE 
B] randi. Ubungasebenzisa enye yalezizindlela ngenkathi ugcina ukuya ocansini noma ubungeke usebenzise 
Here are the products and this is what they do WouId you have used either or these products in your last sex actor would you have still done the 
e as you did the last time you had sex? Option A is a [PRODUCT A] that can [IF SECRECY A IS YES] cannot OF SECRECY A NO] be used 
out your partner knowing, it reduces your chance of getting pregnant by [PREGNANCY PREVENTION A] %, and reduces your risk of HI V by [HIV 
VENTION A], and will cost you [PRICE A]. or would you have used Option B. This is a [PRODUCT B] that can OF SECRECY B IS YES] cannot [IF 
: RECY B NO] be used without your partner knowing, it reduces your chance of getting pregnant by [PREGNANCY PREVENTION B]%. and 
ces your risk of HIV by [HIV PREVENT ON B], and will cost you [PRICE B]? Would you have used either of these the last time you had sex or would 
have used a condom! not used a barrier method like you did last time you had sex? 
C: Neither 
CHOICE 
Nazi izinhlobo zokuvikela, futhi zisebenza lokhu: ubungathanda ukusebenzisa enya yalezizinhlobo ngenkathi 
: ina ukuya ocansini noma ubungenza ngendlela obuwnze ngayo ekuqaleni? 
Indlela yokuqala yi [PRODUCT A] (engasetshenziswa) OR (noma ongeke ukwazi ukuyisebenzisa) [SECRECY A 
YESINO] ngasese umlingani wakho engazi, yehlisa amathuba akho wokukhulelwa [PREGNANCY PREVENTION Al 
%, futhi yehlisa incupheko yakho yokusuleleka ngesanduleli ngculaza [HIV PREVENTION A] %, yona ibiza [PRICE A] 
randi. Noma bowungathanda ukusebenzisa indlela yesibili, [PRODUCT B] (ongayisebenzisa) OR (noma ongeke 
ukwazi ukuyisebenzisa) [SECRECY B YESMO] ngasese umlingani wakho engazi, ukwazi ukuyisebenzisa ngasese 
umlingani wakho engazi, yehlisa amathuba akho woku khulelewa ngamaphesenti [PREGNANCY PREVENTION B) 
137 %. Futhi yehlisa incupheko yakho yokusuleleka ngesanduleli ngculaza (HIV PREVENTION B] %, yona ibiza [PRICE 
B] randi. Ubungasebenzisa enye yalezizindlela ngenkathi ugcina ukuya ocansini noma ubungeke usebenzise 
intlobo vokuzivikela/ ikhondomu nienooba uve wenza naenkathi uacina ukuva ocansini? 
Here are the products and this is what they do. Would you have used either or these products in your last sex act or would you nave SUN done the 
e as you rid the last time you had sex? Option A is a [PRODUCT A] that can [IF SECRECY A IS YES] cannot PF SECRECY A NO] be used 
out your partner knowing, it reduces your chance of getting pregnant by [PREGNANCY PREVENTION A] %, and reduces your risk of HIV by [HIV 
VENTION A], and will cost you [PRICE A], or would you have used Option B This is a [PRODUCT B] that can [IF SECRECY B IS YES] cannot (IF 
RECY B NO] be used without your partner knowing, it reduces your chance of getting pregnant by [PREGNANCY PREVENTION B]%, and 
ices your nsk of HIV by [HIV PREVENT ON B], and will cost you [PRI CE 6]? Would you have used either of these the last time you had sex or would 
have used a condom 1 not used a border method like you did last time you had sex? 
C: Neither 
CHOICE 
IIa 
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Nazi izinhlobo zokuvikela, futhi zisebenza Iokhu: ubungathanda ukusebenzisa enya yalezizinhlobo ngenkathi 
Jgcina ukuya ocansini noma ubungenza ngendlela obuwnze ngayo ekuqaleni? 
138 
lela yokuqala yi (PRODUCT A] (engasetshenziswa) OR (noma ongeke ukwazi ukuyisebenzisa) [SECRECY A 
S/NO] ngasese umlingani wakho engazi, yehlisa amathuba akho wokukhulelwa [PREGNANCY PREVENTION A] 
futhi yehlisa incupheko yakho yokusuleleka ngesanduleli ngculaza [HIV PREVENTION A] %, yona ibiza [PRICE A] 
di. Noma bowungathanda ukusebenzisa indlela yesibili, [PRODUCT B] (ongayisebenzisa) OR (noma ongeke 
vazi ukuyisebenzisa) [SECRECY B YESJNO] ngasese umlingani wakho engazi, ukwazi ukuyisebenzisa ngasese 
lingani wakho engazi, yehlisa amathuba akho woku khulelewa ngamaphesenti [PREGNANCY PREVENTION B] 
Futhi yehlisa incupheko yakho yokusuleleka ngesanduleli ngculaza (HIV PREVENTION B] %, yona ibiza [PRICE 
randi. Ubungasebenzisa enye yalezizindlela ngenkathi ugcina ukuya ocansini noma ubungeke usebenzise 
obo vokuzMkela/ ikhondomu nienaoba uve wenza nqenkathi uqcina ukuva ocansini? 
more are the products ana this is what they do: Would you nave u-. 1 : rr m or tne, a pf )aucts in your last sex act or would you nave son Clone the 
e as you did the last time you had sex? Option A is a [PRODUCT Al Ih i ', m (IF AF(-RECY A IS YES] cannot [IF SECRECY A NO] be used 
out your partner knowing, it reduces your chance of getting pregnant by [PREGNANCY PREVENTION A) %, and reduces your risk of HIV by [HIV 
VENTION A], and will cost you [PRICE A], or would you have used Option B. This is a [PRODUCT B] that can [IF SECRECY B IS YES] cannot [IF 
RECY B NO] be used without your partner knowing, it reduces your chance of getting pregnant by [PREGNANCY PREVENTION B]%. and 
ices your risk of HIV by [HIV PREVENTION B], and will cost you [PRICE B]? Would you have used either of these the last time you had sex or would 
have used a condom/ not used a barrier method like you did last time you had sex? 
Choicel AIBIC: Neither 
CHOICE 
139 IS THIS FLIPCHART VERSION:: D, H, L, P, S, T? No 0 Yes 1[J 0-+0141 
[ONLY FOR FLIPCHART VERSIONS: D, H, L, P, S, 11 
Nazi izinhlobo zokuvikela, futhi zisebenza lokhu: ubungathanda ukusebenzisa enya yalezizinhlobo ngenkathi 
140 u Gina uku a ocansini noma ubun enza ngendlela obuwnze ngayo ekugaleni? 
Here are the products and this is what they do 
same as you did the last time you had sex? 
A 
CHOICE 
your last sex act or would you 
BIC: Neither 
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MDP R 
Male condom 1 
n141 
GET PREFERED METHOD FROM Q 121 
Female condom 2 
Diaphragm 3 
Microbicides 4 
DISTRIBUTIONAL ATTRIBUTES 
Siyabonga kakhulu, ukundlula kulendima enzima 
kulenkulumiswano ebesinayo. Sesizobheka kakhulu manje 
ngendlela yokutholakala noma kwaziwe ngalezindlela 
esesikhulume ngazo (barrier methods) ekuvikeleni I HIV. 
142 Njengoba ushilo ukuthi uyathanda ukusebenzisa indlela No 0 Yes 1 [] 1--0144 
zokuvikela i (FROM 0141) (HIV) ngabe kusasenjalo 
awukakashintshi. 
Thanks a lot for that, that was the most difficult part of this interview Nowwe 
are going to do a similar exercise butthis time it is about distribution and promotion 
of barrier methods for HIV prevention. 
You mentioned above that you think (FROM 0141) would be 
your preferred HIV prevention product, do you still feel that way? 
Male condom 1 
143 Eyiphi ocabanga noma okhetha ukuyisebenzisa? 
Female condom 2 
What do think is now the product you would prefer to use? Diaphragm 3 
Microbicides 4 
Ubungayisebenzisa yini (FROM 0143 OR 141) 
144 ngenkathi ugcina ukuya ocansini? No 0 Yes 1 (] 1-"Q146 
Would you have used (FROM 0143 OR 0141) the very last time you 
had sex? 
Uma isimo sakho besingaguquka esikhathathini esizayo futhi Male condom 1 bewufuna ukuyisebenzisa inhlobo yokuvikela isandulela Female condom 2 145 ngculaza. Yiziphi izinhiobo obowungazithanda? Diaphragm 3 ] 
If your situation were to change in the future and you did want to use a product to Microbicides 4 
prevent sexual transmission of HIV which of these methods would You prefer to use? 
WHAT IS HER PREFERRED BARRIER METHOD? Male condom 1 
146 CHECK 1ST Q145 IF EMPTY THEN CHECK 0143, IF EMPTY, THEN Female condom 2 , Diaphragm 3 CHECK Q141 Microbicides 4 
Bewungathanda ukuthola FROM 146] endaweni eyodwa 
147 lapho ebewungathola khona ezinya izindlala zokuvikela 
a. isandulela ngculaza? 
No 0 Yes 1 a. [] 
Would you prefer to get [From 146] in the same place as you would get any 
of the other HIV prevention products? 
anje sizokhuluma ngendlela yokuvikela esetshenziswa kanye (KUSUKEL 
FROM 0146) kulemibuzo elandelayo. 
Kukuphi la ucabanga ukuthi ungayithola khona ? Esphaza, emtholampilo estolo noma 
148 ekhemisi? 
Now please consider a single use (FROM 0146) throughout the coming questions. 
Where would you prefer to get your single use ? In a Spaza shop, a Clinic, a Supermarket, or in a 
hemist,? 
Spaza shop Clinic Supermarket Chemist 
Uthanda ukuyithola kanjani ? eshelufini, emuntwini othengisayo esitolo, 
enkumbeni efihiakele noma emshinini wem all noma ebhokisini? 
149 
Howwould you like to collect your single use ? From a shelf, from a person behind a counter, in a private 
room or from a dispensing machine or box? 
ZULU-20 Othor 96 
Survey 18-10-2005 Don't know/ Don't remember 98 
Refuse to answer 99 
336 
APPENDICES 
0 
Determinants of women's demand for barrier methods for HIV prevention ' RHRU 
From a shelf 
From a person behind a 
counter 
In a private room 
From a dispensing 
machine or box 
muphi umlayezo ongcono ongcono ongabhalwa kwisisetshenziswa kanye kskho 
okwnza? Bekungaba yilo: Ukuthuthukiswa kwabesimame, Uvikeleko Iwesisu, Injabulo edlulele 
150 oma Uvikeleko Iwesand ulela nculaza? q ryý _ 
Wha[ would best message on the package of your single use to make it most attractive for you and your partner 
o use? Would it be women's empowerment, pregnancy prevention, extra pleasure, HIV prevention? 
Women's Pregnancy Extra HIV 
empowerment prevention pleasure prevention 
Manje sizokwenza esinye isfundo esifana nesakugala esinezindlela ezahluldle zokukhipha 
151 izivikelo zesandulela ngculazi. Kukuphi noma kukanjani lapho ungakwazi ukuthola isivikelo sakho 
se-H IV? Now we are gang to do another exercise like the previous one with cifferent ways to distribute barrier methods for HIV 
prevention Your choices in these questions are: where and how you would like to obtain your HIV prevention products. 
lyiphi yalezizindlela ongathanda ukulanda isiAkelo esisetshenziswa kanye 
Kulendlela ka-A ungathanda ukulanda [SOURCE A] kusukela [COLLECTION METHOD A] ephaketheni 
elibhalwe [MESSAGE A] lizobiza [PRICE A]. Kulendleza ka-B ungathanda ukulanda [SOURCE B] 152 kuaiikaI rrni I CCTIf1AI AACTIJfl11 ßl o., V, ýL of F. oýý oIIV, hýl.., o fRACCA! _C Ot Iis, ki- foourc of 
ottneseways would you prefer to wCt" I , iii u,, r, rIn Option Ayou vould collectyour_in a 
A] from [COLLECTION METHOD A] in packaged for [MESSAGE Al and it would cost JI R: LE IN RAND]_ Rand 
lyiphi yalezizindlela ongathanda ukulanda isMkelo esisetshenziswa kanye 
Kulendlela ka-A ungathanda ukulanda [SOURCE A] kusukela [COLLECTION METHOD Al ephaketheni 
elibhalwe [MESSAGE A] Iizobiza [PRICE A]. Kulendleza ka-B ungathanda ukulanda [SOURCE B] 
kusukela COLLECTION METHOD Be haketheni elibhalwe (MESSAGES) Ilzoblza [PRICE B1. . 163 U GE 19 4f ich of these ways would you prefer to collect your single use upuon A you would collect your 
_ 
me 
[SOURCE A] from [COLLECTION METHOD A] packaged for [MESSAGE Al and it would cost 
-]PRICE 
B)_ Rand In option B 
you would collect your 
_ 
in a [SOURCE B] from [COLLECTION METHOD B] packaged for [MESSAGE B] and itwould cost 
-[PRICE 
B]_Rand 
lyiphi yalezizindlela ongathanda ukulanda isi ike[o esisetshenziswa kanye ? 
Kulendlela ka-A ungathanda ukulanda [SOURCE A] kusukela [COLLECTION METHOD A] ephaketheni 
elibhalwe [MESSAGE A] lizobiza (PRICE A]. Ku[endleza ka-B ungathanda ukulanda [SOURCE BI 
kusukela [COLLECTION METHOD BI e hakethenielibha[we (MESSAGE B lizobiza [PRICE 154 
IýXs lob "- 6xiv Which of these ways would you prefer to collect your single use l In Option A you would collect your 
_ 
in a 
(SOURCE A] from [COLLECTION METHOD A] packaged for [MESSAGE A] and it would cost 
-[PRICE 
BI Rand In Option 8 
you would collect your 
_ 
in a [SOURCE B] from [COLLECTION METHOD B] packaged for [MESSAGE B] and it would cost 
-[PRICE 
B]_ Rand 
version r) j- 
P, S, T 
-Q157 
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lyiphi yalezizindlela ongathanda ukulanda isivikelo esisetshenziswa kanye ? 
Kulendlela ka-A ungathanda ukulanda [SOURCE A] kusukela [COLLECTION METHOD A] ephaketheni 
elibhaiwe [MESSAGE A] lizobiza [PRICE A]. Kulendleza ka-B ungathanda ukulanda [SOURCE B] 
155 
.. nicn orinesewayswoula you prerer to -uect y, dr siri io use , ire upuon Ayou wouia collect your _in 
a 
[SOURCE A] from [COLLECTION METHOD A] packaged for [MESSAGE A] and it would cost 
-[PRICE 
BL_ Rand In Option B 
you would collect your 
_ 
in a [SOURCE B] from [COLLEC"I ION METHOD B] packaged for [MESSAGE B] and it would cost 
_[PRICE 
B]_ Rand 
157 RECORD SET NUMBER FROM BOTTOM RIGHT OF FLIP CHART (] 
158 Siyabonga ka khulu, Iesi bekusigaba sokugcina sezithombe. Thank you very much that was the last of these scenarios 
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SECTION 4: EVALUATION QUESTIONS 
Sesifike ekugcineni ngemibuzo nemibono ebesifuna ukuzazi. Ngaphambi kokuba ngihambe ngizothanda 
ukukubuza imibuzo emincane mayelana nezinto ebesikubuza zona. Lokhu akuphathelene nalokhu 
ebesikukhuluma kodwa ukusisisza ukuthi sibuze kanjani imibuzo ngokuzayo. 
We have now come to the end of our survey questions. but before I leave I would like to ask you just a few questions about your experience with 
this questionnaire, this is no longer part of the survey but to help us improve howwe ask these types of questions in the future 
159 Lenkulumiswano besinayo beyinjani kuwe? How did you find this interview generally? 
a[ 
160 Eyiphi imibuzo ebeyinzima? b[ 1 Which questions did you find difficult? Cl ] 
d1 
161 Beyikhona imibuzo engakuphathanga kahle? No 0 Yes 1 [] -. Q163 Were there any questions that made you feel uncomfortable? 
1 62 Eyiphi leyo mibuzo? b[ ] Which ones were they? C1 ] 
d1 
Indlela imibuzo ebuzwe ngakhona? Beyilula, ixaka noma Easy 1 
163 inzima? Confusing 2 [1 
What did you think of the scenarios we presented? Were they Easy, Difficult 3 
Confusing, Difficult? 
164 Beyinjani lemibuzo kuwe? 
1 Interes nng 
2 Boring [] Were they Interesting or boring? Neither 3 
165 Beyjminingi noma imincane? 
ma 1 TToo 
few 2 [] Were there too many or too few? Neither 3 
166 a. Ingabe siyazi yini ukuthi i microbicide iyavimbela i HIV? No 0 Yes 1 [] --'b Do we know if microbicides prevent HIV? . 
al. Microbicides are currently being tested. Right now we do 
not know if they will prevent H IV. 
b. Ingabe siyazi yini ukuthi i diapragm iyavimbela i HIV? No 0 Yes 1 [] -167 Do we know if the diaphragm prevents HIV? 
b1. The diaphragm is currently being tested. Right now we do 
not know if it will prevent H IV. 
167 a. Unemibuzo ngalengxoxo ebesikhuluma ngayo? No 0 Yes I [] -+ 168 Do you have any questions about this questionnaire? 
b. Emiphi imibuzo onayo? [] What questions do you have? 
Siyabonga isikhathi sakho sokukhulumisana nathi. Besibuza imibuzo ngezindlela ezintsha zokuvikela I (HIV). 
Sithanda ukukukhumbuza ukuthi ama condom obaba no mama enza umsebenzi omkhulu ekuvikeleni i (HIV). 
Njengoba besishilo masiqala konke okushilo kuyaba yimfihlo, yithi kuphela esizokwazi ngezimpendulo osinike 
168 zona. Mangabe uneminye imibuzo ofisa ukuyibuza ungasabi ukuthinta I Reserch Project. 
Thenkyou very much for your participation. We have been asking you questions about some new methods for HIV prevention, however we 
would like to remind you that only male and female condoms have shown any effectiveness against HIV transmission. As mentioned earlier all of 
your responses will be kept confidential, only the research team will have access to the answers. If you have any further questions, please feel free 
to contact the research project. 
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Interviewer feedback questions 
- 
mDp R 
THESE ARE TO BE COMPLETED DIRECTLY FOLLOWING THE INTERVIEWS BY THE INTERVIEWER 
169 INTERVIEW END TIME Hour [] Min. 
170 WAS THE INTERVIEW INTERRUPTED AT ALL? No 0 Yes 1 0-+Q172 
171 EXPLAIN ANY INTERRUPTIONS 
172 WERE THERE ANY OTHER PEOPLE AROUND DURING THE INTERVIEW? No 0 Yes 1 [] 
0-4174 
173 SPECIFY WHO 
174 RE THERE ANY QUESTIONS THAT THE RESPONDENT HAD PROBLEMS ANSWERING? 
No 0 Yes 1 [] 0-+0176 
175 EXPLAIN 
176 WERE THERE ANY QUESTIONS THAT THE RESPONDENT No 0 Yes 1 0--. 0178 
SEEMED TO BE HOLDING BACK INFORMATION ON? 
177 EXPLAIN 
178 DID THE RESPONDENT APPEAR TO BE THINKING ABOUT No 0 Yes I [] EACH DISCRETE CHOICE SCENARIOS? 
179 DID THE RESPONDENT SEEM TO SWATCH TO MAKE YOU No 0 Yes 1 [] HAPPY? 
180 WERE THERE ANY POSITIVE EVENTS DURING THE No 0 Yes 1 [] 0-ºQ182 INTERVIEW (EXPLAIN)? 
181 EXPLAIN 
182 a. WERE THERE ANY NEGATIVE EVENTS DURING TH No 0 Yes 1 [] INTERVIEW (EXPLAIN)? 
b. EXPLAIN 
183 ANY OTHER COMMENTS. No 0 Yes 1 [] 0-. END 
184 COMMENTS 
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Appendix 6.2 Information sheet and informed consent form survey 
Hello, my name is ..... Ia working on a project for the Reproductive Health and HIV Research Unit and 
the London School of Hygiene and Tropical Medicine. I would like to invite you to participate in a 
research study on women from Ekurhuleni. 
Why are we conducting this study? 
Many women in South Africa are infected with HIV every day. In many cases it is because women find it 
difficult to persuade their partners to use condoms during sex. At the moment, the condom is the only 
reliable method of preventing HIV. Researchers are now trying to develop new methods of preventing 
HIV, called microbicides and the diaphragm, which can be used and controlled by women. 
What is this study about? 
This study aims to understand the reason that women use or do not use male or female condoms and the 
reasons they may decide to the use these newer methods, if they are found to be effective. We are 
interested in what you think about these new methods, where you would be interested in obtaining them, 
and how you thing they should be advertised. This study will provide us with important information 
necessary to facilitate access to barrier methods which women can use to protect themselves from HIV. 
REMEMBER: WE ARE NOT PROVIDING ANY PRODUCTS FOR THIS STUDY 
Who can take part? 
You can take part if you: 
  Are willing to answer survey questions 
  Are between the age of 18 and 45 
  Have had sexual intercourse at least once in the past 6 months 
What do you have to do if you agree to take part? 
Respond to survey questions. 
You have been asked to respond to survey questions. The survey will take approximately 30 minutes of 
your time. 
All questionnaires will be kept in a locked cabinet. No one except program staff will be able to view the 
material. After the research has been completed all completed questionnaires will be destroyed. 
This information will be used by us to gain more insights into how to make it as easy as possible for 
women to gain access to HIV prevention. 
Will the study benefit you? 
There is no immediate benefit to you by participating in this part of the study. However, you will be given 
a phone card worth R20.00 as token of thanks for your participation. 
What are the risks? 
The interview may ask some personal questions, but because these interviews are confidential there are 
no risks to you in giving this information. 
Will the information from this survey be confidential? 
Yes, all results of the survey will be confidential. You will not be identified by name on any 
documentation. No one will have access to the questionnaires other than the researchers and all 
questionnaires will be destroyed at the end of the study. 
What hauiDens if you change your mind about taking Dart? 
You can withdraw from the interview at any time without giving a reason. You can also choose not to 
answer any of the questions that you do not want to answer. Withdrawal from the interview or not 
answering specific questions will not negatively affect you. 
What haooens if I have any Droblems during the interview? 
If you have a problem resulting from your participation in this interview, assistance is available from: 
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Fern Terris-Prestholt Dr Catherine McPhail 
Visiting Research Fellow Director: Adolescent Health 
Reproductive Health and HIV Research Unit Reproductive Health and HIV Research Unit 
11th Floor Nurses Home 11th Floor Nurses Home 
CH Baragwanath Hospital CH Baragwanath Hospital 
Soweto Soweto 
Tel: 011 933 1228 Tel: 011 933 1228 
Cell: 072 9350393 (24 hours accessible) Cell: 083 441 5415 (24 hours accessible) 
Fax: 011 933 1227 Fax: 011 933 1227 
Prof Helen Rees Dr Lilani Kumaranayake 
Principal Investigator Principal Investigator 
Reproductive Health and HIV Research Unit Health policy unit 
11th Floor Nurses Home London School of Hygiene and Tropical 
CH Baragwanath Hospital Medicine 
Soweto Keppel Street 
Tel: 011 933 1228 WC IE 7HT 
Cell: 083 572 2057 (24 hours accessible) Tel: 001-902 431-3686 (24 hours accessible) 
Fax: 011 933 1227 Fax: 001-902 431-3689 
You may also discuss any concerns you might have regarding your participation with any of the nurses, 
counsellors or community health workers involved in the study. 
This study is conducted in accordance with the Department of Health Guidelines for the Good Practice 
in the Conduct of Clinical Trials in Human Participants in South (2000), and has received ethical 
approval from the University of the Witwatersrand, Human Research Ethics Committee: (Medical). If 
you have complaints about how you were treated or feel that the study has caused you harm please 
contact: 
Prof Peter Cleaton-Jones 
Chairperson for the Committee for Research on 
Human Subjects 
University of the Witwatersrand, Human Research 
Ethics Committee: (Medical) 
Tel: 011 717 2229 
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STATEMENT OF INFORMED CONSENT 
The participant must complete the following questions herself/with a staff member who did not 
administer the consent 
Have you had an opportunity to read the consent form/have it read to you? YES NO 
Have you had an opportunity to ask questions and discuss this study? YES NO 
Have you received satisfactory answers to all of your questions? YES NO 
Have you received enough information about the study? YES NO 
Do you understand the benefits of the study? YES NO 
Do you understand the risks of the study? YES NO 
Which study staff member have you spoken to about the study? 
PLEASE PRINT HIS/HER NAME: 
Do you understand that you are free to not answer any of the questions at any 
time without having to give a reason for not wanting to answer the question? 
YES NO 
Do you understand that you are free to withdraw from the interview at any time 
without having to give a reason for withdrawing? 
YES NO 
Do you agree to take part in this study? YES NO 
If the participant answers NO to any of the above questions then she may not be enrolled in the study. 
Printed name of Investigator Date 
Signature of participant Time 
Do you agree to the interview being tape recorded? YES NO 
Printed name of Investigator Date 
Signature of participant Time 
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Table A7-1 a. Physical attributes design 
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Table A7-2 b. Distribution attributes design 
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12 235 2 3 1 3 4 1 3 1 
12 236 4 1 4 2 4 2 2 1 
13 237 3 3 3 0 4 3 2 2 
13 238 1 3 4 1 3 1 2 3 
13 239 3 1 2 1 2 3 1 1 
14 240 2 1 3 3 3 4 2 0 
14 241 4 2 2 0 1 1 2 2 
14 242 4 4 3 1 3 1 1 1 
15 243 1 2 3 2 4 2 1 3 
15 244 4 3 1 3 2 2 1 2 
15 245 2 2 2 0 3 2 4 1 
16 246 4 3 2 2 3 3 3 0 
16 247 1 3 2 3 2 2 2 0 
16 248 2 3 2 2 1 2 1 3 
17 249 3 1 1 0 3 2 3 3 
17 250 3 4 1 2 1 1 2 1 
17 251 2 4 3 1 1 2 3 2 
18 252 2 2 1 1 2 3 2 3 
18 253 3 4 2 3 4 1 4 3 
18 254 4 4 4 0 2 4 3 3 
19 255 4 1 3 3 1 3 4 3 
19 256 3 2 3 2 2 1 3 0 
19 257 2 4 4 0 4 3 1 0 
20 258 3 2 4 3 3 4 1 2 
20 259 1 1 1 2 3 3 4 2 
20 260 3 3 4 1 1 2 4 0 
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Appendix 8. Evaluation survey tool 
1. Cluster: 
2. Household number: 
3. Interviewed by: 
q. Date: 
5. Start Time: 
6. 
You have been interviewed about new barrier methods for HIV prevention. Some of the questions 
were pictures, like these. Some women have found them quite difficult. We would like to have a 
short 10-minute discussion about these pictures. The questions I will be asking will not be intimate 
like the previous questions. 
7. Do you agree to participate in this short evaluation? No 0 Yes I [] 
7a Do you agree to this discussion being recorded? No 0 Yes 1 [] 
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8. 
What does this picture represent? [SECRECY YES] 
9. 
What does this picture represent? [SECRECY NO] 
If wrong: did the interviewer mention anything about being able to use the 
product without your partner's knowledge? No 0 Yes 1 [] 
10. What does this represent? [Pregnancy] 
14 a. Which provides stronger protection against pregnancy? 
11 What does this represent? [HIV] 
14 a. Which provides stronger protection against HIV? 
15. 
Now you were given 3 options. What does column C mean? 
16. Did you keep your last sex act in mind when answering these questions? No 0 Yes 1[] 
17. 
Now lets pretend that you are interviewing me. Can you explain to me, what 
I am supposed to do with these pictures? 
18. 
Thanks a lot, now we will move the next set of images. What are these 
questions about? 
-Where and how I would like to collect my HIV prevention product 
19 What are these [Source]? 
20. What are these [Collection method] 
21. What does this mean [package message HIV] 
22. What does this mean [package message women's empowerment] 
23. What does this mean [package message more pleasure]? 
24 What does this mean [package message pregnancy prevention]? 
25. 
Thank you very much for assisting us by answering these questions. 
Do you have any comments about your interview that you would like 
to share with us? 
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Appendix 9. On the concept of SES and poverty 
SES is frequently used in sociological research, for example on social mobility and social 
stratification. There are numerous names for and definitions of socio-economic status (see Box 
A9-1). In general the concept should incorporate `access to resources' and `relative position in 
the society'. This second part is important, as it defines SES as a relative concept. Within a 
community or society, there will be a range of SES'. Given this, measurement of SES is 
concerned with intra-site variation, rather than with measuring inter-site variation. 
Box A9-1 Socio-economic status: terms and definitions 
Terms for SES 
Social class, social status, social stratification, social inequality, socio-economic status and socio- 
economic position. 
Definitions of SES 
Oakes and Rossi (2003): Differential access (realized and potential) to desired resources. 
SES= f(Materiai capital, human capital, social capital) 
Wohlfarth (1997): Amount of socially valued 'good' possessed by a person. 
Hauser and Warren (1997): Characterisation of the placement of persons, families, or neighbourhoods 
with respect to the capacity to consume valued goods. 
Krieger, et al (1997): Relative position in socially ranked hierarchies and chiefly concern status in 
relation to access to and consumption of goods, services, and knowledge. 
Nock and Rossi (1979): The dimension of stratification which translates the objective distribution of 
societal resources into meaningful perceptions of relative desirability. 
Lynch and Kaplan (2000): Socio-economic position the social and economic factors that influence what 
position(s) individuals and groups hold within the structure of society. 
In this thesis the framework defined by Oakes and Rossi (2003) will be applied 14761. They 
reviewed literature in search of conceptual clarity and a theoretical basis for SES. In doing so 
they reviewed SES indicators used through time, but limited to developed countries. 
"For the most part, then, SES measurement today relies almost entirely on data from 
occupational position, education and/or income..... But whereas the task of traditional 
stratification research is to describe the structure of social stratification and to specify 
the processes by which it is generated and maintained, public health research aims to 
investigate how levels of inequality and variation in social context affect health 
outcomes. SES measure in public health may thus need to capture more of the social 
[476 context than indexes of income, education or occupation position can offer. " 
3S1 
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After criticising existing measures, they propose a framework for a new composite measure 
consisting of three types of capital: material capital, human capital and social capital. (see 
upper part of Figure A9-1). 
Socio-economic status 
Access to resources 
Social capital Material capital 
" Financial wealth 
" Expenditures 
" Income 
" Asset ownership 
" Housing material 
" Household amenities 
(electricity, toilet, etc) 
" Participatory wealth ranking 
" Occupational rankings 
" Crowding (People per room) 
Human capital 
" Productive ability 
" Educational attainment 
" Occupational rankings 
" Health status 
" Innate abilities 
" Social networks 
" Norms of trust 
" Norms of reciprocity 
" Household mobility 
(years in location) 
" Voluntary group 
membership 
" Spouse present 
"- Income inequality 
Figure A9-1 Conceptual framework for this socio-economic status index 
Material capital refers to financial well-being, such as income and expenditure (flow variables) 
and assets, household amenities (such as flush toilet, electricity, etc), (stock variables), and 
more. Human capital can be defined as: the knowledge, skills, and experience of people that 
make them economically productive. Human capital can be increased by investing in education, 
health care, and job training [471. Social capital is very difficult to measure and has not 
frequently been included as a measurable component of SES. It incorporates social networks, 
norms of trust, and norms of reciprocity [478,4791. Studies of social capital have tended to stand on 
their own. Surveys to measure social capital tend to be rather intensive and subjective. One of 
the indicators used is duration of residence in a certain location/area. In this survey the question 
"If a person became ill in your home and R100 was needed to pay for treatment or medicines, 
how easy would it be for you to find the money: very easy, easy, quite difficult or very 
difficult? " was included with the aim of capturing social capital. 
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3.1.1.1 Poverty 
Although we are focusing on SES, it might be good to understand the concept of 'poverty'. The 
World Bank (2000) defined poverty as the deprivations of well-being. Well being is measured 
by an individual's possession of income, health, education, assets, housing, societal rights 14801 
Poverty also includes the lack of opportunity, powerlessness and vulnerability [4811. Another 
definition of poverty is: the inadequate command over economic resources [4821. 
Poverty measures describe poverty on two dimensions: absolute and relative poverty. Absolute 
poverty estimates the dollar value of an individuals' income or expenditures. Relative poverty 
describes poverty relative to other members of the society. Poverty lines can be defined as an 
absolute or relative value. An example of absolute poverty line would be the $1 per day, 
whereas income less than 50% of average income is a relative poverty line definition. 
Estimation of household poverty levels in developing countries has received a lot of attention. 
The most common way of measuring poverty is through household surveys using income, 
expenditures or assets as indicators of poverty, however this is often considered a measure of 
socio-economic status [451j More qualitative methods for poverty measurement are through 
[aas] participatory wealth ranking methods 
Although the World Bank definition is broader than economic wellbeing, generally poverty is 
considered as the lack of command over economic resources. Socio-economic status is a 
broader concept encompassing both access to financial wealth and other `desirable' resources. 
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Appendix 10. Determinants of WTP intermediate results 
Table A10-1 Specification of the WTP intervals in the interval regression 
Lower limit Upper limit N= % responses 
Payment scale responses 
Single use 0 Unknown 4 507 50% 
5 5 9 269 26% 
10 10 19 149 15% 
20 20 Unknown 92 9% 
Reusable 0 Unknown 19 270 27% 
20 20 39 442 43% 
40 40 79 173 17% 
80 80 Unknown 132 13% 
Open ended WTP response intervals 
Diaphragm Unknown and 0 0 73 12% 
1 4 21 3% 
5 9 53 9% 
10 19 91 15% 
20 29 132 22% 
30 49 55 9% 
50 99 119 20% 
100 450 65 11% 
Microbicide Unknown and 0 0 141 19% 
1 4 53 7% 
5 9 140 19% 
10 14 126 17% 
15 19 40 5% 
20 29 115 15% 
30 49 59 8% 
50 300 74 10% 
Female condom Unknown and 0 0 119 23% 
1 4 54 10% 
5 9 128 25% 
10 19 132 26% 
20 39 52 10% 
40 250 30 6% 
For the open-ended WTP questions, it was not dear where to limit the intervals as it is a continuous variable. It 
was assumed that the intervals were up to the next round increment. For the lower limit on 0, it is expected that 
the lower limit is 0, but in the same light as the Tobit model is explored, we explore the same concept (i. e. that 
0 might represent a whole range of negative values as well as 0) by estimating the interval models with the 
lower limit of the first interval both as unknown and as 0. 
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Table A 10-2 Determinants of WTP-Full regressions 
OLS 
Values 
seshh2 
age 
EducYrs 
employd 
YrsinLoc 
FCEvUs 
DontWantPreg 
MCEvrUse 
PaidMCS 
In6atMCS 
DiffMC 
MCLastS 
SexDeb 
Cohab 
RiskHigh 
RiskMed 
RiskNo 
Diaphragm Microbicide Female condom Single use 
Coef. P>Itl Coef. P>ItI Coef. P>ItI Coef. P>Itl 
7.588 <0.01 4.227 <0.01 1.785 0.01 0.482 0.04 
-0.547 0.05 -0.476 <0.01 -0.250 0.04 -0.078 0.01 
0.560 0.33 0.194 0.53 0.198 0.35 0.190 0.01 
8.202 0.07 7.386 0.01 4.151 0.02 0.226 0.61 
0.069 0.69 0.088 0.38 0.030 0.66 -0.033 0.06 
-13.853 0.06 -5.230 0.14 -1.688 0.52 0.534 0.58 
-0.660 0.86 -0.953 0.62 -2.196 0.19 -0.807 0.04 
-4.503 0.39 4.720 0.07 0.459 0.86 -0.686 
5.715 0.42 -0.932 0.84 -4.446 0.14 0.078 
4.023 0.43 3.951 0.20 0.451 0.83 1.023 
-1.162 0.77 -0.070 0.98 -1.749 0.32 -0.588 
-1.403 0.74 -0.322 0.91 -0.924 0.75 -0.196 
0.729 0.40 -0.822 0.13 -0.575 0.24 -0.093 
6.786 0.07 
3.064 0.50 
1.834 0.67 
10.911 0.07 
cons 25.649 0.16 
n= 599 
r"2 0.071 
RESET p-value 0.308 
4.651 0.06 -1.883 0.35 0.483 
1.315 0.55 4.515 0.03 0.093 
0.116 0.96 2.654 0.09 0.174 
5.221 0.10 4.945 0.05 0.231 
33.794 <0.01 25.014 0.05 7.641 
731 504 994 
0.089 0.056 0.048 
<0.01 <0.001 0.080 
0.20 
0.92 
0.04 
0.16 
0.71 
0.27 
0.29 
0.87 
0.74 
0.67 
<0.01 
Reusable 
Coef. P>ItI 
4.029 <0.01 
-0.480 <0.01 
0.454 0.09 
1.120 0.55 
0.120 0.11 
0.053 0.99 
-3.776 0.02 
-3.954 0.07 
-0.189 0.95 
4.920 0.02 
-1.085 0.52 
2.687 0.18 
0.152 0.65 
-0.766 0.66 
3.664 0.10 
1.727 0.40 
2.850 0.18 
32.980 <0.01 
994 
0.080 
0.075 
OLS Diaphragm Microbicide Female condom Single use Reusable 
Logarithms Coef. P>t Coef. P>t Coef. P>t Coef. P>t Coef. P>t 
seshh 0.189 <0.01 0.231 <0.01 0.158 <0.01 0.055 0.05 0.117 <0.01 
age -0.018 0.01 -0.020 0.01 -0.012 0.08 -0.012 <0.01 -0.010 <0.01 
EducYrs -0.015 0.36 -0.007 0.65 0.010 0.55 0.017 0.07 0.001 0.92 
employd 0.152 0.17 0.200 0.04 0.186 0.11 0.104 0.07 0.026 0.58 
YrsinLoc -0.001 0.85 0.009 0.04 0.009 0.03 0.001 0.82 0.003 0.08 
FCEvUs -0.386 0.14 0.100 0.60 0.033 0.87 -0.169 0.15 0.054 0.66 
DontWantPreg 0.141 0.14 0.027 0.75 -0.062 0.55 0.048 0.33 -0.027 0.50 
MCEvrUse -0.088 0.52 0.216 0.08 0.005 0.97 -0.054 0.43 -0.098 0.08 
PaidMCS 0.343 0.03 -0.126 0.48 -0.353 0.06 -0.052 0.54 0.022 0.76 
In6atMCS 0.069 0.59 0.087 0.45 0.040 0.74 0.026 0.66 0.086 0.09 
DiffMC -0.089 0.39 -0.154 0.10 -0.065 0.52 0.037 0.48 -0.009 0.83 
MCLastS -0.079 0.53 -0.085 0.45 0.006 0.96 0.028 0.66 0.073 0.14 
SexDeb 0.026 0.20 -0.025 0.18 -0.010 0.62 -0.003 0.82 0.005 0.60 
Cohab 0.153 0.16 0.179 0.08 0.019 0.87 0.125 0.03 0.021 0.65 
RiskHigh -0.016 0.91 -0.020 0.87 0.158 0.28 0.011 0.88 0.119 0.04 
RiskMed 0.046 0.73 -0.059 0.61 0.147 0.23 -0.014 0.82 0.040 0.44 
RiskNo 0.128 0.31 0.132 0.27 0.368 0.01 0.114 0.09 0.133 0.02 
cons 3.247 <0.01 3.252 <0.01 2.294 <0.01 2.161 <0.01 3.491 <0.01 
n= 529 595 390 498 732 
M2 0.070 0.102 0.087 0.0755 0.081 
RESET p-value 0.58 0.45 0.66 0.3876 0.1137 
2 Variable names can be found at the end of the table. 
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Diaphragm Microbicide Female condom Single use Reusable 
TOBIT Coef. P>Itl Coef. P>Itl Coef. P>Itl Coef. P>Itl Coef. P>Iti 
seshh 8.697 <0.01 5.112 <0.01 1.853 0.12 0.766 0.08 4.680 <0.01 
age -0.695 0.03 -0.520 0.01 -0.409 0.01 -0.106 0.07 -0.599 <0.01 EducYrs 0.946 0.20 0.484 0.26 0.428 0.24 0.350 0.01 0.770 0.04 
employd 8.356 0.08 8.341 <0.01 4.682 0.04 0.115 0.89 1.312 0.58 
YrsinLoc 0.057 0.78 0.052 0.67 0.064 0.46 -0.072 0.03 0.138 0.14 FCEvUs -16.692 0.18 -6.751 0.38 -0.716 0.90 2.374 0.26 -1.300 0.83 DontWantPreg -2.249 0.59 -2.355 0.32 -3.007 0.14 -2.164 <0.01 -5.613 0.01 MCEvrUse -4.752 0.42 5.060 0.13 0.857 0.76 -1.145 0.27 -4.470 0.12 PaidMCS 6.589 0.40 -2.031 0.63 -5.540 0.14 0.266 0.84 -0.412 0.91 IntiatMCS 4.310 0.42 4.637 0.13 0.525 0.83 2.067 0.03 6.258 0.02 
DiffMC -0.516 0.91 0.630 0.81 -1.675 0.45 -1.474 0.07 -1.560 0.48 MCLastS -1.792 0.74 1.279 0.68 -0.308 0.90 -0.383 0.68 3.020 0.25 
SexDeb 0.826 0.36 -0.918 0.09 -0.779 0.07 -0.208 0.21 0.121 0.79 
Cohab 7.249 0.12 4.676 0.09 -1.581 0.48 0.434 0.60 -1.664 0.47 RiskHigh 4.469 0.45 1.987 0.56 5.340 0.07 0.164 0.88 3.870 0.19 
RiskMed 2.307 0.68 -0.981 0.76 3.490 0.21 0.551 0.58 2.383 0.39 
RiskNo 13.189 0.02 5.398 0.10 4.663 0.10 0.015 0.99 2.205 0.43 
_cons 
20.797 0.30 29.896 0.01 26.832 <0.01 6.458 0.07 30.315 <0.01 
n= 599 731 504 994 994 
Pseudo rA2 0.009 0.012 0.009 0.011 0.011 
Sigma 48.23 30.42 21.05 10.20 30.40 
With 0 as [0,0] 
Interval Diaphragm Microbicide Female condom Single use Reusable 
regression Coef. P>IzI z Coef. P>Izl Coef. P>Iz) Coef. P>Izl Coef. P>Izl 
seshh 6.898 <0.01 3.600 <0.01 1.290 0.02 0.551 0.03 4.612 <0.01 
age -0.645 0.01 -0.262 0.02 -0.214 0.01 -0.085 0.01 -0.518 <0.01 EducYrs 0.193 0.82 0.048 0.44 0.249 0.15 0.206 0.01 0.489 0.09 
employd 6.901 0.03 3.231 0.03 2.579 0.05 0.333 0.49 1.214 0.56 
Yrsinloc 0.052 0.71 0.026 0.97 0.065 0.17 -0.036 0.06 0.144 0.08 FCEvUs -12.076 0.91 -0.397 0.79 0.400 0.87 0.653 0.56 0.468 0.93 
DontWantPreg 2.710 0.24 -1.529 0.13 -1.093 0.33 -0.869 0.04 -4.022 0.02 MCEvrUse 0.848 0.13 2.680 0.19 -0.913 0.55 -0.713 0.22 -4.153 0.08 PaidMCS 8.931 0.53 -1.593 0.45 -4.105 0.04 0.010 0.99 0.221 0.95 
IntiatMCS 0.722 0.23 2.140 0.22 0.742 0.57 1.116 0.04 5.252 0.02 
DiffMC 0.586 0.75 -0.435 0.98 -0.667 0.54 -0.582 0.20 -1.073 0.56 MCLastS -5.029 0.83 0.377 0.55 1.330 0.37 -0.177 0.76 2.914 0.19 SexDeb 1.201 0.43 -0.211 0.44 -0.166 0.47 -0.101 0.26 0.137 0.71 Cohab 5.388 0.26 1.726 0.37 -0.101 0.93 0.519 0.29 -1.195 0.54 RiskHigh 1.344 0.63 0.872 0.56 3.018 0.05 0.091 0.88 4.061 0.10 
RiskMed 2.172 0.52 -1.119 0.40 2.754 0.05 0.238 0.67 1.856 0.42 
RiskNo 5.439 0.54 1.079 0.61 2.525 0.07 0.358 0.54 3.252 0.17 
_cons 
25.495 <0.01 24.485 <0.01 15.540 <0.01 10.109 <0.01 45.053 <0.01 
n= 599 731 504 994 994 
Pseudo r"2 0.079 0.073 0.055 0.024 0.036 
Sigma 34.40 16.52 11.14 6.28 25.45 
356 
APPENDICES 
Interval 
regression 
With 0 as [., 0] 
Diaphragm 
Coef. P>Izl 
Microbicide 
Coef. P>Izl 
Female condom 
Coef. P>IzI 
seshh 7.890 <0.01 4.253 <0.01 1.366 0.06 
age -0.770 <0.01 -0.294 0.02 -0.315 <0.01 
EducYrs 0.468 0.41 0.207 0.44 0.410 0.09 
employd 7.200 0.08 3.849 0.03 2.958 0.08 
YrsinLoc 0.045 0.80 0.004 0.97 0.089 0.15 
FCEvUs -14.403 0.13 -1.284 0.79 0.961 0.77 
DontWantPreg 1.654 0.62 -2.424 0.13 -1.584 0.27 
MCEvrUse 0.863 0.86 2.937 0.19 -0.783 0.70 
PaidMCS 9.661 0.16 -2.276 0.45 -5.013 0.05 
IntiatMCS 0.811 0.86 2.607 0.22 0.869 0.60 
DiffMC 1.203 0.75 -0.053 0.98 -0.646 0.65 
MCLastS -5.568 0.21 1.283 0.55 1.860 0.32 
SexDeb 1.319 0.07 -0.253 0.44 -0.282 0.34 
Cohab 5.836 0.13 1.723 0.37 0.168 0.91 
RiskHigh 2.351 0.63 1.332 0.56 3.678 0.06 
RiskMed 2.509 0.60 -1.793 0.40 3.382 0.06 
RiskNo 7.146 0.12 1.095 0.61 2.358 0.21 
cons 21.925 0.16 22.559 <0.01 16.483 0.01 
n= 599 731 504 
Pseudo rA2 0.067 0.053 
sigma 38.76 20.04 14.10 
Seshh: household socio-economic status; age: age; EducYrs level of education; employd: employment status; 
YrsinLoc; Years living in location; FCEvUs: ever use of a female condom; DontWantPreg: desire not to get 
pregnant; MCEvrUse: male condom ever use; PaldMCS: whether they had ever paid for male condoms; 
lnitlateMC: if they had initiated condom use themselves the last time they used a condom; DIffMC: having ever 
experienced difficulties negotiating condom use; MCLastS: condom use at last sex act; SexDeb: age at sexual 
debut; Cohab: if they are living with a sexual partner.; RlskHigh, RiskMed, RlskNo, relative to RiskLow their self 
perceived risk of HIV- high, medium, or none, relative to low. 
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Table A 10-3 Determinants of WTP- Reduced regressions 
OLS 
Values 
Diaphragm 
Coef. P>Itf 
seshh3 8.372 <0.01 
age -0.557 0.03 
employd 9.168 0.04 
FCEvUs -13.141 0.07 
MCEvrUse -4.572 0.30 
PaidMCS 5.116 0.46 
IntiatMCS 3.569 0.42 
Cohab 6.155 0.08 
RiskNo 9.447 0.07 
cons 45.784 <0.01 
n= 606 
R2 0.066 
Microbicide 
Coef. P>Itl 
4.295 <0.01 
-0.513 <0.01 
7.442 0.01 
-5.155 0.13 
4.733 0.03 
-1.506 0.74 
4.167 0.17 
4.308 0.08 
4.474 0.11 
23.225 <0.01 
Female condom 
Coef. P>Iti 
1.882 <0.01 
-0.306 0.01 
4.250 0.01 
-2.077 0.39 
0.332 0.86 
-4.349 0.14 
0.329 0.86 
-1.567 0.32 
2.520 0.25 
18.978 <0.01 
Single use 
Coef. P>Itl 
0.647 <0.01 
-0.112 <0.01 
0.471 0.28 
0.201 0.83 
-0.575 0.25 
0.255 0.73 
0.865 0.07 
0.587 0.17 
0.091 0.84 
7.702 <0.01 
Reusable 
Coef. P>ItI 
4.738 <0.01 
-0.505 <0.01 
1.941 0.28 
-0.392 0.93 
-2.023 0.29 
0.093 0.98 
4.030 0.04 
-1.313 0.44 
1.916 0.29 
41.444 <0.01 
RESET p-value* 0.028 
OLS 
Logarithms 
Diaphragm 
Coef. P>Itl 
seshh 0.174 <0.01 
age -0.016 0.02 
employd 0.141 0.19 
FCEvUs -0.348 0.18 
MCEvrUse -0.128 0.28 
PaidMCS 0.345 0.03 
IntiatMCS 0.041 0.73 
Cohab 0.172 0.09 
RiskNo 0.126 0.21 
cons 3.531 <0.01 
n= 533 
R2 0.058 
RESET p-value' 0.783 
745 
0.083 
0.000 
514 
0.041 
0.686 
1012 
0.028 
0.017 
Microbicide 
Coef. P>ItI 
0.218 <0.01 
-0.017 0.01 
0.214 0.02 
0.105 0.59 
0.204 0.07 
-0.156 0.36 
0.059 0.59 
0.163 0.09 
0.167 0.09 
2.688 <0.01 
604 
0.085 
0.673 
Female condom 
Coef. P>Iq 
0.181 <0.01 
-0.010 0.12 
0.195 0.08 
0.021 0.92 
0.027 0.82 
-0.310 0.08 
0.014 0.90 
-0.020 0.85 
0.278 0.01 
2.309 <0.01 
395 
0.067 
0.240 
Single use 
Coef. P>ItI 
0.075 <0.01 
-0.012 <0.01 
0.117 0.03 
-0.145 0.19 
-0.037 0.57 
-0.028 0.74 
0.031 0.59 
0.097 0.07 
0.102 0.06 
2.340 <0.01 
508 
0.059 
0.210 
1012 
0.064 
0.008 
Reusable 
Coef. P>ItI 
0.117 <0.01 
-0.009 <0.01 
0.030 0.51 
0.072 0.54 
-0.060 0.23 
0.014 0.84 
0.077 0.11 
-0.006 0.88 
0.098 0.04 
3.647 <0.01 
744 
0.066 
0.027 
OLS Diaphragm Microbicide Female condom Single use Reusable 
Log (WTP+1) Coef. P>Itl Coef. P>Itl Coef. P>Itl Coef. P>Iq Coef. P>ItI 
seshh 0.276 <0.01 0.271 <0.01 0.167 <0.01 0.097 0.01 0.218 <0.01 
age -0.029 <0.01 -0.021 0.01 -0.029 <0.01 -0.016 <0.01 -0.026 <0.01 
employd 0.147 0.25 0.252 0.02 0.205 0.09 0.052 0.53 0.119 0.30 
FCEvUs -0.442 0.18 -0.055 0.85 0.082 0.77 0.220 0.27 -0.191 0.53 
MCEvrUse -0.159 0.28 0.204 0.10 0.072 0.60 -0.083 0.38 -0.019 0.88 
PaidMCS 0.344 0.09 -0.154 0.40 -0.273 0.16 0.062 0.65 0.035 0.84 
IntiatMCS 0.082 0.56 0.108 0.38 -0.012 0.92 0.178 0.05 0.179 0.14 
Cohab 0.104 0.40 0.062 0.56 -0.033 0.78 0.056 0.48 -0.149 0.17 
RiskNo 0.273 0.03 0.141 0.21 0.039 0.75 -0.032 0.71 -0.042 0.72 
_cons 
3.641 <0.01 2.473 <0.01 2.597 <0.01 1.553 <0.01 3.354 <0.01 
n= 606 745 514 1012 1012 
R2 0.074 0.079 0.055 0.021 0.0447 
RESET p-value* 0.545 0.621 0.396 0.126 0.5361 
Seshh: household soäo-economic status; age: age; employd: employment status; FCEvUs: ever use of a female 
condom; MCEvrUse: male condom ever use; PaidMCS: whether they had ever paid for male condoms; InltateMC: 
if they had initiated condom use themselves the last time they used a condom; Cohab: if they are living with a 
sexual partner. 
3 Variable names at end of table 
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Tobit Diaphragm 
Coef. P>ItI 
seshh 9.984 <0.01 
age -0.745 0.02 
employd 9.722 0.04 
FCEvUs -15.719 0.20 
MCEvrUse -5.123 0.33 
PaidMCS 5.691 0.46 
InfiatMCS 4.193 0.40 
Cohab 6.485 0.14 
RiskNo 11.233 0.02 
cons 47.395 <0.01 
sigma" 48.3389 
n= 606 
pseudo-R2 0.008 
Microbicide Female condom Single use Reusable 
Coef. P>Itl Coef. P>Itl Coef. P>t P>Itl 
5.535 <0.01 2.366 0.03 1.308 0.01 7.247 <0.01 
-0.613 <0.01 -0.490 <0.01 -0.233 <0.01 -0.828 <0.01 8.721 <0.01 5.169 0.02 0.721 0.48 3.316 0.24 
-6.728 0.38 -1.596 0.78 1.316 0.61 -2.402 0.75 
5.775 0.06 1.178 0.65 -1.287 0.27 -2.719 0.40 
-2.183 0.60 -5.131 0.17 0.816 0.61 -0.165 0.97 
4.832 0.09 0.244 0.92 2.129 0.06 6.478 0.04 
4.298 0.09 -1.477 0.49 1.089 0.27 -2.157 0.43 
4.833 0.07 1.783 0.42 -0.399 0.70 1.996 0.48 21.074 <0.01 20.656 <0.01 6.698 <0.01 47.289 <0.01 
30.3494 21.16643 12.61 36.99 
745 514 1012 1012 
0.011 0.007 0.0043 0.0091 
Tobit logs Coef. P>t 
seshh 0.176 <0.01 
age -0.016 0.03 
employd 0.141 0.18 
FCEvUs -0.344 0.23 
MCEvrUse -0.133 0.27 
PaidMCS 0.347 0.05 
IntiatMCS 0.041 0.72 
Cohab 0.169 0.10 
RiskNo 0.129 0.22 
cons 3.535 <0.01 
(sigma 1.05 
n= 533 
pseudo-R2 0.020 
Tobit on 
Log(WTP+1) 
seshh 
age 
employd 
FCEvUs 
MCEvrUse 
PaidMCS 
IntiatMCS 
Cohab 
RiskNo 
cons 
/sigma 
n= 
pseudo-R2 
Diaphragm 
Coef. P>t 
Coef. P>t 
0.222 <0.01 
-0.017 0.01 
0.221 0.02 
0.119 0.68 
0.214 0.06 
-0.174 0.25 
0.051 0.63 
0.160 0.10 
0.174 0.08 
2.654 <0.01 
1.04 
604 
0.028 
Microbicide 
Coef. P>t 
0.308 <0.01 
-0.032 <0.01 
0.154 0.28 
-0.490 0.20 
-0.172 0.30 
0.357 0.14 
0.093 0.55 
0.107 0.44 
0.308 0.03 
3.680 <0.01 
1.52 
606 
0.021 
Tobit with opt- Diaphragm 
out as WTP=O Coef. P>I 
seshh 4.979 0.03 
age -0.537 0.10 
employd 8.589 0.08 
FCEvUs -13.075 0.33 
MCEvrUse 2.692 0.63 
PaidMCS -5.161 0.51 
IntiatMCS 3.277 0.54 
Cohab 4.210 0.38 
RiskNo 7.321 0.14 
cons 4.902 0.66 
sigma"" 61.49 
n= 1012 
pseudo-R2 0.002 
0.315 <0.01 
-0.024 0.01 
0.290 0.03 
-0.098 0.80 
0.235 0.12 
-0.178 0.39 
0.128 0.38 
0.053 0.68 
0.148 0.27 
2.397 <0.01 
1.54 
745 
0.021 
Microbicide 
Coef. P>t 
0.188 <0.01 
-0.010 0.17 
0.188 0.08 
0.029 0.91 
0.034 0.79 
-0.322 0.07 
0.012 0.92 
-0.015 0.88 
0.286 0.01 
2.281 <0.01 
0.93 
395 
0.025 
Female condom 
Coef. P>t 
0.192 0.01 
-0.039 <0.01 
0.245 0.11 
0.115 0.76 
0.114 0.52 
-0.309 0.22 
-0.018 0.91 
-0.024 0.87 
-0.007 0.96 
2.688 <0.01 
1.47 
514 
0.016 
Female condom 
Coef. P>ItI Coef. P>Iq 
4.089 <0.01 1.104 0.29 
-0.766 <0.01 
9.525 <0.01 
-10.573 0.15 
3.782 0.22 
-0.991 0.82 
4.796 0.10 
3.552 0.17 
2.451 0.36 
16.370 0.01 
34.26 
1012 
0.008 
-0.160 0.28 
3.448 0.12 
0.020 1.00 
8.659 <0.01 
-6.165 0.09 
-2.167 0.37 
0.325 0.88 
1.852 0.41 
-11.216 0.03 
26.10 
1012 
0.005 
Coef. P>t 
0.164 <0.01 
- 0.022 <0.01 
0.266 0.02 
- 0.218 0.40 
- 0.039 0.76 
- 0.081 0.62 0.047 0.69 
0.174 0.10 
0.242 0.03 
2.120 <0.01 
0.96 508 
0.031 
Single use 
Coef. P>t 
0.165 0.03 
-0.027 0.01 
0.071 0.66 
0.471 0.26 
-0.147 0.43 
0.127 0.62 
0.338 0.06 
0.079 0.61 
-0.111 0.50 
1.126 <0.01 
Coef. P>t 
0.294 <0.01 
-0.016 0.02 
0.072 0.49 
0.181 0.52 
-0.112 0.36 
0.068 0.66 
0.140 0.21 
-0.054 0.60 
0.214 0.04 
3.287 <0.01 
1.07 
744 
0.034 
Reusable 
Coef. P>t 
0.275 <0.01 
-0.033 <0.01 
0.160 0.29 
-0.296 0.47 
-0.008 0.97 
0.042 0.86 
0.226 0.18 
-0.199 0.17 
-0.084 0.58 
3.317 <0.01 
2.05 2.04 
1012 1012 
0.006 0.011 
Single use 
Coef. P>ItI 
1.045 0.01 
-0.180 <0.01 
0.620 0.45 
1.410 0.51 
-0.951 0.31 
0.590 0.65 
1.723 0.06 
0.782 0.33 
-0.282 0.73 
5.645 <0.01 
10.3098 
1012 
0.005 
Reusable 
Coef. P>ItI 
5.911 <0.01 
-0.652 <0.01 
2.691 0.24 
-2.135 0.73 
-1.925 0.46 
0.203 0.96 
4.983 0.05 
-2.119 0.34 
1.331 0.56 
41.114 <0.01 
30.5775 
1012 
0.008 
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WhenO=[0,0] 
Interval Diaphragm Microbicide Female condom Single use 
regression Coef. P>Izl Coef. P>Izl Coef. P>Izl Coef. P>IzI 
seshh 7.374 <0.01 3.542 <0.01 1.744 <0.01 0.730 <0.01 
age -0.593 0.01 -0.284 <0.01 -0.235 <0.01 -0.122 <0.01 
employd 7.327 0.04 3.328 0.02 2.836 0.02 0.591 0.21 
FCEvUs -10.655 0.17 -0.406 0.91 0.001 1.00 0.294 0.79 
MCEvrUse -1.831 0.63 2.898 0.07 -0.019 0.99 -0.590 0.27 
PaidMCS 7.789 0.21 -1.798 0.47 -3.629 0.05 0.215 0.79 
IntiatMCS 1.506 0.69 2.013 0.23 0.373 0.77 0.953 0.07 
Cohab 5.280 0.09 1.700 0.23 -0.587 0.60 0.622 0.18 
RiskNo 4.198 0.20 1.260 0.38 0.830 0.48 0.187 0.70 
cons 50.461 <0.01 20.976 <0.01 17.629 <0.01 10.225 <0.01 
sigma"' 34.6 16.4 11 6.3 
n= 606 745 514 1012 
pseudo-R2 "" 0.066 0.071 0.042 0.011 
25.5 
1012 
0.029 
When 0=[., 0] 
Interval Diaphragm Microbicide Female Condom 
regression Coef. P>Izl Coef. P>Izl Coef. P>IzI 
seshh 8.760 <0.01 4.386 <0.01 2.108 <0.01 
age -0.747 <0.01 -0.349 <0.01 -0.350 <0.01 
employd 7.906 0.05 4.127 0.01 3.481 0.03 
FCEvUs -12.668 0.18 -1.271 0.63 0.293 0.93 
MCEvrUse -2.209 0.61 3.547 0.03 0.501 0.77 
PaidMCS 8.228 0.23 -2.253 0.63 -4.304 0.07 
InäatMCS 1.937 0.65 2.466 0.22 0.353 0.83 
RiskNo 5.529 0.14 1.390 0.10 0.333 0.83 
_cons 
52.444 <0.01 20.123 <0.01 18.977 <0.01 
sigma" 39.1 20.0 14.2 
n= 606 745 514 
Dseudo-R2'** 0.059 0.067 0.032 
* RESET p-value tests the Ho: that there are no omitted variables. This test is not available in State for TOBIT and 
interval regression models 
sigma represents the standard error of estimate 
' pseudo RA2 is calculated as average of the correlations between the predicted values and the upper and lower 
limits of the intervals 0711. 
seshh: household socio-economic status; age: age; EducYrs level of education; employd: employment status; 
FCEvUs: ever use of a female condom; MCEvrUse: male condom ever use; PaidMCS: whether they had ever paid 
for male condoms; InitiateMC: if they had initiated condom use themselves the last time they used a condom; 
Cohab: if they are living with a sexual partner. 
Excluding Outliers (WTPd , rm<R201(n=3); WTPm a, <R101(n=7); WTPr, =w n<R91(n=5)) 
OLS 
Diaphragm 
Coef. P>t 
seshh 7.372 <0.01 
age -0.566 0.01 
employd 5.032 0.19 
FCEvUs -11.832 0.09 
MCEvrUse -1.672 0.68 
PaidMCS 7.603 0.25 
IntiatMCS 1.256 0.74 
Cohab 6.166 0.07 
RiskNo 4.912 0.20 
cons 45.516 <0.01 
n= 603 
r"2 0.0649 
RESET p-values 0.2968 
Reusable 
Coef. P>IzI 
5.369 <0.01 
-0.541 <0.01 
2.081 0.30 
0.058 0.99 
-2.100 0.32 
0.458 0.89 
4.313 0.05 
-1.826 0.33 
2.202 0.28 
53.933 <0.01 
Microbicide 
Coef. P>t 
3.763 <0.01 
-0.294 0.01 
3.143 0.07 
-1.812 0.57 
2.393 0.16 
-0.068 0.98 
2.332 0.23 
1.212 0.44 
-0.437 0.77 
20.767 <0.01 
737 
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Female condom 
Coef. P>t 
1.631 <0.01 
-0.222 0.01 
3.365 0.02 
-0.292 0.90 
-0.639 0.61 
-4.719 0.01 
1.558 0.25 
-0.930 0.44 
-0.011 0.99 
16.008 <0.01 
509 
0.0508 
0.0444 
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Tobit Coef. P>Itl 
seshh 8.698 <0.01 
age -0.721 0.01 
employd 5.375 0.17 
FCEvUs -13.877 0.18 
MCEvrUse -2.066 0.64 
PaidMCS 8.116 0.21 
IntiatMCS 1.709 0.69 
Cohab 6.455 0.08 
RiskNo 6.275 0.11 
cons 46.934 <0.01 
sigma 40.74 
n= 603 
pseudo-r^2 0.0078 
Coef. P>ItI 
4.637 <0.01 
-0.356 0.01 
3.858 0.04 
-2.746 0.61 
2.933 0.18 
-0.468 0.88 
2.758 0.19 
1.029 0.58 
-0.489 0.80 
19.447 <0.01 
21.83 14.57 
737 509 
0.0101 0.0082 
Coef. P>It 
1.968 0.01 
-0.341 <0.01 
3.963 0.01 
0.130 0.97 
-0.172 0.92 
-5.378 0.04 
1.604 0.33 
-0.837 0.57 
-0.698 0.65 
17.156 <0.01 
Interval regression Coef. P>ItI Coef. P>IzI Coef. P>IzI 
seshh 7.125 <0.01 3.450 <0.01 1.626 <0.01 
age -0.592 0.01 -0.241 0.01 -0.222 <0.01 
employd 6.422 0.07 2.537 0.08 2.494 0.04 
FCEvUs -10.345 0.18 0.311 0.93 0.502 0.83 
MCEvrUse -1.179 0.75 2.223 0.15 -0.214 0.86 
PaidMCS 8.321 0.18 -1.558 0.52 -3.942 0.02 
IntiatMCS 1.044 0.78 1.894 0.25 0.602 0.61 
Cohab 5.240 0.10 0.983 0.47 -0.473 0.66 
RiskNo 3.377 0.30 0.128 0.93 0.239 0.82 
cons 50.205 <0.01 20.568 <0.01 17.159 <0.01 
sigma 34.20 16.01 10.68 
n= 603 737 509 
pseudo RA2' 0.06771 0.06878 0.04179 
seshh: household socio-economic status; age: age; EducYrs level of education; employd: employment 
status; FCEvUs: ever use of a female condom; MCEvrUse: male condom ever use; PaldMCS: whether 
they had ever paid for male condoms; InltiateMC: if they had initiated condom use themselves the last 
time they used a condom; Cohab: if they are living with a sexual partner. 
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Appendix 11. Exploration of key socio-demographic characteristics 
Table A 11-1 Descriptive statistics 
Variable coding 
All 
Count % 
All 1,017 100% 
Condom used at last sex act (MCLastS) No (-1) 699 69% 
Yes (1) 318 31% 
Cohabiting with sexual partner (Cohab) No (-1) 456 45% 
Yes (1) 560 55% 
Current contraceptive use (contr) No (-1) 764 75% 
Yes (1) 253 25% 
Ever experienced difficulties getting partner No (-1) 630 62% 
to use condoms (DiffMC) 
Yes (1) 382 38% 
Employed (emplyd) No (-1) 660 65% 
Yes (1) 357 35% 
Self-perceived risk of HIV (RiskH) High (3) 223 23% 
(RiskM) Medium (2) 260 27% 
(RiskL) Low (1) 234 24% 
(RiskNo) None (0) 261 27% 
Educational attainment Incomplete secondary 457 45% 
Complete secondary 276 27% 
Other (<10% each) 283 28% 
Educational attainment* (educyrs) Mean in years 10.04 
Age (age) Mean in years 31.53 
*This is an approximate number of years of school derived from the average number of years from the schooling 
categories. 
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Table A 11-2 Correlations between key women's characteristics 
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Table A shows the correlations between the socio-demographic characteristics that were 
included in the different models. In this table categorical variables are entered as traditional 
dummy variables rather than effects coded variables. The highest correlation is between 
preferred products (a negative correlation between preferences for microbicides and the 
diaphragm or -. 6); this is not surprising as they are mutually exclusive. The next highest 
correlation is . 48 between household socio-economic status and years of education. This is to be 
expected. Age and cohabiting would also be expected to be correlated, and has a correlation 
coefficient of 0.38. Self perceived risk of HIV displays and interesting pattern with `having 
experience difficulties using a condom' and `used a condom last sex act'. The correlation with 
`difficulties in condom use' moves from significantly negative for women who perceive 
themselves at no risk of HIV to significantly positive for women who perceive themselves at 
high risk. The opposite pattern is observed for the `condom use in last sex act' variable. This is 
interesting as it shows the expected direction of relationships. Moreover, it sheds a light on the 
possible direction of causality in the condom use - HIV risk relationship. It appears that one's 
risk perception is related to their use of protection; whereas one might also argue that condom 
use could be related to the perception of risk at the last sex act, i. e. did not use because the sex 
act was not perceived risky versus considers oneself at high risk because did not use condom. 
However, these correlations are small in magnitude. 
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Appendix 12. Estimation of preferences for product attributes: Random 
Parameters Logit with correlations results and discussion. 
Table A 12-1 Random Parameters Logit with correlations, 25 Runs 
Coefficient p-value 
Random parameters in utility functions 
BDG2 0.56 <0.01 
BMD2 1.22 <0.01 
BSECR 0.18 0.111 
BPRG 6.19 <0.01 
BHIV 12.28 <0.01 
BLNPRC -0.45 <0.01 
C 9.88 <0.01 
Nonrandom parameters in utility functions 
BDG*MClastS 0.51 <0.01 
BMD*MClastS 0.16 0.186 
BSECR*DiffMC 0.32 <0.01 
BPRG*cohab -0.35 0.206 
BHIVRISK 1.83 <0.01 
HIV*cohab -0.27 0.512 
BLPRC*EMP 0.14 <0.01 
C*MCIastS 4.16 <0.01 
C*DiffMC -1.46 <0.01 
C*cohab -0.28 0.448 
Diagonal values in Cholesky matrix, L. 
UsBDG2 1.34 <0.01 
UsBMD2 0.49 0.281 
UsBSECR 0.91 0.028 
NsBPRG 0.23 0.719 
NsBHIV 9.92 <0.01 
NsBLNPRC 0.24 0.102 
NsC 1.97 <0.01 
Below diagonal values in L matrix. V= L*Lt 
BMD2: BDG 3.70 <0.01 
BSEC: BDG 0.74 0.04 
BSEC: BMD 3.22 <0.01 
BPRG: BDG -0.74 0.52 
BPRG: BMD -1.16 0.39 
BPRG: BSE -10.18 <0.01 
BHIV: BDG -11.28 <0.01 
BHIV: BMD -2.89 0.08 
BHIV: BSE -7.09 <0.01 
BHIV: BPR -7.61 <0.01 
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BLNP: BDG 0.50 0.02 
BLNP: BMD -0.57 0.02 
BLNP: BSE -0.25 0.27 
BLNP: BPR -0.12 0.37 
BLNP: BHI -0.56 <0.01 
C: BDG 5.04 <0.01 
C: BMD -8.94 <0.01 
USE -13.37 <0.01 
C: BPR 1.34 0.10 
C: BHI 5.54 <0.01 
C: BLN 2.06 <0.01 
n= 6,102 
LLR -5,387.17 
The critical thing that can be learned from the RPL model is in the covariance matrix. Large 
covariances suggest that individuals with large preferences for on attribute have a large 
preference for the other. This is the case most notably for HIV and the diaphragm, with a strong 
correlation of preferences between high valuation of HIV prevention effectiveness and low 
values for the diaphragm. Using the covariance matrix, packages of attributes could be 
identified. Though interesting in the physical attributes, it is of greater interest in the distribution 
scenarios, where it could guide the composition of how to distribute the different products 
within certain outlets. It is unlikely that we can mix and match the product attributes, so it is not 
really worth the exploration at the current time. The other interesting thing to point out from the 
RPL with correlations output is the standard deviations of the random parameter. All of the 
product attributes were defined as random parameters, which is subsequently tested. We see 
each product attribute has significant level of heterogeneity around the mean. This suggests 
much variation in preferences between women. This is still the case despite trying to capture 
variations in preferences by including a number of SDCs. 
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Appendix 13 Estimation of preferences for distribution strategies 
Appendix 13.1 Estimation of preferences for distribution strategies 
Before considering the model results, the best model to use needs to be identified. The right half 
of Table A 13.1 shows the results of the different RPL runs. For the RPL model, it is not as easy 
to retrieve the omitted categories by rerunning the model with different omitted attribute levels. 
In doing this all the coefficients change. This is due to the estimation method which uses matrix 
multiplication. Even changing the ordering of the variables in the procedure will affect the exact 
coefficients. Therefore 2 runs of each RPL model are presented to show estimates for all 
attribute levels. 
Parameter values represent relative utilities, standardised around 0. The standard deviations 
show if there is significant heterogeneity of preferences that is not captured by the included 
interaction terms. The test for IIA here is done by examining the standard deviations of the 
parameters. RPL relaxes IIA and allows for preference heterogeneity. That means that it allows 
for not all people having the same preferences and tests whether there is a distribution around 
the estimated relative utility. 
In the first set of runs (RPL1) there are potentially 7 random parameters: Collection from a box, 
a private room, or a shelf; advertising for pregnancy prevention, HIV, pleasure and women's 
empowerment. However, only the private room is significant in both runs. These distributions 
are not particularly stable. It is common practice to develop the model by removing variables 
with insignificant distributions from the parameters specified as random. When this is done 
repeatedly, the only variable that continues to have a significant distribution is collection from a 
private room (RPL2). For this reason we have chosen not to reject the IIA assumption and will 
continue from here onwards interpreting parameter estimates from the MNL model. 
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Table A13-1 Estimation of distribution strategy preferences- testing for unobserved 
heterogeneity using the MNL and RPL models 
MNL RPL (runs excluding different attribute levels) 
RPLI a (25its) RPLIb (50 its) RPL2 iteratively identifying 
robustly random parameters 
Coeff. p-value Coeff. p-value Coeff. p-value Coeff. p-value Coeff. p-value 
Source 
Clinic 0.29 <0.01 
Supermarket -0.20 <o. o1 
Pharmacy 0.33 <0.01 
Spaza (comer store) -0.43 <0.01 
Collection method 
Box or dispensing 
machine 
0.04 0.38 
A shelf 0.02 0.65 
A person behind a 
-0.18 <o. o1 counter 
In a private room 0.11 0.01 
Advertising message 
HIV prevention 0.10 0.02 
Women's empowerment 0.13 <0.01 
Enhanced pleasure -0.30 <0.01 
Pregnancy prevention 0.06 0.15 
Price -0.04 <o. o1 
Parameter distributions 
Us Clinic 
Us-Supermarket 
Us_Pharmacy 
Us_Spaza 
Us_Box 
Us-Shelf 
Us-Counter 
Us_Private room 
Us_Ad HIV 
Us_Ad women's empowerment 
Us_Ad pleasure 
Us_Ad pregnancy 
0.61 <0.01 0.407 <o. o1 
-0.45 0.02 -0.257 <0.01 
0.52 <0.01 0.60 <0.01 0.429 <0.01 0.382 <0.01 
-0.70 <0.01 -0.79 <0.01 -0.527 <0.01 -0.500 <0.01 
0.05 0.62 -0.012 0.85 
0.07 0.57 0.028 0.64 
-0.35 <0.01 -0.35 0.01 -0.188 <0.01 -0.196 <0.01 
0.25 0.03 0.28 0.04 0.168 0.03 0.160 0.01 
0.15 0.07 0.22 0.09 0.141 0.03 0.122 0.02 
0.29 0.04 0.162 <o. o1 
-0.67 <o. ol -0.65 0.02 -0.416 <0.01 -0.338 <0.01 
0.21 0.10 0.089 0.15 
-0.07 <0.01 -0.07 <0.01 -0.047 <0.01 -0.040 <0.01 
0.29 0.77 
0.95 0.41 
0.46 0.57 0.30 0.82 
0.87 0.26 0.42 0.65 
2.44 0.01 
2.38 0.08 
0.02 0.99 0.20 0.83 
2.50 0.02 2.30 0.07 
1.85 0.01 0.16 0.89 
1.94 0.04 
1.86 <0.01 1.27 0.25 
1.11 0.04 
2.735 <0.01 1.340 <0.01 
Ts_Price 0.10 0.20 0.18 0.19 
Ilr -1951.17 -1937.02 -1945.85 -1946.430 -1949.428 
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Table A13-2 Price: random distribution functional form in RPL 
Normal 
Coeff. P-value 
Triangular 
Coeff. P-value 
Lognormal 
Coeff. P-value 
BCLIN 0.614 <0.01 0.613 <0.01 1.328 <0.01 
BPHARM 0.52 <0.01 0.521 <0.01 0.817 <0.01 
BSPAZ -0.702 <0.01 -0.701 <0.01 -1.062 <0.01 
BBOX 0.049 0.605 0.048 0.616 -0.031 0.816 
BCNTR -0.352 <0.01 -0.351 <0.01 -0.435 <0.01 
BPVTRM 0.245 0.027 0.246 0.029 0.225 0.178 
BADPREG 0.148 0.103 0.148 0.103 0.246 0.099 
BADHIV 0.206 0.068 0.208 0.074 0.399 0.021 
BADPLS -0.667 <0.01 -0.668 <0.01 -1.081 <0.01 
BPRICE -0.07 <0.01 -0.07 <0.01 -35.19 1 
UsBCLIN 0.291 0.767 0.288 0.767 6.32 <0.01 
UsBPHARM 0.431 0.593 0.456 0.567 2.182 0.083 
UsBSPAZ 0.891 0.244 0.867 0.261 0.259 0.775 
UsBBOX 2.449 0.011 2.439 0.012 0.102 0.905 
UsBCNTR 0.09 0.95 0.016 0.992 0.397 0.59 
UsBPVTRM 2.456 0.017 2.497 0.018 4.397 <0.01 
UsBADPRE 1.109 0.043 1.115 0.043 1.822 0.016 
UsBADHIV 1.848 0.01 1.851 0.013 1.702 0.025 
UsBADPLS 1.863 <0.01 1.859 <0.01 4.204 <0.01 
NsBPRICE 0.04 0.18 0.098 0.199 1.53 1 
WTP values 
BCLIN -8.8 -8.79 -0.04 
BPHARM -7.46 -7.48 -0.02 
BSPAZ 10.06 10.06 0.03 
BBOX -0.71 -0.69 0 
BCNTR 5.05 5.03 0.01 
BPVTRM -3.52 -3.52 -0.01 
BADPREG -2.12 -2.12 -0.01 
BADHIV -2.96 -2.99 -0.01 
BADPLS 9.56 9.58 0.03 
BPRICE 
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Appendix 13.2 Estimation of. "Do women's preferences for distribution strategies 
differ by product? " including the female condom. 
In Table A 13-3, the hypothesis is tested: Do women's preferences for distribution strategies 
differ by product? The estimation allows for variation by male condom (omitted category), 
female condom (FC), microbicide (MCD) and diaphragm (DGM). The specification where all 
products are included appears not to work well, because some of the main effects loose 
significance (private room (BPVTRM) and advertising for HIV (BADHIV)). Only diaphragm 
seems to have different preferences in the MNL model and then only for a few distribution 
strategy attributes characteristics: collection from the box (BBOX), advertising messages for 
HIV (ADHIV) and pregnancy (ADPREG) and price (BPRICE). The MNL model also shows the 
preferences for advertising for pregnancy prevention is higher for microbicides. The RPL model 
does show heterogeneity around the advertising messages (HIV (ADHIV), pregnancy 
(ADPREG), pleasure (ADPLS)), consistent with a priori expectations around using advertising 
to target specific population groups. 
Table A13-3 distribution preferences by product 
2 MNL Interactions for products 2b RPL for all products 
Coeff. P-value WTP Coeff. P-value WTP 
BCLIN 0.26 0.04 9.60 1.06 0.05 ** 14.16 
BPHARM 0.46 0.00 16.85 0.86 0.02 11.51 
BSPAZ -0.50 0.00 *** -18.55 -1.17 0.01 -15.52 
BBOX 0.16 0.13 6.04 0.47 0.20 6.23 
BCNTR -0.21 0.05 * -7.89 -0.59 0.10 * -7.85 
BPVTRM 0.12 0.30 4.27 0.19 0.54 2.52 
BADHIV -0.01 0.95 -0.25 -0.08 0.79 -1.08 
ADPREG 0.18 0.11 6.60 0.48 0.15 6.38 
ADPLS -0.32 0.01 *** -11.62 -0.74 0.05 * -9.91 
BPRICE -0.03 0.00 **" -0.08 0.04 
BCLI DGM -0.08 0.43 -0.05 0.83 BCLI_MCD -0.09 0.29 -0.11 0.64 BCLIN_FC 0.01 0.93 0.30 0.35 
BPHR_DGM 0.12 0.17 0.28 0.23 
BPHR_MCD 0.10 0.22 0.26 0.24 
BPHR_FC 0.08 0.45 0.12 0.63 
BSPZ DGM -0.07 0.42 -0.21 0.30 BSPZ MCD -0.06 0.44 -0.18 0.36 BSPZ FC -0.06 0.55 -0.20 0.40 
BBOX DGM 0.14 0.10 * 0.48 0.14 
BBOXCD 0.03 0.66 0.17 0.47 
BBOX_FC 0.09 0.33 0.30 0.30 
BCNTR_DGM -0.10 0.21 -0.30 0.22 BCNTR_MCD 0.06 0.46 0.09 0.62 
BCNR_FC 0.01 0.92 0.00 1.00 
BPVRM_DGM 0.01 0.93 -0.07 0.78 BPVR_MCD -0.05 0.52 -0.19 0.42 BPVRM_FC 0.01 0.95 -0.10 0.71 
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BAHIV_DGM -0.18 0.03 -0.47 0.09 
BAHIV MCD -0.11 0.15 -0.32 0.19 
BAHIV FC -0.03 0.79 -0.09 0.74 
BAPRG DGM 0.17 0.04 0.36 0.16 
BAPRG MCD 0.13 0.09 * 0.28 0.22 
BAPRG 0.05 0.63 0.19 0.48 
BPLS DGM -0.09 0.32 -0.17 0.47 
BPLS MCD -0.04 0.60 -0.03 0.89 
BAPLS FC 0.03 0.74 0.23 0.44 
BPRC DGM 0.01 0.08 * 0.02 0.15 
BPRC MCD 0.01 0.13 0.02 0.22 
BPRC FC 0.01 0.54 0.00 0.82 
UsBCLIN 2.02 0.12 
UsBPHARM 0.81 0.36 
UsBSPAZ 1.35 0.27 
UsBBOX 2.95 0.03 
UsBCNTR 0.80 0.45 
UsBPVTRM 3.57 0.06 
UsADPREG 1.31 0.09 
UsBADHIV 2.97 0.04 
UsADPLS 2.68 0.03 
TsBPRICE 0.12 0.28 
* 
.. 
.. 
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